Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) Degraders

Dissertation

zur Erlangung des Doktorgrades

der Naturwissenschaften

vorgelegt beim Fachbereich 14

Biochemie, Chemie und Pharmazie

der Johann Wolfgang Goethe-Universität

in Frankfurt am Main

von

Anja Dölle

geboren in Würzburg

Frankfurt am Main (2021)

(D30)

vom Fachbereich Biochemie, Chemie und Pharmazie der

Johann Wolfgang Goethe-Universität Frankfurt als Dissertation angenommen

Dekan: Prof. Dr. Clemens Glaubitz

Gutachter: Prof. Dr. Stefan Knapp

   Prof. Dr. Eugen Proschak

Datum der Disputation:

List of content

1. Introduction

In eukaryotic cells, DNA is tightly wrapped around histone proteins to form nucleosomes.[1] This basic unit of chromatin structure envelops 146 base pair segments of DNA around a histone octamer[2] and is shown in the Cryo-EM structure in **Figure 1**. For cell replication, the unwrapping of DNA is crucial and the process is carried out by various protein complexes. The tightly regulated procedure is mediated by histone tail modifications that widen or close the chromatin structure by altering electrostatic interactions.[2] The post-translational modifications (PTMs),[3] comprising methylation, phosphorylation, ubiquitylation, sumolation, citrullination or acetylation of histone tail residues, control the so-called epigenome which differs in each cell type of each person, and is strongly influenced by the environment and lifestyle of the individual.[2] Although there are many post-translational modifications, the exact modified amino acid of the histone protein is highly specific (see **Figure 1**).[3]

Figure 1: Histone proteins interact with the DNA to form nucleosomes. **(top, left)** Top view of Cryo-EM structure of a histone octamer (with its proteins H2A (yellow), H2B (violet), H3 (green) and H4 (blue)) in complex with DNA (orange). **(top, right)** Side view of histone octamer in complex with DNA. (pdb entry: 6pwv).[4] **(bottom)** Schematic drawing of the main histone modifications patterns on different amino acid residues in normal cells. These modifications are mainly taking place on the N-terminal tails, but they can also occur at C-terminal regions, thereby contributing to an opened or closed chromatin state and driving gene expression. Scheme based on Rodriguez-Paredes and Esteller.[5]

As a result of regulating chromatin accessibility and hence driving gene expression, epigenetic modifications play a crucial role in many cellular processes: as a result, a disruption of PTMs can lead to developmental abnormalities in plants, like failure in tomato fruit ripening,[6-7] and in mammals, e.g. embryo lethality in mice.[8] Additionally to the coordination of developmental processes, adaption to environmental changes[9] and relation to alternative RNA processing[10] are also controlled by epigenetic regulation.

In summary, the influence of the epigenetic status within a cell is enormous, as it regulates the way how the cellular genome manifests itself in different cell types and developmental stages, and if aberrant, how it promotes disease progression and cancer formation.[5]

1.1 Epigenetic regulation in tumorigenesis

Initially, the key concept of cancer formation focused on how genetic mutations lead to an activation of oncogenes and/ or an inactivation of tumor-suppressor genes.[11] Heritable defects of these gene products have been shown to influence essential cellular control pathways that are disturbed in almost all human cancer types.[11] The gained knowledge of control pathway regulation promoted great progression in cancer research. But in the 1990s, an emerging research area investigated the heritable changes that were regulated by epigenetic alterations and are equally critical for human tumorigenesis.[12] These epigenetic alterations comprise abnormal DNA methylation patterns, disordered PTM patterns on histones and structural changes in chromatin organization.[12] Early-stage tumors display global DNA hypomethylation as well as promotor-specific hypomethylation, and demonstrate how epigenetic deregulation leads to the classical transforming events of tumor suppressor or proto-oncogene mutations.[13] Epigenetic mutations can silence the remaining active allele of a mutated tumor suppressor,[14] and in this manner overcome the cellular control mechanisms what potentially might lead to cancer initiation. Disruption of the epigenetic machinery can occur through mutation, deletion or altered expression of any of their components and result in modified gene expression patterns and expression states.[15]

As alterations of epigenetic modifications are a hallmark of cancer, chromatin was identified as one of the earliest targets for cancer therapeutics.[15-16] Early drug development intended altering the chromatin structure with differentiating agents[16-17] and sequencing studies of different cancer types revealed mutations in numerous genes encoding chromatin regulating proteins[18], as listed

in **Table 1**. These proteins have been divided into distinct epigenetic protein classes, according on how their enzymatic activity affects chromatin accessibility.

Table 1: Examples of epigenetic protein complexes and epigenetic mutations that are now known to be perturbed in cancer and affect gene expression and genomic stability.[12, 19-21] Perturbations can occur in epigenetic modifiers, histones or DNA. The list is not exhaustive.

Perturbation	Protein complexes
Histone-modifying enyzmes	MLL1/2/3, CBP/ P300, SETD2, EZH2, JARID1C, UTX, BMI1, LSD1
Nucleosome remodeling	BRG1/ BRM, ARID1A/ 1B/ 2, SNF5, ATRX
Histone PTM readers	BRD4, TRIM33, ING1, BRCA1
	Mutations
Histones and variants	H3K27, H3K34
DNA methylation	DNMT1/ 3A, TET1/ 2, IDH1/ 2, MBDs

In total, more than 700 proteins regulate chromatin function[18, 22-23] and they are often part of multi-domain protein complexes. Beside the catalytic subunit that controls chromatin accessibility, also subunits that recognize and interact with epigenetic modifications are crucial components of histone modifying complexes.[2] Despite the three classes of epigenetic readers, erasers, and writers, also epigenetic movers, shapers and insulators interact with chromatin structure.[24-25]

Proteins that recognize post-translational modifications are classified as epigenetic readers.[26] Well-studied protein families for epigenetic readers are, e.g., bromodomains (BRDs), which recognize acetylated lysine residues. The BRDs have been extensively studied and successfully drugged in cancer treatment.[26] In **Table 1**, the bromodomain BRD4 of the bromodomain and extraterminal domain (BET) family is listed due to its prominent role in super-enhancers (SEs) organization and regulation of oncogene expression in cancer.[27] Targeting BRD4 by inhibiting the acetyl-lysine binding site with small molecules, e.g., the first BRD targeting inhibitor (**JQ1**), was shown to be an effective strategy for cancers like the aggressive NUT midline carcinoma (NMC).[28-29] Beside the outstanding role of BRD4, other BRDs are involved as epigenetic readers in various nucleosome remodeling complexes: in the ATP-dependent human complexes BAF (BRG1/BRM-associated factor) and PBAF (polybromo-associated BAF factor), two bromodomains, SMARCA2/ 4 (SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily A2/ 4), perturbate with the core subunits BRG1/BRM histone-DNA contacts.[30-32] Mutations in BAF components are one of the most frequently observed genetic alteration in cancer.[33-34]

In addition to epigenetic readers, proteins that remove epigenetic marks from histone tails are classified as epigenetic erasers.[24] Within this epigenetic classification, the Histone Deacetylases (HDACs) and Lysine Demethylases (KMDs) are well-studied drug targets.[35-36] Each of them is responsible for the removal of one distinct functional chemical group. The last posttranslational-modifying enzyme class are the epigenetic writers that add post-translational modifications on histone tails. Prominent protein classes are the Histone Acetylases (HATs) and Histone Lysine Methyltransferases (KMTs).[37] The connection between histone acetylation and cancer has been stated and reviewed in many studies.[38-39] Current HDAC inhibitors are evaluated as anti-tumor agent in clinical trials for breast cancer,[40-41] while the development and characterization of HAT inhibitors focusses on other diseases, such as Alzheimer, diabetes and hyperlipidaemia.[42]

The previous stated examples focused on acetylated histone modifications and their influence in cancer. Acetyl groups remove the positive charge of the histones and are generally associated with an opened chromatin structure, while methylation of histone tail residues can turn genes "on" and "off" by granting or denying DNA accessibility.[3] Histone tail methylation is a complex process and dependent on the modified amino acid residue (lysines, arginines and histidines) and the methylation state (mono-, di- and trimethylation), it can serve different purposes in cellular processes: generally, methylation on the histone lysines H3K9, H3K27 and H4K20 is associated with a repressed chromatin state, while methylation of H3K4, H3K36 and H3K79 are considered to mark an opened chromatin state and activate gene transcription.[43-45] Many studies demonstrated how mutations and misregulations of histone lysine methyltransferases (KMTs), demethylases and methyl-lysine-binding proteins are connected to various diseases, thus making them effective therapeutic targets for cancer treatments.[46-47] The histone demethylation process is carried out by lysine demethylases like LSD1[48] and the JARID1 familiy[49] – epigenetic erasers that are known to be perturbed in cancer, as previously listed in **Table 1**. Equally involved in cancer formation is the class of histone lysine methyltransferases (KMTs) which are categorized as epigenetic writers. KMTs comprise proteins like MLL1-3 and SET1D which are relevant drug targets, as shown in the non-exhaustive list in **Table 1**. Within histone lysine methylation, H3K4 methylation is an evolutionary conserved motif that marks active gene transcription[50-51] and is highly enriched at the promotor region and transcription start site.[51] The family of Histone lysine Methyltransferases and its adaptor proteins are described in the following chapter.

1.2 Histone lysine methyltransferases

The methylation of lysine residues is catalyzed by over 100 existing histone lysine methyltransferases (KMTs) which are able to add methylation marks on six distinct lysine residues at the histone tail H3 (K4, K9, K23, K27, K36 and K79) as well as on lysine (K20) of histone H4.[52-54] The SET1/MLL (mixed lineage leukemia) family of methyltransferases is conserved from yeast to mammals which attach the mono-, di-, or tri-methylation of H3K4 by their catalytic SET (Suppressor of variegation 3–9, Enhancer of Zeste, Trithorax) domain.[37, 55-56] While in yeast, only one KMT is able to catalyze all three states of methylation, six H3K4 methyltransferases are found in human: MLL1 (MLL/KMT2A), MLL2 (KMT2B), MLL3 (KMT2C), MLL4 (KMT2D), SETD1A (KMT2F) and SETD1B (KMT2G).[57-58] The MLL protein is encoded by the *Mll1* gene, located on chromosome 11q23.3.[57-58] In 1992, the involvement of *Mll1* in haematological malignancies, including acute lymphoid leukaemia and acute myeloid leukaemia was revealed.[59-61] The chromosomal translocation with different partner genes[62] creates a hybrid transcription factor that drives malignancy by reactivating the expression of developmentally important genes, e.g., *HOX* genes.[63] *HOX* gene products are vital for MLL-fusion cells to maintain the malignant, stem-like state and the progression of tumorigenesis.[63-64]

Regarding structural similarity, all MLL family members share an evolutionarily conserved SET domain that catalyzes the transfer of methyl moiety from S-adenosylmethionine to the ε-amine of lysine 4 of Histone H3[65]. The SET1 KMTs represent the active subunit in large chromatin modifying enzyme complexes, as shown in the Cryo-EM in **Figure 2**, although their enzymatic activity itself is low and association with additional adaptor proteins is required for enhanced methyltransferase activity.[37] These adaptor proteins are associated in the so-called 'WRAD' complex that consist of four highly conserved protein types: WD40-repeat containing protein 5 (WDR5), Retinoblastoma Binding Protein 5 (RbBP5), Absent-Small-Homeotic-2-Like protein (ASH2L) and a Dumpy-30 protein (DPY30) homodimer.[66-69] *In vitro* experiments showed that in absence of WRAD complex, MLL1 is only a weak mono methyltransferase, while in the presence of WDR5, RbBP5 and ASH2L, MLL1 displays robust di- and moderate tri-methyltransferase activity.[66, 69-70]

Figure 2: Cryo-EM structure of the MLL1 KMT complex in complex with DNA (orange) and a histone octamer (green) (pdb entry: 6pwv).[4] The activity of the wheat-colored active MLL1 SET domain with S-adenosylmethionine (light green) is enhanced with the association of the WRAD complex, consisting out of four proteins: WDR5 (grey), RbBP5 (pink), ASH2L (red) and DYP30 homodimer (dark green).

Contary to all other core subunits, the DYP30 homodimer does not interact directly with the histone methyltransferase.[71-72] Nevertheless, it has been shown to be important for genome-wide H3K4 methylation[73-74] as it is thought to stimulate methylation activity by structural arrangements, leading to an amplification of ASH2L protein expression.[72] ASH2L forms a heterodimer with RbBP5 that directly binds and activates all catalytic subunits and stabilizes the interaction between the SET domain and its substrates.[75-76] The weak interaction between MLL1 and the RbBP5-ASH2L dimer is further enhanced by WDR5 which interacts with MLL1 and RbBP5 at its two binding sites.[50, 77] This scaffolding function is crucial for the structural integrity and enhanced methyltransferase activity of the complex.[66, 78] Studies have shown that depletion of WDR5 leads to reduction of H3K4 methylation levels in cells[66] and in animals.[79] These observations were not seen when MLL1 was removed from cells.[66, 79-80] Inhibition of the WDR5-MLL1 interaction led to a decrease in MLL1 KMT activity, and resulted in decreased H3K4 methylation at *HOX* genes.[50] The results suggested that it may be relevant to treat MLL1-fusion cancers with WDR5 inhibitors, although the exact mechanism of action remained unknown. Further proof-of-concept

experiments showed that pharmacological inhibition of WDR5 can reduce the growth of cancer cells *in vitro*, including those derived from KMT2A (MLL1)-rearranged[81-82] and C/EBPa mutant leukemias,[83] neuroblastoma,[84] and breast cancers,[85] as well as those expressing p53 gain-of-function variants.[86]

A study of mice bearing histone and DNA methylation defects showed the surprising finding that MLL-associated H3K4 methyltransferase activity is not required *in vivo*, as mice with a homozygous deletion of the MLL SET domain were born with a relatively mild phenotype.[87] Moreover, MLL-deficient cells showed no global changes in H3K4 methylation.[88] On the other hand, the expression of many genes is affected by the loss of MLL, indicating that MLL may regulate transcription independently of its active KMT domain.[63-64, 88] Since not all known functions of the adaptor proteins have been investigated, these proteins may be responsible for SET-independent transcriptional regulation. Contrary to the studies that showed the pharmacological relevance of WDR5 inhibitors, no small molecule based ligands have been published for the other WRAD subunits RbBP5, ASH2L and DYP30.[89] Targeting MLL-*r* cancers focus thus mostly on inhibiting the MLL-Menin[90-92] or MLL-WDR5 protein protein interaction (PPI).[50, 83, 93-96]

1.3 WD40-repeat containing protein 5 (WDR5)

WDR5 most prominent role is in scaffolding the assembly of epigenetic writer complexes such as the previously described MLL/SET histone methyltransferases (MLL)[50, 66, 72, 97], but also the non-specific lethal (NSL)[98] and Ada2-containing (ATAC) histone acetyltransferase (HAT).[99] The latter listed complex shows that WDR5 also plays an important role in other epigenetic marks, e.g., in the ATAC complex that drives H4K16 acetylation. [99] Other chromatin remodeling enzymes that interact with WDR5 include HDACs 1-3,[100] and the chromatin remodeling enzyme CHD8, that is involved in H3K4 trimethylation.[101]

The class of WD40-repeat containing proteins typically forms a seven-bladed propeller structure, as shown in **Figure 3**. Due to its characteristic shape, WDR5 possesses a large surface that allows various protein-protein interactions (PPIs). WDR5 interacts with many different proteins and is thought to indirectly affect intracellular H3K4 methylation as it also binds to long non-coding RNAs (lncRNAs)[102] which are known to mediate gene transcription. Among all of the protein interaction partners, the most prominent are the MLL-fusion oncoproteins and the transcription factor family MYC.[77, 97, 103] As shown in **Figure 3**, WDR5 has two binding sites, called WDR5-interacting site (Win) and WDR5-binding motif (WBM). The Win site is a deep binding pocket in the center of the

propeller and recognizes arginine containing motifs (ARA). The motifs are found in several WDR5 interaction partners, including Histone H3, KANSL1 of the NSL complex and all five MLL/ SET family members.[97-98] In contrast to the Win site, the WBM site is a narrow cleft on WDR5s' surface to which peptide sequences of the WRAD interaction partner RbBP5 or the transcription factor c-MYC bind.[103]


Figure 3: **(left)** Apo crystal structure of WDR5. Like all WD40 proteins, WDR5 consists out of a seven-bladed propeller of beta sheets (pdb entry: 2h14). **(right)** Side view of the WDR5 protein with interaction partners onboth binding sites: the wheat colored MLL1 peptide binds on the deep Win site in the center of WDR5, while the pink colored c-Myc peptide MbIIIb binds to WDR5 on a shallow cleft on the surface, the so called WBM side (pdb entry: 3eg6 and 4y7r).

WDR5 has emerged as a promising drug target for anti-cancer therapies as it is overexpressed in various cancer typer like leukemia[104], bladder cancer[105], hepatocellular carcinoma[106], and breast cancer.[85, 107] Furthermore, WDR5 is involved in malignant processes such as the epithelial to mesenchymal transition and cell motility[85, 100] and it serves as critical cofactor for the retinoic acid receptor.[108]

WDR5 and its interaction with MYC

Among all listed interaction partners of WDR5, one stands out: the transcription factor family MYC which controls the expression of many distinct genes, ranging from cell cycle progression to DNA replication to cell proliferation in healthy tissue, but is also responsible for tumorigenesis, metastasis and a poor prognosis of survival in various cancer types.[109-110] Aberrant MYC expression causes one third of all cancer deaths.[111] MYCs dimerizes with MAX to a heterodimer (as seen in

Figure 4), which is able to recognize E-box motifs on DNA and starts trancsprition of target genes.[111]

Figure 4: Crystal structure of the MYC-MAX heterodimer in complex with DNA (pdb entry: 1nkp). The crystal structure shows the dependency of the MYC protein structure on the interaction partner.

The shape of the MYC protein depends highly on its interaction partners and does not contain any druggable binding pockets. [111] Thus, one way to target the protein is through the indirect targeting of MYCs' interaction partners, e.g. MAX, Aurora A kinase and WDR5.[111-113] The seven interaction sites, called MYC boxes (Mb), are highly conserved and interact with various proteins to perform multiple cellular functions, as shown in **Figure 5**. These cellular functions reach from chromatin remodeling, modification and association to promotor binding and classify the MYC family as master regulators for gene expression.


Figure 5: Schematic illustration of the MYC protein structure (blue) with its protein-protein interaction domains (0, I, II, IIIa, IIIb, IV and BR-HLH-LZ; colored in purple-reddish). Due to the various interaction sites and engagement partners, MYC performs different cellular tasks. Figure taken and modified from Baluapuri *et al*.[111]

As shown in **Figure 3**, the interacting sequence of MYC (Myc box IIIb peptide, MbIIIb) binds to the shallow cleft on WDR5s' surface. A disruption, caused by mutations of amino acids, of the WDR5-MYC interaction attenuates MYCs' ability to localize on chromatin.[111] Inhibiton of WDR5 with a small molecule decreased WDR5/ N-Myc complex formation, resulting in reduced N-Myc target gene expression and diminished cell growth in neuroblastoma cells.[114] These observations, along with the previous seen effects on cancer cells bearing a MLL-fusion hybrid, repurpose WDR5 as therapeutical drug target in cancer therapy. While the outcome of both studies, the cell death, had been proved, the mechanism of action how WDR5 inhibition leads to the observed cell killing, was not clear.[82]

Mechanism of action and biological relevance of WDR5 inhibition and depletion

In 2019, Aho *et al.* investigated for the first time the mechanism of cell inhibition by WDR5.[81] Using chromatin immunoprecipitation sequencing (ChIP-Seq), the authors found that the WDR5 Win site interacts directly with chromatin.[81] WDR5 inhibition resulted in changes that were detectable within minutes in the transcription of WDR5-bound protein synthesis genes (PSGs), as shown in **Figure 6**.

Figure 6: Ribosomogram, displaying ribosome subunits of **(top)** small and **(bottom)** large subunit ribosomal protein genes (RPGs). Green-colored boxes indicate that WDR5 is bound to each RPG in the indicated cell type, blue-colored boxes indicate gene repression upon WIN site inhibition. LoVo cell data are from Bryan *et al.*,[84] MV4-11 data are taken from Aho *et al.*[81] Figure taken and modified from Bryan *et al.*[84]

Thus, the main biological role of WDR5 seems to be non-epigenetic.[82] The mapping of WDR5s' localization on chromatin in MV4-11 cells (bearing one of the most common MLL fusion *AF4*) revealed that WDR5 did not bind to loci of expected developmentally important genes, e.g. the previously described *HOX* genes,[79] but is associated with genes that are connected to protein synthesis (PSGs).[81, 84] Among these genes, approximately 40 out of 80 ribosomal protein genes (RPGs) are WDR5 targets, as well as genes encoding nucleolar RNAs and translation initiation factors.[84] The authors investigated the effects of a small molecule Win site inhibitor **C6** (and its

negative control **C6nc**) and found that Win site inhibition results in a decreased expression of PSGs, which in turn results in a reduced translational capacity of MV4-11 cells. The imbalance and deficiency of ribosomal subunits was associated with nucleolar stress response and resulted in p53-dependent cell death, as illustrated in the proposed mechanism in **Figure 7**. So, the sensitivity of MLL-fusion leukaemia cells to Win site inhibition results from their tendency to retain p53.[114] Also, MLL-fusion oncoproteins tend to drive ectopic protein synthesis as part of their tumorigenic program and are therefore triggered by Win site inhibition.[84, 115]

Figure 7: Proposed mechanism of Win site inhibition by Aho *et al.*: **(left)** WDR5 binds with its Win interaction site to the transcription start site (green arrow) at genes relevant for protein synthesis to ensure balanced production of ribosomal subunits, nucleolar and translation factors. **(right)** Inhibition ("i") of the Win site displaces WDR5 from chromatin. This results in reduced PSG expression, causing an imbalance of ribosomal subunits. This failsafe mechanism induces nucleolar stress and p53-dependent cell death. Figure modified from Aho *et al.*[82]

Bryan *et al.* continued the investigation of the WDR5 mechanism by examining different mouse and human cancer cell lines.[84] Their results showed that a conserved set of 94 genes were bound by WDR5 and encoded proteins involved in translation processes, including PSGs and RPGs.[84] In conclusion, the expression of PSGs was stated as a general regulatory function of WDR5 and can be influenced by Win site inhibition. Furthermore, they found that cell lines that tend to retain p53[114] – similar to MLL-fusion oncogenes – are sensitive to Win site inhibition.[84] Consistent with this, small molecule inhibition reduced MYCN-amplified, p53 wild-type neuroblastoma cells.[84, 114] Beside just inhibiting enzymatic function of WDR5, the authors performed WDR5 depletion experiments to gain insights into the phenotypic consequences of Win site functions by using the dTAG approach in neuroblastoma cells.[84] Consistent with Win site inhibition, depletion also

indicated that the predominant role of WDR5 is to regulate expression of PSGs, as shown in **Figure 8**. However, slight differences in the biological clustering of the two different approaches have been observed, e.g. WDR5 depletion has more widespread effects on neuronal differentiation, while inhibition showed enhanced effects on the expression of genes linked to cell cycle.[84]


Figure 8: WDR5 phenocopies by WIN site inhibition and WDR5 depletion. **(a)** Immunoblotting for WDR5 in **(top)** LoVo or **(bottom)** K562 cells in which endogenous WDR5 is treated by the Win site inhibitor **C6** or negative control **C6nc**. GAPDH serves as loading control. **(b)** Immunoblotting for WDR5 in CHP-134 cells in which endogenous WDR5 is depleted by the dTAG (dTAG47) approach. GAPDH serves as loading control. **(c)** Top GO enrichment categories for genes repressed by inhibtion and depletion (common repressed), induced by inhibtion and depletion (common induced), repressed by inhibition but not by depletion (inhibition repressed), induced by inhibition but not by depletion (inhibition induced), repressed by depletion but inhibtion (depletion repressed) and induced by depletion but inhibtion (depletion induced). Numbers to the right show genes number in each category. Figure taken and modified from Bryan *et al.*[84]

In addition to the similarities in regulating PSG expression, the differences indicate that not all functions of WDR5 might be disabled by Win site blockade.[84] All in all, the surprising findings of the non-epigenetic mechanism of action highlights again the moonlighting abilities of WDR5.[102] Taking the surprising findings that WDR5 influences non-epigenetic processes as well as the association of oncogenic drivers on both binding sides of WDR5, indicate that a classical inhibitor approach may have limited success in studying the overall effects of WDR5 on cellular processes. Therefore, Proteolysis targeting chimeras (PROTACs) that induce protein degradation instead of inhibiting the enzymatic function, are an elegant way to drug a cellular multitasker like WDR5.[102]

1.4 Proteolysis targeting chimera

Proteolysis-targeting chimaeras (PROTACs) are heterobifunctional molecules containing two different ligands: one warhead for the protein of interest (POI) and a second ligand that binds to an E3 ubiquitin ligase.[116-117] Both ligands are bridged by a chemical linker. The heterobifunctional molecule can create proximity between both proteins,[116] as shown in **Figure 9**, and induce formation of a ternary complex. The ubiquitin transfer from the E2 enzyme to the protein of interest leads to proteasomal degradation and release of the small molecule which can enter a new cycle of target protein degradation (TPD).[116-117]

Figure 9: Mechanism of action (MoA) of proteolysis targeting chimeras (PROTACs). **(top)** Schematic structure of a heterobifunctional molecule, also called PROTAC. **(bottom)** A PROTAC mediates proximity between an E3 Ligase and the target protein. Ubiquitin transfer results in proteasomal degradation of the target protein and the recovery of the PROTAC molecule. Figure taken from Gu *et al*.[118]

PROTACs expand the toolbox of chemical matter by redirecting the activity of the Ubiquitin-Proteasome-System.[119] Contrary to the occupancy-driven binding event of small molecule inhibitors, PROTACs rely on an event-driven mechanism of action, making them attractive for undruggable proteins (like transcription factors)[120] or proteins with scaffolding functions.[112, 121] Due to the different MoA, PROTACs harboring a weak affinity ligand for the target protein can also result in an effective binder.[122-123] In comparison to nucleic acid-based approaches that suppress protein synthesis, PROTAC-mediated degradation works independently from protein half-life times.[124]

Ubiquitin transfer to ε-amino function of lysine residues is catalyzed by three enzymes: the ubiquitin-activating enzyme E1, the ubiquitin-conjugating enzyme E2 and the ubiquitin ligase E3. In an ATP-dependend reaction, the E1 enzyme attaches ubiquitin through a reactive thioester bond.[125] In the next step os the cascade, the E1 transfers the ubiquitin to the E2 enzyme.[125] The E2 enzymes determine which type of ubiquitin chain is made.[125] In general, polyubiquitin chains can be linked through seven lysines in ubiquitin (K6, K11, K27, K29, K33, K48 and K63).[125] Together

with the E3 enzyme that determines substrate specifity, the E2 transfers the Ubiqutin chains directly or indirectly to the target protein.[125] The role of each enzyme within the ubiquitination process is reflected in the existence of over 600 different E3 ligases, while there are 30 – 50 different E2s and only two E1s and encoded in the human genome.[125-126]

E3 ligases can be divided into HECT, RING and HECT-RING-hybrids.[127] The difference between HECT and RING E3 ligases lies in the ubiquitin transfer to the substrate: HECT E3s receive ubiquitin from E2 enzymes and catalyze the transfer direct to the target protein, while RING E3s associate with E2s and the target protein to mediate the transfer.[127] Also RING E3s can function as monomers, dimers or multi-subunit protein complexes.[127] Among the multi-subunit E3s, the Cullin-RING Ligases (CRLs) are the largest E3 ligase family. Each E3 is composed of a modular E3 core containing specific Cullin proteins (CUL1, CUL2/5, CUL3, CUL4) and RBX1 (RING-box1 proteins) and different substrate specifity modules (e.g., Skp1, EloB/C, and DDB1).[127] In PROTAC technique, the substrate receptor of the E3 ligase is addressed by the heterobifunctional molecule. With growing popularity of PROTACs, several E3 ligases have been addressed with small molecules: to date, the E3 ligases MDM2,[128] IAP,[129] RNF4,[130] βTRCP,[131] parkin[132] and DCAF16[133] are druggable with potent ligands. The most prominent and frequently used E3 ligases are Cereblon (CRBN) and the Von-Hippel-Lindau (VHL) protein.[134-137] The model of a crystal structure of the CRL4^{CRBN} E3 ligase is shown in **Figure 10**,[137] to get a better visibility of the multi-domain complexes and their druggable receptor subunit. The ligand thalidomide addresses the E3 ligase CRBN and rose tragic prominence by being administered in the 1950s as pharmaceutical drug "Contergan" to pregnant women, but has revived as PROTAC component in cancer treatment to date.[138] The binary affinity to CRBN is rather moderade (10 µM),[139] but sufficient for inducing degradation on various targets, while literature-known and optimized ligands of the other popular E3 ligase VHL display nanomolar potencies (185 nM).[140] Similar to CRL4^{CRBN} E3 ligase, the VHL E3 ligase contains a CUL2 and RBX1 core subunit, but differs in the adaptor subunits Elongin B and C (EloB/ C) as well as the VHL receptor.[141]

Figure 10: Model of a crystal structure of the CRL4^{CRBN} E3 ligase in complex with thalidomide. (pdb entry: 4a0k and 4ci3).[137] Thalidomide (green) binds to Cereblon (CRBN, blue), the recocnition unit of the CRL4^{CRBN} E3 ligase. As substrate specifity module, the DNA-damage binding protein 1 (DDB1, cyan) is associated to CRBN and the core subunits, Cullin 4 (CUL4A, gold) and RING Box protein 1 (RBX1, brown).

Targeted protein degradation (TPD) displays many strengths compared to classical inhibition of the enzymatic activity, as PROTACS do not necessarily need to bind to the active site, thus expanding the sphere of the druggable proteome,[119] and they can act in a catalytic manner which allows a substoichiometric dose of the PROTAC.[122] Over the last two decades, TPD has been shown to be a powerful tool for addressing diverse disease-causing proteins. The majority of early studies focused on the development of degraders that utilized well-validated chemical compounds. These PROTACs degraded proteins such as hormone receptors, bromodomains and kinases.[117, 142-144] The androgen receptor degrader ARV-110 and the estrogen receptor degrader ARV-471 are currently the first degrader molecules examined in clinical trials phase 1/2.[143] Apart from hormone receptors, also BET family proteins[145-147] and protein kinases[123, 148-163] – both protein classes involved in oncologic diseases – have been successfully targeted for degradation. Over the past decade growing awareness and popularity of the TPD field led to a broader application system of PROTACs, including multifunctional proteins like SMARCA2[164], TRIM24[165] or tau.[166]

2. Objective

WDR5 is a biologically interesting target because it acts as a scaffolding subunit to ensure stability and function of KMT complexes,[83] it recruits the transcription factor MYC to chromatin[103] and it regulates the gene expression of ribosomal subunits.[84] Targeting WDR5 function has been shown to be a promising approach for inhibiting leukemia (MLL-rearranged) and neuroblastoma (MYC-dependent) cell growth by inducing p53-dependent apoptosis. WDR5s' role as conserved regulator of protein synthesis genes is also likely to play a role, as increased ribosome activity is common in cancers.[82]

Both interaction sites of WDR5 are associated with oncogenic drivers, so an inhibition of one binding site may have limited success. Instead, molecules that induce degradation of the entire protein offer a perspective to fully understand WDR5s' impact. This work describes the design and synthesis of WDR5 degrader molecules and their biological evaluation.

Literature-known WDR5 ligands

The aim of targeting WDR5 with small molecules has been successfully achieved by various groups with different chemical scaffolds. To date, most efforts have been made to target the Win site of WDR5. As shown in **Scheme 1**, several chemical motifs have been developed to bind to the to this site: while the chemical probe **OICR-9429** by Grebien *et al*.[83, 93] and **DDO-2117** by Li *et al*.[94] incorporated a methyl-piperazine scaffold, the later developed WDR5 ligands by Wang *et al*.[167] and **C6** by Aho *et al*.[81] used pyrroloimidazole and imidazolimine-based scaffolds. All chemical groups mimic the consensus sequence 'ARA' that is contained in the peptide sequence of the interaction partners of WDR5 such as the SET/MLL family.

Scheme 1: Chemical structures of WDR5 ligands. As arginine mimic, either **(top)** piperazine-based[83, 94] or **(bottom)** imidazole-based[81, 167] ligands can be used for WDR5 Win site inhibition.

All published Win site ligands showed excellent binding affinities to the WDR5 protein, with **OICR-9429** showing the weakest affinity with 98 nM *in vitro* and 1 μM affinity *in cellulo*.[83, 93] The second piperazine-based WDR5 ligand **DDO-2117** displays a cellular affinity of 7.6 nM.[94] The two pyrroloimidazole based scaffolds displayed a higher affinity[167] than the piperazine scaffolds and bound slightly deeper into the Win pocket. The recently published ligand **C6** showed an even stronger binding affinity in the picomolar range (K_d: 0.1 nM).[81] Beside ligands that bind to the Win site of WDR5, several ligands have also been published that show nanomolar affinity to the WBM site.[168] They were able to disrupt WDR5 and MYC protein protein interaction, although high doses (50 μM) were required to observe the desired effect, suggesting off-target toxicity effects.[168]

WDR5 small molecule antagonist OICR-9429

The small molecule **OICR-9429** was developed in 2015 and is the first small molecule to target WDR5. Its pharmacological activity has been shown in various cancer cell lines *in vitro*, thereby inhibiting cancer growth of MLL1-rearranged and C/EBPa mutant leukemias, neuroblastoma, and breast cancers.[83, 85, 93, 106, 114]

OICR-9429 interacts with the WDR5 Win site, as depicted in **Figure 11**: the methyl-piperazine moiety binds deep into the binding pocket and interacts via a waterbridge with the carbonyl function of the Cystein 261 backbone. A second waterbridge-mediated interaction is observed between the nitrogen of the Cystein 261 backbone and the carbonyl oxygen of the (trifluoromethyl)nicotinic acid moiety. Further interactions involve the two nitrogen atoms of the **OICR-9429** amide functions which form bonds with the polar amino acids of Serine 91 and Aspartic acid 107. In addition to the observed polar interactions, the Win site contains many non-polar amino acids, e.g. several benzyl systems of Phenylalanine 133 or Tyrosine 191, that facilitate π-stackings of the biaryl moieties of **OICR-9429** and enhance the interaction.

Figure 11: WDR5 Win site (grey) interaction of **OICR-9429** (pink): two water bridge-mediated interactions between the CYS261 backbone and the Methylpiperazine moiety, respectively, the carbonyl function of the amide function anchor the small molecule in the Win site binding pocket. Further interactions between the amine of the amide bonds of the (Trifluoromethyl)nicotinic acid and the amino acid residues of SER91 and ASP107 provide additional affinity. The **OICR-9429** biaryl system is stabilized by non-polar, aromatic residues like PHE133 and TYR191 (pdb entry: 4ql1).[83]

Summed up, all WDR5 Win site ligands demonstrate therapeutic effects and contribute to the studying of the biological functions of WDR5. The effects of WDR5 Win site inhibition by the **OICR-9429** or **C6** were described in various studies in the previous chapters, so the following chapter will focus on the modification of the the published ligands into heterobifunctional molecules.

PROTAC design strategy

At the beginning of the project, only the piperazine and the pyrroloimidazole-based inhibitors were known, while the high affinity imidazolimine inhibitor **C6** was published later by Aho *et al*. Thus, the picomolar affine ligand **C6** was not incorporated into PROTAC development. Furthermore, the arginine-mimicking motif imidazolimine of **C6** hindered the synthesis of PROTAC molecules. The pyrroloimidazole-derived degraders were synthesized and characterized as a side project in the Master theses of Janik Weckesser and Dominic Löw, and are therefore only briefly explained in this work. Taken together, the synthetic work focused on WDR5 PROTACs containing predominantly the **OICR-9429** and marginally the **DDO-2117** inhibitors. During biological evaluation, both PROTAC types were compared. As shown in **Figure 12**, the two distinct scaffolds have different exit vectors of the Win binding pocket. This variation of the exit vectors was used to develop two subsets of PROTACs in order to increase the possibility of successful ternary complex formation.

OICR-9429
piperazine based WDR5 ligand

pyrroloimidazole based ligand

Figure 12: Exit vectors out of the WDR5 Win site binding pocket. **(top, left)** Side view of crystal structure overlay of WDR5 surface (light grey) with WDR5 ligands **OICR-9429** (pink; pdb entry: 4ql1) and a

pyrroloimidazole-based ligand from Wang *et al*. (blue; pdb entry: 6dak). **(top, right)** Top view of overlayed crystal structures of pyrroloimidazole and **OICR-9429** ligand. The different exit points are marked as red spheres and show the attachment points of the designed degrader series (pdb entries: 4ql1 and 6dak).[83, 167] **(bottom)** Chemical structures of the exit points of the pyrroloimidazole and the **OICR-9429** derived degraders. The red marked carbon atoms indicate the attachment points for PROTAC design.

The chosen exit points differ in the mentioned angle, but also in the relative height: the **OICR-9429** was modified to exit the binding pocket, almost at the end of the Win site on top of the surface, while the linker attachment point of the pyrroloimidazole-based inhbitior was set deeper in the binding pocket to create a different exit vector. **Scheme 2** shows a schematic drawing on how the PROTAC building blocks need to be connected to form a heterobifunctional molecule.

Scheme 2: Schematic drawing of the chemical structures of the heterobifunctional molecules. Both WDR5 ligand scaffolds (yellow) are connected to different linkers (red) and different E3 ligase ligands (blue). As representative E3 ligase ligands, the upper ligand is Pomalidomide that addresses the E3 ligase Cereblon, and the ligand below is VHL that addresses the E3 ligase Von-Hippel-Lindau. The dotted lines represent the bonds that need to be formed between the building blocks.

3. Results and Discussion

3.1 Retrosynthetic approach

Scheme 3 shows the retrosynthetic approach for modifying the **OICR-9429** ligand to suitable ligands for linker attachment. In contrast to the pyrroloimidazole scaffold, the π-stacking of the **OICR-9429** Biaryl system is suitable to maintain affinity (as seen in the crystal structure in **Figure 11**), so the linker was attached on top of the biaryl system, resulting in linker exposure on the WDR5 surface (as indicated in **Figure 12**). To reduce steric clashes with the linker and to reduce the molecular mass of the target compound, the originally methyl-morpholino ring of **OICR-9429** was not incorporated into synthesis.

Scheme 3: Retrosynthetic approach for addressing WDR5 with **OICR-9429** derived scaffolds.

3.2 Synthesis route for OICR-9429 modified WDR5 ligands (6a-d)

According to **Scheme 3**, several WDR5 ligands (**6a-d**) (with different benzoic acid motifs and aromatic systems at the exit site) were synthesized. The synthesis route is shown in **Scheme 4**: educts (**1**) and (**2**) formed intermediate (**3**) in a nucleophilic aromatic substitution. The reduction reaction of the aromatic nitro group lead to intermediate (**4**) which was coupled via a Suzuki-Miyaura cross coupling to yield either a biaryl system of a benzene-indole system (**5a**) or two benzenes (**5b**). The benzene-indole biaryl system was chosen due to a publication from Getlik *et*

al. that showed improved affinity upon using that scaffold.[93] To generate affinity to WDR5, an amide coupling reactions of the primary amine (**5a,b**) with the various benzoic acids were carried out to form the final modified ligands for PROTAC development (**6a-d**). The *in situ* deprotection resulted in a free carboxylic acid or a free amine function of the indole that served as attachment point. The modified ligands were then connected to various E3 ligase linkers.


Scheme 4: Synthetic procedure to obtain WDR5 ligands (**6a-d**). a) DIEA, EtOH, 80 °C, 16 h; b) Zn, NH₄Cl, Dioxane/ water (3/1), rt, 30 min; c) Boronic acid, XPhos Pd G3, NaHCO₃, Dioxane/ water (3/1), 85 °C, 16 h; d) **6a**: Carboxylic acid, HATU, DIEA, DMF, rt, 16h or **6b-d**: 1. Carboxylic acid, SOCl₂, CH₂Cl₂/ ACN (1/1), 50 °C, 3 h; 2. pyridine, CH₂Cl₂/ ACN (1/1), 50 °C, 16h.

A detailed synthetic description of the complete process follows below.

Description of synthesis steps a) and b)

In the first part of the synthetic route, the precursor 5-bromo-2-(4-methylpiperazin-1-yl)aniline (**4**) was synthesized. The molecule was obtained in a two-step synthesis as shown in **Scheme 5**. The two starting materials 4-Bromo-1-Fluoro-2-Nitrobenzene (**1**) and 1-Methylpiperazine (**2**) reacted in a nucleophilic aromatic substitution reaction to 1-(4-bromo-2-nitrophenyl)-4-methylpiperazine (**3**). In this reaction, the base DIEA was used to scavenge the resulting hydrofluoric acid. The electron density of the aromatic system (**1**) is remarkably reduced due to the three (-I/ -M) substituents, so the piperazine easily substitutes the fluoride atom. Contrary to

nucleophilic substitutions of type 1 or type 2, the S$_N$Ar rate is generally increased when the leaving group is fluorine due to the differences in the energy transition state: the highest energy transition state for this two-step addition-elimination process occurs in the first step which is the rate-determining step. This results in the formation of a high energy Meisenheimer-like complex. The effect of the greater electron withdrawal capacity of the fluorines stabilizes the resulting negative charge on the complex compared to the other halogens. The displacement of the leaving group occurs rapidly and does not affect the overall rate of reaction. The reaction in this work, as well as described in the literature, was carried out under heating (80 °C) for several hours in ethanol and gave excellent yields of 95+% for 1-(4-bromo-2-nitrophenyl)-4-methylpiperazine (**3**). These high yields are also observed in the literature.[93]

Scheme 5: Steps a) and b) to synthesise precursor 5-bromo-2-(4-methylpiperazin-1-yl)aniline (**4**).

In the next step, the aromatic nitro group was reduced to an aniline derivative under mild reduction conditions, using zinc and ammonium chloride in a dioxane/ water mixture. Other reduction attempts that used hydrogen and palladium on carbon failed in terms of product isolation and producd various uncharacterisable by-products. The product (**4**) could be isolated by a variant of the Béchamp reduction, a mild reduction that does not hydrate the aromatic ring system and aromatic-bound halogens. The reaction was carried out by stirring all reactants at room temperature for thirty minutes. Thereby, a discoloration from the orange nitro compound to the bright rose-colored amine was observed and indicated the reaction progress. Dioxane was removed from the reaction solution and the weak acidic water phase was neutralized with sodium bicarbonate. Extraction of the uncharged amine with an organic solvent led to the desired product (**4**) in high purity and excellent yields (with an overall yield of 90%).

Description of synthesis steps c) and d)

Next synthesis steps included the attachment of the second aryl system and the final attachment point for the E3 ligase linker molecule. As shown in **Scheme 6** and **Scheme 7**, both intermediates

(**5a**) and (**5b**) were obtained in a Suzuki-Miyaura cross coupling. In initial experiments, (**5a**) was prepared using Pd XPhos G3 as catalyst and sodium hydroxide in a toluene/ water mixture. Initially, the product was obtained in 28% yield and in subsequent experiments, the system was optimized by varying the catalyst, the base and the solvent. Here, the system that relied on Pd(Ph$_3$)$_4$, potassium carbonate in a toluene/ water mixture achieved the best yield of 43%. The rather modest yield is probably related to the Boc-group of the indole system: by heating at 100 °C for a long period (16-24 h) in a strongly basic environment, a cleavage of the protecting group is possible. The resulting amine is more difficult to isolate in an aqueous environment and thus might explain the low yield. However, when the solvent system was changed to dimethoxyethane, a yield of 41% was also isolated. Experiments carried out in a microwave were not successful.

In contrast to the difficulties in isolating the quantitative amounts of (**5a**), (**5b**) could be obtained in high yields with different systems. The best system for cross coupling used catalyst Xphos Pd G3, sodium hydroxide as base and a toluene/ water mixture. As *tert*-butyl esters are also likely to be cleaved under basic conditions, the amount of water was limited to a minimum (1 mL). However, the other experiments using Pd(Ph$_3$)$_4$, potassium carbonate in a toluene/ water mixture gave a yield of 73%, showing clear favor for product formation of the less reactive *tert*-butylester (**5b**) over the more reactive Boc-protected indole (**5a**).

The next step was the derivatization of the amine (**5b**) to amides (**6a-c**) as shown in **Scheme 6**. As initial experiment, the inexpensive building block 3-methylbenzoic acid was used for establishing the synthesis route. This simple aryl decoration was used in a publication from Getlik *et al*. and showed an affinity to WDR5 of 0.37 µM *in vitro.*[93] For the synthesis of *tert*-butyl 5-(3-(3-methylbenzamido)-4-(4-methylpiperazin-1-yl)phenyl)-1H-indole-1-carboxylate (**6a**), the amide bond formation was carried out by using the uronium salt 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxide hexafluorophosphate (HATU) in the polar, aprotic solvent *N,N*-Dimethylformamide. The coupling reagent HATU has widely been used for various amide bond formations. A pre-activation of the carboxylic acid with the coupling reagent and DIEA has been shown to enhance the overall reaction speed,[169-170] and resulting in only small amounts of epimers and high yields, even for sterically hindered carboxylic acids/amino acids.[171] The azabenzotriazole scaffold of HATU enables the formation of a highly reactive *NO*-ester *in situ*, and additives such as the thermally unstable and explosive HOBt used in amide bond formation with the popular coupling reagent EDC-HCl, are redundant. The beneficial effect on the enhanced reaction rate can be attributed to the nitrogen atom in 7-position of the azabenzotriazole, which stabilizes the leaving group by its electron withdrawing effect.[172] The nitrogen atom also stabilizes a seven-centered transition state, in which the neighboring-group effect facilitates the

deprotonation and release of the final amide. For amide coupling via HATU, 3-methylbenzoic acid was activated for 20 min with the coupling reagent to form an active ester. Subsequently, amine (**5b**) was dissolved in DMF with an non-nucleophilic base (*N,N*-Diisopropylethylamine, DIEA) and added to the pre-activated reaction solution. The obtained yield of the amide bond formation via HATU of tert-butyl 5-(3-(3-methylbenzamido)-4-(4-methylpiperazin-1-yl)phenyl)-1H-indole-1-carboxylate (**6a**) was 74%.

Scheme 6: Steps c) and d) to synthesize piperazine-based WDR5 ligands *tert*-butyl 5-(3-(3-methylbenzamido)-4-(4-methylpiperazin-1-yl)phenyl)-1H-indole-1-carboxylate (**6a**), *tert*-butyl 5-(3-(5-

amino-2-chloro-4-fluoro-3-methylbenzamido)-4-(4-methylpiperazin-1-yl)phenyl)-1H-indole-1-carboxylate (**6b**) and *tert*-butyl 5-(4-(4-methylpiperazin-1-yl)-3-(6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamido)phenyl)-1H-indole-1-carboxylate (**6c**).

Scheme 7: Steps c) and d) to synthesize the piperazine-based WDR5 ligand *tert*-butyl 4'-(4-methylpiperazin-1-yl)-3'-(6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamido)-[1,1'-biphenyl]-4-carboxylate (**6d**).

In contrast to WDR5 ligand (**6a**), the amide bond formation for (**6b-d**) required more drastic reaction conditions to make the coupling reaction feasible. This is due to the strongly deactivated carboxylic acid on the Trifluormethyl-pyridinone ring. Initially, *tert*-butyl 5-(4-(4-methylpiperazin-1-yl)-3-(6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamido)phenyl)-1H-indole-1-carboxylate (**6c**) was aimed to be synthesized by using the coupling reagent HATU, but no product formation between the deactivated carboxylic acid and the unreactive aniline (**5a**) was observed. As shown in **Scheme 6** and **Scheme 7**, activation of the carboxylic acid with an excess of thionyl chloride, to form a more electrophilic acyl chloride, led to successful product formation. Solvents were varied from methylene chloride to mixtures of methylene chloride and acetonitrile to obtain a better solubility of the carboxylic acid, and pyridine was added as a base. Usually, the acyl chloride was prepared first, and the excess of thionyl chloride was removed under vacuum. The crude product was then re-dissolved in a methylene chloride and acetonitrile mixture. Subsequently, amines (**5a**) or (**5b**) were dissolved with pyridine in methylene chloride and added to the crude acid chloride. The reaction solution was stirred overnight under heating (50 °C) and product formation was observed by TLC and ESI-MS. The purification was carried out on a reverse-phase column chromatography system to obtain excellent yields of 80+ % for 5-amino-2-chloro-4-fluoro-3-methylbenzene derivate (**6b**) and high yields for the derivatives (**6c**) and (**6d**).

For molecules (**6c**) and (**6d**), two side products were isolated and characterized by ESI and ^{1}H-NMR. Both side products result from a second reaction between the amine and the acyl chloride and were obtained in a yield of approx. 25%. Additionally to the isolated by-products, a small

fraction of amine (**5a**) or (**5b**) was isolated after purification, indicating a partly degradation of the acyl chloride due to minimal traces of oxygen. The observation of side product formation occurred in experiments where the solid amines were added to the suspended acyl chloride. Herein, the reaction conditions were modified and amine (**5a**) or (**5b**) was pre-dissolved in DCM, before being added to the acyl chloride. This resulted in higher yields of the desired product.

side product of (**6c**)   side product of (**6d**)

Scheme 8: Isolated side products of WDR5 ligands (**6c,d**), obtained in yields of approx. 25%.

The final step in obtaining the molecule derived from **DDO-2117**, *tert*-butyl 5-(3-(5-amino-2-chloro-4-fluoro-3-methylbenzamido)-4-(4-methylpiperazin-1-yl)phenyl)-1H-indole-1-carboxylate (**6b**), was a reduction reaction of a nitro group to a primary amine. While reduction with tin chloride or with Hydrogen gas with palladium on carbon were not successful, WDR5 ligand *tert*-butyl 5-(3-(5-amino-2-chloro-4-fluoro-3-methylbenzamido)-4-(4-methylpiperazin-1-yl)phenyl)-1H-indole-1-carboxylate (**6b**) could be obtained in a yield of 25% using zinc and ammonium chloride.

In summary, the overall yield from starting materials (**1**) and (**2**) showed molecule (**6d**) as most favorable product of all four WDR5 ligands, with a total yield of 64% over four reaction steps. As the Suzuki-Miyaura cross coupling step for the WDR5 ligands (**6a-c**) showed a rather moderate yield, the followed-up amide bond formation in good yields could not cover up this reaction step. The resulting overall yields were thus in a signifiable lower range. For molecule (**6a**), an overall yield of 29% was obtained. The same range was observed for molecule (**6c**) that was isolated with 30%. The yield of WDR5 ligand (**6b**) decreased to 9% due to the additional reaction step of the nitro reduction. After the chemical synthesis of these four different WDR5 ligands was achieved successfully, the next step was the biophysical evaluation to determine binding affinity to WDR5.

3.3 Biophysical and biological evaluation of WDR5 ligands (6a-d)

The synthesized ligands (**6a-d**) were tested *in vitro* in terms of their binding affinity by the Differential Scanning Flourimetrie (DSF) assay and for their cell permeability and target engagement using the NanoBRET™ assay. The results of both assays are shown in **Table 2**.

The DSF assay, also called thermal shift assay (TSA), measures the thermal stabilization (ΔT_m) of a protein-ligand complex and can serve as indication for a binding interaction between ligand and protein. This method for validating proteins *in vitro* as well as the NanoBRET™ assay system will be discussed in more detail in the PROTACs evaluation chapter. The DSF method is simple, inexpensive and allows the prediction of a binding tendency of the investigated WDR5 ligands. The unselective and literature-known ligand (**6a**) displayed the lowest shift, and surprisingly molecule (**6b**) also showed a rather moderate thermal stabilization of the WDR5 protein. Ligand (**6c**) showed a thermal stabilization in the range of the high-affinity binder **OICR-9429**, known from literature. The highest thermal stabilization was observed for the WDR5 ligand (**6d**) which showed a significant thermal stabilization ΔT_m of almost 21 K and suggested improved potency towards WDR5.

As the ligands (**6a**) and (**6b**) showed only weak shifts, the NanoBRET™ assay focused on WDR5 ligands (**6c**) and (**6d**). BRET measurements monitor the cellular binding affinity (IC_{50}) of the ligand to the target protein and can indicate the cellular permeability of a compound (a limiting factor for insoluble molecules with a high molecular weight.) WDR5 ligand (**6c**) displayed an affinity of 15 μM, while the **OICR-9429** and ligand (**6d**) showed single-digit micromolar potency towards WDR5. The differences between the parent compound **OICR-9429** and its PROTAC-applicable ligands (**6c,d**) are possibly due to the missing morpholine ring system. The missing morpholine might lead to the observed decreased solubility of the compounds in the NanoBRET™ assay.

Table 2: DSF and NanoBRET[TM] data for WDR5 ligands (**6a-d**). DMSO and **OICR-9429** served as controls. Each measurement was carried out in triplicates to determine the thermal shift (ΔT_m) and the standard deviation (SD) and in duplicates for the cellular affinity (IC$_{50}$). n.d: not determined.

ID	ΔT_m [K]	SD [K]	IC$_{50}$ [µM]
DMSO	0.0	0.2	≥ 50 µM
OICR-9429	13.3	0.1	1.7
6a	1.2	0.1	n.d.
6b	3.5	0.2	n.d.
6c	12.7	0.3	15
6d	20.8	0.6	5.4

Summed up, the data indicate that ligand (**6d**) was the preferred ligand for PROTAC modifications, and thus several degraders were developed – based on (**6d**) with various linker motifs and E3 ligases.

3.4 Synthesis route for OICR-9429 modified WDR5 PROTACs (7a-e), (8a-j) and (9a-c)

Since the WDR5 ligand (**6d**) was found to be the most promising ligand for a degrader synthesis, the corresponding E3 ligase linker molecules were designed to complement the *tert*-butyl ester function of (**6d**). As a corresponding chemical function, a primary amine was chosen. Analogous to molecules (**6a-d**), the amine function had to be protected in order to be spared from interactions in previous reaction steps. As seen in **Scheme 9** and **Scheme 10**, the E3 ligase linker products for the two most commonly addressed E3 ligases Cereblon (CRBN) and Von-Hippel-Lindau (VHL) were generated by amide bond formation. As this reaction occurred in a basic environment, linkers that protected the amine with a *tert*-Butyloxycarbonyl (Boc) group were used as starting material. For the synthesis of the VHL and MDM2 addressing PROTACs, the commercially available ligands were used, while the CRBN-addressing ligand (**L0**) was synthesized in-house. 4-Flouropomalidomide (**L0**) was gained by heating 4-fluoroisobenzofuran-1,3-dione and 3-aminopiperidine-2,6-dione hydrochloride in pyridine overnight. Pyridine served in this reaction as solvent and base. After stirring overnight, product formation, which was monitored by TLC, was moderate. After removal of the pyridine, the reaction mixture was dissolved in water and DCM.

The extraction of the crude product proved to be challenging, as the solution did not separate well in the separator funnel, possibly due to educt residues of 3-aminopiperidine-2,6-dione hydrochloride and a difficult separation of, aqueous and organic layer. In addition, both educts and the product tended to be very polar, which complicated the extraction that had to be carried out at least six times. The organic phases were washed with 1 M HCl to remove pyridine residues and brine to remove water traces. The repetitive extraction process was successful because only the desired product peak was observed on TLC at 254 nm. However, traces of 3-aminopiperidine-2,6-dione hydrochloride were observed when staining the TLC with potassium permanganate. Column chromatography led to isolation of the desired product (**L0**) in high purity as observed by NMR, but with a low yield of 33%. Possible optimizations for this reaction would be a prolonged reaction time with an additional water trap to shift equilibrium towards product formation.

In a subsequent nucleophilic aromatic substitution, the fluorine of (**L0**) was substituted by the free amine of the different Boc-protected linker chains, as shown in **Scheme 9**. Mild reaction conditions were chosen as the Boc protecting group can also be cleaved in a basic environment at high temperatures: the used amount of Hünigs' base was limited to two equivalents. *N*-Methyl-2-pyrrolidon (NMP) was chosen as solvent due to its high polarity. Analogous to the synthesis of the educt (**L0**), the extraction of the very polar molecules had to be repeated frequently to separate the polar products from the aqueous phase. The expectation that the long and thus more hydrophilic [PEG] linker molecules would lead to lower yields, was not observed. E3 ligase linker molecules (**L3**) and (**L4**) gave higher yields (around 50%) than shorter E3 ligase linker products (**L1**) and (**L2**) (around 30%). The best yield was achieved when the aromatic-bridged diamine linker was attached to 4-Flouropomalidomide (**L0**). A possible change of the solvent to, e.g., DMSO, combined with higher heating temperatures, could optimization the nucleophilic substitution.

Scheme 9: Synthesis of E3 ligase ligand pomalidomide (**L0**) and E3 ligase linkers (**L1-L5**) addressing the E3 ligase Cereblon (CRBN).

Beside the immunomodulatory drugs thalidomide, lenalidomide and pomalidomide, which target the E3 ligase Cereblon (CRBN) and are most commonly used for PROTAC design, ligands addressing the E3 ligase Von-Hippel-Lindau (VHL) were also used in this study. The herein used VHL ligand VH032 was commercially available and coupled to different purchasable linker, comprising [PEG] (**L6-L8**), aliphatic (**L9-L13**) or aromatic linker (**L14**) motifs, as shown in **Scheme 10**. The amide formation was carried out using HATU as coupling reagent and Hünigs' base in DMF, and the desired products were isolated in high purity and yields ranging from 30% to 87%. The lowest yields were observed when the heaviest linker moieties was attached to the VHL ligand, namely the [PEG]$_4$ moiety. The steric complexity could potentially be compensated by increasing the electrophilicity of the carboxylic acid, e.g. by generating acyl chlorides. When using acyl chlorides, attention should be paid to the protecting groups: the very reactive reagent is able to cleave Boc and *tert*-butylester groups under certain conditions.[173] In summary, six of nine E3 ligase linkers were obtained in very good/ satisfying yields and with high purity as determined by NMR and HPLC.

Scheme 10: Synthesis procedure of E3 ligase linkers (**L6-L14**) addressing the E3 ligase Von-Hippel-Lindau (VHL).

To generate the heterobifunctional molecules, the deprotection of the *tert*-butylester function of WDR5 ligand (**6d**) and the deprotection of the Boc-protected amine of the linkers (**L1-L14**) was carried out *in situ* with a mixture of trifluoracetic acid (TFA) in dichloromethane. Both components were stirred separately for a period between 30 min and 2 h, and the deprotection was monitored by TLC. Due to the stable ester bond, the deprotection of the *tert*-butyl ester of (**6d**) occurred slower than the deprotection of the amine E3 ligase linkers (**L1-L14**). After removing the solvent and excess TFA, both active species were transferred in one flask and the amide reaction was carried out by using HATU in DMF. Product formation was observed within a few hours by TLC and TLC-ESI. The reaction was quenched with water. To remove the solvent DMF and the base DIEA, saturated sodium bicarbonate was added, and the solution was extracted with dichloromethane or ethyl acetate. After evaporation, the crude product was purified by a preparative HPLC system. The isolated products were extracted with sodium bicarbonate to remove the TFA that was used as additive in HPLC solvents. In this way, the isolated heterobifunctional molecules (**7a-e**), (**8a-j**) and (**9a-c**) were obtained. The synthetic steps of the **OICR-9429** based PROTAC molecules that

address CRBN are shown in **Scheme 11**. **Scheme 12** shows the chemical structures of the synthesized PROTACs (**8a-j**) addressing the VHL E3 ligase.

Scheme 11: Synthesis scheme of WDR5 degraders (**7a-e**) based on ligand (**6d**) addressing E3 ligase CRBN. The type and nature of the linker is indicated in blue.

The generally higher yields of the CRBN-addressing PROTACs (**7a-e**) up to 86% might be due to their lower molecular weight and thus their more small molecule-like character that simplified laboratory handling. Furthermore, these PROTAC possessed a remarkable yellow colour which visually simplified the extraction and purification process. In contrast to the CRBN-addressing PROTACs, the more peptide-like structured VHL PROTACs and MDM2 PROTACS possessed a higher molecular weight and thus less-favored properties. Nevertheless, the highest isolated yields were, respectively, 67% for the VHL-addressing PROTAC (**8d**) and 25% for the MDM2-based degrader (**9b**).

Scheme 12: Chemical structures and obtained yield of WDR5 degraders (**8a-j**) addressing the E3 ligase Von-Hippel-Lindau (VHL). The synthesis steps start from intermediate (**6d**). The type and nature of the linker is indicated in blue.

For the synthesis of the MDM2 targeting PROTACs (**9a-c**), the synthesis route was changed as the MDM2 ligand Idasanutlin is very expensive. Thus, the linker was directly attached to ligand (**6d**) and then coupled to idasanutlin in an amide formation reaction, as shown in **Scheme 13**. The obtained [PEG]$_1$-conjugated intermediate (**6e**) was obtained in a good yield and high purity. The more polar intermediate (**6g**) showed a lower yield. The low yield of intermediate (**6f**) is likely due

to the reduced reactivity due to steric constraints. After isolating the intermediates, all three molecules were coupled to the carboxylic acid function of Idasanutlin. As Idasanutlin itself is a heavyweighted molecule, the coupling reaction was hampered by the steric constraints. Due to the incomplete reaction profile, the three MDM2-addressing PROTACs were isolated in low yields, but showed a satisfying purity (> 95%). Further reaction optimizations should focus on increasing the electrophilicity of Idasanutlin by attempting different coupling reagents.

Scheme 13: Synthesis route of WDR5 degraders (**9a-c**) addressing the E3 ligase MDM2. The synthesis steps start from intermediate (**6d**). The type and nature of the linker is indicated in blue.

In adittion to the PROTACs (**7a-e**), (**8a-j**) and (**9a-c**), which used ligand (**6d**), degraders based on ligands (**6a**) and (**6c**) were also to be synthesised, but this failed due to difficulties in purification. It is likely that the two reactive position on the indole ring – the nitrogen atom in 1-position as well as the carbon atom in 3-position – performed a nucleophilic attack of the E3 ligase linker active ester, thereby generating two different linked PROTACs in low yields. These experiments have been discarded.

All in all, a subset of heterobifunctional molecules was synthesized successfully. The generated PROTACs covered various linker length and types which is crucial for degradational activity. Also, a variation of addressing E3 ligase ligands was imbedded into the synthesis. Thus, the 18 generated PROTACs allow a structure-activity-relationship (SAR) study on WDR5 degradation.

3.5 Synthesis of pyrroloimidazole derived degraders (**16a,b**) and (**20a-g**)

This chapter briefly summarizes the synthesis efforts of two master theses by Dominic Löw and Janik Weckesser. The synthetic schemes for generating pyrroloimidazole based molecules addressing either CRBN or VHL were slightly modified from the work of Wang *et al*.,[167] and are shown in **Scheme 14** and **Scheme 15**. Analogous to the published synthesis, both synthesis routes started with educt (**10**) that underwent a Vilsmeier-Haack-like intramolecular cyclisation to form aryl bromide (**11**). Intermediate (**11**) reacted with (3-cyano-4-methoxyphenyl)boronic acid in a Suzuki-Miyaura cross coupling to give the biaryl system (**12**). Reduction of the nitrile group led to amine (**13**) which was then coupled with the according carboxylic acid to yield the amide (**14**). The mild ether deprotection of intermediate (**14**) by Borontribromide led to the free phenol (**15**). To generate the CRBN-addressing PROTACs, the E3 ligase linkers with a free hydroxy moiety were connected via a Mitsunobu reaction, resulting in the products (**16a,b**).

Scheme 14: Synthesis of WDR5 degraders (**16a,b**) addressing the E3 ligase CRBN: a) POBr$_3$, ACN, MW, 70 °C, 2 h; b) (3-cyano-4-methoxyphenyl)boronic acid, XPhos PdG3, NaOH, THF/H$_2$O, 80 °C, 21 h; c) LiAlH$_4$, THF, 60 °C - rt, 21 h; d) 3,4-dichlorobenzoic acid, HATU, DIEA, DMF, rt, 16 h; e) 1. BBr$_3$, CH$_2$Cl$_2$, -78 °C – rt, 21 h; 2. NaOH/H$_2$O; f) Linker-OTs, K$_2$CO$_3$, DMF, 70 °C, 16-22.5 h or DEAD, PPh$_3$, -10 °C to rt, 16 h.

Beside the two CRBN-addressing PROTACs (**16a,b**), PROTACs with the pyrroloimidazole-based scaffold addressing the VHL E3 ligase were additionally synthesized. For the synthesis of the VHL addressing PROTACs, the previously described amine (**13**) was coupled to 2-(3,4-dichlorophenyl)acetic acid to form intermediate (**17**). The methoxy ether of intermediate (**17**) was cleaved under mild conditions to the corresponding phenol (**18**) and was then reacted in a nucleophilic substitution reaction with the tosylated linker derivatives to yield intermediates (**19a-**

g). The deprotection of the *tert*-butyl ester (**19a-g**) was carried out in an acidic environment, and a subsequent amide bond formation with the VH032 yielded the VHL-based PROTACs (**20a-g**).

n = 1   **19a**
n = 2   **19b**
n = 3   **19c**
n = 4   **19d**
n = 5   **19e**
n = 6   **19f**
n = 7   **19g**

PEG linker chain
n = 1   **20a**
n = 2   **20b**
n = 3   **20c**
n = 4   **20d**
n = 5   **20e**
n = 6   **20f**
n = 7   **20g**

Scheme 15: Synthesis of WDR5 degraders (**20a-g**) addressing the E3 ligase VHL: a) 2-(3,4-dichlorophenyl)acetic acid, EDC, HOBt, DIEA, DMF, rt, 16 h; b) 1. BBr_3, CH_2Cl_2, -78 °C – rt, 21 h; 2. $NaOH/H_2O$; c) Linker-OTs, K_2CO_3, DMF, 70 °C, 16-22.5 h; d) 1. TFA/ CH_2Cl_2 (1/1), rt, 1.5 h; 2. HATU, DIEA, DMF, VHL hydrochloride linker, rt, 3-18 h. The type and nature of the linker is indicated in blue.

The chemical and biological results have already been discussed and published in two Master theses. Thus, the pyrroloimidazole scaffold molecules (**20a-g**) are discussed here only as references.

3.6 Biophysical Evaluation of WDR5 PROTACs (7a-e), (8a-j) and (9a-c)

In vitro characterization of PROTAC molecules

To gain a first insight into the binding affinity of the synthesized PROTACs to WDR5, differential scanning fluorimetry (DSF) measurements were performed. The obtained temperature shifts ΔT_m are listed in **Table 3**. The small molecule antagonist (**OICR-9429**) was used as a reference and assay validation, as previously described in the literature.[83] Beside DMSO that served as reference compound, the inhibitors Idasanutlin, VH032 and a modified thalidomide were included in the experiments. All E3 ligase ligands alone did not result in significant temperature shifts of WDR5, suggesting that the E3 ligase moieties itself do not bind to the protein-of-interest. The comparison of intermediates of the MDM2 targeting PROTACs (**6e-g**) showed a substantial decrease in temperature shifts: while the parent compound (**6d**) showed an initial ΔT_m shift of more than 20 K, the [PEG] modified intermediates (**6e-g**) only achieved a ΔT_m value of 4-5 K. It is likely that the bulky *tert*-Butylester of ligand (**6d**) performs additional interactions on the hydrophobic surface of WDR5 which in turn gets lost by linker attachment. In general, the ΔT_m data of the measured PROTACs correlated with the nature of the introduced linker: mostly aliphatic-bridged PROTACs (**8e-i**) showed weaker thermal stabilization compared to more polar and thus more soluble [PEG]-bridged PROTACs like (**8a**) or (**8c**). Comparison of similar heterobifunctional molecules that have the same linker chain but address different E3 ligases, e.g. (**7a**), (**8a**) and (**9a**), showed that the shortest [PEG]-linker ([PEG]$_1$) resulted in higher melting temperature shifts than PROTACs containing longer [PEG] chains. Many PROTACs displayed a ΔT_m shift similar to the (**OICR-9429**) ligand and thus indicated to be potent *in vitro* binders. Only the MDM2 addressing PROTACs (**9a-c**) lost their affinity towards WDR5, possibly due to their large size and associated less favorable physiochemical properties or steric constrains.

Table 3: Thermal shift experiments of **OICR-9429** derived molecules (**6d-g**), degraders (**7a-e**), (**8a-j**), (**9a-c**) and the negative controls (**nc_VHL**) and (**nc_WDR5**). ΔT_m: thermal shift change; SD: standard deviation. As negative controls, DMSO, Thalidomide, Idasanutlin and VH032 were used. As positive control **OICR-9429** was used. Table adapted with permission from "Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) Degraders by Dölle, Adhikari *et al*.[174] Copyright 2021 American Chemical Society.

ID	Linker	E3 Ligase	ΔT_m [K][a]	SD [K][a]
DMSO	-	-	0.0	0.3
OICR-9429	-	-	13.3	0.1

Table 3. (continued)

VH032	-	VHL	-0.4	0.1
Thalidomide	-	CRBN	0.0	-0.1
Idasanutlin	-	MDM2	-0.2	0.1
6d	-	-	20.8	0.6
6e		-	5.7	0.4
6f		-	4.1	0.6
6g		-	4.2	0.7
7a		CRBN	13.6	0.2
7b		CRBN	12.7	0.3
7c		CRBN	9.0	0.5
7d		CRBN	11.9	0.3
7e		CRBN	12.5	0.6
8a		VHL	15.3	0.2
8b		VHL	7.7	0.5
8c		VHL	12.5	0.2
8d	-	VHL	15.6	0
8e		VHL	11.0	0.3
8f		VHL	10.4	0.7
8g		VHL	13.2	0.1
8h		VHL	9.7	2.8
8i		VHL	3.5	0.4
8j		VHL	14.0	0

Table 3. (continued)

9a	[structure: $-(CH_2CH_2-O)_1-$]	MDM2	0.9	0.2
9b	[structure: $-(CH_2CH_2-O)_7-$]	MDM2	0.3	0.4
9c	[para-substituted benzyl linker]	MDM2	0.7	0.2

[a]Thermal shift ΔT_m values given are the mean of triplicate measurements. DSF assays were performed at 2 µM protein concentration and a final compound concentration of 10 µM.

Since the DSF assay only indicates a binding tendency and cannot state a correct binding affinity (K_D) value, the binding affinities of the synthesized PROTACs (**7a**), (**8a**) and (**8e-j**) to WDR5 were determined by isothermal titration calorimetry (ITC). This biophysical method detects the released or consumed heat along a binding event where the ligand interacts with the protein under a constant temperature. The biophysical properties are listed in **Table 4** and titration curves of aliphatic-bridged PROTACs (**8g,i**) are shown in **Figure 13**. All other binding curves can be found in the **Experimental Chapter 7**. The CRBN-based PROTAC (**7a**) as well as the VHL-based PROTAC (**8a**) were chosen for ITC measurements due to their identical linker structure, their comparably low molecular weight and because they displayed the highest ΔT_m value within their cluster. The comparison showed that binding affinity did not correlate well with ΔT_m shifts, as the CRBN-addressing PROTAC (**7a**), which showed less thermal stabilization, had a three times higher affinity for WDR5 than the highly thermal stabilized VHL-addressing PROTAC (**8a**). Also, the DSF measurements revealed that PROTACs (**8e-i**) showed an unexpected variety of thermal stabilization with ΔT_m shifts ranging from 3.5 K to 13 K. These ligands were therefore chosen for further characterization by ITC. All examined PROTACs (**8e-i**) showed binding affinities in a low nanomolar range and did not correlate well with the ΔT_m data. A decrease in solubility was observed for degraders with long aliphatic linker (especially (**8h**) and (**8i**)) that made data collection by ITC challenging. This effect also observed in the titration curves that showed nearly an instant saturation (see titration curve of (**8i**) in **Figure 13**.) Several experimental parameters were changed to obtain titration curves of a higher quality, but nor the use of higher concentrations of PROTAC, neither the reduced injection volume of WDR5 protein resulted in improved titration curves. The limited solubility of these PROTACs complicated the comparison of thermodynamic parameters, and so the thermodynamic data measured on PROTACs containing longer aliphatic and aromatic linkers such as (**8h**), (**8i**) and (**8j**) have to be treated carefully. Despite

all these technical challenges, all heterobifunctional molecules showed excellent affinity to WDR5 in the single- or double-digit nanomolar K_d range.

Figure 13: ITC curves for VHL-addressing PROTACs (**8g**) and (**8i**). The titration curve of (**8i**) shows the limiting solubility of the hexyl-bridged PROTAC within the ITC experiments.

The analysis of the thermodynamic properties of the examined PROTACs in **Table 4** revealed large negative binding enthalpies (-10 to -4.9 kcal/mol). Beside PROTAC (**8a**) that showed a negative entropy change (TΔS) of -0.2 kcal/mol, all other entropy changes were favourable, ranging from +0.7 to +4.5 kcal/mol. Furthermore, enthalpy-entropy compensation was observed for PROTACs with large favourable ΔH values, as shown for molecules (**8a**), (**8f**) and (**8i**): all compounds possessed large negative binding enthalpies of -10 kcal/mol with close to zero entropy changes (-0.2 to 1.1 kcal/mol). On the other hand, compounds like (**8e**) that displayed large positive entropy changes (+ 4.5 kcal/mol) showed small binding enthalpy (ΔH= -6.3 kcal/mol). These thermodynamic compensation mechanisms might be possibly due to water displacement as the polar [PEG]$_1$ linker of PROTAC (**8a**) showed an unfavourable binding entropy change while the aliphatic linker bridged PROTACs showed an increased binding entropy term.

Table 4: Thermodynamic properties of **OICR-9429** derived molecule (**6d**) and degraders (**7a**), (**8a**), (**8e-j**). K_D: dissociation constant; SD: standard deviation; n: stoichiometry; ΔH: enthalpy change ΔS: entropy change. Table adapted with permission from "Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) Degraders by Dölle, Adhikari *et al.*[174] Copyright 2021 American Chemical Society.

ID	K_D [nM][a]	SD [nM][a]	n	ΔH [kcal/mol]	$T\Delta S$ [cal/mol·K]
6d	25	6	1.0	-9.4	0.8
7a	12	4	1.0	-8.1	2.6
8a	41	9	1.0	-10	-0.2
8e	9	2	1.1	-6.3	4.5
8f	6	2	1.0	-10	1.1
8g	18	5	1.1	-7.4	3.2
8h	12	4	1.0	-9.3	1.4
8i	11	3	1.1	-10	0.7
8j	33	5	1.0	-7.9	2.2

[a]K_d values were derived from ITC measurements (carried out as duplicate, except for (**8i**) that was measured in a single measurement) and calculated by assuming a sigmoidal dose–response relationship (four parameters). The errors of the fits were calculated using standard deviation and a confidence interval of 68%.

Summed up, the gained thermodynamic data gave a small insight into the binding mechanism of the different PROTACs and stated the high *in vitro* binding affinity of these large molecules to WDR5. Beside the determination of the binding affinity, the ITC measurements highlighted the value of using orthogonal assay systems. The two assays showed that similar ΔT_m shifts resulted in some cases in very different binding affinities. Another finding was that PROTACs with high ΔT_m shift were not necessarily more affine than PROTACs with a moderate ΔT_m shift. This observation was also observed for the pyrroloimidazole-based inhibitor (**17**) and PROTAC (**20b**) that showed a substantial lower ΔT_m shift of around 4 – 5 K, but the binding affinity measured by ITC was still in a two- to three-digit nanomolar range.

In cellulo characterization of PROTAC molecules

Due to the characteristic large molecular weight of heterobifunctional molecules, cellular permeability can be limiting factor for PROTACs. To address this question, BRET (Bioluminescence Resonance Energy Transfer) experiments were performed to determine the cellular permeability

and potency (IC$_{50}$) of the synthesized PROTACs. The biophysical technique of the proximity-based assay relies on the naturally occurring dipole-dipole energy transfer from a donor enzyme to an acceptor fluorophore. If both interacting partners are in close proximity (less than 10 nM), light emission from the acceptor results in a quantifable signal.[175] The herein developed BRET assay monitored the luminescence of an engineered Nanoluciferase-tagged WDR5 system. N-terminally and C-terminally tagged WDR5 NanoLuc fusion constructs were transfected to HEK293 cells, resulting in an overexpression of the luminescence energy donor. A small molecule-based tracer served as flourescence acceptor. To establish this assay, three BODIPY fluorescent tracer molecules (**21a-c**) based on WDR5 ligand (**6d**) were synthesized. The synthetic procedures of the tracer molecules (**21a-c**) via their intermediates (**6e,h,i**) are shown in **Scheme 16**. The amide coupling of the [PEG] linker chains to intermediates resulted in overall good yields, and subsequent coupling with the *N*-succinimide activated *N*-succinimide activated BODIPY dye also resulted in good yields of the final tracer molecules. Due to the large molecular weight and the high solubility of the [PEG]$_9$-bridged tracer (**21b**) in the aqueous phase, a lower yield was obtained.

Scheme 16: Synthesis of NanoBRET™ tracer molecules (**21a-c**) via intermediates (**6e,h,i**).

In order to determine the best assay system, the generated tracer molecules (**21a-c**) were titrated into HEK293 cells containing the engineered WDR5 NanoLuc fusion constructs. These experiments revealed that the [PEG]$_3$ bridged tracer (**21c**) and the C-terminally tagged Nanoluc-WDR5 construct as most suitable combination for cellular BRET assays, as shown in **Figure 14**.

Figure 14: Cellular permeability and target engagement studies were performed with the BRET assay. **(a)** Tracer titration of all three synthesized tracer molecules and either C-terminal or N-terminal Nanoluc-tagged WDR5 (WDR5-C or WDR5-N). **(b)** and **(c)** NanoBRET™ dose response curves of PROTAC (**8g**), WDR5 ligand (**6d**) and reference compound **OICR-9429** in **(b)** intact cells as well as in **(c)** lysed cells. Figure reprinted (adapted) with permission from "Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) Degraders by Dölle, Adhikari *et al*.[174] Copyright 2021 American Chemical Society.

The following BRET measurements of all degraders were performed in lysed as well as in living cells. The different assay formats were used to compare cell penetration as well as cellular affinity towards WDR5, and the obtained data of the BRET measurements are shown in **Table 5**. The experiments were carried out three times as duplicate measurements, and within the measurements itself, a wide shift/ variety of the binding curves was observed. For example, the reference compound **OICR-9429** showed in all three measurements different binding affinities, ranging from three-digit nM to single-digit µM values, although a cellular potency of 1 µM has been reported in literature.[83] Thus, the obtained data of the PROTACs rather indicate an affinity interval than fixed values. Due to the catalytic mechanism of action of PROTAC molecules, the binary affinity to the protein-of-interest is negligible and efficient degradation for moderate affine PROTACs has been described in literature.[122]

A significant decrease in affinity was observed when parent compound (**6d**) was elongated to the final PROTACs(**7a-e**), (**8a-j**) and (**9a-c**). Significant changes in affinity could be observed by comparing the attached E3 ligase ligands and the nature of the linker: most Cereblon (CRBN) targeting PROTACs (**7a-e**) displayed similar cellular potencies in both assay formats. VHL targeting PROTACs (**8a-j**) showed weaker cellular activity, possibly due to the peptide like nature of the ligand. Interestingly, an affinity determination for all VHL addressing PROTACs, no matter of the linker nature, could be achieved in lysed cells (only the aliphatic linker containing PROTAC (**8g**) showed a two-digit µM affinity in the intact cellular experiment). Comparing all linker variants of the VHL-addressing PROTACs – the aliphatic-bridged PROTACs (**8e-i**), the [PEG]-bridged variants (**8a-c**), the directly linked degrader (**8d**) and the aromatic linked molecule (**8j**) – indicated that the

weak solubility might be the limiting factor for this observation. Furthermore, the limiting solubility has already been a limiting factor in the ITC experiments. Regarding the MDM2 addressing PROTACs (**9a-c**), the BRET measurements confirmed the weak *in cellulo* activity of these molecules to WDR5, as indicated *in vitro* in the DSF assay. Summed up, the MDM2 targeting degraders were excluded from further experiments.

Table 5. *In cellulo* data of WDR5 antagonist **OICR-9429**, the modified inhibitor (**6d**) and degraders (**7a-e**), (**8a-j**) and (**9a-c**). IC$_{50}$: cellular binding affinity; SD: Standard deviation. Table adapted with permission from "Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) Degraders by Dölle, Adhikari *et al*.[174] Copyright 2021 American Chemical Society.

ID	Linker	E3 ligase	NanoBRET[TM]	
			IC$_{50}$ ± SD [µM][a]	IC$_{50}$ lysate ± SD [µM][a]
OICR-9429	-	-	0.31 ± 0.06	1.85 ± 0.07
6d	-	-	0.14 ± 0.03	0.08 ± 0.01
7a		CRBN	4.30 ± 1.17	0.99 ± 0.11
7b		CRBN	4.18 ± 0.53	1.22 ± 0.04
7c		CRBN	14.1 ± 0.2	2.87 ± 0.01
7d		CRBN	4.92 ± 0.98	1.05 ± 0.03
7e		CRBN	1.18 ± 0.12	0.85 ± 0.02
8a		VHL	8.65 ± 0.43	0.74 ± 0.04

Table 5. (continued)

8b	(PEG, n=2)	VHL	≥50	5.21 ± 0.25
8c	(PEG, n=4)	VHL	12.5 ± 0.6	1.54 ± 0.01
8d	-	VHL	1.59 ± 0.20	0.99 ± 0.05
8e	(alkyl)	VHL	≥50	3.93 ± 0.14
8f	(alkyl)	VHL	≥50	3.29 ± 0.03
8g	(alkyl)	VHL	13.6 ± 0.3	2.15 ± 0.03
8h	(alkyl)	VHL	≥50	4.95 ± 0.09
8i	(alkyl)	VHL	≥50	15.8 ± 0.8
8j	(para-xylyl)	VHL	15.8 ± 1.9	2.99 ± 0.25
9a	(PEG, n=1)	MDM2	≥50	≥50
9b	(PEG, n=7)	MDM2	≥50	≥50
9c	(para-xylyl)	MDM2	≥50	≥50

[a]IC_{50} values were derived from BRET duplicate measurements and calculated by assuming a normalized 3-parameter curve fit; n.d.: not determined.

Another limitation of the herein established BRET assay system was observed for the pyrroloimidazole based degraders (**20a-g**): the used tracer (**21c**) could not be displaced by the small molecules and thus, no cellular affinity could be determined. Nevertheless, the heterobifunctional molecule (**20b**) was able to induce degradation of WDR5, concluding that at least this PROTAC must be able to bind to WDR5 *in cellulo* and that the BRET assay system retains limitations. A possible hypothesis for the missing tracer displacement might be the different binding modes of the used inhibitor. In summary, the herein established BRET assay for WDR5 indicates that several degrader molecules are cell permeable and bind to WDR5 in cells and lysates, indicating that they might be suitable compounds for cellular usage.

3.7 PROTAC-mediated degradation of cellular WDR5

HiBiT assay and Immunoblotting

Besides cellular permeability and target engagement, PROTAC molecules need to mediate a stable ternary complex to induce protein degradation. The generated proximity between both proteins leads ideally to ubiquitylation of the target protein and subsequent proteasomal degradation. To analyze PROTAC-mediated degradation of WDR5 in cells, the open reading frame of WDR5 was fused with a luciferase peptide, called HiBiT, followed by a transfection into the AML cell line MV4-11 (MV4-11^WDR5-HiBiT) and co-transfected with the second part of the luciferase (Large Bit, LgBit). Similar to the previously described BRET assay, the emitting signal can be used to quantify the degradation rate.[176] To compare the expression levels of WDR5-HiBiT to endogenously expressed WDR5, Immunoblotting was performed previously to PROTAC treatment and demonstrated similarity of both expression levels, as shown in **Figure 15**. Afterwards, the engineered MV4-11^WDR5-HiBiT cells were treated with various concentrations of the synthesized PROTACs for 24 hours and the depletion of WDR5-HiBiT was determined by measuring luciferase activity. **Figure 15** shows that the depletion was achieved for numerous PROTACs. None of the Cereblon addressing PROTACs induced cellular degradation of WDR5, whereas the aliphatic and aromatic linker bridged molecules (**8e-j**) that recruited VHL E3 ligase resulted in a successful degradation. The observed depletion of WDR5-HiBiT varied greatly between the different degraders, resulting in different degradation efficacies and concentrations, as listed in **Table 6**. Within the effective PROTAC series, compound (**8g**) that linked both functional binding moieties by a butyl chain, showed a maximum depletion of $58 \pm 3\%$ and DC_{50}-values of 53 ± 10 nM, indicating the catalytic nature that is observed by PROTACs. Within the HiBiT curves that are shown in **Figure 15**, the Hook effect was observed with increasing PROTAC concentrations. This behavior is due to binding site competition and thus

less efficient ternary complex formation. Linker shortening or linker elongation lowered degradation efficacy to 20 – 30%. The substitution of a carbon atom to an oxygen, like in the chemical structures of pentyl-bridged PROTAC (**8h**) and [PEG]$_1$-bridged PROTAC (**8a**), resulted in a complete loss of degradational activity.


Figure 15: Cellular degradation studies on WDR5. (**a**) Immunoblot of HiBiT-tagged (+) and endogenous (-) WDR5 in MV4-11 cells. Vinculin was used as loading control. (**b**) WDR5 levels based on luciferase measurements. MV4-11$^{WDR5-HiBiT}$ cells were treated with different concentrations of (**8g**) for 24 h. (**c**) WDR5 levels based on luciferase measurements. MV4-11$^{WDR5-HiBiT}$ cells were treated with different concentrations of degraders (**8a**), (**8e**), (**8f**), (**8h**) and (**8i**) for 24 h. (**d**) Quantification of WDR5 D$_{max}$ (maximal degradation) from HiBiT assay for degraders with different aliphatic linkers. MV4-11$^{WDR5-HiBiT}$ cells were treated with different concentrations of degraders for 6 h or 24 h and measured for luciferase activity of linkers comprising ethyl to hexyl motifs (**8e-8i**). Figure reprinted (adapted) with permission from "Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) Degraders by Dölle, Adhikari *et al.*[174] Copyright 2021 American Chemical Society.

Table 6. HiBiT data of WDR5 ligand (**6d**) and degraders (**7a-e**) and (**8a-j**). Table adapted with permission from "Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) Degraders by Dölle, Adhikari *et al.*[174] Copyright 2021 American Chemical Society.

			HiBiT Assay		
ID	**Linker**	**E3 ligase**	**DC$_{50}$** $[\mu M]^a$	**DC$_{max}$** $[\mu M]^b$	**D$_{max}$** $[\%]^c$
6d	-	-	no	no	no
7a		CRBN	no	no	no
7b		CRBN	no	no	no

Table 6. (continued)

			DC$_{50}$^{a}	DC$_{max}$^{b}	D$_{max}$^{c}
7c		CRBN	no	no	no
7d		CRBN	no	no	no
7e		CRBN	no	no	no
8a		VHL	no	no	no
8b		VHL	no	no	no
8c		VHL	no	no	no
8d	-	VHL	no	no	no
8e		VHL	0.63 ± 0.07	3.3	34 ± 3
8f		VHL	0.12 ± 0.01	1.1	40 ± 4
8g		VHL	0.05 ± 0.01	1.1	58 ± 3
8h		VHL	0.92 ± 0.06	≥10	40 ± 5
8i		VHL	0.92 ± 0.31	≥10	41 ± 5
8j		VHL	N/A	0.12	31 ± 2

^{a}DC$_{50}$: half-maximal degradation concentration, calculated with the dose–response (four parameters) equation; ^{b}DC$_{max}$: maximal degradation concentration; ^{c}D$_{max}$: maximal degradation; no: no degradation; N/A: not applicable.

Two inactive variants of PROTAC (**8g**) served as negative controls to validate that WDR5 degradation is caused by PROTAC treatment. The HiBiT assay data and the chemical structures of both negative controls are shown in **Figure 16**. Both molecules were synthesized analogue to the

previously described synthesis route, one containing the inactive epimer of the VHL ligand (**22**), and one containing an inactive WDR5 ligand (**23**) that uses a morpholine scaffold instead of the methyl piperazine. Alongside to the negative controls, also effects of parent compound (**6d**) on cellular degradation was tested in the experiments. The increased HiBiT signal of WDR5 levels by ligand (**6d**) treatment (as observed in **Figure 16a**) is most likely induced by ligand binding and thus an effect on WDR5 stability.

Additional biophysical data of the negative controls (**22**) and (**23**), e.g. DSF results, and cellular data from the BRET and HiBiT assay are listed in **Table 7**. Comparing the biological data of the negative control (**22**) to the active PROTAC (**8g**) shows that the affinity towards WDR5 in the DSF and BRET assay is maintained and in a similar range to the PROTAC molecule, and only the degradational efficacy is lost. The negative control of the WDR5 ligand, compund (**23**), already showed weak activity in the DSF assay and no degradational effects in the HiBiT assay. With this data, molecule (**23**) was excluded from BRET measurements.

Figure 16: Cellular degradation studies on WDR5. MV4-[11WDR5-HiBiT] cells were treated with different concentrations of **(a)** WDR5 ligand (**6d**), PROTAC (**8g**) and VHL negative control (**22/ nc_VHL**) and **(b)** PROTAC (**8g**) and WDR5 negative control (**23/ nc_WDR5**) for 24 h. Figure reprinted (adapted) with permission from

Table 7. Biophysical and biological data of the negative controls of PROTAC (**8g**). Negative control (**22**) inhibits binding to VHL, while negative control (**23**) inhibits binding to WDR5. Table adapted with permission from "Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) Degraders by Dölle, Adhikari *et al.*[174] Copyright 2021 American Chemical Society.

ID	$\Delta T_m \pm$ SD [K][a]	NanoBRET™		HiBiT Assay	
		$IC_{50} \pm$ SD [µM][b]	IC_{50} lysate $\pm$ SD [µM][b]	$DC_{50} \pm$ SD [µM][c]	$DC_{max} \pm$ SD [µM][d]
DMSO	0.0 ± 0.3	> 50	> 50	no	no
OICR-9429	13.3 ± 0.1	0.31 ± 0.06	1.85 ± 0.07	no	no
8g	13.2 ± 0.1	13.6 ± 0.3	2.15 ± 0.03	0.05 ± 0.01	1.1
22/ nc_VHL	12.2 ± 0.1	4.26 ± 0.46	1.12 ± 0.03	no	no
23/ nc_WDR5	0.0 ± 0.2	n.d.	n.d.	no	no

[a]Thermal shift ΔT_m values given are the mean of triplicate measurements. DSF assays were performed at 2 µM protein concentration and a final compound concentration of 10 µM.
[b]IC_{50} values were derived from BRET duplicate measurements and calculated by assuming a normalized 3-parameter curve fit; n.d.: not determined.
[c]DC_{50}: half-maximal degradation concentration, calculated with the dose–response (four parameters) equation
[d]DC_{max}: maximal degradation concentration; no: no degradation.

Within the pyrroloimidazole-based PROTAC series, only PROTAC (**20b**), containing a [PEG]$_2$ linker motif, was able to induce degradation of WDR5. The induced depletion by PROTAC (**20b**) was in a similar range to (**8g**) but differentiated in the effective maximal degradation concentration (DC_{max}). In similar manner to the **OICR-9429** derived PROTAC (**8g**), a negative control using the inactive VH032 ligand (**24**) was synthesized and tested alongside to the active degrader and the parent compound (**17**).[174]

In addition to the HiBiT results, degradation of untagged WDR5 in MV4-11[WDR5-HiBiT] cells was monitored using immunoblotting for various time points (6 hours, 24 hours and 72 hours). The PROTAC induced efficient depletion of WDR5, and the dose-dependency and gratifyingly

degradation efficacy of the protein resembled the depletion observed in the HiBiT system, as shown in **Figure 17**. Other immunoblotting studies confirmed the depletion efficacy of the other degraders (**8e,f**) and (**8h-j**) in naive MV4-11 cells. As shown in **Figure 17**, degradation of WDR5 through (**8g**) was also shown to be efficient in human leukemia cell line HL-60.


Figure 17: **(a)** Immunoblot of WDR5. MV4-11[WDR5-HiBiT] cells were treated with different concentration of (**8g**) for 24 h and compared with DMSO treated or naive MV4-11 cells. Vinculin was used as loading control (as in all further immunoblot experiments). Quantification is based on both protein bands (endogenous /HiBiT tagged WDR5). **(b)** Immunoblot of WDR5. Naive MV4-11 cells were treated with different concentration of (**8g**) for 72 h and compared with DMSO treated cells. **(c)** Immunoblot of WDR5. HL-60 cells were treated with different concentrations of (**8g**) for 24 h. Figure reprinted (adapted) with permission from "Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) Degraders by Dölle, Adhikari *et al*.[174] Copyright 2021 American Chemical Society.

Proteasome-dependent mechanism of action studies

Additional experiments were performed by B. Adhikari to test if the PROTACs induce degradation by inducing ubiquitylation and proteasomal degradation. The results of the experiments are shown in **Figure 18**. In a protein stability measurement, protein translation was blocked by incubating PROTAC- and vehicle-treated cells with cycloheximide. The WDR5 levels were examined by immunoblotting at several time points and the PROTAC-treated cells showed a decreased protein stability of WDR5 in comparison to the vehicle treated cells.

In a quantitative PCR (qPCR) experiment in MV4-11 cells, effects of the compounds (**6d**) and (**8g**) on WDR5 transcription was examined and a transcriptional effect could be excluded as the mRNA levels did not decrease.

An additional rescue experiment showed that WDR5 depletion requires binding of (**8g**) to WDR5 and that nor WDR5 ligand (**6d**) neither VH032 are able to induce degradation. WDR5 levels could be restored by excess co-incubation of MV4-11 cells with ligand (**6d**).

Figure 18: Degrader-induced depletion of WDR5 depends on the ubiquitin system. **(a)** Immunoblot and quantification of WDR5 levels by the cycloheximide (CHX) chase assay. WDR5 protein stability was evaluated by treating 1 μM (**8g**) or DMSO incubated MV4-11 cells for 0, 1, 2, 6 and 12 h with cycloheximide (CHX). The data is mean ± SD from n=2 biological replicates. **(b)** Quantitative RT-PCR analysis of WDR5 mRNA levels. RNA was extracted from MV4-11 cells incubated with 1 μM (**8g**), 1 μM (**6d**) for 24h. WDR5 expression levels were normalized with a reference gene (*B2M*). Bars represents mean ± SD of n= 3 technical replicates. **(c)** Immunoblot of WDR5. MV4-11 cells were treated for 6 h with 1 μM (**8g**) or 5 μM (**6d**) or 10 μM VHL-ligand or combination of them. Figure reprinted (adapted) with permission from "Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) Degraders by Dölle, Adhikari *et al*.[174] Copyright 2021 American Chemical Society.

For the pyrroloimidazole-based PROTAC (**20b**), other experiments, e.g. proteasomal inhibition with MG132 and neddylation inhibition with MLN4924, to prove a proteasome-mediated mechanism were performed. Similar to PROTAC (**8g**), the depletion of endogenous WDR5 was shown in various cancer cell lines by inducing protein ubiquitylation and degradation.[174]

Selectivity profile of PROTAC (8g) mediated WDR5 degradation by quantitative proteomics

Quantitative proteomic studies were performed by B. Adhikari and N. Berner from the TU Munich to get an insight into the selectivity profile of PROTAC-mediated WDR5 degradation. Therefore, cellular protein levels of MV4-11 cells had been treated with PROTAC (**8g**) and compared to untreated cells by mass spectrometry. The obtained volcano plots in **Figure 19** showed that among 5805 detected proteins, only the WDR5 protein was significantly and substantially depleted ($-\log_{10}p > 3$, $\log_2 FC < -0.5$). Further experiments showed that WDR5 inhibition with ligand (**6d**) as well as ligand (**17**) did not significantly alter WDR5 levels ($-\log_{10}p < 1.2$, $\log_2 FC < 0.2$).

Figure 19: Volcano plot exhibiting global proteomics change upon PROTAC treatment. MV4-11 cells were treated with (**left**) 1 µM (**8g**) or (**right**) 5 µM (**20b**) for 9 h and lysates were analyzed by quantitative proteomics. WDR5 (purple) and depleted proteins (red): 60S Ribosomal protein L22-like 1, RPL22L1; DNA repair protein, XRCC3; Human Ribosomal biogenesis factor, C8orf59; INO80 complex subunit E, INO80E; DNA-directed RNA polymerase III subunit, RPC10, Heterogeneous nuclear ribonucleoprotein U, HNRNPU. Figure reprinted (adapted) with permission from "Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) Degraders by Dölle, Adhikari *et al*.[174] Copyright 2021 American Chemical Society.

Analysis of the obtained Proteomic data of PROTAC (**8g**)-treated MV4-11 cells hinted that WDR5 influences transcriptional processes, as also stated by the literature: Bryan *et al*. depleted endogenous WDR5 via the dTAG approach in neuroblastoma cells and compared degradation versus inhibition.[84] The authors found slightly differences in the biological clustering of the two distinct approaches: WDR5 depletion had more extensive effects on neuronal differentiation, while inhibition showed enhanced effects on the expression of genes linked to cell cycle.[84] Further proteomic experiments with the WDR5 Win site ligand **C6** from Guarnaccia *et al*. showed that WDR5 depletion influenced inter alia proteins with links to tRNA synthetases.[177] In this study, the observed effects of a phenotypic response to WDR5 depletion is moderate, most likely due to the incomplete degradation profile of (**8g**). Nevertheless, WDR5 depletion tends to downregulate ribosomal proteins, e.g. Heterogeneous nuclear ribonucleoprotein U (HNRNPU), Human Ribosomal biogenesis factor (C8orf59), or 60S Ribosomal protein L22-like 1 (RPL22L1) and thus indicate WDR5 is conntected to the expression of genes linked to protein synthesis.

Analogue to PROTAC (**8g**), Proteomic analysis for PROTAC (**20b**) has been performed and also showed a significant depletion of WDR5, as displayed in **Figure 19**. The observed proteomic effect was smaller than for PROTAC (**8g**), although the required concentration was adjusted. Beside WDR5 depletion, two other proteins involved in transcription and translational processes were depleted alongside to WDR5: the CGG triplet repeat-binding protein 1 (CGGBP1) and the Coiled-

coil domain-containing protein 117 (CCDC117). In alignment with PROTAC (**8g**) mediated WDR5 depletion, the observed effects are weak due to the incomplete WDR5 degradation by PROTAC (**20b**). Both proteomic experiments with different PROTACs proved the hypothesis of WDR5s' role in non-epigenetic processes.

The enriched proteins upon Win site blockade from Guarnaccia *et al*. had few connections and represented various biological processes e.g., transcription, ubiquitylation and chromatin remodeling.[177] The proteomic experiments upon treatment with parent compound (**6d**) are displayed in **Figure 20** showed an enriched profile of proteins involved in ferritinophagy (NCOA4), pentose phosphate pathway (PGD) and glycolysis (DLD/ PFKL) and had few connections. Quantitative proteomic analysis of pyrroloimidazole ligand (**17**) revealed that treatment enriched the structure protein Aktin and the protein Chromosome 7 Open Reading Frame 26 (C7orf26) that is assumed to be involved in transcriptional processes. Both ligands do not cause a decrease in WDR5 levels.

Figure 20: Volcano plot exhibiting global proteomics change upon Win site ligand binding. MV4-11 cells were treated with 1μM (**6d**) 5 μM (**17**) for 9 h and lysates were analyzed by quantitative proteomics. WDR5 (purple) and depleted proteins (red): CGG triplet repeat-binding protein 1, CGGBP1; Coiled-coil domain-containing protein 117, CCDC117. The enriched proteins are (green): Nuclear receptor coactivator 4, NCOA4; 6-phosphogluconate dehydrogenase, PGD; Tryptophan-tRNA ligase, WARS; Dihydrolipoyl dehydrogenase, DLD; ATP-dependent 6-phosphofructokinase, PFKL; 2-dihydroxy-3-keto-5-methylthiopentene dioxygenase, ADI1; Stomatin-like protein 2, STOML2; Chromosome 7 Open Reading Frame 26 (C7orf26), Actin. Figure reprinted (adapted) with permission from "Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) Degraders by Dölle, Adhikari *et al*.[174] Copyright 2021 American Chemical Society.

Comparing the proteomic data of ligand (**6d**) and (**17**) suggests that further experiments are necessary to evaluate the observed effects. While treatment with PROTAC (**8g**) affects various

proteins that are involved in transcriptional and translational processes in the nucleus, the enriched effects of parent compound (**6d**) as well as (**17**) relate to proteins located in the cytoplasm. As **Figure 19** indicates, these proteins are not influenced by WDR5 degradation and thus the proteomic data upon ligand treatment might be overestimated. Another hypothesis would be that the WDR5 ligands are able to act as molecular glue between the surface of WDR5 and the enriched proteins: as the elongation of the WDR5 ligands to heterobifunctional molecules removed the molecular glue like properties, the observed effect were no longer detectable in the proteomic studies.

To validate the proteomic results, additional qPCR experiments to check the mRNA levels and immunoblots of the enriched and repressed proteins would be a suitable tool to determine the influence of WDR5 on these proteins. As the overall effect is only weak, knockdown studies on WDR5 and subsequent analysis of the interactions could provide more clear results.

All in all, the PROTAC mediated degradation of cellular WDR5 was shown in various assays and control experiments. Various PROTACs with two different WDR5 ligand scaffolds successfully induced degradation of WDR5 upon three days after treatment. The **OICR-9429** derived PROTAC (**8g**) was shown to be the most effective degrader in terms of degradation efficacy (58%) and required concentration (1 µM). PROTAC (**20b**) containing the pyrroloimidazole scaffold also showed favorable properties (54% degradation upon treatment with a dose of 3 µM).

3.8 Crystallization of the ternary complex

The formation of a ternary complex between the target protein and the E3 ligase is the main goal of the proximity-generating heterobifunctional molecule. This protein formation was shown to be the crucial step for the success of TPD.[160, 178] Further studies validated that PROTAC-mediated ubiquitination depends on the existence of a ternary complex equilibria and also the dose-dependent degradation efficacy is consistent with ternary complex formation. A criterion for measuring ternary complex stability is the so-called cooperativity factor α which is calculated out of the binary and ternary binding constants of a protein complex[179] and commonly determined by the biophysical methods ITC or SPR. The target protein is preferentially recruited in a positively cooperative ternary complex with the respective E3 ligase.[180] A time-resolved study by Roy and coworkers examined two different PROTACs that addressed the ternary complex formation of BRD4 and CRBN.[179] The study demonstrated that a long-lasting and stable ternary complex correlates with an enhanced degradation profile. Farnaby and Koegl explained the activity of a

PROTAC targeting the BAF chromatin remodeling complex by means of the obtained ternary complex crystal structure, making ternary complex characterization critically important in PROTAC development.[160, 164]

To understand the molecular mechanism of WDR5 degradation and to further improve the degradation profile of PROTAC (**8g**), crystallization studies on the WDR5/ VHL system had been performed. As the crystal structure was obtained successfully within a few attempts, time-consuming cooperativity studies that usually require a huge amount of both proteins, have been postponed. The crystal structure of the ternary complex between WDR5, PROTAC (**8g**) and VHL/ Elongin B/ Elongin C was obtained with a resolution of 2.5 Å, as shown in **Figure 21**. In contrast to the predicted model[174] and the assumption that proteins involved in degradational processes tend to stabilize the ternary complex by large surface interactions[164, 180-181], a rather diminished overlap of the protein surfaces was observed withing the crystal structure. Most of the published ternary complex crystal structures investigated the bromodomain family[164, 180-181] that occur as small subunits (ca. 15 kDa) in large chromatin modifying enzymes and often interact in a positively cooperative ternary complex with the E3 ligase. For the 37 kDa heavy WDR5 protein, two additional PPIs between the amino acid side chains of Lysine 259 (WDR5) and Aspartic acid 92 (VHL) as well as the carbonyl function of the Tyrosine 191 and Asparagine 214 backbone (both WDR5) with Arginine 69 (VHL) were observed.

Figure 21: **(top)** Crystal structure of the WDR5/ (**8g**)/ VHL ternary complex. Protein surfaces are displayed to show the minimal overlap between WDR5 (grey) and VHL (blue)/ Elonging B (purple)/ Elonging C (lightblue). The red and blue colored surface spots represent the additional PPI interactions. **(bottom, outlined)** Close-up of the interaction site shows that PROTAC (**8g**) (pink) is mainly responsible for the PPI. Additional PPIs occur between the side chains of LYS259 and ASP92 as well as the backbone of TYR191, ASN214 and the side chain of ARG69.

The surprising few interactions between both proteins within the crystal structure indicated that the main reason for successful WDR5 degradation lies in the high affinity and chemical stability of PROTAC (**8g**) towards WDR5 and VHL. The high affinity has already been shown *in vitro* measurements by ITC (as shown in **Figure 10** and **Table 3**), while the long-lasting chemical stability of the compound was observed by Immunoblotting experiments for a timeframe of up to 72 hours (see **Figure 14**). Though the crystal structure provided an insight into the binding mode, a structural improvement of PROTAC (**8g**) maintained challenging due to the linker exposure towards the solvent and non-existing opportunities to stabilize the ternary complex with an

improved degrader molecule. Nevertheless, short and unipolar motifs like alkines could be implemented into PROTAC design.

3.9 Development of the chemical probe Homer

An advantage of the degradation approach is that targeted protein degradation removes a protein entirely from the cell such as for instance the moonlighting multitasker WDR5, while inhibition of WDR5 alone would only show cellular effects of the respective inhibited binding site. Although the degradation profile is not quantitative, the herein observed effects suggested that PROTAC (**8g**) might be a suitable tool for exploring WDR5 manifold cellular functions. As shown in **Table 8**, the low DC_{50} and DC_{max} values indicate a catalytic turnover, and the proteomic effects clearly demonstrate the substantial and significant depletion of WDR5 in a cellular environment. The control experiments, e.g. the CHX chase assay, the qPCR and the rescue experiment showed the proteasome-dependent mechanism of action as well as the necessity of PROTAC (**8g**) to bind to WDR5. The crystal structure of the ternary complex demonstrates the binding mode of the PROTAC. Thus, the WDR5 PROTAC (**8g**), alongside with its two negative controls (**22/ nc_VHL** and **23/ nc_WDR5**), was revised successfully as an open-source chemical probe via the donated chemical probes program under the name **Homer** (https://www.thesgc.org/chemical-probes/homer).

Table 8: Probe criteria for the WDR5 PROTAC probe **Homer**.

Probe criteria	Homer
Potency	o K_d (ITC): 18 nM
Activity	Proteasome-dependent degradation; rescue experiments with free VHL ligand and WDR5 ligand in addition to **Homer**
In cell validation	o IC_{50} (NanoBRET): 13.6 µM
Evidence and quantification of target engagement and degradation	o DC_{50}: 53 nM and D_{max}: 58% o Concentration course for degradation o Evidence of E3, ubiquitin and proteasome-dependence: CHX assay, qPCR
Off-target activity in cells	o proteomics: only depletion of WDR5 ($-\log_{10}p > 3$, $\log_2 FC < -0.5$)
Control compounds	2 negative controls: **nc_VHL** and **nc_WDR5**
Recommendation on use	1 µM (evaluated at 6h, 24h, 72h)

4. Summary

Cancer is a serious disease for anyone affected, threatening the long-term well-being and life of the patient. For the society and the healthcare system, cancer causes massive economic costs, revealing an urgent need for novel and more effective therapies. Recent progress in cancer therapy came from the field of molecular targeted therapies, which inhibit the function of proteins that drive tumor progression, as well as immunotherapies, which increase the ability of the immune system to recognize and eliminate tumor cells. Both therapeutic approaches aim to overcome the major side effects that occurs in classical chemotherapy, in particular the toxicity to all dividing cells. In addition to the enourmous achievements in cancer diagnosis and treatment, elementary questions about cellular processes remain unsolved which limits therapeutical options.

One class of oncoproteins that drives leukemia growth are the protein class of mixed lineage leukemia (MLL) histone lysine methytransferases.[50, 59, 62] The multi-domain protein complexes mark specific histone tails of the chromatin structure by methylation, enabling gene transcription. Genetic fusions of the *mll* gene, so-called rearragments, result in MLL-fusion products that drive development of acute myeloid lekemia (AML).[60, 182] Another oncoprotein responsible for the aggressive progression of various cancer types is the transcription factor family MYC.[109-110] Several studies showed that the amplification of neuroblastoma cells depends on MYC and that high cellular MYC levels regulate the expression of genes crucial for transcriptional processes and tumour growth.[109-110, 114, 183-184] Due to the instable protein structure of MYC and its lack of binding pockets, MYC is still considered as undruggable.[109-110] Thus, the pharmacological efforts on targeting the oncogene focusses on indirect targeting strategies, e.g. by inhibiting the interaction partners of the transcription factor.

Both the MLL histone lysine methyltransferase family and the transcription factor family MYC interact with an approximately 37 kDa protein called WD40-repeat containing protein 5 (WDR5). Several studies have shown that this scaffolding protein is a promising drug target.[82] Due to its propeller-shaped structure, WDR5 has a large surface with two binding sites. Both binding sites are involved in binding MLL complex proteins, thereby ensuring the stability and function of the MLL1 complex.[57] In the context of MLL misregulation, inhibition of WDR5 emerged as a promising strategy for the treatment of MLL-rearragend leukemia.[50, 83, 93-95, 185-186] Further studies showed that WDR5 mediates the interaction between MYC and chromatin via its two binding sites and

thus WDR5 was evaluated as a promising and druggable interaction partner for MYC-dependent cancer types.[81, 84, 86, 102, 168, 177]

In summary, WDR5 has significant roles in scaffold functions and in engaging multiple binding partners at different binding sites. Thus, inhibition of the individual protein-protein interactions results in only a partial knockdown of the enzymatic function. Although the developed WDR5 anatagonists[81, 83, 167-168, 177] demonstrated the great potential of this drug target, a classic inhibitory approach of only one binding site limits the studies of investigating WDR5s' overall impact on cellular processes. This limitation could be overcome by the proteasomal degradation of the entire protein removing the essential protein-protein interactions. A new class of small molecules, called PROTACs (Proteolysis targeting chimeras), induce chemically the degradation of the respective target proteins by the cell-own ubiquitin/proteasome symstem[117, 122] PROTACs have already demonstrated the successful degradation of several protein classes.[116, 118, 122] Due to the induction of selective and efficient target protein degradation, this class of small molecules offers a novel approach for investigating the effects of individual proteins on cellular mechanisms. First PROTACs have been optimized for therapeutic uptake and are currently undergoing clinical tirals.[187]

This aim of this thesis was the design and synthesis of WDR5 degrader molecules, using two distinct ligand scaffolds, diverse linker types as well as three ligands for different druggable E3 ligases. A set of eighteen PROTACs with the WDR5 small molecule antagonist **OICR-9429** was successfully synthesized in this thesis, as well as nine PROTACs bearing a pyrroloimidazole scaffold supervised in two master projects. This study evaluated the different steps of PROTAC-mediated target protein degradation. First, the *in vitro* affinity of the PROTACs to WDR5 was proven in two orthogonal biophysical assays, while the herein developed BRET assay showed cellular permeability and target engagement of the PROTACs. The degradation efficacy was evaluated in the context of a structure-activity-relationship study and revealed that degradation efficacy is affected by minimal changes in linker length and composition. Further biological experiments examined the proteasomal mechanism of action in MLL-rearragend cancer cells. The successful formation of the ternary complex was obtained by protein crystallography and completed the mechanism of action studies. The outcome of this study led to potent PROTACs and demonstrated that PROTAC-induced protein degradation can be achieved with different exit vectors and linker types. The best degrader was published as chemical probe **Homer** (https://www.thesgc.org/chemical-probes/homer) by the chemical probe program of the Structural Genomics Consortium. The obtained results reinforce WDR5 as potential cancer target and PROTAC technique as suitable method to explore proteins with manifold cellular functions like WDR5.[174]

5. Conclusion and Outlook

Since 2015, the biological relevance of the WD40-repeat containing protein 5 has continuously increased due to investigative research that aims to illuminate biological mechanisms and find new therapeutic approaches for severe diseases.[82, 102] WDR5 has been rising as promising therapeutic target since its various interaction partners drive major oncogenic processes.[114] These oncogenic drivers are e.g., the transcription factor family MYC[103] that play a crucial role in neuroblastoma amplification[114], and the MLL/ SET HMT complexes where rearrangements drive acute leukemia progression.[79, 83] Both proteins rely on WDR5s' scaffolding role that recruit MYC to chromatin or ensure the stability and function of HMT complexes. Targeting WDR5 function was shown to be a promising approach for inhibiting leukemia (MLL-rearranged) and neuroblastoma (MYC-dependent) cell growth by inducing p53-dependent apoptosis.[114] In addition to these well-established functions, WDR5 has additionally been shown to influence the expression of ribosomal subunits, making the moonlighting protein interesting for other cancer types, as alterations of ribosome biogenesis are a common feature of cancers.[82, 188]

This thesis focused on the development to temper both oncogenic functions by degrading the scaffolding protein WDR5 using the PROTAC technique. The herein designed and developed heterobifunctional molecules relied on diverse WDR5 ligand scaffolds, that created different exit vectors from the WDR5 Win binding site, and comprised different E3 ligase ligands targeting Cereblon (**7a-e**), VHL (**8a-j**) and MDM2 (**9a-c**). The degrader molecules have been evaluated in various assays, starting from *in vitro* assays such as DSF and ITC which showed the high affinity of the PROTACs towards WDR5, to cellular assays that showed good cell permeability and on-target activity (BRET assay) or monitored degradation of WDR5 for a cluster of PROTACs (HiBiT). Further experiments showed the proteasome-mediated mechanism of action as well as the selectivity of WDR5 depletion.

However, only VHL-based PROTACs (**8e-j**) led to successful degradation and small changes in linker length and linker type resulted in significant changes in degradation efficacy. The herein used leukemia cell lines attested an incomplete degradation profile of the degraders and will need further investigation. Experiments from B. Adhikari from the University of Würzburg showed that cells could be sensitized to a better degradation profile by overexpressing VHL. This resulted in an increased degradation efficacy and suggested that using the heterobifunctional molecules in cell lines with higher VHL levels will also increase WDR5 degradation. The ongoing proliferation experiments showed that a more efficient depletion is required to see stronger attenuation of

cancer cell growth. This is limited with the high amount of required concentration, and thus future medicinal chemists should focus on the chemical improvement of PROTAC (**8g**) lead structure. Chemical modifications on the PROTAC scaffold could either be achieved by increasing solubility of the molecule or by enforcing ternary complex formation. Increasing solubility for the **OICR-9429** derived degrader series would suggest implementing the original morpholine system, which was used in the **OICR-9429** scaffold to generate solubility, while maintaining the exit vector of PROTAC (**8g**). ADME and PK/ PD studies could provide a more detailed feedback for cellular permeability. Regarding the BRET measurements of PROTACs (**20a-g**), the development of a pyrroloimidazole based tracer could likely determine the binding affinity of the PROTACs. Looking at the data from the HiBiT assay and combining them with the obtained crystal structure of the ternary complex, the **OICR-9429** degrader series showed some space for chemical improvement, e.g. implementing alkine functions. While the HiBiT assay indicated that small changes in linker length – shortening/ prolonging of the butyl chain or substituting the alkyl chain into a [PEG] linker – effected the degradation profile extensively, the crystal structure showed a less favorable positioning of both proteins towards each other. This suggests that the cooperativity of ternary complex formation might not be favored, but additional biophysical experiments like SPR or ITC measurements and biological point mutation studies would be required to prove this hypothesis. As this work focused on the synthetic development of functional WDR5 degraders, the resulting additional biophysical questions have been upstaged.

A medicinal chemistry approach to improve the degradation profile beside improving the **OICR-9429** based degrader series would focus also on the pyrroloimidazole based scaffold of the PROTAC series (**20a-g**). An attempt to improve solubility could be the substitution of one [PEG] linker unit by a piperazine moiety. A better solubility might lower the required concentration in an aqueous environment, and proliferative effects of could be observed at lower concentrations. Another effect of the insertion of a piperazine moiety would be that the resulting PROTAC might be more rigid. Speculating about the outcome, this chemical change could either result in a more stable and long-lasting ternary complex (resulting in enhanced degradation efficacy) or the degradation could be completely abolished if the pyrroloimidazole based PROTAC contains a twisted exit vector and thus requires flexibility. To investigate this issue, a second ternary complex crystal structure would be beneficial.

In terms of biological experiments, additional qPCRs and Immunoblots of downregulated proteins in the proteomic experiments would potentialy give an insight on WDR5s' role in transcriptional processes. Therefore, compounds (**8g)** or (**20b**) presented here would already be suitable to

address this question, as the effects have already been observed in the global proteomic change in **Figure 19** and **Figure 20**. Otherwise, knock-down studies on WDR5 could be informative to clearify WDR5 interaction partners. ChIP- and RNA-Sequencing experiments of PROTACs would show commonalities and differences between the inhibitory versus the degradational approach. For *in vivo* studies, PROTACs with an improved degradation profile and solubility would definitely be required.

Although the herein investigated system has limitations and needs further characterization and optimization, it demonstrates the potential of the PROTAC approach. The heterobifunctional molecules presented here are suitable chemical tools that will allow comprehensive evaluation of WDR5 degradation in diverse cancer types and the potential of this strategy for drug discovery.

6. Deutsche Zusammenfassung

Für jeden Betroffenen ist die Diagnose Krebs ein schwerwiegender Einschnitt in der Lebensqualität und -führung, da die Behandlung oftmals mit langen Chemotherapien einhergeht. Die enormen Kosten der Krebsbehandlungen stellen für das Gesundheitssystem eine hohe Belastung dar, die den Bedarf an neuer, günstiger und vor allem effizienter therapeutischer Ansätze verdeutlicht. Moderne Durchbrüche in der Krebsbehandlung stammen aus dem Forschungsbereich der zielgerichteten Molekulartherapie, eine Methode um spezifische Funktionen von Onkoproteinen zu inhibieren, oder aus dem Gebiet der Immuntherapien, die auf eine Stärkung des Immunsystems abzielt und damit Krebszellen effektiver vernichtet. Abgesehen von den beachtlichen Erfolgen beider Ansätze bei der Behandlung von Krebspatienten, bleiben auf dem Gebiet der Onkologie weiterhin Fragen zu den grundlegenden biologischen Prozessen unbeantwortet. Das Verständnis dieser Prozesse könnte Wege zur Überwindung, der im Verlauf der Therapie häufig auftretenden Medikamentenresistenzen, aufzeigen und Möglichkeiten für neue Therapieansätze eröffnen.

Zu den Onkoproteinen, die das Tumorwachstum in Leukemiezellen stark beeinflussen, gehören die Proteine der Klasse der *mixed lineage leukemia* (MLL) Histonmethyltransferasen. [50, 59, 62] Die großen, aus vielen Domänen bestehenden Proteinkomplexe markieren Histonenden der Chromatinstruktur mit Methylgruppen, um diese für die Gentranskription zugänglich zu machen. Genetische Fusionen des *mll* Gens, sogenannte Rearragments, führen zu MLL-fusion Produkten, die erheblich zum Verlauf der aggressiven akuten myeloischen Leukämie (AML) beitragen. [60, 182]

Ein weiteres Onkoprotein ist für den Krankheitsverlauf vieler Krebsarten relevant, unter anderem weil dessen Überexprimierung in einem Drittel aller humanen Tumore beobachtet wurde: die Transkriptionsfaktorfamilie MYC.[109-110] Auf molekularer Ebene sorgt MYC für die Transkription einer Vielzahl von Genen, deren Expression in direkter Abhängigkeit zu jeweiligen MYC Konzentration stehen. Studien belegen, dass hohe MYC Level die Expression von Genen regulieren, die essentiell für den Transformationsprozess und somit das Tumorwachstum sind. [109-110, 114, 183-184] So zeigte sich unter anderem einen Zusammenhang zwischen MYC und der Amplifikation von Neuroblastomazellen auf.[114] Da der Transkriptionsfaktor weder eine sabile tertiäre Proteinstruktur noch eine für Inhibitoren adressierbare Bindetasche aufweist, gilt MYC bis heute als *undruggable*. Neuere Forschungsansätze basieren auf der Inhibierung von Interaktionspartnern des Onkoproteins.

Sowohl die Histonmethyltransferase MLL1, als auch der Transkriptionsfaktor MYC interagieren mit einem ca. 37 kDa Protein namens WD40-*repeat containing* Protein 5 (WDR5), das durch seine propellerförmige Struktur eine Oberfläche mit insgesamt zwei Bindestellen aufweist. Mehrere Studien

zeigten, dass WDR5 die Stabilität und somit die Funktion epigenetischer Proteinkomplexe wie SET/ MLL und NSL gewährleistet. [57, 82] In diesem Kontext wurde WDR5 als relevantes Target für die *MLL-rearragend* akute lymphatische Leukämie (ALL) postuliert. [50, 83, 93-95, 185-186] Weitere Studien zeigten zusätzliche Rollen von WDR5, wie die Interaktion zwischen WDR5 und dem Onkoprotein MYC sowie dessen Rekrutierung zum Chromatin.[81, 84, 102, 168, 177] Dabei nutzt WDR5 seine zwei Bindestellen, um einerseits die Interaktion mit dem Transkriptionsfaktor und andererseits mit den Bindemotiven der Chromatinstruktur zu ermöglichen.[81, 84, 86, 102, 168, 177]

Seit 2015 wurden erfolgreich mehrere niedermolekulare Wirkstoffe für die Inhibierung von WDR5 entwickelt. Dabei zielten die meisten der literaturbekannten Inhibitoren auf die Argininmotiv-erkennende *WDR5-interacting* (Win) Bindestelle, eine große, hydrophobe Bindetasche im Zentrum des WDR5-Propellers.[81, 83, 93-95, 167, 185] Für das weniger zugängliche WDR5-*binding* Motiv (WBM), das eher einem kleinen Zwischenraum, denn einer Bindetasche auf der WDR5 Oberfläche ähnelt, konnten jedoch ebenfalls in den letzten Jahren erfolgreich Inhibitoren entwickelt werden.[168] Die Resultate der besser erforschten Win Inhibitoren zeigten, dass WDR5 ein erfolgsversprechendes Target zur Inhibierung von leukämischen (*MLL-r*-abhängigen) und neuroblastomatischen (MYC-abhängigen) Zellwachstum ist.[82-83, 102]

Häufig beschriebene Nachteile in Krebstherapien stellen entwickelte Wirkstoffresistenzen sowie eine erhöhte Wirkstofftoleranz dar.[189] Eine dadurch bedingte Erhöhung der Dosis führt zu unerwünschten zellulären Effekten und Toxizitäten. Die PROTAC (Proteolysis targeting chimera) Technik beruht auf einem katalytischen Effekt und minimiert somit mögliche *off-target* Effekte.[122] Die heterobifunktionellen Moleküle induzieren den Abbau des Zielproteins über das zelleigene Ubiquitin-Proteasom-System anstatt dessen Enzymfunktion zu inhibieren.[116, 118, 122] Der PROTAC induziert einen stabilen ternären Komplex zwischen dem Zielprotein und einer E3 Ubiquitin Ligase, was die Übertragung von Ubiquitin und eine anschließende Erkennung durch das Proteasom ermöglicht. Nach dem zelleigenen Abbau des Zielproteins wird der PROTAC freigesetzt und kann einen neuen Zyklus der Proteindegradation einleiten, was die erforderliche Menge an Wirkstoff verringert. Zahlreiche onkologisch relevante Zielproteine wurden bereits erfolgreich über das Ubiquitin-Proteasom-System (UPS) abgebaut und erste PROTACs befinden sich bereits in klinischen Studien.[187]

Da beide Bindestellen des WDR5 Proteins Interaktionen mit onkologisch bedeutsamen Faktoren eingehen, würde eine einseitige Inhibierung nur die Effekte der jeweiligen Bindestelle aufzeigen. Diese Limitierung könnte jedoch durch die Entwicklung von WDR5 PROTACs aufgehoben werden, da alle Gerüstfunktionen des Proteins und Protein-Protein-Interaktionen durch die Degradierung von WDR5 entfernt werden würden.

Diese Dissertation beschäftigte sich mit dem Design, der Synthese sowie der biophysikalischen und biologischen Evaluierung von WDR5 PROTACs. Ausgehend von literaturbekannten WDR5 Liganden, dem **OICR-9429**[83, 93], **DDO-2117**[94] sowie einem pyrroloimidazol-basiertem Liganden[167], wurden zwei verschiedene PROTAC Typen entworfen. Diese beiden Molekültypen besitzen einen unterschiedlichen geometrischen Austrittswinkel, wodurch die Chance auf eine erfolgreiche Komplexbildung zwischen WDR5, PROTAC und E3 Ligase erhöht wird. Da die Synthese des pyrroloimidazol-basierten Liganden in zwei Masterarbeiten diskutiert und evaluiert wurde, liegt der synthetische Fokus dieser Dissertation auf dem Piperazin-basierten WDR5 Liganden. Als Leitstruktur fungierten die Verbindungen **OICR-9429** sowie **DDO-2117**. In einem ersten Syntheseplan wurden vier verschiedene WDR5 Liganden (**6a-d**), beruhend auf dem Arginin-Mimetika Methylpiperazin, aufgebaut. Im letzten Syntheseschritt wurden verschieden dekorierte Benzoesäuren verwendet, um den Liganden mit der höchsten Affinität zu generieren. In anschließenden biochemischen und biophysikalischen Evaluierungen der verschiedenen Liganden durch Thermofluor (DSF) und Biolumineszenz-Resonanzenergietransfer (BRET) Messungen zeigte sich Ligand (**6d**) als am geeignetsten für die Weiterentwicklung von PROTACs. Ausgehend vom WDR5 Ligand (**6d**) wurden heterobifunktionelle Moleküle mit verschiedenen Linkersystemen ([PEG]- und alkyl-basiert, sowie aromatisch verbrückt) und verschiedenen E3 Ligase Liganden (Cereblon, VHL und MDM2) synthetisiert.

Die Affinität der **OICR-9429**-basierten PROTACs (**7a-e**), (**8a-j**) und (**9a-c**) wurde anschließend in *in vitro* Messungen validiert. Die DSF Messungen der Cereblon- (**7a-e**) und VHL-adressierenden PROTACs (**8a-j**) deuteten auf eine hohe Affinität hin, während die MDM2-adressierenden PROTACs (**9a-c**) beinahe komplett ihre Affinität verloren. Orthogonale ITC Messungen ausgewählter Cereblon- und VHL-adressierenden PROTACs zeigten zweistellig nanomolare Affinitäten der heterobifunktionellen Moleküle. Die zelluläre Permeabilität der großen Moleküle wurde in einem hier etablierten BRET Assay untersucht. Zur Assay-Etablierung wurden drei Tracer (**21a-c**), basierend auf BODIPY Konjugaten, synthetisiert und getestet, bevor die PROTACs in intakten und lysierten Zellen vermessen wurden. Während die zellulären Affinitäten von Cereblon- und VHL-adressierenden PROTACs sich im niedrigen µM Bereich bewegten, wurden die nicht zellgängigen MDM2 PROTACs von weiteren Experimenten ausgeschlossen. Die hierin erzielten Resultate aus den durchgeführten Assays zeigen somit das Potenzial der Cereblon- und VHL-adressierenden PROTACs.

Die Degradierungeffizienz der WDR5 PROTACs (**7a-e**) und (**8a-j**) wurden in der Leukämie Zelllinie MV4-11 untersucht, da diese die am meisten auftretende MLL-fusion Mutation *AF4* birgt. Dabei wurde in zwei orthogonalen Assaysystemen der Proteinabbau von WDR5 nachgewiesen: sowohl der für das WDR5 Protein neu etablierte HiBiT Assay als auch die Western Blots quantifizierten den Abbau des WDR5 Proteins. Der beobachtete Abbau war bei einem PROTAC mit dem Pyrroloimidazol Grundgerüst (**20b**), sowie bei sechs der **OICR-9429**-basierten PROTACs (**8e-j**) erfolgreich. Bei beiden PROTAC Typen

konnten die heterobifunktionellen Moleküle, die die VHL E3 Ligase addressierten, einen endogenen WDR5 Abbau hervorrufen. Die chemische Struktur des Linkers der verwendeten PROTACs steuerte die Effizienz des Abbaus: das über eine Butyl-Kette verknüpfte Molekül (**8g**) erzielte dabei die höchste WDR5 Degradierungseffizient von insgesamt 58%. Zwei Negativkontrollen (**22** und **23**) wurden zusätzlich synthetisiert und anschließend vermessen, um die Effektivität von (**8g**) zu bestätigen.

Weitere Kontrollexperimente zeigten, dass der Abbau des WDR5 Proteins durch die heterobifunktionellen Moleküle stammte. Der *Cycloheximide chase assay* zeigte einen signifkanten Unterschied in der Proteinstabilität in den mit PROTAC (**8g**) behandelten Zellen.. Um einen Effekt auf die WDR5 Transkription auszuschließen, wurden die WDR5 mRNA Level in einer quantitative Polymerase-Kettenreaktion (qPCR) bestimmt. In einem dritten Experiment wurde über Westernblots gezeigt, dass der PROTAC (**8g**) verantwortlich für den proteasomalen Abbau des WDR5 Proteins ist: während Zellen, die mit dem VHL- oder dem WDR5-Liganden keinerlei Änderung der WDR5 Level aufwiesen, konnte bei PROTAC-behandelten Zellen eine verminderte Proteinkonzentration detektiert werden. Weiterhin blieben die zellulären WDR5 Level erhalten, wenn neben PROTAC-Behandlung ein Überschuss an WDR5 Ligand (**6d**) hinzugegeben wurde. Die durchgeführten Experimente belegen, dass die hier synthesierten PROTACs verantwortlich für den WDR5 Abbau sind.

Die Selektivität des effizientesten WDR5 PROTACs (**8g**) wurde in proteomische Messungen verifiziert. Die beobachteten Effekte sind durch den unvollständigen WDR5 Abbau schwach ausgeprägt, jedoch ist aus den Experimenten ersichtlich, dass nur das WDR5 Protein selektiv und in signifikanten Mengen abgebaut wird.

Da die hier generierten PROTACs das WDR5 Protein unvollständig abbauten, wurden Modelling- sowie Kristallisationsstudien zur möglichen Verbsserung des Moleküls (**8g**) durchgeführt. Die Bildung und Stabilität des ternären Komplexes zwischen Zielprotein, PROTAC und E3 Ligase ist hierbei essentiell für den Erfolg des Proteinabbaus, sodass vor allem nach Möglichkeiten gesucht wurden, den ternären Komplex zwischen WDR5, VHL und (**8g**) zu stabilisieren. Die Daten des Modellings stützten sich auf die Annahme der Kooperativität, die von einer Stabilisierung des Komplex durch zusätzliche Protein-Protein-Interaktionen ausgeht, während die erhaltene Komplexstruktur nur geringe Interaktionen zwischen beiden Proteinen zeigte. Die geringen PPI beschränken die Möglichkeiten für eine chemische Optimierung des PROTACs und künftige Arbeiten zielen vermehrt auf eine Verbesserung der Löslichkeit und Affinität der heterobifunktionellen Moleküle ab.

In weiterführenden biologischen Experimenten konnte gezeigt werden, dass die Degradierung aufgrund der VHL E3 Ligase Expressionslevel in den *AF4* Krebszellen limitiert ist: eine Überexpression von VHL Protein steigerte hierbei den WDR5 Abbau.[174] Dies bedeutet, dass für zukünftige

Untersuchungen die VHL Level berücksichtigt werden müssen um den WDR5 Abbau und seine biologischen Auswirkungen noch genauere Erforschungen braucht.

Zusammenfassend wurden in dieser Arbeit eine Reihe von PROTACs für das WDR5 Protein entwickelt, die erst in biophysikalischen Assays und anschließend in biologischen Systemen charakterisiert wurden. Diese Studie zeigt die Abhängigkeit zwischen Linkerlänge und Degradierungeffizienz auf, sowie die Notwendigkeit, PROTACs mit verschiedenen Grundgerüsten, Linkern und E3 Ligase Liganden zu synthetisieren. Die umfassende Charakterisierung der PROTACs auf chemischen und biologischem Weg ermöglichte es, PROTAC (**8g**) unter dem Namen **Homer** (https://www.thesgc.org/chemical-probes/homer) im Rahmen des *donated chemical probes* Portals zu veröffentlichen, um möglichst weitreichende Untersuchungen der unzähligen WDR5 Funktionen zu ermöglichen.

7. Experimental part

7.1 General and measuring instruments

General

Unless otherwise stated, all reactions in this work were carried out at 25 °C under an argon atmosphere. Distillations marked "removed under reduced pressure/in vacuo" were carried out with a rotary evaporator under membrane pump vacuum at 40 °C. Drying of the substances, for solids and high-boiling liquids, was performed in the high vacuum of an oil pump or in a vacuum drying oven at 40 °C. The molecular weights in brackets () refer to the natural isotope distribution. The numerical values in square brackets [] refer to the masses of the most common isotopes ^{1}H, ^{12}C, ^{14}N, ^{16}O, ^{23}Na and ^{32}S.

Chemicals and solvents

All chemicals and solvents used, were purchased from commercial suppliers as *Abcr*, *Acros Organics*, *Alfa Aesar*, *ChemPur*, *Carl Roth*, *Fischer Scientific*, *Fluka*, *Fluorochem UK*, *Merck*, *Santa Cruz Biotechnology*, *Sigma Aldrich*, *TCI Europe* and *VWR International*. The solvents were used in different degrees of purity: per analysi (p.a.), HPLC-grade and analytical grade. Unless otherwise indicated, all chemicals and solvents were used for synthesis without further purification. Deuterated solvents for NMR measurements were purchased from *Eurisotop*, France.

Chromatographic methods

Thin-layer chromatography (TLC)

For analytical thin-layer chromatography, silica gel coated aluminum plates with fluorescence indicator from *Merck KGaA* (TLC silica gel 60 F$_{254}$ plates) were used. The chromatographic zones were detected with UV light of the wavelength λ = 254 nm (fluorescence quenching) and the wavelength λ = 365 nm (autofluorescence). In addition, *p*-anisaldehyde, cerium molybdate, 2,4-dinitrophenylhydrazine (DNP) and ninhydrin solution were used as staining reagents for the detection:

- *p*-Anisaldehyde solution: 3.7 mL *p*-Anisaldehyde, 5 mL concentrated sulfuric acid, 1.5 mL glacial acetic acid, 135 mL absolute EtOH.
- Dinitrophenylhydrazine (DNP) solution: 12 g 2,4-Dinitrophenylhydrazine, 60 mL concentrated sulfuric acid and 80 mL H$_2$O in 200 mL of 95% EtOH.
- Ninhydrin solution: 1.5 g Ninhydrin, 15 mL glacial acetic acid, 500 mL MeOH.

- Cerium molybdate solution: 12 g Ammonium molybdate, 0.5 g ceric ammonium molybdate, and 15 mL concentrated sulfuric acid in 235 mL of H_2O. TLC plates were immersed in the respective solution and then developed under the action of heat using a heat gun. The solvent mixtures specified correspond to the volume ratios.

Preparative Column Chromatography

Column chromatographic purifications were performed on silica gel with a particle size of 0.040-0.063 mm from *Macherey-Nagel*, unless otherwise specified. Flash chromatographic purifications were carried out with a PuriFlash XS system from *Interchim* and with silica columns of 15 µm, 30 µm and 50 µm particle size or RP C18 columns. Solvents were used in HPLC grade or technical grade purity. The noted solvent mixtures correspond to volume ratios.

Product purification was also performed on an Agilent 1260 Infinity II LC System [Eclipse XDB-C18 column (7 µM, 21.2 × 250 mm)] using a gradient of water/MeCN + 0.1% TFA (98:2–5:95) over 40 min with a flow rate of 21 mL/min.

High Performance Liquid Chromatography (HPLC)

The purity of the final compounds was determined to >95% using an HPLC system an Agilent 1260 Infinity II LC System [Eclipse XDB-C18 column (4.6 × 250 mm, 5 µm)] coupled to an Agilent InifinityLab LC/MSD using a gradient of water/MeCN + 0.1% TFA (98:2–5:95) over 25 min at a flow rate of 1 mL/min.

NMR spectroscopy

All samples were dissolved in deuterated solvent and measured on one of the following devices:

- *Bruker* DPX 250: 250 MHz ^{1}H-NMR
- *Bruker* Avance 300: 300 MHz ^{1}H-NMR, 75 MHz ^{13}C-NMR
- *Bruker* Avance 400: 400 MHz ^{1}H-NMR, 101 MHz ^{13}C-NMR
- *Bruker* Avance 500: 500 MHz ^{1}H-NMR, 126 MHz ^{13}C-NMR
- *Bruker* DRX 600: 600 MHz ^{1}H-NMR, 150 MHz ^{13}C-NMR
- *Bruker* Avance 700: 700 MHz ^{1}H-NMR, 176 MHz ^{13}C-NMR
- *Bruker* Avance 800: 800 MHz ^{1}H-NMR, 201 MHz ^{13}C-NMR

The values given for the chemical shift (δ) refer to the signal of the particular deuterated solvent used in reference to the tetramethylsilane standard at δ = 0 ppm.

- CD_2Cl_2: δ(^{1}H) = 5.32 ppm, δ(^{13}C) = 54.00 ppm
- $CDCl_3$: δ(^{1}H) = 7.26 ppm, δ(^{13}C) = 77.16 ppm

- CD₃OD: $\delta(^1H)$ = 3.31 ppm, $\delta(^{13}C)$ = 49.00 ppm

- (CD₃)₂CO: $\delta(^1H)$ = 2.05 ppm, $\delta(^{13}C)$ = 29.84 ppm

- D₂O: $\delta(^1H)$ = 4.79 ppm

- DMSO-d₆: $\delta(^1H)$ = 2.50 ppm, $\delta(^{13}C)$ = 39.52 ppm

^{1}H-broadband decoupling was performed on the ^{13}C-NMR-spectra. The obtained spectra were either evaluated with the software *TopSpin 3.2* from *Bruker* or *MestReNova* from *Mestrelab Research SL*.

Mass spectrometry

Mass spectrometry was measured as a service at the Faculty of Biochemistry, Chemistry and Pharmacy at Goethe University, D-60438 Frankfurt am Main, Germany.

- High resolution mass spectrometry (FTMS + p MALDI-HRMS) was performed using a MALDI LTQ XL Orbitrap spectrometer from *Thermo Scientific*. The samples were measured without solvent in a HCCA matrix.

- Mass spectrometry (ESI) was measured in solution on a Surveyor MSQ spectrometer from *ThermoFisher* or directly from TLC using TLC-MS interface 2 from *Camag*.

- Mass spectrometry (p MALDI) was measured without solvent in a HCCA matrix on a Voyager-DE STR spectrometer from *Perseptive Biosystems* (today: *Applied Biosystems*).

7.2 Biological methods

Protein Expression and purification

Plasmids of WDR5A (aa 1-334 and aa 33-334) were a kind gift of M. Vedadi from the SGC Toronto. Expression and purification were performed in collaboration with A. Krämer from the Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, D-60438 Frankfurt am Main, Germany. Briefly, WDR5 was overexpressed in *E. coli* BL21 using TB media. Protein expression was induced by addition of 0.5 mM IPTG and cells were grown overnight at 18 °C. Next morning, the cells were harvested and resuspended in Lysis buffer (50 mM HEPES buffer, pH 7.5, 500 mM NaCl, 20 mM imidazole, 0.5 mM TCEP and 5% glycerol). For purification, the cells were lysed by sonication and centrifuged. The supernatant was loaded onto a Nickel-Sepharose column that had been equilibrated with 30 mL lysis buffer. The column was washed with 100 mL lysis buffer. WDR5 was eluted by an imidazole step gradient (50, 100, 200, 300 mM). Fractions containing WDR5 were pooled together, concentrated, and loaded onto a Superdex 200 16/60 HiLoad gel filtration column

equilibrated with final buffer (25 mM HEPES pH 7.5, 300 mM NaCl and 0.5 mM TCEP). The protein was concentrated to approx. 400 µM. The buffer was kept and used for ITC experiments.

DSF

Ligand binding to WDR5 protein was detected on an MX3005P qPCR system from Agilent Technologies as described elsewhere.[190] The measurements were assisted by A. Krämer from the Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, D-60438 Frankfurt am Main, Germany, who also provided the proteins. Briefly, protein was buffered in 25 mM HEPES (pH 7.5), 500 mM NaCl, 0.5 mM TCEP and diluted to a final concentration of 2 µM, and the fluorescent dye SYPRO Orange was added at a dilution of 1:1000. Compounds were dissolved in DMSO (10 mM) and added at a final concentration of 10 µM to 20 µL of protein-dye mix in a 96-well plate. Real-time melting curves were then recorded by heating the samples from 25 to 96 °C in 71 cycles (heating rate of 270 K/h, excitation/emission filters = 492/610 nm), and the melting point, T_m, was calculated using the Boltzmann equation.

ITC

Binding constant (K_d), stoichiometry (n) and thermodynamic binding parameters (ΔH, ΔS and ΔG) of ligand−protein interactions were determined on a Nano-ITC from TA Instruments as described elsewhere.[191] The measurements were assisted by A. Krämer from the Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, D-60438 Frankfurt am Main, Germany., who also provided the protein. Briefly, compounds were diluted to a final concentration of 10−25 µM in buffer and placed into the sample cell. Proteins (80−120 µM) were added using an initial injection of 3 or 4 µL, followed by 12-30 injections of 6 or 8 µL at 22 °C. Collected data were corrected by subtraction of pure DMSO injection heats. Data were analyzed by assuming a sigmoidal dose−response relationship (four parameters). Errors of fits were calculated using standard deviation and a confidence interval of 68% in GraphPad Prism.

NanoBRET[TM]

The assay originally developed by *Promega* was performed in HEK293T cells by L. Berger from the Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, D-60438 Frankfurt am Main, Germany, as described previously.[174] Briefly, Full-length WDR5 was obtained as plasmids cloned in frame with a N- or C-terminal NanoLuc-fusion pNLF1 vector (Collaboration with SGC Toronto). Plasmids were transfected into HEK293T cells using FuGENE HD (Promega, E2312) and proteins were allowed to express for 20 h. Serially diluted inhibitor and Tracer molecule (**21c**) at a concentration of 1 µM determined previously as the Tracer (**21c**) $K_{D,app}$ were pipetted into white 384-

well plates (Greiner 781 207) using an Echo acoustic dispenser (Labcyte). The corresponding protein-transfected cells were added and reseeded at a density of 2×10^5 cells/ml after trypsinization and resuspending in Opti-MEM without phenol red (Life Technologies). The system was allowed to equilibrate for 2 hours at 37 °C/5% CO_2 prior to BRET measurements. To measure BRET, NanoBRET™ NanoGlo Substrate and Extracellular NanoLuc Inhibitor (Promega, N2540) was added as per the manufacturer's protocol, and filtered luminescence was measured on a PHERAstar plate reader (BMG Labtech) equipped with a luminescence filter pair (450 nm BP filter (donor) and 610 nm LP filter (acceptor). Competitive displacement data were then graphed using GraphPad Prism 8 software using a normalized 3-parameter curve fit with the following equation: $y = \frac{100}{1+10^{x-\log{(IC_{50})}}}$.

Crystallization and structure determination

Crystallization and structure determination of the compound synthesized in this work in complex with WDR5 and VHL were performed in collaboration with A. Krämer and M. Schwalm from the Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, D-60438 Frankfurt am Main, Germany. The VHL plasmid was a kind gift of A. Ciulli from the University of Dundee. Protein expression and purification were performed by A. Krämer from the Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, D-60438 Frankfurt am Main, Germany.

Immunoblotting

All procedures were performed by B. Adhikari from the University of Würzburg, Theodor-Boveri-Institut, Am Hubland, D-97974 Würzburg, Germany.[174]

Cell culture. Human MV4-11 (male) and human HL-60 (female) cells were cultured in RPMI-1640, whereas human HEK293 (female) cells were cultured in DMEM at 37 °C in 5% CO_2. Both media were supplemented with 10% FBS and 1% penicillin/streptomycin solution.

Immunoblotting. After compound treatment, cells were lysed in RIPA lysis buffer (50 mM HEPES pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate) and supplemented with protease and phosphatase inhibitors for 20 min at 4 °C head-over-tail. Supernatant had been collected after centrifugation. Bicinchoninic acid (BCA) assay was used for protein quantification. Equal amounts of protein were separated by Bis-Tris-PAGE and transferred to PVDF membranes (Millipore). The membranes were incubated with 5% (w/v) non-fat dry milk in TBS-T (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% (v/v) Tween-20 for 1 h at room temperature for blocking and then incubated with the primary antibody overnight at 4 °C. For visualization, horseradish peroxidase (HRP)-labelled secondary antibodies were used and detected using chemiluminescent HRP substrate (Millipore) in LAS4000 Mini (Fuji). The signal was quantified using ImageJ or Image Studio

Lite (LI-COR Biosciences). Vinculin was used as a loading control. Antibodies used in this study were: WDR5 (Santa Cruz Biotechnology; sc-393080) and vinculin (Sigma; V9131).

HiBit assay

All procedures were performed by B. Adhikari from the University of Würzburg, Theodor-Boveri-Institut, Am Hubland, D-97974 Würzburg, Germany.[174]

Cloning. WDR5-HiBiT was cloned by PCR amplification of vector containing full length WDR5 using forward primer: CGCACCGGTATGGCGACGGAGGAGAAGAAGC and reverse primer: CGCGACGCGTTTAGCTAATCTTCTTGAACAGCCGCCAGCCGCTCACACCGGAGCTCCCGCAGTCACTCTTCCAC AGT. The PCR product was inserted into pRRL-PGK vector using AgeI/MluI restriction sites. HA-tagged VHL was cloned by PCR amplification of cDNA from MV4-11 cells as template (forward primer: CGCACCGGTATGTACCCTTACGACGTGCCCGACTACGCCGGGAGCTCCGGTCCCCGGAGGGCGGAGAAC and reverse primer: GGACTAGTTCAATCTCCCATCCGTTGATGTG) and inserted into pRRL-SFFV vector using AgeI/SpeI sites. The sequence of the cloned VHL was identified as isoform 1 by sanger sequencing.

MV4-11$^{WDR5-HiBiT}$ cell line generation. Lentiviral infection was used to generate stable MV4-11$^{WDR5-HiBiT}$, MV4-11^{VHL} and MV4-11$^{WDR5-HiBiT/VHL}$ cells. Lentivirus was produced using plasmids psPAX2, pMD2.G and HiBiT-WDR5 or HA-VHL plasmid in HEK293 cells. MV4-11 cells were infected with filtered virus supernatant and selected after 72 h of infection for generation of MV4-11$^{WDR5-HiBiT}$ and MV4-11^{VHL} cells. MV4-11$^{WDR5-HiBiT}$ cells were used to prepare MV4-11$^{WDR5-HiBiT/VHL}$ cells.

HiBiT assay. HiBiT assay was performed as described previously. MV4-11$^{WDR5-HiBiT}$ or MV4-11$^{WDR5-HiBiT/VHL}$ cells were seeded and treated with serial dilutions of compounds for 6 h or 24h. Nano-Glo HiBiT Lytic Detection System (Promega) was used for the assay. Luminescence was measured on a GloMax 96 Microplate Luminometer (Promega). DC_{50} was calculated using lower concentrations (showing sigmoidal behaviour) with the dose–response (four parameters) equation.

Cycloheximide Chase Assay

All procedures were performed by Bikash Adhikari from the University of Würzburg, Theodor-Boveri-Institut, Am Hubland, D-97974 Würzburg, Germany.[174]

Cycloheximide chase assay was performed as described previously. MV4-11 cells were treated with 50 µg/ml CHX with or without PROTACs for different time points. The cells were harvested in RIPA buffer and probed for immunoblotting. The intensity of WDR5 band at 0 h was set as 1. The mean ± SD from n=2 biological experiments were plotted as $\log_{10}$ values.

Quantitative PCR (qPCR)

All procedures were performed by B. Adhikari from the University of Würzburg, Theodor-Boveri-Institut, Am Hubland, D-97974 Würzburg, Germany.[174]

RT-qPCR. RT-qPCR was performed as described previously. Total RNA was extracted using peqGOLD TriFast (Peqlab). cDNA synthesis was carried out and cDNA were analysed by qPCR on a StepOnePlus Real-Time PCR System (Thermo Fisher Scientific) using the SYBR Green Master Mix (Thermo Fisher Scientific). Equal amounts of cDNA and SYBR Green Master Mix were added along with WDR5 primers (forward: CCAGTCTCGGCCGTTCATTT, reverse: CGTTCGGGGAGAACTTCACA). For analysis, expression was normalized to β2-microglobulin expression. qPCR was done in technical triplicates.

Quantitative Proteomics

All procedures were performed by B. Adhikari from the University of Würzburg, Theodor-Boveri-Institut, Am Hubland, D-97974 Würzburg, Germany, and Nicola Berner from the Technical University of Munich, 85354 Freising, Germany.[174]

4 million MV4-11 cells (in 10 ml) were seeded at least in triplicates for each treatment evening before the treatment. Cells were treated for 9 h with either 1 µM (**6d**), 1 µM (**8g**), 5 µM (**20b**), 5 µM (**17**) or DMSO. After treatment, cells were washed twice with ice cold PBS, supplemented with protease and phosphatase inhibitor, and lysed in SDS lysis buffer (2% SDS in 40 mM Tris-HCl, pH 7.6). In order to reduce viscosity, the sample was sonicated using a sonication water bath, boiled at 95 °C for 10 min and trifluoroacetic acid was added to a final concentration of 1 %. To neutralize the sample (final pH 7.6-8.0), 300 mM N-methylmorpholin was added to a final concentration of 2 %. The protein concentration in cell lysate was determined using the Pierce^{TM} BCA Protein Assay Kit (ThermoScientific) according to the protocol of the manufacturer. The beads suspension for sp3 sample workup was prepared by mixing magnetic SeraMag-A and SeraMag-B beads (10 µl per sample of each type; Cytiva) in a ratio of 1:1, washing them three times with ddH$_2$O and resuspending them in 10 µL ddH$_2$O per sample. A total of 200 µg per sample was mixed with 10 µl beads suspension. Acetonitrile was added to a final concentration of 70 % and incubated at room temperature, 18 min, 800 rpm. After discarding the supernatant, beads were washed twice using 200 µl 80% ethanol. For reduction and alkylation, beads were resuspended in 70 µl of 2 mM CaCl$_2$ in 40 mM Tris pH 7.6. Proteins were reduced with 10 mM dithiothreitol (DTT) for 45 min at 37 °C and 800 rpm, and alkylated with 55 mM chloroacetamide (CAA) at room temperature in the dark for 30 min. Proteins were digested (1:50 trypsin/substrate weight) overnight at 37 °C and 1000 rpm. Samples were centrifuged (5 min, 20000 rcf), sonicated 3 times for 30 sec and supernatant was collected. Beads were washed once with 100 µl ddH$_2$O, sonicated 3 times for 30 sec, and supernatants were combined with previous supernatants. Samples were acidified with formic acid (FA) to a final concentration of 1 %. Peptides

were desalted using tC18 RP solid-phase extraction cartridges (Waters Corp.; wash solvent: 0.1% FA; elution solvent: 0.1% FA in 50% acetonitrile (ACN). Samples were frozen at −80 °C freezer, dried in a SpeedVac, reconstituted in 0.1 % FA and peptide concentration was determined using a NanoDrop and stored at -20 °C until LC-MS^2 analysis.

A micro-flow LC-MSMS setup with a Q Exactive HF-X mass spectrometer (Thermo Fisher Scientific) was used as described in detail in previous publications. 50 µg peptides dissolved in 0.1 % FA were directly injected onto the microflow LC system. Online chromatography was performed using a commercially available Thermo Fisher Scientific Acclaim PepMap 100 C18 LC column (2 µm particle size, 1 mm ID × 150 mm; catalog number 164711). Column temperature was maintained at 55 °C using the integrated column oven. Peptides were delivered at a flow rate of 50 µl/min and separated using a two-step linear gradient (120 min) ranging from 1-24 % (105 min) and 24-35 % (15 min) of LC solvent B (0.1 % FA, 3 % DMSO in ACN) in LC solvent A (0.1 % FA, 3 % DMSO. The Q Exactive HF-X was operated as follows: positive polarity; spray voltage 4 kV, capillary temperature 320 °C; vaporizer temperature 200 °C. The flow rates of sheath gas, aux gas and sweep gas were set to 40, 3, and 0, respectively. TopN was set to 50. Full MS was readout in the orbitrap, resolution was set to 120,000 and the mass range was set to 360–1300. Full MS AGC target value was 3E6 with a maximum IT of 100 ms and RF lens value was set to 40. Peptide match was set to preferred and default charge state was set to 2. The dynamic exclusion duration was set to 40 s and exclude isotopes was switched on. For readout of MS2 spectra, orbitrap resolution was set to 15,000 and the mass range was set to 200–2000. The isolation width was set to 1.3 m/z, the first mass was fixed at 100 m/z, NCE was 28. The AGC target value was set to 1E5 at a maximum IT of 22 ms.

Protein and peptide identification and quantification was performed using MaxQuant (version 1.6.12.0) by searching the MS^2 data against all canonical protein sequences as annotated in the UniProt reference database (human proteins only, downloaded 24.08.2020) using the search engine Andromeda. Carbamidomethylated cysteine was set as fixed modification; oxidation of methionine and N-terminal protein acetylation were set as variable modification. Trypsin/P was specified as proteolytic enzyme and up to two missed cleavage sites were allowed. The minimum peptide length was set to seven and all data were adjusted to 1 % peptide-spectrum-match (PSM) and 1 % protein false discovery rate (FDR). LFQ based quantification was enabled including the match between runs option and without normalization.

Data analysis was performed using the Perseus software suite (version 1.6.14.0) and Microsoft Excel on identified and quantified protein groups as provided in the proteinGroups.txt file. Proteingroups.txt was filtered for contaminants and reverse hits, and median centric normalization and log2 transformation were performed. The pyrrolimidazole-based ligand (**17**) treated replicate 1 showed high differences to the other conditions and was not considered for further analysis. Entries were

filtered for at least three valid values in one condition. Two-sample t-test were performed (S0:0.1, permutation-based FDR: 5%, number of randomizations: 250). For principal component analysis (PCA) remaining missing values were replaced from normal distribution (width 0.3, down shift: 1.8).

The mass spectrometry proteomics data and complete MaxQuant search results have been deposited to the ProteomeXchange Consortium (http://www.proteomexchange.org/).

7.3 Experimental part of chapter 3

7.3.1 Synthesis of WDR5 ligands

Synthesis of 1-(4-bromo-2-nitrophenyl)-4-methylpiperazine (3)

5 mL (39.7 mmol, 1.00 eq) 5-Bromo-2-Fluoro-Nitrobenzene was dissolved in 20 mL EtOH. 4 mL (39.7 mmol, 1.00 eq) N-Methylpiperazine and 13.5 mL (79.4 mmol, 2.00 eq) DIEA were added and the reaction mixture was stirred for 5 h at 80 °C. The reaction was cooled to rt and the solvent was removed under reduced pressure. The reaction mixture was diluted with water and extracted 8x with DCM. The combined organic phases were washed with 1 M HCl, saturated NaCl solution, dried over $MgSO_4$ and filtered. The crude product was purified via CC (gradient: 0 % to 10 % MeOH in DCM). Other attempts of the synthesis of (**3**) are listed in **Table 9**.

Table 9: Synthesis of 1-(4-bromo-2-nitrophenyl)-4-methylpiperazine (**3**).

N-Methylpiperazine	5-Bromo-2-Fluoro-Nitrobenzene	DIEA	(**3**)
4 mL, 39.7 mmol, 1.00 eq	5 mL, 39.7 mmol, 1.00 eq	13.5 mL, 79.4 mmol, 2.00 eq	11.1 g, 37 mmol, 95 %.
4 mL, 39.7 mmol, 1.00 eq	5 mL, 39.7 mmol, 1.00 eq	13.5 mL, 79.4 mmol, 2.00 eq	12.9 g, 38.7 mmol, 97 %.

Yield: 11.1 g, 37 mmol, 95 % of an orange powder.

R_f (5% MeOH/ CH_2Cl_2): 0.54.

ESI: (calculated): [M+H$^+$] 300.03 g/mol

(found): [M+H$^+$] 299.98 g/mol.

^{1}H NMR (250 MHz, CDCl$_3$) δ = 7.94 (d, ^4J = 2.3 Hz, 1H), 7.65 (dd, ^3J = 8.7 Hz, ^4J = 2.4 Hz, 1H), 7.17 (d, ^3J = 8.7 Hz, 1H), 3.43 (m, 4H), 3.25 (m, 4H), 2.80 (s, 3H) ppm.

Synthesis of 5-bromo-2-(4-methylpiperazin-1-yl)aniline (4)

2.00 g (7.40 mmol, 1.00 eq) 1-(4-bromo-2-nitrophenyl)-4-methylpiperazine **3** was suspended in a mixture of 1,4-Dioxane and water (3:1). 3.20 g (37 mmol, 7.50 eq) Ammonium chloride was added, followed by a slow addition of 2.60 g (37 mmol, 7.50 eq) Zinc dust. The reaction mixture was stirred until a colour change from orange to light pink was observed. The solvent was removed under reduced pressure. The reaction mixture was diluted with saturated NaHCO$_3$ solution and extracted 6x with DCM. The combined organic phases were washed with saturated NaCl solution, dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. Other attempts of the synthesis of (**4**) are listed in **Table 10**.

Table 10: Synthesis of 1-(4-bromo-2-nitrophenyl)-4-methylpiperazine (**4**).

(**3**)	Ammonium chloride	Zinc dust	(**4**)
1.00 g, 3.34 mmol, 1.00 eq	1.40 g, 25.1 mmol, 7.50 eq	1.65 g, 25.1 mmol, 7.50 eq	733 mg, 2.71 mmol, 81%
200 mg, 0.67 mmol, 1.00 eq	269 mg, 5.03 mmol, 7.50 eq	328 mg, 5.03 mmol, 7.50 eq	145mg, 0.54 mmol, 80 %
1.00 g, 3.34 mmol, 1.00 eq	1.40 g, 25.1 mmol, 7.50 eq	1.65 g, 25.1 mmol, 7.50 eq	841 mg, 3.11 mmol, 93%
1.00 g, 3.34 mmol, 1.00 eq	1.40 g, 25.1 mmol, 7.50 eq	1.65 g, 25.1 mmol, 7.50 eq	752 mg, 2.78 mmol, 83%

Yield: 1.57 mg, 5.81 mmol, 79% of a light pink solid.

R_f (5% MeOH/ CH$_2$Cl$_2$): 0.3.

ESI: (calculated): [M+H$^+$] 270.06 g/mol

(found): [M+H$^+$] 270.03 g/mol.

HPLC: RT = 10.9 min (254 nm, 99%).

^{1}H NMR (250 MHz, CDCl$_3$) δ = 6.96 – 6.70 (m, 3H), 4.01 (s, 2H), 2.92 (t, ^3J = 4.5 Hz, 4H), 2.60 (s, 4H), 2.39 (s, 3H) ppm.

Synthesis of *tert*-butyl 5-(3-amino-4-(4-methylpiperazin-1-yl)phenyl)-1*H*-indole-1-carboxylate (5a)

1.58 g (4.42 mmol, 1.4 eq) 1-Boc-Indole-5-Boronic acid was dissolved in an Argon-purged solvent solution (1,4-Dioxane/ Water (3:1)) and 2.1 g (15.4 mmol, 5 eq) potassium carbonate was added. The reaction mixture was stirred for 5 min at rt under Argon atmosphere, then 832 mg (3.08 mmol, 1 eq) 5-bromo-2-(4-methylpiperazin-1-yl)aniline and 262 mg (0.31 mmol, 0.1 eq) XPhos Pd G3 were added. The reaction was stirred at 95 °C for 18 h under Argon atmosphere. The reaction mixture was cooled to rt, filtered over celite and washed with MeOH. The solvent was removed under reduced pressure. The reaction mixture was diluted with water and extracted 3x with DCM. The crude product was purified via FC (0 % to 10 % MeOH/ DCM). Other attempts to synthesize (**5b**) are listed in **Table 11**.

Table 11: Synthesis of *tert*-butyl 5-(3-amino-4-(4-methylpiperazin-1-yl)phenyl)-1*H*-indole-1-carboxylate (**5b**).

Boronic acid	(**4**)	Base	XPhos Pd G3	Temperature/ Heating time	(**5b**)
356 mg, 1.04 mmol, 1.4 eq	200 mg, 740 µmol, 1 eq	511 mg, 3.70 mmol, 5 eq NaOH	62.6 mg, 74 µmol, 0.1 eq	90 °C/ 18 h	160 mg, 393 µmol, 53%

Yield: 814 mg, 2.00 mmol, 65% of a yellow solid.

R_f (5% MeOH/ CH_2Cl_2): 0.13.

ESI: (calculated): [M+H$^+$] 407.24 g/mol

(found): [M+H$^+$] 407.29 g/mol.

HPLC: RT = 12.5 min (254 nm, 100%).

^{1}H NMR (300 MHz, CDCl$_3$) δ = 8.16 (d, ^3J = 8.6 Hz, 1H), 7.72 (s, 1H), 7.61 (d, ^3J = 3.5 Hz, 1H), 7.52 (dd, ^3J = 8.7, ^4J =1.3 Hz, 1H), 7.14 – 6.98 (m, 3H), 6.59 (d, ^3J = 3.6 Hz, 1H), 4.07 (s, 2H), 3.02 (s, 4H), 2.62 (s, 4H), 2.39 (s, 3H), 1.69 (s, 9H) ppm.

Synthesis of N-(5-bromo-2-(4-methylpiperazin-1-yl)phenyl)-3-methylbenzamide

630 mg (4.63 mmol, 1 eq) 2-Methylbenzoic acid and 2.64 mg (6.94 mmol, 1.5 eq) HATU were dissolved in 1 mL DMF. 1.6 mL (9.25 mmol, 2 eq) DIEA was added. The mixture was stirred for 5 min, then 1.50 g (5.55 mmol, 1 eq) 5-bromo-2-(4-methylpiperazin-1-yl)aniline were added. The solution was stirred at rt for 40 h. The reaction was stopped with 1 mL water. Saturated NaHCO$_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated NaHCO$_3$ solution, dried over MgSO$_4$ and filtered. The solvent of the

organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the FC system. The evapored fraction was dissolved in 2M HCl in diethyl ether.

Yield: 687 mg, 2.03 mmol, 44% of a white solid.

R_f (1% MeOH/ CH_2Cl_2): 0.12.

ESI: (calculated): [M+H$^+$] 388.10 g/mol

(found): [M+H$^+$] 388.09 g/mol.

^{1}H NMR (500 MHz, DMSO) δ = 10.46 (s, 1H, H(Cl) salt), 9.49 (s, 1H, NH), 8.32 (d, ^3J = 2.4 Hz, 1H), 7.75 (m, 2H), 7.46 (m, 2H), 7.37 (dd, ^3J = 8.5, ^4J = 2.4 Hz, 1H), 7.24 (d, ^3J = 8.6 Hz, 1H), 3.52 (m, 2H), 3.28 – 3.02 (m, 6H), 2.85 (s, 3H), 2.42 (s, 3H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 165.2, 141.5, 138.2, 134.4, 134.1, 132.7, 128.8, 128.2, 127.5, 124.6, 124.4, 123.0, 117.0, 53.0, 48.2, 39.5, 30.7, 21.0 ppm.

Synthesis of *tert*-butyl 5-(3-(3-methylbenzamido)-4-(piperazin-1-yl)phenyl)-1*H*-indole-1-carboxylate (6a)

318 mg, (0.82 mmol, 1 eq) of N-(5-bromo-2-(4-methylpiperazin-1-yl)phenyl)-3-methylbenzamide were suspended in 20 mL of an Argon purged Toluene/ Water mixture (3/1) and 364 mg (1.06 mmol, 1.3 eq) tert-butyl   5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate,   165 mg (4.01 mmol, 5 eq) sodium hydroxide and 69 mg (80 µmol, 0.1 eq) XPhos Pd G3 catalyst were added to the solution. The reaction mixture was heated at 95 °C for 20 h. After cooling to rt, the mixture was filtrated over celite, washed with MeOH and the excess solvent was evapored. The remaining solid was diluted with water and CH_2Cl_2, the aqueous phase extracted 3x with CH_2Cl_2, dried over $MgSO_4$ and the

excess solvent was evapored. The crude product was purified via FC (MeOH/ CH_2Cl_2) to give a white foam.

Yield: 320 mg, 611 µmol, 74% of a white foam.

R_f (1% MeOH/ CH_2Cl_2): 0.32.

ESI: (calculated): [M+H$^+$] 525.28 g/mol

(found): [M+H$^+$] 525.18 g/mol.

HPLC: RT = 14.2 min (254 nm, 96%).

^{1}H NMR (250 MHz, MeOD) δ = 8.59 (s, 1H), 8.17 (d, ^3J = 8.8 Hz, 1H), 7.78 (m, 3H), 7.64 (d, ^3J = 3.7 Hz, 1H), 7.57 (d, ^3J = 8.7 Hz, 1H), 7.46 (d, ^3J = 4.8 Hz, 3H), 7.35 (d, ^3J = 8.3 Hz, 1H), 6.67 (d, ^3J = 3.6 Hz, 1H), 3.00 (t, ^3J = 4.3 Hz, 4H), 2.67 (s, 4H), 2.47 (s, 3H), 2.38 (s, 3H), 1.70 (s, 9H) ppm.

Synthesis of *N*-(5-(1*H*-indol-5-yl)-2-(piperazin-1-yl)phenyl)-3-methylbenzamide

A mixture of 1 mL TFA and 1 mL CH_2Cl_2 was added to 184 mg (433 µmol, 1 eq) *tert*-butyl 5-(3-(3-methylbenzamido)-4-(piperazin-1-yl)phenyl)-1*H*-indole-1-carboxylate. The solution was stirred at rt for 30 min, then statured NaHCO$_3$ was added. The mixture was extracted 4x with CH_2Cl_2, washed with brine, dried over MgSO$_4$, filtered and excess solvent was evapored.

Yield: 164 mg, 386 µmol, 89% of a white solid.

R_f (10% MeOH/ CH_2Cl_2): 0.62.

ESI: (calculated): [M+H$^+$] 425.23 g/mol

(found): [M+H$^+$] 425.16 g/mol.

^{1}H NMR (250 MHz, CDCl$_3$) δ = 11.06 (s, 1H), 9.60 (s, 1H), 8.83 (d, ^3J = 2.0 Hz, 1H), 8.49 (s, 1H), 7.90 (m, 1H), 7.78 (s, 1H), 7.74 (d, ^3J = 7.0 Hz, 1H), 7.50 – 7.42 (m, 3H), 7.39 (s, 2H), 7.27 (d, ^3J = 8.2 Hz, 1H), 2.97 (m, 4H), 2.62 (s, 4H), 2.45 (s, 3H), 2.36 (s, 3H) ppm.

Synthesis of tert-butyl 5-(3-(2-chloro-4-fluoro-3-methyl-5-nitrobenzamido)-4-(4-methylpiperazin-1-yl)phenyl)-1H-indole-1-carboxylate

37 mg, (160 μmol, 1 eq) of 2-chloro-4-fluoro-3-methyl-5-nitrobenzoic acid was dissolved in 1 mL DCM/ acetonitrile and 101 μL (1.19 mmol, 7.5 eq) thionyl chloride. The reaction mixture was stirred for 3 h at 50 °C until a colour change from clear to yellow was observed. Excess thionyl chloride was removed under reduced pressure and the acyl chloride was evapored on a high vacuum line for 5 min. The acyl chloride was diluted with 2 mL of DCM and a solution of 3 mL containing 65 mg (160 μmol, 1 eq) *tert*-butyl 5-(3-amino-4-(4-methylpiperazin-1-yl)phenyl)-1*H*-indole-1-carboxylate and 26 μL (320 μmol, 2.00 eq) pyridine was added. The reaction mixture was stirred at 50 °C for 18 h. The reaction mixture was cooled to rt, diluted with water and extracted 3x with DCM. The crude product was purified by FC (0 % to 10 % MeOH/ DCM). Other attempts to synthesize the product are listed in **Table 12**.

Table 12: Synthesis of tert-butyl 5-(3-(2-chloro-4-fluoro-3-methyl-5-nitrobenzamido)-4-(4-methylpiperazin-1-yl)phenyl)-1H-indole-1-carboxylate.

(**5b**)	Product Yield
160 mg, 0,39 µmol	198 mg, 0.32 µmol, 82%.
112 mg, 0.28 µmol	144 mg, 0.23 µmol, 83%.
42 mg, 0.11 µmol	47 mg, 90 µmol, 86%.

Yield: 93 mg, 149 µmol, 93% of a red powder.

R_f (5% MeOH/ CH$_2$Cl$_2$): 0.49.

ESI: (calculated): [M+H$^+$] 622.22 g/mol, [M-Boc$^+$] 522.17 g/mol

          (found): [M+H$^+$] 622.13 g/mol, [M-Boc$^+$] 522.29 g/mol.

HPLC: RT = 13.4 min (254 nm, 95%).

^{1}H NMR (500 MHz, CD$_2$Cl$_2$) δ = 8.73 (d, ^4J = 1 Hz, 1H), 8.19 (d, ^3J = 7.7 Hz, 1H), 8.09 (d, ^3J = 8.3 Hz, 1H), 7.74 (d, ^4J = 1.1 Hz, 1H), 7.55 (d, ^4J = 3.5 Hz, 1H), 7.51 (dd, ^3J = 8.6 Hz, ^4J =, 1.5 Hz, 1H), 7.37 (dd, ^3J = 8.2 Hz, ^4J = 2.0 Hz, 1H), 7.27 (d, ^3J = 8.2 Hz, 1H), 6.56 (d, ^3J = 3.6 Hz, 1H), 2.87 (t, ^3J = 4.3 Hz, 4H), 2.45 - 2.40 (m, 4H), 2.41 (s, 3H), 2.21 (s, 3H), 1.59 (s, 9H) ppm.

Synthesis of tert-butyl 5-(3-(5-amino-2-chloro-4-fluoro-3-methylbenzamido)-4-(4-methylpiperazin-1-yl)phenyl)-1H-indole-1-carboxylate (6b)

100 mg (160 µmol, 1.0 eq) tert-butyl 5-(3-(2-chloro-4-fluoro-3-methyl-5-nitrobenzamido)-4-(4-methylpiperazin-1-yl)phenyl)-1H-indole-1-carboxylate were dissolved in 6 mL dioxane/ water (3/1). 42 mg (800 µmol, 5.0 eq) ammonium chloride and 52 mg (800 µmol, 5.0 eq) Zinc dust were added to the reaction solution and stirred for 1.5 h. The reaction mixture was stirred until a colour change from orange to light pink was observed. The solvent was removed under reduced pressure. The reaction mixture was diluted with saturated $NaHCO_3$ solution and extracted 6x with DCM. The combined organic phases were washed with saturated NaCl solution, dried over $MgSO_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified by FC.

Yield: 23 mg, 40.5 µmol, 25% of a white solid.

R_f (5% MeOH/ CH_2Cl_2): 0.25.

ESI: (calculated): [M+H$^+$] 592.25 g/mol

         (found): [M+H$^+$] 592.28 g/mol.

^{1}H NMR (400 MHz, CD_2Cl_2) δ = 9.16 (s, 1H), 8.85 (s, 1H), 8.17 (d, ^3J = 7.9 Hz, 1H), 7.83 (s, 1H), 7.69 − 7.52 (m, 2H), 7.40 - 7.30 (m, 2H), 7.00 (d, ^3J = 8.9 Hz, 1H), 6.64 (s, 1H), 3.94 (s, 2H, NH), 2.93 (s, 4H), 2.51 (s, 4H), 2.35 (s, 3H), 2.28 (s, 3H), 1.68 (s, 9H) ppm.

Synthesis of *tert*-butyl 5-(3-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4-(4-methylpiperazin-1-yl)phenyl)-1*H*-indole-1-carboxylate (6c)

33 mg, (159 µmol, 1 eq) of 6-Hydroxy-4-(trifluoromethyl)nicotinic acid was dissolved in 1 mL DCM/ acetonitrile and 58 µL (797 µmol, 5 eq) thionyl chloride. The reaction mixture was stirred for 3 h at 50 °C until a colour change from clear to yellow was observed. Excess thionyl chloride was removed under reduced pressure and the acyl chloride was evapored on a high vacuum line for 5 min. The acyl chloride was diluted with 2 mL of DCM and a solution of 3 mL containing 65 mg (159 µmol, 1 eq) *tert*-butyl 5-(3-amino-4-(4-methylpiperazin-1-yl)phenyl)-1*H*-indole-1-carboxylate and 26 µL (319 µmol, 2.00 eq) pyridine was added. The reaction mixture was stirred at 50 °C for 18 h. The reaction mixture was cooled to rt, diluted with water and extracted 3x with DCM. The crude product was purified via FC (0 % to 10 % MeOH/ DCM). Other attempts to synthesize (**6b**) are listed in **Table 13**.

Table 13: Synthesis of *tert*-butyl 5-(3-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4-(4-methylpiperazin-1-yl)phenyl)-1*H*-indole-1-carboxylate (**6c**).

Nicotinic acid	(**5b**)	Thionyl chloride	pyridine	(**6b**)
24 mg, 118 µmol, 1.0 eq	48 mg, 118 µmol, 1.0 eq	75 µL, 886 µmol, 7.5 eq	19 µL, 236 µmol, 2.0 eq	47 mg, 79 µmol, 67%

Yield: 45 mg, 75.5 µmol, 48% of a white powder.

R$_f$ (5% MeOH/ CH$_2$Cl$_2$): 0.1.

ESI: (calculated): [M+H$^+$] 596.25 g/mol

          (found): [fragment$^+$] 455.29 g/mol (100); [M+H$^+$] 596.32 g/mol (90).

HPLC: RT = 12.3 min (254 nm, 98%).

^{1}H NMR (600 MHz, MeOD) δ = 8.26 (d, ^4J = 1.7 Hz, 1H), 8.18 (d, ^3J = 8.4 Hz, 1H), 8.03 (s, 1H), 7.81 (d, ^3J = 1.3 Hz, 1H), 7.64 (d, ^3J = 3.7 Hz, 1H), 7.61 – 7.52 (m, 2H), 7.37 (d, ^3J = 8.3 Hz, 1H), 6.94 (s, 1H), 6.67 (d, ^3J = 3.6 Hz, 1H), 3.61 (m, 2H), 3.28 (m, 4H), 3.16 (m, 2H), 2.96 (s, 3H), 1.69 (s, 9H) ppm.

Synthesis of *tert*-butyl 3'-amino-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate (5b)

395 mg (1.78 mmol, 1.2 eq) (4-(*tert*-butoxycarbonyl)phenyl)boronic acid was dissolved in an Argon-purged solvent solution (1,4-Dioxane/ Water (3:1)) and 288 mg (7.40 mmol, 5.0 eq) Sodium hydroxide was added. The reaction mixture was stirred for 5 min at rt under Argon atmosphere, then 400 mg (1.48 mmol, 1.0 eq) 5-bromo-2-(4-methylpiperazin-1-yl)aniline and 171 mg (148 μmol, 0.1 eq) Pd(PPh$_3$)$_4$ were added. The reaction was stirred at 90 °C for 18 h under Argon atmosphere. The reaction mixture was cooled to rt, filtered over celite and washed with MeOH. The solvent was removed under reduced pressure. The reaction mixture was diluted with water and extracted 3x with DCM. The crude product was purified via FC (0 % to 10 % MeOH/ DCM). Other attempts to synthesize 3'-amino-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate (**5b**) are listed in **Table 14**.

Table 14: Synthesis 3'-amino-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate (**5b**).

Boronic acid	(**4**)	NaOH	Pd(PPh$_3$)$_4$	Heating temperature	(**5b**)
395 mg, 1.78 mmol, 1.2 eq	400 mg, 1.48 mmol, 1.0 eq	288 mg, 7.40 mmol, 1.2 eq	171 mg, 148 μmol, 0.1 eq	100°C/ 17 h	395 mg 1.08 mmol, 73%
658 mg, 2.96 mmol, 1.6 eq	495 mg, 1.83 mmol, 1.0 eq	270 mg, 6.75 mmol, 3.7 eq	210 mg, 180 μmol, 0.1 eq	100 °C/ 17 h	600 mg, 1.63 mmol, 89%

Yield: 395 mg, 1.08 mmol, 73% of a white solid.

R_f (5% MeOH/ CH_2Cl_2): 0.28.

ESI: (calculated): [M+H$^+$] 368.23 g/mol

(found): [M+H$^+$] 368.13 g/mol.

HPLC: RT = 11.9 min (254 nm, 94%).

^{1}H NMR (500 MHz, CD_2Cl_2) δ = 7.98 (d, ^3J = 8.5 Hz, 2H), 7.59 (d, ^3J = 8.5 Hz, 2H), 7.06 (d, ^3J = 8.7 Hz, 1H), 6.99 (m, 2H), 3.97 (s, 1H), 2.97 (s, 4H), 2.61 (s, 4H), 2.35 (s, 3H), 1.58 (s, 9H) ppm.

^{13}C NMR (126 MHz, CD_2Cl_2) δ = 165.9, 145.5, 142.4, 139.8, 136.5, 130.8, 130.1, 126.8, 120.4, 117.6, 113.8, 81.1, 56.0, 51.0, 46.1, 28.3 ppm.

Synthesis of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate (6d)

56 mg, (272 µmol, 1.00 eq) of 6-Hydroxy-4-(trifluoromethyl)nicotinic acid was dissolved in 1 mL DCM/ acetonitrile and 228 µL (2.72 mmol, 10 eq) thionyl chloride. The reaction mixture was stirred for 3 h at 50 °C until a colour change from clear to yellow was observed. Excess thionyl chloride was removed under reduced pressure and the acyl chloride was evapored on a high vacuum line for 5 min. The acyl chloride was diluted with 2 mL of DCM and a solution of 3 mL containing 100 mg (272 µmol, 1.00 eq) 3'-amino-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and 44 µL (544 µmol, 2.00 eq) pyridine was added. The reaction mixture was stirred at 50 °C for 18 h. The reaction mixture was cooled to rt, diluted with water and extracted 3x with DCM. The crude product was purified via FC (0 % to 10 % MeOH/ DCM). Other attempts to synthesize (**6d**) are listed in **Table 15**.

Table 15: Synthesis of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate (**6d**).

Nicotinic acid	(**5a**)	Thionyl chloride	pyridine	(**6d**)
49 mg, 239 µmol, 1.1 eq	80 mg, 217 µmol, 1.0 eq	183 µL, 2.17 mmol, 10 eq	35 µL, 435 µmol, 2.0 eq	64 mg, 115 µmol, 53 %
192 mg, 0.93 mmol, 1.5 eq	228 mg, 0.62 mmol, 1.0 eq	522 µL, 6.2 mmol, 10 eq	101 µL, 1.24 mmol, 2.0 eq	167 mg, 0.3 mmol, 48 %

Yield: 109 mg, 196 µmol, 72% of a white solid.

R_f (5% MeOH/ CH_2Cl_2): 0.21.

ESI: (calculated): [M+H$^+$] 557.23 g/mol

(found): [M+H$^+$] 557.08 g/mol.

HPLC: RT = 12.9 min (254 nm, 93%).

^{1}H NMR (500 MHz, CDCl$_3$) δ = 8.97 (s, 1H), 8.69 (s, 1H), 8.04 (d, ^3J = 8.3 Hz, 2H), 7.89 (s, 1H), 7.66 (d, ^3J = 8.3 Hz, 2H), 7.48 – 7.30 (m, 2H), 6.95 (s, 1H), 3.05 (s, 4H), 2.78 (s, 4H), 2.51 (s, 3H), 1.61 (s, 9H) ppm.

^{13}C NMR (75 MHz, DMSO) δ = 164.8, 163.1, 161.1, 143.7, 143.2, 139.5 (m), 138.6 (q, ^2J = 32 Hz), 135.0, 134.1, 132.7, 130.1, 129.8, 126.4, 124.0, 122.1 (q, ^1J = 273 Hz), 121.0, 118.9 (m), 111.6 (m), 80.7, 52.8, 48.1, 42.3, 27.8 ppm.

Synthesis of 4-(4-bromo-2-nitrophenyl)morpholine

1 mL (8.16 mmol, 1.00 eq) 5-Bromo-1-Flouro-2-Nitrobenzole and 704 µL (8.16 mmol, 1.00 eq) Morpholine were suspended in 5 mL EtOH and stirred at 80 °C for 18 h. The reaction was cooled to rt and the solvent was removed under reduced pressure. The reaction mixture was diluted with water and extracted 8x with DCM. The combined organic phases were washed with 1 M HCl, saturated NaCl solution, dried over MgSO$_4$ and filtered. The crude product was purified via CC (gradient: 25% to 50% EA in cHex).

Yield: 1.73 g, 6.03 mmol, 74% of an orange powder.

R$_f$ (33% EA/ cHex): 0.47.

^{1}H NMR (250 MHz, MeOD) δ = 7.91 (d, ^4J = 2.4 Hz, 1H), 7.67 (dd, ^3J = 8.8 Hz, ^4J = 2.4 Hz, 1H), 7.22 (d, ^3J = 8.8 Hz, 1H), 3.85 – 3.66 (m, 4H), 3.04 – 3.00 (m, 4H) ppm.

Synthesis of 5-bromo-2-morpholinoaniline

1.73 g (6.03 mmol, 1.00 eq) 4-(4-bromo-2-nitrophenyl)morpholine was suspended in a mixture of 1,4-Dioxane and water (3:1). 2.96 g (45.2 mmol, 7.50 eq) Ammonium chloride was added, followed by a slow addition of 2.42 g (45.2 mmol, 7.50 eq) Zinc dust. The reaction mixture was stirred until a colour change from orange to light pink was observed. The solvent was removed under reduced pressure. The reaction mixture was diluted with saturated $NaHCO_3$ solution and extracted 6x with DCM. The combined organic phases were washed with saturated NaCl solution, dried over $MgSO_4$, filtered and the solvent was removed under reduced pressure.

Yield: 603 mg, 2.39 mmol, 39% of a light pink solid

R_f (10% MeOH/ CH_2Cl_2): 0.74.

^{1}H NMR (250 MHz, MeOD) δ = 6.89 – 6.84 (m, 2H), 6.74 (dd, ^3J = 8.4 Hz, ^4J =2.3 Hz, 1H), 3.88 – 3.77 (m, 4H), 2.91 – 2.74 (m, 4H) ppm.

Synthesis of tert-butyl 4'-morpholino-3'-(6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamido)-[1,1'-biphenyl]-4-carboxylate

555 mg (2.50 mmol, 1.6 eq) (4-(*tert*-butoxycarbonyl)phenyl)boronic acid was dissolved in an Argon-purged solvent solution (1,4-Dioxane/ Water (3:1)) and 187 mg (4.68 mmol, 3.0 eq) Sodium hydroxide

was added. The reaction mixture was stirred for 5 min at rt under Argon atmosphere, then 400 mg (1.48 mmol, 1.0 eq) 5-bromo-2-morpholinoaniline and 132 mg (156 µmol, 0.1 eq) Pd XPhos G3 were added. The reaction was stirred at 93 °C for 24 h under Argon atmosphere. The reaction mixture was cooled to rt, filtered over celite and washed with MeOH. The solvent was removed under reduced pressure. The reaction mixture was diluted with water and extracted 3x with DCM. The crude product was purified via FC (0 % to 10 % MeOH/ DCM) to give 439 mg (1.24 mmol, 79%) of a white tert-butyl 3'-amino-4'-morpholino-[1,1'-biphenyl]-4-carboxylate.

74 mg (355 µmol, 1.20 eq) 6-Hydroxy-4-(trifluoromethyl)nicotinic acid was dissolved in 1 mL DCM/ acetonitrile and 218 µL (3 mmol, 10 eq) thionyl chloride. The reaction mixture was stirred for 3 h at 50 °C until a colour change from clear to yellow was observed. Excess thionyl chloride was removed under reduced pressure and the acyl chloride was evapored on a high vacuum line for 5 min. The acyl chloride was diluted with 2 mL of DCM and a solution of 3 mL containing 105 mg (296 µmol, 1.00 eq) of tert-butyl 3'-amino-4'-morpholino-[1,1'-biphenyl]-4-carboxylate and 48 µL (592 µmol, 2.00 eq) pyridine was added. The reaction mixture was stirred at 50 °C for 18 h. The reaction mixture was cooled to rt, diluted with water and extracted 3x with DCM. The crude product was purified via FC (0 % to 10 % MeOH/ DCM).

Yield: 99 mg, 182 µmol, 51% of a white solid.

R_f (10% MeOH/ CH_2Cl_2): 0.23.

ESI: (calculated) [M+H$^+$] 544.21 g/mol
          (found) [M+H$^+$] 544.21 g/mol.

^{1}H NMR (250 MHz, MeOD) δ = 8.80 (s, 1H), 8.65 (s, 1H), 8.39 (d, ^4J = 1.9 Hz, 1H), 8.00 (d, ^3J = 8.3 Hz, 2H), 7.78 (s, 1H), 7.70 (d, ^3J = 8.3 Hz, 2H), 7.53 (dd, ^3J = 8.3 Hz, ^4J = 2.0 Hz, 1H), 7.33 (d, ^3J = 8.4 Hz, 1H), 6.95 (s, 1H), 3.85 – 3.78 (m, 4H), 2.98 – 2.92 (m, 4H), 1.60 (s, 9H) ppm.

Synthesis of tert-butyl (2-(2-(3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxamido)ethoxy)ethyl)carbamate (6e)

20 mg (36 µmol, 1.0eq) tert-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate were dissolved in 0.5 mL DCM and 0.5 mL TFA and stired at rt for 1 h. Excess solvent was evapored. The solid was dissolved in 0.5 mL DMF, then 125 µL (720 µmol, 20 eq) DIEA and 16.4 mg (43 µmol, 1.2 eq) HATU were added. After 15 min, a solution of 7.7 mg (38 µmol, 1.05 eq) tert-butyl (2-(2-aminoethoxy)ethyl)carbamate in 0.5 mL DMF was added. The solution was stirred for 3 h at rt. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO₃, then the reaction was extracted 3x with EA. The organic phase was dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The crude product was purified using by HPLC.

Yield: 18 mg, 26.2 µmol, 73% of a white solid.

ESI: (calculated) [M+H⁺] 687.31 g/mol
        (found) [M+H⁺] 687.52 g/mol.

HPLC: RT = 11.6 min (254 nm, 96%).

^{1}H NMR (400 MHz, DMSO) δ = 9.47 (s, 1H), 8.52 (t, ^3J = 5.4 Hz, 1H), 8.13 (d, ^3J = 2.1 Hz), 7.97 (s, 1H), 7.93 (d, ^3J = 8.4 Hz, 2H), 7.68 (d, ^3J = 8.5 Hz, 2H), 7.52 (dd, ^3J = 8.4 Hz, ^4J = 2.2 Hz), 7.27 (d, ^3J = 8.4 Hz, 1H), 6.82 (s, 1H), 6.76 (s, 1H), 3.55 − 3.52 (m, 2H), 3.47 − 3.38 (m, 4H), 3.11 − 3.06 (m, 2H), 2.99 − 2.85 (m, 4H), 2.50 (s, 4H) 2.23 (s, 3H), 1.36 (s, 9H) ppm.

^{13}C NMR (101 MHz, DMSO) δ = 168.0, 166.0, 162.8, 161.2, 144.9, 142.2, 140.0, 139.5 (q, ^2J = 35 Hz), 134.2, 133.00 132.3, 132.2, 128.3, 127.9, 126.0, 123.9, 122.6 (q, ^1J = 240 Hz), 122.3, 121.0, 120.4, 119.1 (m), 110.3 (m), 77.59, 68.99, 68.7, 54.7, 51.0, 45.7, 39.1, 38.9, 28.2 ppm.

Synthesis of tert-butyl (1-(3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-1-oxo-5,8,11,14,17,20,23-heptaoxa-2-azapentacosan-25-yl)carbamate (6f)

20 mg   (36 µmol,   1.00 eq)   tert-butyl   3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate were dissolved in 1 mL DCM and 1 mL TFA and stired at rt for 0.5 h. Excess solvent was evapored. The solid was dissolved in 2 mL DMF, then 300 µL (280 µmol, 20 eq) DIEA and 16.4 mg (43 µmol, 1.2 eq) HATU were added. After 15 min, a solution of 17.7 mg (38 µmol, 1.05 eq) tert-butyl (23-amino-3,6,9,12,15,18,21-heptaoxatricosyl)carbamate in 1 mL DMF was added. The solution was stirred for 3 h at rt. The reaction mixture was quenched with 2 mL water and 2 mL saturated $NaHCO_3$, then the reaction was extracted 3x with EA. The organic phase was dried over $MgSO_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using by RP-FC.

Yield: 10 mg, 10.5 µmol, 29% of a colourless oil.

R_f (10% MeOH/ CH_2Cl_2): 0.25.

ESI: (calculated) [M+H$^+$] 951.47 g/mol

        (found [M+H$^+$] 951.95 g/mol.

HPLC: RT = 11.8 min (254 nm, 94%).

^{1}H NMR (400 MHz, DMSO) δ = 9.46 (s, 1H), 8.53 (t, ^3J = 5.7 Hz, 1H), 8.12 (d, ^4J = 2.2 Hz, 1H), 7.97 (s, 1H), 7.94 (d, ^3J = 8.5 Hz, 2H), 7.68 (d, ^3J = 8.5 Hz, 2H), 7.53 (dd, 3J = 8.4 Hz, ^4J = 2.2 Hz, 1H), 7.27 (d, ^3J =

8.4 Hz, 1H), 6.82 (s, 1H), 6.72 (t, ^3J = 5.3 Hz, 1H), 3.59 – 3.47 (m, 28H), 3.44 (m, 2H), 3.36 (t, ^3J = 6.1 Hz, 4H), 3.05 (q, ^3J = 6.0 Hz, 2H), 2.96 – 2.85 (m, 4H), 2.24 (s, 3H), 1.36 (s, 9H) ppm.

Synthesis of tert-butyl (4-((3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxamido)methyl)benzyl)carbamate (6g)

20 mg (36 µmol, 1.00 eq) tert-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate were dissolved in 1 mL DCM and 1 mL TFA and stirred at rt for 0.5 h. Excess solvent was evapored. The solid was dissolved in 2 mL DMF, then 300 µL (280 µmol, 20 eq) DIEA and 16.4 mg (43 µmol, 1.2 eq) HATU were added. After 15 min, a solution of 8.9 mg (38 µmol, 1.05 eq) tert-butyl (4-(aminomethyl)benzyl)carbamate in 1 mL DMF was added. The solution was stirred for 3 h at rt. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 3x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using by RP-FC.

Yield: 14 mg, 19.5 µmol, 54% of a colourless oil.

R$_f$ (10% MeOH/ CH$_2$Cl$_2$): 0.11.

ESI: (calculated) [M+H$^+$] 719.32 g/mol
         (found [M+H$^+$] 719.54 g/mol.

HPLC: RT = 12.2 min (254 nm, 91%).

^{1}H NMR (400 MHz, MeOD) δ = 8.29 (d, ^4J = 1.8 Hz, 1H), 7.99 (s, 1H), 7.92 (d, ^3J = 8.4 Hz, 2H), 7.72 (d, ^3J = 8.4 Hz, 2H), 7.52 (dd, ^3J = 8.3 Hz, ^4J = 2.1 Hz, 1H), 7.34 (m, 3H), 7.25 (d, ^3J = 8.1 Hz, 2H), 6.92 (s, 1H), 4.57 (s, 2H), 4.21 (s, 2H), 3.01 (s, 4H), 2.69 (s, 4H), 2.39 (s, 3H), 1.44 (s, 9H) ppm.

7.3.2 Synthesis of E3 ligase linker

Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (L0)

2.00 g (12.0 mmol, 1.00 eq) 4-Fluoroisobenzofuran-1,3-dione and 1.98 g (12.0 mmol, 1.00 eq) 3-Aminopiperidine-2,6-dione were dissolved in 15 mL pyridine and stirred for 18 h at 110 °C. The solution was cooled to rt and the pyridine was removed under reduced pressure. The crude solution was dissolved in water and DCM. The aqueous phase was separated and extracted 6x with DCM. The combined organic phases were washed with 1 M HCl and saturated NaCl solution. The combined organic phases were dried over MgSO$_4$, filtered and excess solvent was removed under reduced pressure. The crude product was purified by column chromatography.

Yield: 1.13 g, 4.09 mmol, 33% of a yellow solid.

R$_f$ (5% MeOH/ CH$_2$Cl$_2$): 0.53.

ESI: (calculated): [M+2H$^+$] 278.06 g/mol
         (found): [M+2H$^+$] 278.96 g/mol.

^{1}H NMR (250 MHz, DMSO) δ = 11.13 (s, 1H, 17-H), 7.95 (ddd, ^3J = 8.3 Hz, ^3J = 7.5 Hz, ^4J = 4.6 Hz, 1H), 7.80 – 7.70 (m, 2H), 5.18 – 5.10 (m, 1H), 2.96 – 2.81 (m, 1H), 2.65 – 2.43 (m, 2H), 2.06 (m, 1H) ppm.

Synthesis of tert-butyl (2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)carbamate (L1)

150 mg (543 µmol, 1.00 eq) 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione, 111 mg (543 µmol, 1.00 eq) tert-butyl (2-(2-aminoethoxy)ethyl)carbamate and 189 µL (1.09 mmol, 2.00 eq) DIEA were dissolved in 5 mL NMP and stirred at 80 °C for 16 h. The solution was cooled to rt and diluted with EA and saturated NaHCO₃ and saturated NaCl solution. The mixture was extracted 3x with EA, dried over MgSO₄, filtered and excess solvent was removed under reduced pressure. The crude product was purified by Flash Chromatography.

Yield: 102 mg, 177 µmol 33% of a yellow solid.

R_f (30% Cyclohexane/EA): 0.46.

ESI: (calculated): [M+Na⁺] 483.19 g/mol
          (found): [M+Na⁺] 483.23 g/mol.

HPLC: RT = 12.8 min (254 nm, 100%).

1H NMR (600 MHz, MeOD) δ = 7.52 (t, ^3J = 7.8 Hz, 1H), 7.06 – 7.02 (m, 2H), 5.05 (dd, ^3J = 12.4 Hz, ^4J = 5.3 Hz, 1H), 3.68 (t, ^3J = 5.2 Hz, 2H), 3.68 – 3.46 (m, 4H), 3.23 (t, ^3J = 5.5 Hz, 2H), 2.85 (ddd, ^2J = 19.2 Hz, ^3J = 14.3 Hz, ^4J = 5.2 Hz, 1H), 2.78 – 2.66 (m, 2H), 2.16 – 2.06 (m, 1H), 1.41 (s, 9H) ppm.

13C NMR (126 MHz, MeOD) δ = 174.6, 171.5, 170.7, 169.2, 158.4, 148.2, 137.2, 133.8, 118.3, 112.1, 111.2, 80.1, 70.9, 70.4, 50.2, 49.0, 43.2, 41.3, 32.2, 28.7, 23.8 ppm.

Synthesis of *tert*-butyl (2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethyl)carbamate (L2)

100 mg (362 μmol, 1.00 eq) 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione, 84.5 mg (362 μmol, 1.00 eq) tert-butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate and 126 μL (724 μmol, 2.00 eq) DIEA were dissolved in 5 mL NMP and stirred at 80 °C for 16 h. The solution was cooled to rt and diluted with EA and saturated NaHCO$_3$ and saturated NaCl solution. The mixture was extracted 3x with EA, dried over MgSO$_4$, filtered and excess solvent was removed under reduced pressure. The crude product was purified by Flash Chromatography.

Yield: 102 mg, 177 μmol 33% of a yellow solid.

R$_f$ (30% Cyclohexane/EA): 0.25.

ESI: (calculated): [M+Na$^+$] 599.27 g/mol
        (found): [M+Na$^+$] 599.36 g/mol.

HPLC: RT = 11.1 min (254 nm, 100%).

^{1}H NMR (600 MHz, MeOD) δ = 7.55 (dd, ^3J = 8.5 Hz, ^3J = 7.2 Hz, 1H), 7.05 (dd, ^2J = 13.7, ^3J = 7.8 Hz, 2H), 5.07 – 5.04 (m, 1H), 3.69 – 3.68 (m, 2H), 3.65 – 3.62 (m, 10H), 3.45 – 3.42 (m, 2H), 3.07 (t, ^3J = 6.4 Hz, 2H), 2.89 – 2.83 (m, 1H), 2.76 – 2.70 (m, 2H), 2.12 – 2.10 (m, 1H), 1.94 – 1.89 (m, 4H) ppm.

^{13}C NMR (126 MHz, MeOD) δ = 174.6, 171.7, 170.7, 169.3, 148.2, 137.3, 133.9, 118.0, 111.8, 111.0, 71.4, 71.2, 71.1, 70.4, 70.2, 50.2, 41.4, 39.95, 32.2, 30.1, 28.1, 23.8, 18.5 ppm.

Synthesis of *tert*-butyl (17-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)carbamate (L3)

200 mg (720 µmol, 1.0 eq) 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione, 84.5 mg (720 µmol, 1.0 eq) tert-butyl (17-amino-3,6,9,12,15-pentaoxaheptadecyl)carbamate and 242 µL (1.45 mmol, 2.0 eq) DIEA were dissolved in 5 mL NMP and stirred at 80 °C for 16 h. The solution was cooled to rt and diluted with EA and saturated NaHCO$_3$ and saturated NaCl solution. The mixture was extracted 3x with EA, dried over MgSO$_4$, filtered and excess solvent was removed under reduced pressure. The crude product was purified by Flash Chromatography.

Yield: 210 mg, 330 µmol, 46% of a yellow oil.

R$_f$ (33% Cyclohexane/ 67% EA): 0.13.

ESI: (calculated): [M+Na$^+$] 659.29 g/mol
        (found): [M+Na$^+$] 659.30 g/mol.

HPLC: RT = 12.8 min (254 nm, 93%).

^{1}H NMR (250 MHz, DMSO) δ = 11.08 (s, 1H), 7.58 (dd, ^3J = 8.4 Hz, ^3J = 7.2 Hz, 1H), 7.15 (d, ^3J = 8.6 Hz, 1H), 7.04 (d, ^3J = 7.0 Hz, 1H), 6.73 (t, ^3J = 4.7 Hz, 1H), 6.60 (t, ^3J = 5.6 Hz, 1H), 5.05 (dd, ^3J = 12.5 Hz, ^4J = 5.4 Hz, 1H), 3.62 (t, ^3J = 5.3 Hz, 2H), 3.58 – 3.43 (m, 16H), 3.41 – 3.23 (m, 4H), 3.05 (q, ^3J = 6.0 Hz, 2H), 2.99 – 2.77 (m, 1H), 2.61 - 2.55 (m, 2H), 2.04 - 2.02 (m, 1H), 1.36 (s, 9H) ppm.

Synthesis of *tert*-butyl (23-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18,21-heptaoxatricosyl)carbamate (L4)

200 mg (720 µmol, 1.0 eq) 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione, 337 mg (720 µmol, 1.0 eq) tert-butyl (23-amino-3,6,9,12,15,18,21-heptaoxatricosyl)carbamate and 242 µL (1.45 mmol, 2.0 eq) DIEA were dissolved in 5 mL NMP and stirred at 80 °C for 16 h. The solution was cooled to rt and diluted with EA and saturated NaHCO$_3$ and saturated NaCl solution. The mixture was extracted 3x with EA, dried over MgSO$_4$, filtered and excess solvent was removed under reduced pressure. The crude product was purified by Flash Chromatography.

Yield: 271 mg, 374 µmol, 52% of a yellow oil.

R$_f$ (50% Cyclohexane/ 50% EA): 0.17.

ESI: (calculated): [M+Na$^+$] 747.34 g/mol
         (found): [M+Na$^+$] 747.41 g/mol.

HPLC: RT = 12.7 min (254 nm, 100%).

^{1}H NMR (600 MHz, MeOD) δ = 7.52 (dd, ^3J = 8.4, 7.2 Hz, 1H), 7.06 - 7.02 (m, 2H), 5.06 - 5.03 (m, 1H), 3.71 (t, ^3J = 5.3 Hz, 2H), 3.64 - 3.61 (m, 4H), 3.62 – 3.57 (m, 20H), 3.50 - 3.47 (m, 4H), 3.21 (t, ^3J = 5.5 Hz, 2H), 2.93 – 2.81 (m, 1H), 2.76 - 2.70 (m, 2H), 2.13 - 2.11 (m, 1H), 1.43 (s, 9H) ppm.

^{13}C NMR (126 MHz, MeOD) δ = 174.5, 171.3, 170.6, 169.1, 158.2, 148.1, 137.2, 133.7, 118.2, 112.0, 111.1, 80.0, 71.6, 71.6, 71.6, 71.5, 71.5, 71.4, 71.2, 71.0, 70.5, 50.2, 43.2, 41.2, 32.2, 28.80, 23.77 ppm.

Synthesis of tert-butyl (4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)methyl)benzyl)carbamate (L5)

150 mg (543 µmol, 1.0 eq) 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione, 128 mg (543 µmol, 1.0 eq) tert-butyl (4-(aminomethyl)benzyl)carbamate and 284 µL (1.63 mmol, 2.0 eq) DIEA were dissolved in 7 mL DMF and stirred at 80 °C for 16 h. The solution was cooled to rt and diluted with EA and saturated NaHCO$_3$ and saturated NaCl solution. The mixture was extracted 3x with EA, dried over MgSO$_4$, filtered and excess solvent was removed under reduced pressure. The crude product was purified by Flash Chromatography.

Yield: 148 mg, 301 µmol, 55 % of a yellow oil.

R$_f$ (5% MeOH/ CH$_2$Cl$_2$): 0.31.

ESI: (calculated): [M+Na$^+$] 515.19 g/mol

(found): [M+Na$^+$] 515.27 g/mol.

HPLC: RT = 13.4 min (254 nm, 76%).

^{1}H NMR (250 MHz, MeOD) δ = 7.46 (dd, ^3J = 8.3 Hz, ^3J = 7.3 Hz, 1H), 7.30 - 7.27 (m, 3H), 7.19 -7.16 (m, 1H), 7.04 (d, ^3J = 7.1 Hz, 1H), 6.93 (d, ^3J = 8.5 Hz, 1H), 4.79 - 4.73 (m, 1H), 4.55 (s, 2H), 4.21 (s, 2H), 2.89 – 2.61 (m, 1H), 2.49 - 2.47 (m, 1H), 2.39 - 2.33 (m, 1H), 2.12 - 2.01 (m, 1H), 1.42 (s, 9H) ppm.

Synthesis of tert-butyl (2-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropoxy)ethyl)carbamate (L6)

71 mg (307 µmol, 1.0 eq) 3-(2-((tert-butoxycarbonyl)amino)ethoxy)propanoic acid were dissolved in 5 mL dry DMF, 140 mg (368 µmol, 1.2 eq) HATU and 107 µL (613 µmol, 2.0 eq) DIEA were added. The solution was stirred for 5 min at rt, then 150 mg (322 µmol, 1.1 eq) VHL ligand 1 hydrochloride were added to the solution and stirred under Argon atmosphere for 4 h. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 5x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using an RP-FC system.

Yield: 80 mg, 124 µmol, 40% of a white solid.

R$_f$ (10 %MeOH/ CH$_2$Cl$_2$): 0.15.

ESI: (calculated): [M+H$^+$] 646.31 g/mol

(found): [M+H$^+$] 646.32 g/mol.

HPLC: RT = 12.1 min (254 nm, 99%).

^{1}H NMR (500 MHz, DMSO) δ = 8.98 (s, 1H), 8.55 (t, ^3J = 6.0 Hz, 1H), 7.92 (d, ^3J = 9.4 Hz, 1H), 7.42 (d, ^3J = 8.4 Hz, 2H), 7.38 (d, ^3J = 8.4 Hz, 2H), 6.69 (t, ^3J = 5.5 Hz, 1H), 5.12 (d, ^3J = 3.6 Hz, 1H), 4.56 (d, ^3J = 9.4 Hz, 1H), 4.49 – 4.39 (m, 2H), 4.35 (s, 1H), 4.22 (dd, ^3J = 15.8 Hz, ^4J = 5.4 Hz, 1H), 3.66 (d, ^3J = 4.0 Hz, 1H), 3.63 (s, 1H), 3.57 (d, ^3J = 11.3 Hz, 2H), 3.40 – 3.33 (m, 2H), 3.05 (q, ^3J = 6.0 Hz, 2H), 2.59 – 2.50 (m, 1H), 2.44 (s, 3H), 2.40 – 2.29 (m, 1H), 2.06 – 1.97 (m, 1H), 1.92 (dd, ^3J = 8.5 Hz, ^4J = 4.5 Hz, 1H), 1.36 (s, 9H), 0.93 (s, 9H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 171.9, 170.0, 169.5, 155.5, 151.4, 147.7, 139.5, 131.2, 129.6, 128.6, 127.4, 77.6, 68.87, 66.6, 58.7, 56.4, 56.3, 41.67, 39.9, 35.4, 28.2, 26.3, 15.9 ppm.

Synthesis of tert-butyl (2-(2-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropoxy)ethoxy)ethyl)carbamate (L7)

49 mg (178 µmol, 1.0 eq) 2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatetradecan-14-oic acid were dissolved in 5 mL dry DMF, 82 mg (214 µmol, 1.2 eq) HATU and 62 µL (356 µmol, 2.0 eq) DIEA were added. The solution was stirred for 5 min at rt, then 100 mg (214 µmol, 1.2 eq) VHL ligand 1 hydrochloride were added to the solution and stirred under Argon atmosphere for 4 h. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 5x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using an RP-FC system.

Yield: 97 mg, 141 µmol, 80 % of a white solid.

R$_f$ (10 % MeOH/ CH$_2$Cl$_2$): 0.32.

ESI: (calculated): [M+Na$^+$] 712.33 g/mol
         (found): [M+Na$^+$] 712.32 g/mol.

HPLC: RT = 12.1 min (254 nm, 100 %).

^{1}H NMR (500 MHz, MeOD) δ = 8.87 (s, 1H), 7.89 (d, ^3J = 9.2 Hz, 1H), 7.47 (d, ^3J = 8.3 Hz, 2H), 7.44 − 7.39 (m, 2H), 4.66 (s, 1H), 4.56 (dd, ^2J = 20.9 Hz, ^3J = 12.2 Hz, 2H), 4.50 (s, 1H), 4.36 (d, ^3J = 15.5 Hz, 1H), 3.89

(d, ^3J = 11.0 Hz, 1H), 3.80 (dd, ^3J = 11.0 Hz, ^4J = 3.9 Hz, 1H), 3.74 (dt, ^3J = 10.9 Hz, ^4J = 5.3 Hz, 2H), 3.60 (s, 4H), 3.49 (t, ^3J = 5.6 Hz, 2H), 3.20 (m, 2H), 2.58 (m, 1H), 2.52 – 2.48 (m, 1H), 2.48 (s, 3H), 2.21 (m, 1H), 2.09 (m, 1H), 1.42 (s, 9H), 1.04 (s, 9H) ppm.

^{13}C NMR (126 MHz, MeOD) δ = 174.4, 173.7, 172.1, 158.4, 152.8, 149.0, 140.3, 133.4, 131.5, 130.4, 129.0, 80.1, 71.4, 71.2, 71.1, 68.3, 60.8, 58.9, 58.0, 43.7, 41.3, 38.9, 37.3, 36.8, 28.8, 27.0, 15.8 ppm.

Synthesis of tert-butyl ((S)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-18,18-dimethyl-15-oxo-3,6,9,12-tetraoxa-16-azanonadecyl)carbamate (L8)

65 mg (178 μmol, 1.0 eq) 2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azaicosan-20-oic acid were dissolved in 5 mL dry DMF, 82 mg (214 μmol, 1.2 eq) HATU and 62 μL (356 μmol, 2.0 eq) DIEA were added. The solution was stirred for 5 min at rt, then 100 mg (214 μmol, 1.2 eq) VHL ligand 1 hydrochloride were added to the solution and stirred under Argon atmosphere for 4 h. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 5x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using an RP-FC system.

Yield: 42 mg, 53.9 μmol, 30% of a colourless oil.

R$_f$ (10% MeOH/ CH$_2$Cl$_2$): 0.22.

ESI: (calculated): [M+Na$^+$] 800.39 g/mol
        (found): [M+Na$^+$] 800.48 g/mol.

HPLC: RT = 12.1 min (254 nm, 99%).

^{1}H NMR (500 MHz, MeOD) δ = 8.88 (s, 1H), 7.47 (d, ^3J = 8.3 Hz, 2H), 7.42 (d, ^3J = 8.3 Hz, 2H), 4.65 (s, 1H), 4.60 – 4.52 (m, 2H), 4.50 (s, 1H), 4.36 (d, ^3J = 15.5 Hz, 1H), 3.89 (d, ^3J = 11.1 Hz, 1H), 3.80 (dd, ^3J = 11.0 Hz, ^4J = 3.9 Hz, 1H), 3.76 – 3.70 (m, 2H), 3.63 – 3.61 (m, 10H), 3.60 – 3.58 (m, 2H), 3.49 (t, ^3J = 5.6 Hz, 2H), 3.21 (t, ^3J = 5.6 Hz, 2H), 2.56 (dd, ^3J = 7.5 Hz, ^4J = 5.3 Hz, 1H), 2.48 (s, 4H), 2.26 – 2.18 (m, 1H), 2.13 – 2.04 (m, 1H), 1.43 (s, 9H), 1.04 (s, 9H) ppm.

^{13}C NMR (126 MHz, MeOD) δ = 174.5, 173.7, 172.1, 158.4, 152.8, 149.0, 140.3, 133.4, 131.5, 130.4, 129.0, 80.1, 71.6, 71.5, 71.4, 71.3, 71.1, 68.3, 60.8, 58.9, 58.0, 43.7, 41.3, 38.9, 37.4, 36.8, 28.8, 27.0, 15.8 ppm.

Synthesis of tert-butyl (3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)carbamate (L9)

40 mg (214 µmol, 1.0 eq) 3-((tert-butoxycarbonyl)amino)propanoic acid were dissolved in 2 mL dry DMF, 98 mg (257 µmol, 1.2 eq) HATU and 75 µL (428 µmol, 2.0 eq) DIEA were added. The solution was stirred for 5 min at rt, then 100 mg (214 µmol, 1.0 eq) VHL ligand 1 hydrochloride were added to the solution and stirred under Argon atmosphere for 4 h. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 5x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using an RP-FC system.

Yield: 62 mg, 103 µmol, 48% of a white solid.

R$_f$ (10% MeOH/ CH$_2$Cl$_2$): 0.42.

ESI: (calculated): [M+2H$^+$] 603.31 g/mol

(found): [M+2H$^+$] 603.26 g/mol.

^{1}H NMR (300 MHz, MeOD) δ = 9.01 (s, 1H), 7.48 (d, ^3J = 8.0 Hz, 2H), 7.42 (d, ^3J = 7.4 Hz, 2H), 4.59 (d, ^3J = 12.9 Hz, 2H), 4.53 − 4.50 (m, 2H), 4.36 (d, ^3J = 15.2 Hz, 1H), 3.92 (d, ^3J = 11.4 Hz, 1H), 3.80 (d, ^3J = 10.2 Hz, 1H), 3.38 − 3.24 (m, 2H), 2.53 − 2.43 (m, 2H), 2.49 (s, 3H), 2.31 − 2.15 (m, 1H), 2.10 (m, 1H), 1.42 (s, 9H), 1.04 (s, 9H) ppm.

^{13}C NMR (75 MHz, MeOD) δ = 174.5, 173.7, 172.3, 153.3, 148.2, 140.6, 131.1, 130.5, 130.4, 129.6, 129.0, 80.2, 71.1, 60.8, 59.1, 58.0, 49.0, 43.7, 38.9, 38.6, 38.1, 36.8, 36.5, 28.7, 27.0, 15.4 ppm.

Synthesis of tert-butyl (4-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutyl)carbamate (L10)

44 mg (214 µmol, 1.0 eq) 4-((tert-butoxycarbonyl)amino)butanoic acid were dissolved in 2 mL dry DMF, 98 mg (257 µmol, 1.2 eq) HATU and 75 µL (428 µmol, 2.0 eq) DIEA were added. The solution was stirred for 5 min at rt, then 100 mg (214 µmol, 1.0 eq) VHL ligand 1 hydrochloride were added to the solution and stirred under Argon atmosphere for 4 h. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 5x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using an RP-FC system.

Yield: 61 mg, 99.2 µmol, 46% of a white solid.

R$_f$ (10% MeOH/ CH$_2$Cl$_2$): 0.45.

ESI: (calculated): [M+Na$^+$] 639.30 g/mol
        (found): [M+Na$^+$] 639.43 g/mol.

^{1}H NMR (300 MHz, MeOD) δ = 8.95 (s, 1H), 7.47 (d, ^3J = 8.4 Hz, 2H), 7.44 – 7.38 (m, 2H), 4.55 (m, 4H), 4.36 (d, ^3J = 15.5 Hz, 1H), 3.91 (m, 1H), 3.80 (m, 1H), 3.05 (t, ^3J = 6.8 Hz, 2H), 2.48 (s, 3H), 2.29 (m, 2H), 2.24 – 2.15 (m, 1H), 2.08 (m, 1H), 1.85 – 1.65 (m, 2H), 1.43 (s, 9H), 1.04 (s, 9H) ppm.

^{13}C NMR (75 MHz, MeOD) δ = 175.4, 174.5, 172.4, 153.1, 148.6, 140.4, 133.7, 131.2, 130.4, 129.4, 129.0, 79.9, 71.1, 60.8, 59.2, 58.0, 43.7, 40.7, 38.9, 36.5, 33.9, 28.8, 27.4, 27.0, 15.6 ppm.

Synthesis of tert-butyl (5-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamate (L11)

39 mg (178 µmol, 1.0 eq) 5-((tert-butoxycarbonyl)amino)pentanoic acid were dissolved in 5 mL dry DMF, 82 mg (214 µmol, 1.2 eq) HATU and 62 µL (356 µmol, 2.0 eq) DIEA were added. The solution was stirred for 5 min at rt, then 100 mg (214 µmol, 1.2 eq) VHL ligand 1 hydrochloride were added to the solution and stirred under Argon atmosphere for 4 h. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 5x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using an RP-FC system.

Yield: 59 mg, 93.8 µmol, 53 % of a white solid.

R$_f$ (10 % MeOH/ 90 % CH$_2$Cl$_2$): 0.37.

ESI: (calculated): [M+Na$^+$] 652.31 g/mol
         (found): [M+Na$^+$] 652.27 g/mol.

HPLC: RT = 12.1 min (254 nm, 100 %).

^{1}H NMR (500 MHz, MeOD) δ = 8.87 (s, 1H), 7.46 (d, ^3J = 8.3 Hz, 2H), 7.41 (d, ^3J = 8.3 Hz, 2H), 4.63 (s, 1H), 4.56 (dd, ^2J = 19.3 Hz, ^3J = 11.8 Hz, 2H), 4.50 (s, 1H), 4.36 (d, ^2J = 15.5 Hz, 1H), 3.90 (d, ^3J = 11.1 Hz, 1H), 3.80 (dd, ^3J = 10.9 Hz, ^4J = 3.9 Hz, 1H), 3.04 (t, ^3J = 6.9 Hz, 2H), 2.47 (s, 3H), 2.30 (m, 2H), 2.22 (m, 1H), 2.09 (m, 1H), 1.68 – 1.58 (m, 2H), 1.49 (m, 2H), 1.42 (s, 9H), 1.04 (s, 9H) ppm.

^{13}C NMR (126 MHz, MeOD) δ = 166.3, 165.0, 162.8, 149.0, 143.3, 139.5, 130.8, 123.9, 122.0, 120.9, 119.5, 70.3, 61.6, 51.3, 49.5, 48.5, 34.2, 31.4, 29.4, 27.0, 26.7, 21.0, 19.3, 17.6, 14.7, 6.3 ppm.

Synthesis of tert-butyl (6-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)carbamate (L12)

41 mg (178 µmol, 1.0 eq) 6-((tert-butoxycarbonyl)amino)hexanoic acid were dissolved in 5 mL dry DMF, 82 mg (214 µmol, 1.2 eq) HATU and 62 µL (356 µmol, 2.0 eq) DIEA were added. The solution was stirred for 5 min at rt, then 100 mg (214 µmol, 1.2 eq) VHL ligand 1 hydrochloride were added to the solution and stirred under Argon atmosphere for 4 h. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 5x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using an RP-FC system.

Yield: 100 mg, 155 µmol, 87 % of a white solid.

R$_f$ (5% MeOH/ CH$_2$Cl$_2$): 0.24.

ESI: (calculated): [M+Na$^+$] 666.32 g/mol

        (found): [M+Na$^+$] 666.30 g/mol.

HPLC: RT = 12.3 min (254 nm, 100 %).

^{1}H NMR (500 MHz, MeOD) δ = 8.88 (s, 1H), 7.47 (d, ^3J = 8.4 Hz, 2H), 7.41 (d, ^3J = 8.3 Hz, 2H), 4.63 (s, 1H), 4.58 (m, 1H), 4.53 (m, 1H) 4.50 (s, 1H), 4.36 (m, 1H), 3.91 (d, ^3J = 11.0 Hz, 1H), 3.80 (dd, ^3J = 10.9 Hz, ^4J = 3.9 Hz, 1H), 3.01 (m, 2H), 2.47 (s, 3H), 2.28 (m, 2H), 2.21 (m, 1H), 2.13 − 2.05 (m, 1H), 1.66 − 1.59 (m, 2H), 1.51 − 1.44 (m, 2H), 1.42 (s, 9H), 1.34 (m, 2H), 1.04 (s, 9H) ppm.

^{13}C NMR (126 MHz, MeOD) δ = 175.9, 174.5, 172.3, 158.5, 152.8, 149.0, 140.3, 133.4, 131.5, 130.4, 129.0, 79.8, 71.1, 60.8, 59.0, 58.0, 43.7, 41.2, 38.9, 36.5, 30.6, 28.8, 27.5, 27.0, 26.7, 15.8 ppm.

Synthesis of tert-butyl (7-(((_S_)-1-((2_S_,4_R_)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)carbamate (L13)

44 mg (178 μmol, 1.0 eq) 7-((tert-butoxycarbonyl)amino)heptanoic acid were dissolved in 5 mL dry DMF, 82 mg (214 μmol, 1.2 eq) HATU and 62 μL (356 μmol, 2.0 eq) DIEA were added. The solution was stirred for 5 min at rt, then 100 mg (214 μmol, 1.2 eq) VHL ligand 1 hydrochloride were added to the solution and stirred under Argon atmosphere for 4 h. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 5x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using an RP-FC system.

Yield: 76 mg, 115 μmol, 65% of a white solid.

R$_f$ (5% MeOH/ 95 % CH$_2$Cl$_2$): 0.28.

ESI: (calculated): [M+Na$^+$] 680.34 g/mol

(found): [M+Na$^+$] 680.31 g/mol.

HPLC: RT = 12.5 min (254 nm, 94%).

^{1}H NMR (500 MHz, MeOD) δ = 8.87 (s, 1H), 8.64 (t, ^3J = 6.0 Hz, 1H), 7.80 (d, ^3J = 9.0 Hz, 1H, NH), 7.46 (d, ^3J = 8.3 Hz, 2H), 7.41 (d, ^3J = 8.3 Hz, 2H), 4.66 – 4.62 (m, 1H), 4.61 – 4.56 (m, 1H), 4.54 (d, ^3J = 15.5 Hz, 1H), 4.50 (s, 1H), 4.36 (d, ^3J = 15.5 Hz, 1H), 3.91 (d, ^3J = 11.1 Hz, 1H), 3.80 (dd, ^3J = 10.9 Hz, ^4J = 3.9 Hz, 1H), 3.01 (t, ^3J = 7.0 Hz, 2H), 2.47 (s, 3H), 2.37 – 2.23 (m, 2H), 2.22 – 2.18 (m, 1H), 2.08 (m, 1H), 1.61 (dt, ^3J = 14.2 Hz, ^4J = 7.2 Hz, 2H), 1.49 – 1.43 (m, 2H), 1.42 (s, 9H), 1.35 – 1.31 (m, 4H), 1.04 (s, 9H) ppm.

^{13}C NMR (126 MHz, MeOD) δ = 176.0, 174.4, 172.3, 158.5, 152.8, 149.0, 140.3, 133.4, 131.5, 130.3, 129.0, 79.7, 71.1, 60.8, 59.0, 58.0, 43.7, 41.3, 38.9, 36.5, 30.8, 29.9, 28.8, 27.5, 27.0, 26.9, 15.8 ppm.

Synthesis   of   tert-butyl   (4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethyl)benzyl)carbamate (L14)

81 mg (307 µmol, 1.0 eq) 2-(4-(((tert-butoxycarbonyl)amino)methyl)phenyl)acetic acid were dissolved in 5 mL dry DMF, 140 mg (368 µmol, 1.2 eq) HATU and 107 µL (613 µmol, 2.0 eq) DIEA were added. The solution was stirred for 5 min at rt, then 150 mg (322 µmol, 1.1 eq) VHL ligand 1 hydrochloride were added to the solution and stirred under Argon atmosphere for 4 h. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 5x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using an RP-FC system.

Yield: 65 mg, 95.9 µmol, 31% of a yellow solid.

R$_f$ (10% MeOH/ CH$_2$Cl$_2$): 0.11.

ESI: (calculated): [M+H⁺] 678.33 g/mol

         (found): [M+H⁺] 678.34 g/mol.

HPLC: RT = 12.5 min (254 nm, 100%).

¹H NMR (500 MHz, DMSO) δ = 8.98 (s, 1H), 8.57 (t, ^3J = 6.1 Hz, 1H), 8.07 (d, ^3J = 9.3 Hz, 1H), 7.42 (d, ^3J = 8.4 Hz, 2H), 7.39 (d, ^3J = 8.4 Hz, 2H), 7.33 (t, ^3J = 6.3 Hz, 1H), 7.20 (d, ^3J = 8.0 Hz, 2H), 7.13 (d, ^3J = 8.0 Hz, 2H), 5.11 (d, ^3J = 3.6 Hz, 1H), 4.51 (d, ^3J = 9.4 Hz, 1H), 4.47 – 4.40 (m, 2H), 4.34 (s, 1H), 4.22 (dd, ^3J = 15.8 Hz, ^4J = 5.5 Hz, 1H), 4.08 (d, ^3J = 6.1 Hz, 2H), 3.66 (m, 1H), 3.62 (d, ^3J = 13.2 Hz, 2H), 3.41 (d, ^3J = 13.8 Hz, 1H), 2.45 (s, 3H), 2.06 – 1.98 (m, 1H), 1.90 (m, 1H), 1.38 (s, 9H), 0.91 (s, 9H) ppm.

¹³C NMR (126 MHz, DMSO) δ = 171.9, 170.0, 169.5, 155.7, 151.4, 147.7, 139.5, 138.1, 134.9, 131.1, 129.6, 128.9, 128.6, 127.4, 126.7, 77.7, 68.8, 58.7, 56.4, 56.4, 43.1, 41.6, 40.0, 35.4, 28.2, 26.3, 15.9 ppm.

Synthesis of tert-butyl (5-(((S)-1-((2S,4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamate (L15)

5.63 g (30.9 mmol, 1.00 eq) 4-Bromobenzonitrile and 4.5 mL (30.9 mmol, 1.00 eq) 4-Methylthiazole were dissolved in 25 mL Dimethylacetamide and 2 mL water. 6.00 g (61.8 mmol, 2.00 eq) potassium acetate and 32 mg (3.09 mmol, 0.10 eq) palladium(II)acetate were added. The mixture was stirred for 24 h at 115°C. Excess solvent was removed under reduced pressure. The reaction mixture was dissolved with water and ethyl acetate. The phases were separated and the aqueous phase was extracted four times with ethylacetate. The combined organic phases were dried over MgSO4, filtered and excess solvent was removed under reduced pressure. The purification of the crude product was done by column chromatography to obtain 2.36 g (11.6 mmol, 38%) of 4-(4-methylthiazol-5-yl)benzonitrile.

This product was dissolved in THF and added slowly to 24 mL (23.1 mmol, 2.00 eq) of a cold solution of 1M LiAlH$_4$ in THF. The reaction mixture was allowed to reach rt and then heated at 40 °C for 18 h. The reaction mixture was cooled to rt and water was added slowly. The solution was filtered and washed with 10% MeOH/ CH$_2$Cl$_2$. The solvent was removed under reduced pressure, then the crude mixture was diluted with CH$_2$Cl$_2$. The phases were separated, the aqueous phase was extracted four times with CH$_2$Cl$_2$. The combined organic phases were dried over MgSO4, filtered and excess solvent was removed under reduced pressure to obtain 2.00 g (9.79 mmol, 84 %) of crude (4-(4-methylthiazol-5-yl)phenyl)methanamine.

351 mg (1.52 mmol, 1.05 eq) (2S,4S)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid and 661 mg (1.74 mmol, 1.20 eq) HATU were dissolved in 7 mL DMF. 505 µL (2.89 mmol, 2.00 eq) DIEA were added and the mixture was stirred for 15 min at rt. 296 mg (1.45mmol, 1.00 eq) (4-(4-methylthiazol-5-yl)phenyl)methanamine was added to the mixture and stirred for 3 h at rt. The reaction was stopped with 1 mL water. Saturated NaHCO$_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated NaHCO$_3$ solution, dried over MgSO$_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was done by Flash Chromatography to obtain 286 mg (685 µmol, 47%) of tert-butyl (2S,4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carboxylate.

The obtained product was dissolved in 1 mL TFA and 1 mL CH$_2$Cl$_2$ and stirred for 1h at rt. Excess solvent was removed under reduced pressure. 158 mg (685 µmol, 1.00 eq) (S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoic acid and 312 mg (822 µmol, 1.20 eq) HATU were dissolved in 5 mL DMF. 238 µL (1.37 mmol, 2.00 eq) DIEA were added and the mixture was stirred for 15 min at rt. 286 mg (685 µmol, 1.00 eq) of deprotected tert-butyl (2S,4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carboxylate was dissolved in 1 mL DMF and DIEA was added until the pH was basic. The mixture was added to the active ester species and stirred for 3 h at rt. The reaction was stopped with 1 mL water. Saturated NaHCO$_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated NaHCO$_3$ solution, dried over MgSO$_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was done by Flash Chromatography to obtain 242 mg (456 µmol, 67%) tert-butyl ((S)-1-((2S,4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate.

114 mg (216 µmol, 1.00 eq) tert-butyl ((S)-1-((2S,4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate were dissolved in 1 mL TFA and 1 mL CH$_2$Cl$_2$ and stirred for 1h at rt. Excess solvent was removed under reduced pressure. 47 mg (216 µmol, 1.00 eq) 5-((tert-butoxycarbonyl)amino)pentanoic acid, 98 mg (258µmol, 1.20 eq)

HATU and 75 µL (429 µmol, 2.00 eq) DIPEA were dissolved in 1 mL DMF and stirred for 15 min at rt. The deprotected amine was dissolved in 1 mL DMF and DIEA was added until the pH was basic. The mixture was added to the active ester species and stirred for 3 h at rt. The reaction was stopped with 1 mL water. Saturated $NaHCO_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated $NaHCO_3$ solution, dried over $MgSO_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on a preparative HPLC system.

Yield: 60 mg, 95.3 µmol, 44% of a white solid.

ESI: (calculated) [M+Na$^+$] 652.31 g/mol
        (found) [M+Na$^+$] 652.31 g/mol.

HPLC: RT = 12.0 min (254 nm, 100%).

^{1}H NMR (500 MHz, MeOD) δ = 8.92 (s, 1H), 7.53 – 7.35 (m, 4H), 4.63 (s, 1H), 4.59 – 4.52 (m, 2H), 4.51 - 4.48 (m, 1H), 4.36 (d, ^3J = 15.5 Hz, 1H), 3.91 - 3.89 (m, 1H), 3.80 (dd, ^3J = 11.0 Hz, ^4J = 3.9 Hz, 1H), 3.04 (t, ^3J = 6.9 Hz, 2H), 2.48 (s, 3H), 2.38 – 2.17 (m, 3H), 2.11 - 2.06 (m, 1H), 1.68 – 1.56 (m, 2H), 1.51 - 1.46 (m, 2H), 1.42 (s, 9H), 1.04 (s, 9H) ppm.

^{13}C NMR (126 MHz, MeOD) δ = 175.7, 174.5, 172.3, 158.5, 153.0, 148.7, 140.4, 133.6, 131.3, 130.4, 129.0, 79.8, 71.1, 60.8, 59.0, 58.0, 49.0, 43.7, 40.9, 38.9, 36.5, 36.2, 30.5, 28.8, 27.0, 24.2, 15.7 ppm.

7.3.3 Synthesis of heterobifunctional molecules

Synthesis of *N*-(4'-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (7a)

16.0 mg (28.7 µmol, 1.00 eq) of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was diluted in 1 mL DCM and 1 mL TFA was added. In a second vial, 14.0 mg (30.1 µmol, 1.05 eq) of *tert*-butyl (2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)carbamate was diluted in 1 mL DCM and 1 mL TFA was added. The two reaction mixtures were stirred for 1 h at rt. Excess solvent and TFA was removed under reduced pressure.

The deprotected species of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was dissolved in 0.5 mL DMF and 49 µL (0.29 mmol, 10 eq) DIEA was added until the pH of the solution was basic. 13.0 mg (34.4 µmol, 1.20 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The TFA salt of *tert*-butyl (2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)carbamate was dissolved in 0.5 mL DMF and 11 µL (65 µmol, 2.00 eq) DIEA were added to the solution. The mixture was added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 4.5 h. The reaction was stopped with 1 mL water. Saturated $NaHCO_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated $NaHCO_3$ solution, dried over $MgSO_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was done via a HPLC system.

Yield: 17.2 mg, 20.4 µmol, 71% of a yellow solid.

MALDI: (calculated): [M+H$^+$] 843.31 g/mol

(found): [M+H$^+$] 843.41 g/mol.

HPLC: RT = 11.6 min (254 nm, 100%).

HRMS: (calculated) [M+H$^+$] 843.3072 g/mol

(found) [M+H$^+$] 843.3067 g/mol.

^{1}H NMR (500 MHz, DMSO) δ = 12.54 (s, 1H), 11.08 (s, 1H), 9.52 (s, 1H), 8.53 (t, ^3J = 5.6 Hz, 1H), 8.14 (d, ^4J = 1.8 Hz, 1H), 8.00 (s, 1H), 7.91 (d, ^3J = 8.4 Hz, 2H), 7.66 (d, ^3J = 8.4 Hz, 2H), 7.60 – 7.48 (m, 2H), 7.28 (d, ^3J = 8.4 Hz, 1H), 7.15 (d, ^3J = 8.6 Hz, 1H), 7.02 (d, ^3J = 7.0 Hz, 1H), 6.83 (s, 1H), 6.63 (t, ^3J = 5.7 Hz, 1H), 5.03 (dd, ^3J = 12.8 Hz, ^{4}J = 5.4 Hz, 1H), 3.66 (t, ^3J = 5.4 Hz, 2H), 3.61 (t, ^3J = 6.0 Hz, 2H), 3.48 (dd, ^3J = 13.3 Hz, ^4J = 4.9 Hz, 4H), 2.99 (s, 4H), 2.91 – 2.80 (m, 1H), 2.75 (s, 4H), 2.58 - 2.57 (m, 1H), 2.52 (s, 1H), 2.42 (s, 3H), 2.01 - 1.98 (m, 1H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 172.7, 170.1, 168.9, 167.3, 166.0, 162.9, 161.1, 146.4, 144.3, 142.1, 139.3, 138.5 (q, ^2J = 33 Hz), 136.2, 134.5, 133.0, 132.3, 132.1, 127.9, 126.0, 123.9, 122.3, 122.0 (q, ^1J = 275 Hz), 120.6, 119.0, 117.5, 111.7, 110.7, 109.2, 68.8, 68.8, 54.1, 50.1, 48.5, 44.8, 41.7, 31.0, 25.5, 22.1 ppm.

Synthesis of *N*-(4'-((2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (7b)

15.0 mg (27.0 µmol, 1.00 eq) of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was diluted in 1 mL DCM and 1 mL TFA was added. In a second vial, 16.0 mg (28.0 µmol, 1.05 eq) of *tert*-butyl (2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethyl)carbamate was diluted in 1 mL DCM and 1 mL TFA was added. The two reaction mixtures were stirred for 1 h at rt. Excess solvent and TFA was removed under reduced pressure.

The deprotected species of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was dissolved in 0.5 mL DMF and 40 µL (459 µmol, 9.00 eq) of DIEA was added until the pH of the solution was basic. 15 mg (40.5 µmol, 1.50 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The deprotected species of *tert*-butyl (2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethyl)carbamate was dissolved in 0.5 mL DMF and 10 µL (54 µmol, 2.00 eq) DIEA were added to the solution. The mixture was added to the active ester of AD100 and stirred at rt for 2.5 h. The reaction was stopped with 1 mL water. Saturated NaHCO₃ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated NaHCO₃ solution, dried over MgSO₄ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the HPLC system.

Yield: 8.58 mg, 8.95 µmol, 33% of a light yellow solid.

MALDI: (calculated) [M+H⁺] 959.39 g/mol

(found) [M+H$^+$] 959.47 g/mol.

HPLC: RT = 11.8 min (254 nm, 98%)

HRMS: (calculated) [M+H$^+$] 959.3909 g/mol

(found) [M+H$^+$] 959.3905 g/mol.

^{1}H NMR (500 MHz, DMSO) δ = 11.08 (s, 1H), 9.45 (s, 1H), 8.44 (t, ^3J = 5.5 Hz, 1H), 8.12 (d, ^4J = 1.7 Hz, 1H), 7.98 (s, 1H), 7.91 (d, ^3J = 8.4 Hz, 2H), 7.67 (d, ^3J = 8.4 Hz, 2H), 7.61 − 7.54 (m, 1H), 7.51 (dd, ^3J = 8.3 Hz, ^4J = 2.2 Hz, 1H), 7.26 (d, ^3J = 8.4 Hz, 1H), 7.08 (d, ^3J = 8.6 Hz, 1H), 7.01 (d, ^3J = 7.0 Hz, 1H), 6.81 (s, 1H), 6.65 (t, ^3J = 5.9 Hz, 1H), 5.04 (dd, ^3J = 12.7 Hz, ^4J = 5.4 Hz, 1H), 3.61 − 3.35 (m, 21H), 2.95 − 2.89 (m, 3H), 2.91 - 2.84 (m, 1H), 2.62 − 2.55 (m, 1H), 2.23 (s, 3H), 2.07 − 1.95 (m, 1H), 1.85 − 1.72 (m, 5H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 172.8, 170.1, 168.8, 167.3, 165.8, 162.8, 162.3, 146.4, 144.8, 142.1, 139.0, 138.5 (q, ^2J = 32 Hz), 136.2, 134.2, 133.2, 132.2, 132.2, 127.8, 126.0, 123.9, 122.2, 122.0 (q, ^1J = 275 Hz), 120.4, 118.8, 117.1, 111.7, 110.3, 109.0, 69.8, 69.7, 69.7, 69.6, 68.3, 68.2, 54.7, 51.0, 48.5, 45.8, 40.4, 36.7, 35.8, 31.0, 29.4, 28.9, 22.1 ppm.

Synthesis of *N*-(4'-((17-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (7c)

15.0 mg (27.0 µmol, 1.00 eq) of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was diluted in 1 mL DCM and 1 mL TFA was added. In a second vial, 18.0 mg (28.0 µmol, 1.05 eq) of *tert*-butyl (17-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)carbamate was diluted in 1 mL DCM and 1 mL TFA was added. The two reaction mixtures were stirred for 1 h at rt. Excess solvent and TFA was removed under reduced pressure.

The deprotected species of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was dissolved in 0.5 mL DMF and 47 µL (0.27 mmol, 10 eq) DIEA was added until the pH of the solution was basic. 12.0 mg (32.0 µmol, 1.20 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The TFA salt of *tert*-butyl (17-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)carbamate was dissolved in 0.5 mL DMF and 11 µL (65 µmol, 2.00 eq) DIEA were added to the solution. The mixture was added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 4.5 h. The reaction was stopped with 1 mL water. Saturated $NaHCO_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated $NaHCO_3$ solution, dried over $MgSO_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the HPLC system.

Yield: 23.6 mg, 23.1 µmol, 86% of a yellow oil.

MALDI: (calculated): [M+H$^+$] 1019.4121 g/mol

      (found): [M+H$^+$] 1019.52 g/mol.

HPLC: RT = 11.6 min (254 nm, 100%).

HRMS: (calculated) [M+H$^+$] 1019.4121 g/mol

(found) [M+H$^+$] 1019.4117 g/mol.

^{1}H NMR (500 MHz, DMSO) δ = 11.10 (s, 1H), 9.20 (s, 1H), 8.59 (d, ^3J = 5.2 Hz, 1H), 8.32 (d, ^4J = 1.7 Hz, 1H), 8.14 (s, 1H), 7.94 (d, ^3J = 8.3 Hz, 6H), 7.68 (d, ^3J = 8.4 Hz, 6H), 7.57 (dd, ^3J = 8.4 Hz, ^3J = 7.3 Hz, 1H), 7.46 (dd, ^3J = 8.3 Hz, ^4J = 2.0 Hz, 1H), 7.29 (d, ^3J = 8.4 Hz, 1H), 7.13 (t, ^3J = 8.4 Hz, 1H), 7.06 – 6.94 (m, 1H), 6.58 (dd, ^2J = 12.2 Hz, ^3J = 6.4 Hz, 1H), 6.46 (s, 1H), 5.05 (dd, ^3J = 12.7 Hz, ^4J = 5.4 Hz, 1H), 3.67 – 3.32 (m, 28H), 2.89 (t, ^3J = 4.4 Hz, 4H), 2.60 – 2.56 (m, 1H), 2.48 (s, 1H), 2.28 – 2.25 (m, 1H), 2.22 (s, 3H), 2.08 – 1.95 (m, 1H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 172.8, 170.1, 168.9, 167.3, 165.9, 163.1, 161.1, 146.4, 142.9, 142.0, 139.5, 138.6 (q, ^2J = 32 Hz), 136.2, 135.3, 133.2, 132.6, 132.1, 128.0, 126.1, 123.9, 122.3, 122.1 (q, ^1J = 275 Hz), 121.0, 119.0, 117.4, 111.7, 110.7, 109.2, 69.8, 69.8, 69.7, 69.6, 68.9, 68.9, 52.8, 48.6, 48.1, 42.4, 41.7, 38.9, 31.0, 22.1 ppm.

Synthesis of N-(4'-((23-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18,21-heptaoxatricosyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (7d)

15.0 mg (27.0 μmol, 1.00 eq) of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was diluted in 1 mL DCM and 1 mL TFA was added. In a second vial, 20.0 mg (28.0 μmol, 1.05 eq) of *tert*-butyl (23-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18,21-heptaoxatricosyl)carbamate was diluted in 1 mL DCM and 1 mL TFA was added. The two reaction mixtures were stirred for 1 h at rt. Excess solvent and TFA was removed under reduced pressure.

The deprotected species of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was dissolved in 0.5 mL DMF and 47 μL (0.27 mmol, 10 eq) DIEA was added until the pH of the solution was basic. 12.0 mg (32.0 μmol, 1.20 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The TFA salt of *tert*-butyl (23-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18,21-heptaoxatricosyl)carbamate was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. The mixture was added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 4.5 h. The reaction was stopped with 1 mL water. Saturated NaHCO$_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated NaHCO$_3$ solution, dried over MgSO$_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the HPLC system.

Yield: 20.5 mg, 18.5 μmol, 69% of a yellow oil.

MALDI: (calculated) [M+H$^+$] 1107.46 g/mol

(found) [M+H$^+$] 1107.52 g/mol.

HPLC: RT = 11.7 min (254 nm, 97%).

HRMS: (calculated) [M+H$^+$] 1107.4645 g/mol

        (found) [M+H$^+$] 1107.4638 g/mol.

^{1}H NMR (500 MHz, DMSO) δ = 12.51 (s, 1H), 11.08 (s, 1H), 9.47 (s, 1H), 8.54 (t, ^3J = 5.6 Hz, 1H), 8.12 (d, ^4J = 2.0 Hz, 1H), 7.98 (s, 1H), 7.94 (d, ^3J = 8.4 Hz, 2H), 7.68 (d, ^3J = 8.4 Hz, 2H), 7.60 - 7.55 (m, 1H), 7.52 (dd, ^3J = 8.3 Hz, ^4J = 2.2 Hz, 1H), 7.26 (d, ^3J = 8.4 Hz, 1H), 7.13 (d, ^3J = 8.6 Hz, 1H), 7.03 (d, ^3J = 7.0 Hz, 1H), 6.82 (s, 1H), 6.59 (t, ^3J = 5.7 Hz, 1H), 5.05 (dd, ^3J = 12.7 Hz, ^4J = 5.4 Hz, 1H), 3.61 (t, ^3J = 5.4 Hz, 2H), 3.58 – 3.41 (m, 32H), 3.33 – 3.25 (m, 2H), 2.95 – 2.89 (m, 4H), 2.89 – 2.83 (m, 1H), 2.61 - 2.51 (m, 2H), 2.23 (s, 3H), 2.06 – 1.96 (m, 1H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 172.7, 170.0, 168.9, 167.3, 165.9, 162.8, 161.1, 146.4, 144.9, 142.2, 139.2, 138.5 (q, ^2J = 32 Hz), 136.2, 134.2, 132.9, 132.2, 132.1, 127.9, 126.0, 123.9, 122.3, 122.0 (q, ^1J = 275 Hz), 120.4, 119.0, 117.4, 111.7, 110.64 109.2, 69.8, 69.8, 69.7, 69.6, 68.9, 68.9, 54.7, 51.0, 48.6, 45.7, 41.7, 31.0, 22.1 ppm.

Synthesis   of   N-(4'-((4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)methyl)benzyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (7e)

13.0 mg (23.0 µmol, 1.00 eq) of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was diluted in 1 mL DCM and 1 mL TFA was added. In a second vial, 12.0 mg (25.0 µmol, 1.05 eq) of AD130 was diluted in 1 mL DCM and 1 mL TFA was added. The two reaction mixtures were stirred for 1 h at rt. Excess solvent and TFA was removed under reduced pressure.

The deprotected species of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. 10.0 mg (28.0 µmol, 1.20 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The deprotected species of tert-butyl (4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)methyl)benzyl)carbamate was dissolved in 0.5 mL DMF and DIEA were added until the pH of the solution was basic. The mixture was added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 3 h. The reaction was stopped with 1 mL water. Saturated $NaHCO_3$ solution and saturated NaCl solution were added, and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated $NaHCO_3$ solution, dried over $MgSO_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the HPLC system.

Yield: 7.6 mg, 6.9 µmol, 30% of a yellow solid as TFA salt (1:2/ product: TFA.)

MALDI: (calculated): [M+Na$^+$] 897.29 g/mol; [M+H$^+$] 875.31 g/mol

       (found): [M+Na$^+$] 897.20 g/mol (100); [M+H$^+$] 875.22 g/mol (70).

HRMS: (calculated): [M+H$^+$] 875.3123 g/mol

(found): [M+H$^+$] 875.3120 g/mol.

HPLC: RT = 12.1 min (254 nm, 95%).

^{1}H NMR (500 MHz, DMSO) δ = 11.09 (s, 1H), 10.11 (s, 1H), 9.61 (s, 1H), 9.08 (t, ^3J = 5.9 Hz, 1H), 8.25 - 8.22 (m, 1H), 8.04 (s, 1H), 7.95 (d, ^3J = 8.4 Hz, 2H), 7.69 (d, ^3J = 8.4 Hz, 2H), 7.56 (dd, ^3J = 8.3 Hz, ^4J = 2.1 Hz, 1H), 7.450 - 7.47 (m, 1H), 7.38 – 7.28 (m, 3H), 7.28 – 7.15 (m, 3H), 7.00 (d, ^3J = 7.0 Hz, 1H), 6.95 (d, ^3J = 8.6 Hz, 1H), 6.84 (s, 1H), 5.08 - 5.04 (m, 1H), 4.56 (d, ^3J = 4.4 Hz, 2H), 4.49 (d, ^3J = 4.8 Hz, 2H), 3.55 - 3.52 (m, 2H), 3.33 – 3.19 (m, 4H), 3.08 - 3.04 (m, 2H), 2.92 – 2.82 (m, 4H), 2.59 - 2.54 (m, 2H), 2.04 -2.00 (m, 1H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 173.3, 170.5, 169.2, 167.7, 166.3, 163.6, 161.6, 146.6, 143.4, 142.5, 140.6, 139.5, 139.0, 138.6, 136.6, 135.8, 133.6, 133.1, 132.6, 129.0, 128.5, 126.6, 126.4, 126.1, 125.9, 124.4, 122.9, 122.6 (d, ^1J = 275 Hz), 121.5, 119.0, 118.1, 111.3, 111.2, 110.0, 53.3, 49.0, 48.6, 45.9, 43.0, 42.9, 31.4, 22.6 ppm.

Synthesis of 6-hydroxy-N-(4'-((2-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropoxy)ethyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8a)

30 mg (47 µmol, 1.05 eq) tert-butyl (2-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropoxy)ethyl)carbamate were dissolved in 1 mL CH_2Cl_2 and 1 mL TFA was added. The solution was stirred for 1 h at rt. Excess solvent was removed under reduced pressure.

25 mg (45 µmol, 1.00 eq) *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate were dissolved in 1 mL CH_2Cl_2 and 1 mL TFA was added. The solution was stirred for 1 h at rt. Excess solvent was removed under reduced pressure. The crude species was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. 20.5 mg (54 µmol, 1.20 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The crude species of tert-butyl (2-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropoxy)ethyl)carbamate were dissolved in 0.5 mL DMF and DIEA were added until the pH of the solution was basic. The mixture was added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 4 h. The reaction was stopped with 1 mL water. Saturated $NaHCO_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated $NaHCO_3$ solution, dried over $MgSO_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the preparative HPLC system.

Yield: 27.4 mg, 26.6 µmol, 59% of a white solid.

MALDI: (calculated): [M+Na$^+$] 1050.41 g/mol

(found): [M+Na$^+$] 1050.20 g/mol.

HRMS: (calculated): [M+Na$^+$] 1050.4129 g/mol

(found): [M+Na$^+$] 1050.4121 g/mol.

HPLC: RT = 11.3 min (254 nm, 97%).

^{1}H NMR (500 MHz, DMSO) δ = 9.47 (s, 1H), 8.97 (s, 1H), 8.56 (t, ^3J = 6.1 Hz, 1H), 8.50 (t, ^3J = 5.5 Hz, 1H), 8.12 (d, ^3J = 2.1 Hz, 1H), 8.02 − 7.91 (m, 4H), 7.68 (d, ^3J = 8.5 Hz, 2H), 7.52 (dd, ^3J = 8.4 Hz, ^4J= 2.2 Hz, 1H), 7.45 − 7.33 (m, 4H), 7.26 (d, ^3J = 8.4 Hz, 1H), 6.82 (s, 1H), 5.13 (s, 1H), 4.56 (d, ^3J = 9.4 Hz, 1H), 4.46 − 4.38 (m, 2H), 4.35 (s, 1H), 4.24 - 4.20 (m, 1H), 3.71 − 3.58 (m, 4H), 3.58 − 3.48 (m, 2H), 3.44 - 3.41 (m, 4H), 2.98 − 2.85 (m, 4H), 2.61 − 2.52 (m, 1H), 2.44 − 2.34 (m, 2H), 2.23 (s, 3H), 2.07 − 1.99 (m, 1H), 1.96 − 1.84 (m, 1H), 0.92 (s, 9H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 171.9, 170.0, 169.6, 165.9, 162.8, 161.2, 151.4, 147.7, 144.9, 142.2, 139.5, 139.2, 138.5 (q, ^2J = 32 Hz), 134.2, 132.9, 132.2, 131.2, 129.6, 128.6, 127.9, 127.4, 126.0, 123.9, 122.3, 122.0 (d, ^1J = 275 Hz), 120.4, 119.0, 111.7, 68.9, 68.6, 66.6, 58.7, 56.4, 56.3, 54.7, 51.0, 45.7, 41.7, 39.0, 37.9, 35.6, 35.4, 26.3, 15.9 ppm.

Synthesis of 6-hydroxy-*N*-(4'-((2-(2-(3-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropoxy)ethoxy)ethyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8b)

18.0 mg (32.0 µmol, 1.00 eq) of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was diluted in 1 mL DCM and 1 mL TFA was added. In a second vial, 23.4 mg (34.0 µmol, 1.05 eq) of tert-butyl (2-(2-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropoxy)ethoxy)ethyl)carbamate was diluted in 1 mL DCM and 1 mL TFA was added. The two reaction mixtures were stirred for 1 h at rt. Excess solvent and TFA was removed under reduced pressure.

The deprotected species of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. 18.4 mg (49.0 µmol, 1.50 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The TFA salt of tert-butyl (2-(2-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropoxy)ethyl)carbamate was dissolved in 0.5 mL DMF and 11 µL (65 µmol, 2.00 eq) DIEA were added to the solution. The mixture was added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 2.5 h. The reaction was stopped with 1 mL water. Saturated $NaHCO_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated $NaHCO_3$ solution, dried over $MgSO_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the HPLC system.

Yield: 11.1 mg, 10.4 µmol, 33% of a white solid.

MALDI: (calculated): [M+Na$^+$] 1094.44 g/mol

(found): [M+Na$^+$] 1094.44 g/mol.

HPLC: RT = 11.3 min (254 nm, 100%).

HRMS: (calculated): [M+Na$^+$] 1094.4392 g/mol

(found): [M+Na$^+$] 1094.4384 g/mol.

^{1}H NMR (600 MHz, DMSO) δ = 9.92 (s, 1H), 9.59 (s, 1H), 8.97 (s, 1H), 8.56 (t, ^3J = 5.6 Hz, 2H), 8.22 (s, 1H), 8.04 (s, 1H), 7.95 - 7.90 (m, 3H), 7.69 (d, ^3J = 8.2 Hz, 2H), 7.55 (dd, ^3J = 8.3 Hz, ^4J = 1.4 Hz, 1H), 7.42 - 7.37 (m, 4H), 7.31 (d, ^3J = 8.3 Hz, 1H), 6.83 (s, 1H), 4.55 (d, ^3J = 9.4 Hz, 1H), 4.49 − 4.38 (m, 2H), 4.35 (s, 1H), 4.22 (dd, ^3J = 15.8 Hz, ^4J = 5.5 Hz, 2H), 3.68 - 3.65 (m, 1H), 3.64 − 3.56 (m, 3H), 3.56 − 3.47 (m, 8H), 3.46 - 4.42 (m, 2H), 3.28 - 3.25 (m, 2H), 3.24 - 3.19 (m, 2H), 3.06 - 3.02 (m, 2H), 2.87 (s, 3H), 2.53 (s, 1H), 2.44 (s, 3H), 2.40 − 2.29 (m, 1H), 2.08 − 2.00 (m, 1H), 1.96 − 1.86 (m, 1H), 0.93 (s, 9H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 171.9, 170.0, 169.6, 165.9, 163.1, 161.1, 151.5, 147.7, 142.9, 142.0, 139.5, 139.1, 138.5 (q, ^2J = 32 Hz), 135.3, 133.2, 132.64, 131.2, 129.6, 128.6, 128.0, 127.4, 126.1, 123.9, 122.32, 122.1 (q, ^1J = 275 Hz), 121.0, 119.0, 118.8, 111.6, 69.6, 69.5, 69.0, 68.9, 66.9, 58.7, 56.4, 56.3, 52.85, 48.1, 42.4, 41.7, 38.0, 35.7, 35.4, 26.3, 15.9 ppm.

Synthesis of 6-hydroxy-*N*-(4'-(((*S*)-17-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-18,18-dimethyl-15-oxo-3,6,9,12-tetraoxa-16-azanonadecyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8c)

18.0 mg (32.0 µmol, 1.00 eq) of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was diluted in 1 mL DCM and 1 mL TFA was added. In a second vial, 26.4 mg (34.0 µmol, 1.05 eq) of tert-butyl ((S)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-18,18-dimethyl-15-oxo-3,6,9,12-tetraoxa-16-azanonadecyl)carbamate was diluted in 1 mL DCM and 1 mL TFA was added. The two reaction mixtures were stirred for 1 h at rt. Excess solvent and TFA was removed under reduced pressure.

The deprotected species of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. 18.4 mg (49.0 µmol, 1.50 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The deprotected species of tert-butyl ((S)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-18,18-dimethyl-15-oxo-3,6,9,12-tetraoxa-16-azanonadecyl)carbamate was dissolved in 0.5 mL DMF and 11 µL (65 µmol, 2.00 eq) DIEA were added to the solution. The mixture was added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 2.5 h. The reaction was stopped with 1 mL water. Saturated NaHCO₃ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated NaHCO₃ solution, dried over MgSO₄ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the HPLC system.

Yield: 2.34 mg, 2.02 µmol, 6% of a white solid.

MALDI: (calculated) [M+H$^+$] 1160.51 g/mol

       (found) [M+H$^+$] 1160.58 g/mol.

HPLC: RT = 11.4 min (254 nm, 99%).

HRMS: (calculated) [M+Na$^+$] 1182.4916 g/mol

       (found) [M+Na$^+$] 1182.4913 g/mol

^{1}H NMR (500 MHz, DMSO) δ = 9.76 (s, 1H), 9.57 (s, 1H), 8.97 (s, 1H), 8.56 (t, ^3J = 5.4 Hz, 2H), 8.21 (d, ^4J = 1.8 Hz, 1H), 8.03 (s, 1H), 7.95 (d, ^3J = 8.4 Hz, 2H), 7.90 (d, ^3J = 9.4 Hz, 1H), 7.69 (d, ^3J = 8.4 Hz, 2H), 7.56 (dd, ^3J = 8.3 Hz, ^4J = 2.1 Hz, 1H), 7.40 (q, ^3J = 8.3 Hz, 5H), 7.31 (d, ^3J = 8.4 Hz, 1H), 6.84 (s, 1H), 5.12 (s, 1H), 4.54 (d, ^3J = 9.4 Hz, 1H), 4.48 − 4.39 (m, 2H), 4.35 (s, 1H), 4.21 (dd, ^3J = 15.9 Hz, ^4J =5.5 Hz, 1H), 3.68 - 3.64 (m, 1H), 3.64 − 3.57 (m, 4H), 3.56 − 3.41 (m, 20H), 3.25 − 3.15 (m, 2H), 3.05 - 3.00 (m, 2H), 2.86 (s, 3H), 2.44 (s, 3H), 2.37 - 2.30 (m, 1H), 2.07 − 1.99 (m, 1H), 1.95 − 1.85 (m, 1H), 0.93 (s, 9H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 171.9, 170.0, 169.5, 165.9, 163.1, 161.1, 151.5, 147.6, 142.9, 142.0, 139.5, 139.1, 138.5 (q, ^2J = 33 Hz), 135.4, 133.2, 132.7, 131.2, 129.6, 128.6, 128.0, 127.4, 126.1, 123.9, 122.3, 122.1 (q, ^1J = 277 Hz), 121.0, 118.9, 111.7, 69.8, 69.7, 69.7, 69.6, 69.5, 68.9, 68.9, 66.9, 58.7, 56.4, 56.3, 52.8, 48.1, 42.4, 41.7, 38.0, 35.7, 35.4, 26.3, 15.9 ppm.

Synthesis of 6-hydroxy-N-(4'-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8d)

20 mg (36 μmol, 1.00 eq) *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate were dissolved in 1 mL CH_2Cl_2 and 1 mL TFA was added. The solution was stirred for 1 h at rt. Excess solvent was removed under reduced pressure. The crude species was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. 16.4 mg (43 μmol, 1.20 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. 17.0 mg (36 μmol, 1.00 eq) VHL ligand 1 was dissolved in 0.5 mL DMF and added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 4 h. The reaction was stopped with 1 mL water. Saturated $NaHCO_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated $NaHCO_3$ solution, dried over $MgSO_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the preparative HPLC system.

Yield: 22.2 mg, 24.3 μmol, 67% of a white solid.

ESI: (calculated): [M+H$^+$] 913.37 g/mol
        (found): [M+H$^+$] 913.63 g/mol.

MADLI: (calculated): [M+Na$^+$] 935.35 g/mol
        (found): [M+Na$^+$] 935.10 g/mol.

HRMS: (calculated) [M+Na$^+$] 935.3496 g/mol,

(found) [M+Na$^+$] 935.3486 g/mol.

HPLC: RT = 11.8 min (254 nm, 96%).

^{1}H NMR (600 MHz, DMSO) δ = 9.94 (s, 1H), 9.59 (s, 1H), 8.99 (s, 1H), 8.59 (t, ^3J = 5.7 Hz, 1H), 8.23 (s, 1H), 8.03 (d, ^3J = 10.0 Hz, 2H), 7.98 (d, ^3J = 7.8 Hz, 2H), 7.69 (d, ^3J = 7.8 Hz, 2H), 7.56 (d, ^3J = 8.3 Hz, 1H), 7.41 (q, ^3J = 8.1 Hz, 4H), 7.33 (d, ^3J = 8.3 Hz, 1H), 6.84 (s, 1H), 4.80 (d, ^3J = 9.0 Hz, 1H), 4.47 (t, ^3J = 8.1 Hz, 1H), 4.47 – 4.41 (m, 2H), 4.39 (s, 1H), 4.25 (dd, ^3J = 15.7 Hz, ^4J = 5.3 Hz, 1H), 3.75 (s, 2H), 3.54 – 3.52 (m, 2H), 3.29 – 3.17 (m, 2H), 3.23 – 3.19 (m, 2H), 3.06 – 3.02 (m, 2H), 2.87 (s, 3H), 2.45 (s, 3H), 2.10 – 2.03 (m, 1H), 1.96 – 1.90 (m, 1H), 1.05 (s, 9H) ppm.

^{13}C NMR (151 MHz, DMSO) δ = 171.9, 169.5, 166.2, 162.9, 161.1, 151.5, 147.8, 142.9, 142.4, 139.5, 139.4, 138.8 (q, ^2J = 33 Hz), 134.5, 132.7, 132.4, 131.2, 129.7, 128.7, 128.5, 127.5, 126.0, 124.0, 122.3, 121.1 (q, ^1J = 275 Hz), 120.6, 119.1, 111.6, 68.9, 58.8, 57.3, 56.5, 52.8, 48.1, 41.7, 40.4, 37.9, 35.6, 26.5, 15.9 ppm.

Synthesis of 6-hydroxy-N-(4'-((3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8e)

21.6 mg (36 µmol, 1.00 eq) tert-butyl (3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)carbamate were dissolved in 1 mL CH_2Cl_2 and 1 mL TFA was added. The solution was stirred for 1 h at rt. Excess solvent was removed under reduced pressure.

20 mg (36 µmol, 1.00 eq) *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate were dissolved in 1 mL CH_2Cl_2 and 1 mL TFA was added. The solution was stirred for 1 h at rt. Excess solvent was removed under reduced pressure. The crude species was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. 16.4 mg (43 µmol, 1.20 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The crude species of tert-butyl (3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)carbamate was dissolved in 0.5 mL DMF and DIEA were added until the pH of the solution was basic. The mixture was added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 4 h. The reaction was stopped with 1 mL water. Saturated $NaHCO_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated $NaHCO_3$ solution, dried over $MgSO_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the preparative HPLC system.

Yield: 26.8 mg, 18.6 µmol, 43% of a white solid as TFA salt (1:4/ product: TFA.)

MALDI: (calculated): [M+Na$^+$] 1006.39 g/mol

(found): [M+Na$^+$] 1006.42 g/mol.

HRMS: (calculated): [M+Na$^+$] 1006.3867 g/mol

(found): [M+Na$^+$] 1006.3870 g/mol.

HPLC: RT = 11.2 min (254 nm, 100%).

^{1}H NMR (600 MHz, DMSO) δ = 10.24 (s, 1H), 9.92 (s, 1H), 8.97 (s, 1H), 8.56 (t, ^3J = 5.5 Hz, 1H), 8.50 - 8.48 (m, 1H), 8.34 (s, 1H), 8.16 (s, 1H), 8.01 (d, ^3J = 9.2 Hz, 1H), 7.94 (d, ^3J = 8.3 Hz, 2H), 7.67 (d, ^3J = 7.8 Hz, 2H), 7.59 (d, ^3J = 8.5 Hz, 1H), 7.40 (dd, ^2J = 22.6 Hz, ^{3}J = 7.6 Hz, 4H), 7.34 (d, ^3J = 8.3 Hz, 1H), 7.31 (s, 1H), 4.57 (d, ^3J = 9.2 Hz, 1H), 4.47 − 4.39 (m, 2H), 4.36 (s, 1H), 4.22 (dd, ^3J = 15.9 Hz, ^4J = 5.3 Hz, 1H), 3.72 − 3.64 (m, 2H), 3.59 − 3.52 (m, 2H), 3.49 (dd, ^3J = 15.9 Hz, ^4J = 7.6 Hz, 2H), 3.31 (d, ^3J = 11.4 Hz, 2H), 3.06 (s, 4H), 2.86 (s, 3H), 2.62 − 2.54 (m, 2H), 2.44 (s, 3H), 2.09 − 1.99 (m, 1H), 1.95 − 1.87 (m, 1H), 0.93 (s, 9H) ppm.

^{13}C NMR (151 MHz, DMSO) δ = 171.9, 170.4, 169.6, 165.8, 163.1, 161.1, 151.5, 147.6, 142.9, 142.0, 139.5, 139.0, 138.5 (q, ^2J = 32 Hz), 135.3, 133.3, 132.6, 131.2, 129.6, 128.6, 127.9, 127.4, 126.1, 124.0, 122.4, 122.1 (q, ^1J = 279 Hz), 121.0, 118.9, 111.7, 68.9, 58.7, 56.5, 56.4, 52.9, 48.1, 42.4, 41.7, 38.0, 36.3, 35.3, 34.9, 26.4, 15.9 ppm.

Synthesis of 6-hydroxy-N-(4'-((4-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8f)

22.1 mg (36 µmol, 1.00 eq) (4-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutyl)carbamate were dissolved in 1 mL CH_2Cl_2 and 1 mL TFA was added. The solution was stirred for 1 h at rt. Excess solvent was removed under reduced pressure.

20 mg (36 µmol, 1.00 eq) *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate were dissolved in 1 mL CH_2Cl_2 and 1 mL TFA was added. The solution was stirred for 1 h at rt. Excess solvent was removed under reduced pressure. The crude species was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. 16.4 mg (43 µmol, 1.20 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The crude species of (4-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutyl)carbamate was dissolved in 0.5 mL DMF and DIEA were added until the pH of the solution was basic. The mixture was added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 4 h. The reaction was stopped with 1 mL water. Saturated $NaHCO_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated $NaHCO_3$ solution, dried over $MgSO_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the preparative HPLC system.

Yield: 14.7 mg, 14.7 µmol, 41% of a white solid.

ESI: (calculated): [M+H$^+$] 998.42 g/mol

(found): [M+H$^+$] (70) 998.35 g/mol.

MALDI: (calculated): [M+Na$^+$] 1020.40 g/mol

(found): [M+Na$^+$] 1020.34 g/mol.

HRMS: (calculated) [M+Na$^+$] 1020.4024 g/mol,

(found) [M+Na$^+$] 1020.4010 g/mol.

HPLC: RT = 11.3 min (254 nm, 100%).

^{1}H NMR (600 MHz, DMSO) δ = 9.82 (s, 1H), 9.58 (s, 1H), 8.97 (s, 1H), 8.55 (t, ^3J = 6.0 Hz, 1H), 8.52 (t, ^3J = 5.5 Hz, 1H), 8.21 (s, 1H), 8.03 (s, 1H), 7.95 (d, ^3J = 8.2 Hz, 3H), 7.69 (d, ^3J = 8.3 Hz, 2H), 7.56 (dd, ^3J = 8.3 Hz, ^4J = 1.9 Hz, 1H), 7.40 (dd, ^2J = 22.3 Hz, ^3J = 8.1 Hz, 4H), 7.32 (d, ^3J = 8.4 Hz, 1H), 6.84 (s, 1H), 4.56 (d, ^3J = 9.3 Hz, 1H), 4.43 (dd, ^3J = 14.8 Hz, ^4J = 6.9 Hz, 2H), 4.36 (s, 1H), 4.22 (dd, ^3J = 15.8 Hz, ^4J = 5.4 Hz, 1H), 3.71 - 3.63 (m, 2H), 3.52 (d, ^3J = 11.2 Hz, 2H), 3.28 (d, ^3J = 7.4 Hz, 4H), 3.22 - 3.18 (m, 2H), 3.05 - 3.01 (m, 2H), 2.87 (s, 3H), 2.44 (s, 3H), 2.37 − 2.30 (m, 1H), 2.25 - 2.20 (m, 1H), 2.05 - 2.00 (m, 1H), 1.95 − 1.87 (m, 1H), 1.81 − 1.72 (m, 2H), 0.95 (s, 9H) ppm.

^{13}C NMR (201 MHz, DMSO) δ = 171.9, 171.8, 169.6, 165.8, 162.8, 161.0, 151.4, 147.7, 144.8, 142.0, 139.5, 139.1, 138.7 (q, ^2J = 33 Hz), 134.3, 133.2, 132.2, 131.1, 129.6, 128.6, 127.9, 127.4, 126.0, 124.0, 122.4, 122.0 (q, ^1J = 276 Hz), 120.4, 119.0, 111.6, 68.9, 58.5, 56.2, 56.1, 52.6, 48.0, 42.1, 41.4, 38.7, 37.7, 35.1, 32.4, 26.2, 25.4, 15.6 ppm.

Synthesis of 6-hydroxy-*N*-(4'-((5-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8g/ Homer)

18.0 mg (32.0 µmol, 1.00 eq) of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was diluted in 1 mL DCM and 1 mL TFA was added. In a second vial, 21.4 mg (34.0 µmol, 1.05 eq) of *tert-butyl* (5-(((R)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamate was diluted in 1 mL DCM and 1 mL TFA was added. The two reaction mixtures were stirred for 1 h at rt. Excess solvent and TFA was removed under reduced pressure.

The deprotected species of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. 18.4 mg (49.0 µmol, 1.50 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The deprotected species of *tert*-butyl (5-(((R)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamate was dissolved in 0.5 mL DMF and 11 µL (65 µmol, 2.00 eq) DIEA were added to the solution. The mixture was added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 2.5 h. The reaction was stopped with 1 mL water. Saturated NaHCO$_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated NaHCO$_3$ solution, dried over MgSO$_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the HPLC system.

Yield: 7.42 mg, 7.33 µmol, 23% of a white solid.

MALDI: (calculated): [M+H$^+$] 1012.43 g/mol

(found): [M+H$^+$] 1012.53 g/mol.

HPLC: RT = 11.4 min (254 nm, 100%).

HRMS: (calculated) [M+Na$^+$] 1034.4180 g/mol

(found) [M+Na$^+$] 1034.4171 g/mol.

^{1}H NMR (500 MHz, DMSO) δ = 9.77 (s, 1H), 9.57 (s, 1H), 8.97 (s, 1H), 8.55 (t, ^3J = 6.1 Hz, 1H), 8.50 (t, ^3J = 5.6 Hz, 1H), 8.21 (d, ^4J = 1.8 Hz, 1H), 8.03 (s, 1H), 7.94 (d, ^3J = 8.4 Hz, 2H), 7.86 (d, ^3J = 9.3 Hz, 1H), 7.68 (d, ^3J = 8.4 Hz, 2H), 7.55 (dd, ^3J = 8.3 Hz, ^4J = 2.1 Hz, 1H), 7.42 -7.39 (m, 4H), 7.32 (d, ^3J = 8.4 Hz, 1H), 6.84 (s, 1H), 5.12 (s, 1H), 4.54 (d, ^3J = 9.4 Hz, 1H), 4.48 − 4.38 (m, 2H), 4.35 (s, 1H), 4.21 (dd, ^3J = 15.9 Hz, ^4J = 5.5 Hz, 1H), 3.70 − 3.63 (m, 2H), 3.55 - 3.46 (m, 2H), 3.29 − 3.23 (m, 4H), 3.07 - 3.02 (m, 2H), 2.86 (s, 3H), 2.53 − 2.50 (m, 2H), 2.44 (s, 3H), 2.35 − 2.26 (m, 1H), 2.19 - 2.14 (m, 1H), 2.09 − 1.99 (m, 1H), 1.93 - 1.88 (m, 1H), 1.60 − 1.47 (m, 4H), 0.94 (s, 9H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 172.0, 172.0, 169.7, 165.8, 163.2, 151.4, 147.7, 144.6, 142.1, 139.5, 139.1, 138.1 (d, ^2J = 32 Hz), 134.4, 133.2, 132.5, 131.2, 129.6, 128.6, 127.9, 127.4, 126.0, 123.7, 121.8, 122.3 (q, ^1J = 276 Hz), 120.5, 117.7, 111.7, 68.9, 58.7, 56.3, 56.3, 54.8, 51.1, 45.8, 41.6, 38.7, 37.9, 35.2, 34.7, 28.9, 26.4, 23.1, 15.9 ppm.

Synthesis of 6-hydroxy-*N*-(4'-((6-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8h)

18.0 mg (32.0 µmol, 1.00 eq) of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was diluted in 1 mL DCM and 1 mL TFA was added. In a second vial, 21.9 mg (34.0 µmol, 1.05 eq) of *tert*-butyl (6-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)carbamate was diluted in 1 mL DCM and 1 mL TFA was added. The two reaction mixtures were stirred for 1 h at rt. Excess solvent and TFA was removed under reduced pressure.

The deprotected species of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. 18.4 mg (49.0 µmol, 1.50 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The deprotected species of *tert*-butyl (6-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)carbamate was dissolved in 0.5 mL DMF and 11 µL (65 µmol, 2.00 eq) DIEA were added to the solution. The mixture was added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 2.5 h. The reaction was stopped with 1 mL water. Saturated $NaHCO_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated $NaHCO_3$ solution, dried over $MgSO_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the HPLC system.

Yield: 6.65 mg, 6.48 µmol, 20% of a white solid.

MALDI: (calculated) [M+Na⁺] 1048.43 g/mol; [M+H⁺] 1026.45 g/mol

   (found) [M+Na⁺] 1048.43 g/mol [M+H⁺] 1026.44 g/mol.

HPLC: RT = 11.4 min (254 nm, 100%).

HRMS: (calculated) [M+Na⁺] 1048.4337 g/mol

   (found) [M+Na⁺] 1048.4338 g/mol.

^{1}H NMR (500 MHz, DMSO) δ = 9.96 (s, 1H), 9.59 (s, 1H), 8.98 (s, 1H), 8.56 (t, J = 6.0 Hz, 1H), 8.48 (t, J = 5.6 Hz, 1H), 8.22 (d, J = 2.0 Hz, 1H), 8.04 (s, 1H), 7.94 (d, J = 8.5 Hz, 2H), 7.84 (d, J = 9.3 Hz, 1H), 7.68 (d, J = 8.4 Hz, 2H), 7.55 (dd, J = 8.3, 2.2 Hz, 1H), 7.45 − 7.36 (m, 4H), 7.32 (d, J = 8.4 Hz, 1H), 6.84 (s, 1H), 4.54 (d, J = 9.4 Hz, 1H), 4.47 − 4.38 (m, 2H), 4.35 (s, 1H), 4.22 (dd, J = 15.9, 5.4 Hz, 1H), 3.68 - 3.65 (m, 2H), 3.53 (d, J = 11.2 Hz, 2H), 3.28 - 3.20 (m, 6H), 3.04 (t, J = 11.3 Hz, 2H), 2.87 (s, 3H), 2.44 (s, 3H), 2.31 − 2.22 (m, 1H), 2.17 - 2.10 (m, 1H), 2.05 - 2.01 (m, 1H), 1.93 - 1.87 (m, 1H), 1.56 - 1.50 (m, 4H), 1.35 − 1.25 (m, 2H), 0.93 (s, 9H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 172.1, 172.0, 169.7, 165.7, 163.1, 161.1, 151.5, 147.7, 142.9, 141.9, 139.5, 139.0, 138.5 (q, ^2J = 33 Hz), 135.4, 133.5, 132.6, 131.2, 129.6, 128.6, 127.9, 127.4, 126.1, 123.9, 122.3, 122.1 (q, ^1J = 276 Hz) 121.0, 118.9, 118.8, 111.6, 68.9, 58.7, 56.4, 56.3, 52.8, 48.1, 42.4, 41.7, 38.0, 35.2, 34.9, 29.0, 26.4, 26.2, 25.3, 15.9 ppm.

Synthesis of 6-hydroxy-*N*-(4'-((7-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8i)

18.0 mg (32.0 µmol, 1.00 eq) of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was diluted in 1 mL DCM and 1 mL TFA was added. In a second vial, 22.3 mg (34.0 µmol, 1.05 eq) of (7-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)carbamate was diluted in 1 mL DCM and 1 mL TFA was added. The two reaction mixtures were stirred for 1 h at rt. Excess solvent and TFA was removed under reduced pressure.

The deprotected species of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. 18.4 mg (49.0 µmol, 1.50 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The deprotected species of (7-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)carbamate was dissolved in 0.5 mL DMF and 11 µL (65 µmol, 2.00 eq) DIEA were added to the solution. The mixture was added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 2.5 h. The reaction was stopped with 1 mL water. Saturated NaHCO$_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated NaHCO$_3$ solution, dried over MgSO$_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the HPLC system.

Yield: 4.67 mg, 4.49 µmol, 14% of a white solid.

MALDI: (calculated): [M+H$^+$] 1040.21 g/mol

(found): [M+H$^+$] 1040.25 g/mol.

HPLC: RT = 11.6 min (254 nm, 98%).

HRMS: (calculated) [M+Na$^+$] 1062.45 g/mol

(found) [M+Na$^+$] 1062.45 g/mol.

^{1}H NMR (500 MHz, DMSO) δ = 12.55 (s, 1H), 9.52 (s, 1H), 8.97 (s, 1H), 8.55 (t, ^3J = 6.0 Hz, 1H), 8.46 (t, ^3J = 5.6 Hz, 1H), 8.17 (s, 1H), 8.01 (s, 1H), 7.93 (d, ^3J = 8.4 Hz, 2H), 7.84 (d, ^3J = 9.4 Hz, 1H), 7.68 (d, ^3J = 8.4 Hz, 2H), 7.54 (dd, ^3J = 8.3 Hz, ^4J = 2.1 Hz, 1H), 7.40 (q, ^3J = 8.3 Hz, 4H), 7.30 (d, ^3J = 8.4 Hz, 1H), 6.83 (s, 1H), 5.11 (d, ^3J = 3.6 Hz, 1H), 4.54 (d, ^3J = 9.4 Hz, 1H), 4.49 − 4.38 (m, 2H), 4.35 (s, 1H), 4.21 (dd, ^2J = 16.0 Hz, ^3J = 5.4 Hz, 1H), 3.72 − 3.58 (m, 2H), 3.26 (dd, ^3J = 13.3 Hz, ^4J = 6.7 Hz, 4H), 3.05 (s, 4H), 2.44 (s, 3H), 2.32 − 2.28 (m, 1H), 2.19 − 2.07 (m, 1H), 2.07 − 1.98 (m, 1H), 1.93 - 1.88 (m, 1H), 1.52 - 1.47 (m, 4H), 1.31 - 1.23 (m, 3H), 0.93 (s, 9H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 172.1, 171.9, 169.7, 165.7, 163.1, 161.1, 151.4, 147.7, 142.9, 141.8, 139.5, 139.1, 138.5 (q, ^2J = 32 Hz), 135.4, 133.5, 132.6, 131.2, 129.6, 128.6, 127.9, 127.4, 126.1, 123.9, 123.1, 122.3, 122.1 (q, ^1J = 273 Hz), 121.0, 119.0, 111.6, 68.9, 58.7, 56.3, 56.3, 52.8, 48.1, 42.3, 41.6, 38.4, 38.0, 35.2, 34.8, 29.1, 26.4, 25.4, 15.9 ppm.

Synthesis of 6-hydroxy-N-(4'-((4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethyl)benzyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8j)

32 mg (47 µmol, 1.05 eq) tert-butyl (4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethyl)benzyl)carbamate were dissolved in 1 mL CH_2Cl_2 and 1 mL TFA was added. The solution was stirred for 1 h at rt. Excess solvent was removed under reduced pressure.

25 mg (45 µmol, 1.00 eq) *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate were dissolved in 1 mL CH_2Cl_2 and 1 mL TFA was added. The solution was stirred for 1 h at rt. Excess solvent was removed under reduced pressure. The crude species was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. 20.5 mg (54 µmol, 1.20 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The crude species of tert-butyl (4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethyl)benzyl)carbamate was dissolved in 0.5 mL DMF and DIEA were added until the pH of the solution was basic. The mixture was added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 4 h. The reaction was stopped with 1 mL water. Saturated $NaHCO_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated $NaHCO_3$ solution, dried over $MgSO_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the preparative HPLC system.

Yield: 14.4 mg, 13.6 µmol, 30% of a white solid.

MALDI: (calculated): [M+H$^+$] 1060.44 g/mol

(found): [M+H$^+$] 1060.17 g/mol.

HRMS: (calculated): [M+Na$^+$] 1082.4180 g/mol

(found): [M+Na$^+$] 1082.4171 g/mol.

HPLC: RT = 11.6 min (254 nm, 100%).

^{1}H NMR (500 MHz, DMSO) δ = 9.47 (s, 1H), 9.04 (t, ^3J = 6.0 Hz, 1H), 8.98 (s, 1H), 8.56 (t, ^3J = 6.1 Hz, 1H), 8.12 (d, ^4J = 2.1 Hz, 1H), 8.09 (d, ^3J = 9.3 Hz, 1H), 8.01 – 7.93 (m, 3H), 7.69 (d, ^3J = 8.5 Hz, 2H), 7.53 (dd, ^3J = 8.4 Hz, ^4J = 2.2 Hz, 1H), 7.40 (q, ^3J = 8.4 Hz, 4H), 7.27 (d, ^3J = 8.4 Hz, 1H), 7.24 (s, 4H), 6.82 (s, 1H), 5.11 (d, ^3J = 3.1 Hz, 1H), 4.51 (d, ^3J = 9.4 Hz, 1H), 4.47 (d, ^3J = 5.8 Hz, 2H), 4.45 – 4.39 (m, 2H), 4.33 (s, 1H), 4.22 (dd, ^3J = 15.9 Hz, ^4J = 5.5 Hz, 1H), 3.71 – 3.58 (m, 3H), 3.44 (d, ^3J = 13.9 Hz, 2H), 2.91 (t, ^3J = 4.3 Hz, 4H), 2.50 (s, 4H), 2.44 (s, 3H), 2.24 (s, 3H), 2.07 – 1.97 (m, 1H), 1.92 - 1.86 (m, 1H), 0.92 (s, 9H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 171.9, 170.0, 169.5, 165.8, 162.8, 161.1, 151.4, 147.72, 145.0, 142.3, 139.5, 139.2, 138.5 (q, ^2J = 32 Hz), 137.6, 135.1, 134.2, 132.9, 132.2, 131.2, 129.6, 129.0, 128.6, 128.0, 127.4, 127.0, 126.1, 124.0, 122.4, 122.0 (d, ^1J = 275 Hz), 120.4, 119.0, 111.6, 68.9, 58.7, 56.5, 56.4, 54.7, 51.0, 45.7, 42.4, 41.7, 41.5, 37.9, 35.4, 26.3, 15.9 ppm.

Synthesis of N-(4'-((2-(2-(4-((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxamido)-3-methoxybenzamido)ethoxy)ethyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (9a)

15.2 mg (21 µmol, 1.05 eq) Intermediate (**6e**) was dissolved in 2 mL TFA/ CH$_2$Cl$_2$ and stirred for 1h at rt. Excess solvent was removed under reduced pressure. 13 mg (21 µmol, 1.0 eq) Idasanutlin, 9.6 mg (25µmol, 1.2 eq) HATU and 7 µL (42 µmol, 2.0 eq) DIEA were dissolved in 1 mL DMF and stirred for 15 min at rt. Then, a solution of deprotected (**6e**) and 73µL (420 µmol, 10 eq) DIEA in 1 mL DMF were added to the solution and stirred for 12 h at rt. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 3x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified by HPLC. The gained product was then dissolved in ethyl acetate and a solution of saturated NaHCO$_3$ and saturated NaCl solution and extracted with ethyl acetate. The combined organic phases were dried over MgSO$_4$ and the solvent was removed under reduced pressure.

Yield: 3.0 mg, 2.5 µmol, 12% of a clear oil.

MALDI: (calculated) [M+H$^+$] 1184.49 g/mol,
        (found) [M+H$^+$] 1184.40 g/mol.

HRMS: (calculated) [M+Na$^+$] 1206.3805 g/mol,
        (found) [M+Na$^+$] 1206.3821 g/mol.

HPLC: RT = 14.4 min (254 nm, 98%).

¹H NMR (400 MHz, DMSO) δ = 10.45 (s, 1H), 10.40 (s, 1H), 9.45 (s, 1H), 8.53 (t, ^3J = 5.5 Hz, 1H), 8.48 (t, ^3J = 5.5 Hz, 1H), 8.35 (s, 1H), 8.32 (d, ^3J = 8.5 Hz, 2H), 8.13 (d, ^4J = 1.9 Hz, 1H), 7.92 (d, ^3J = 8.4 Hz, 2H), 7.73 (t, ^3J = 7.3 Hz, 2H), 7.67 (d, ^3J = 8.4 Hz, 2H), 7.60 - 7.56 (m, 4H), 7.53 - 7.50 (m, 3H), 7.44 – 7.38 (m, 1H), 7.38 – 7.31 (m, 4H), 7.25 (d, ^3J = 8.4 Hz, 1H), 6.81 (s, 1H), 4.65 – 4.54 (m, 4H), 4.40 - 4.33 (m, 2H), 3.99 - 3.95 (m, 2H), 3.92 (s, 3H), 3.90 (s, 3H), 3.60 - 3.57 (m, 5H), 3.48 - 3.43 (m, 8H), 2.92 – 2.88 (m, 4H), 1.69 - 1.60 (m, 2H), 1.39 - 1.36 (m, 1H), 1.28 - 1.24 (m, 2H), 0.96 (s, 9H) ppm. Contains rotameres.

Synthesis of N-(4'-((1-(4-((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxamido)-3-methoxyphenyl)-1-oxo-5,8,11,14,17,20,23-heptaoxa-2-azapentacosan-25-yl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (9b)

8.9 mg (9 µmol, 1.0 eq) Intermediate (**6f**) was dissolved in 2 mL TFA/ CH_2Cl_2 and stirred for 1h at rt. Excess solvent was removed under reduced pressure. 5.5 mg (9 µmol, 1.0 eq) Idasanutlin, 4 mg (11 µmol, 1.2 eq) HATU and 3 µL (18 µmol, 2.0 eq) DIEA were dissolved in 1 mL DMF and stirred for 15 min at rt. Then, a solution of deprotected (**6f**) and 31 µL (180 µmol, 10 eq) DIEA in 1 mL DMF were added to the solution and stirred for 12 h at rt. The reaction mixture was quenched with 2 mL water and 2 mL saturated $NaHCO_3$, then the reaction was extracted 3x with EA. The organic phase was dried over $MgSO_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified by HPLC. The gained product was then dissolved in ethyl acetate and a solution of saturated $NaHCO_3$ and saturated NaCl solution and extracted with ethyl acetate. The combined organic phases were dried over $MgSO_4$ and the solvent was removed under reduced pressure.

Yield: 3.3 mg, 2.2 µmol, 25% of a clear oil.

MALDI: (calculated) [M+H$^+$] 1448.56 g/mol,

(found) [M+H$^+$] 1448.53 g/mol.

HRMS: (calculated) [M+Na$^+$] 1470.5378 g/mol,

(found) [M+Na$^+$] 1470.5392 g/mol.

HPLC: RT = 14.6 min (254 nm, 96%).

^{1}H NMR (400 MHz, DMSO) δ = 10.47 (s, 1H), 10.40 (s, 1H), 9.46 (s, 1H), 8.53 (t, ^3J = 5.5 Hz, 1H), 8.48 (t, ^3J = 5.4 Hz, 1H), 8.36 (d, ^3J = 8.8 Hz, 1H), 8.32 (d, ^3J = 8.4 Hz, 2H), 8.12 (d, ^4J = 2.1 Hz, 1H), 7.92 (d, ^3J =

8.5 Hz, 2H), 7.73 (t, ^3J = 7.2 Hz, 2H), 7.67 (d, ^3J = 8.5 Hz, 2H), 7.60 - 7.56 (m, 5H), 7.54 − 7.51 (m, 2H), 7.50 - 7.48 (m, 1H), 7.40 (dd, ^3J = 8.4 Hz, ^4J = 2.4 Hz, 1H), 7.38 − 7.34 (m, 3H), 7.34 − 7.32 (m, 1H), 7.25 (d, ^3J = 8.4 Hz, 1H), 6.82 (s, 1H), 4.65 − 4.54 (m, 4H), 4.41 - 4.33 (m, 2H), 3.99 - 3.95 (m, 2H), 3.92 (s, 3H), 3.90 (s, 3H), 3.60 - 3.57 (m, 5H), 3.49 − 3.41 (m, 8H), 2.91 - 2.90 (m, 4H), 1.68 - 1.61 (m, 2H), 1.44 − 1.33 (m, 2H), 0.96 (s, 9H) ppm. Contains rotameres.

Synthesis of N-(4'-((4-((4-((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxamido)-3-methoxybenzamido)methyl)benzyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (9c)

13.5 mg (24 µmol, 1.0 eq) Intermediate (**6g**) was dissolved in 2 mL TFA/ CH$_2$Cl$_2$ and stirred for 1h at rt. Excess solvent was removed under reduced pressure. 15.7 mg (25 µmol, 1.1 eq) Idasanutlin, 11 mg (29 µmol, 1.2 eq) HATU and 8 µL (49 µmol, 2.0 eq) DIEA were dissolved in 1 mL DMF and stirred for 15 min at rt. Then, a solution of deprotected (**6g**) and 84 µL (490 µmol, 10 eq) DIEA in 1 mL DMF were added to the solution and stirred for 12 h at rt. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 3x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified by HPLC. The gained product was then dissolved in ethyl acetate and a solution of saturated NaHCO$_3$ and saturated NaCl solution and extracted with ethyl acetate. The combined organic phases were dried over MgSO$_4$ and the solvent was removed under reduced pressure.

Yield: 3.7 mg, 3.0 µmol, 13% of a clear oil.

MALDI: (calculated) [M+K$^+$] 1254.36 g/mol,
         (found) [M+K$^+$] 1254.32 g/mol.

HRMS: (calculated) [M+Na$^+$] 1238.3856 g/mol,
         (found) [M+Na$^+$] 1238.3894 g/mol.

HPLC: RT = 14.7 min (254 nm, 98%).

^{1}H NMR (250 MHz, DMSO) δ = 10.40 (s, 1H), 9.13 (s, 1H), 9.04 (s, 1H), 8.96 (s, 1H), 8.49 (s, 3H), 8.44 (s, 1H), 8.31 (d, ^3J = 9.1 Hz, 2H), 8.20 (d, ^3J = 11.9 Hz, 1H), 7.98 (d, ^3J = 7.9 Hz, 2H), 7.69 (d, ^3J = 7.4 Hz, 2H), 7.61 (s, 2H), 7.57 – 7.52 (m, 2H), 7.52 – 7.47 (m, 1H), 7.39 (s, 1H), 7.36 (s, 2H), 7.29 (s, 4H), 6.52 (s, 1H), 6.13 (s, 1H), 4.59 - 4.58 (m, 2H), 4.51 – 4.41 (m, 4H), 3.91 (s, 4H), 3.57 - 3.50 (m, 6H), 3.47 (d, ^3J = 4.8 Hz, 2H), 3.11 (d, ^3J = 5.1 Hz, 2H), 3.03 - 2.99 (m, 2H), 2.44 – 2.37 (m, 1H), 0.97 (s, 9H) ppm. Contains rotameres.

Synthesis of 6-hydroxy-N-(4'-((5-(((S)-1-((2S,4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (22/ nc_VHL)

20 mg (36 µmol, 1.00 eq) *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate (**6d**) were dissolved in 1 mL CH$_2$Cl$_2$ and 1 mL TFA was added. The solution was stirred for 1 h at rt. Excess solvent was removed under reduced pressure. The crude species was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. 16.4 mg (43 µmol, 1.20 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. 17.0 mg (36 µmol, 1.00 eq) tert-butyl (5-(((S)-1-((2S,4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamate (**L15**) was dissolved in 1 mL DCM and 1 mL TFA and stirred for 1 h at rt. Excess solvent was removed under reduced pressure. The crude species was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. The solution was added to the active ester of *tert*-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 4 h. The reaction was stopped with 1 mL water. Saturated NaHCO$_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated NaHCO$_3$ solution, dried over MgSO$_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the preparative HPLC system. The gained product was then dissolved in ethyl acetate and a solution of saturated NaHCO$_3$ and saturated NaCl solution and extracted with ethyl acetate. The combined organic phases were dried over MgSO$_4$ and the solvent was removed under reduced pressure.

Yield: 9 mg, 8.9 µmol, 18% of a white oil.

MALDI: (calculated) [M-CH$_3$-tBu+2H$^+$] 941.35 g/mol,

(found) [M-CH$_3$-tBu+2H$^+$] 941.45 g/mol.

HRMS: (calculated) [M+Na$^+$] 1034.4180 g/mol,

(found) [M+Na$^+$] 1034.4169 g/mol.

HPLC: RT = 11.4 min (254 nm, 100%).

^{1}H NMR (250 MHz, MeOD) δ = 9.03 (s, 1H), 8.26 (d, ^4J = 1.9 Hz, 1H), 8.03 (s, 1H), 7.91 (d, ^3J = 8.3 Hz, 2H), 7.71 (d, ^3J = 8.3 Hz, 2H), 7.56 (dd, ^3J = 8.5 Hz, ^4J = 2.0 Hz, 1H), 7.44 (dd, ^2J = 15.1 Hz, ^3J = 7.8Hz, 4H), 7.37 (d, ^4J = 2.1 Hz, 1H), 6.94 (s, 1H), 4.63 (s, 1H), 4.56 (s, 1H), 4.50 (s, 2H), 4.35 (d, ^3J = 15.7 Hz, 1H), 3.91 (d, ^3J = 10.7 Hz, 1H), 3.80 (dd, ^3J = 10.9 Hz, ^4J = 3.6 Hz, 1H), 3.64 - 3.60 (m, 2H), 3.44 - 3.39 (m, 2H), 3.36 – 3.24 (m, 4H), 3.20 - 3.15 (m, 2H), 2.97 (s, 3H), 2.47 (s, 3H), 2.39 - 2.33 (m, 2H), 2.28 – 2.15 (m, 1H), 2.13 - 2.08 (m, 1H), 1.79 – 1.59 (m, 4H), 1.04 (s, 9H) ppm.

Synthesis of 6-hydroxy-N-(4'-((5-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamoyl)-4-morpholino-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (23/ nc_WDR5)

21.0 mg (39.0 µmol, 1.00 eq) of tert-butyl 4'-morpholino-3'-(6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamido)-[1,1'-biphenyl]-4-carboxylate was diluted in 1 mL DCM and 1 mL TFA was added. In a second vial, 24 mg (39.0 µmol, 1.00 eq) of *tert-butyl* (5-(((R)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamate was diluted in 1 mL DCM and 1 mL TFA was added. The two reaction mixtures were stirred for 1 h at rt. Excess solvent and TFA was removed under reduced pressure.

The deprotected species of *tert*-butyl 4'-morpholino-3'-(6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamido)-[1,1'-biphenyl]-4-carboxylate was dissolved in 0.5 mL DMF and DIEA was added until the pH of the solution was basic. 29.4 mg (77.0 µmol, 2.00 eq) HATU was added. The reaction mixture was stirred for 20 min at rt. The deprotected species of *tert-butyl* (5-(((R)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamate was dissolved in 0.5 mL DMF and 67 µL (387 µmol, 10.0 eq) DIEA were added to the solution. The mixture was added to the active ester of *tert*-butyl 4'-morpholino-3'-(6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamido)-[1,1'-biphenyl]-4-carboxylate and stirred at rt for 2.5 h. The reaction was stopped with 1 mL water. Saturated NaHCO$_3$ solution and saturated NaCl solution were added and the reaction mixture was extracted 4x with EA. The combined organic phases were washed with saturated NaHCO$_3$ solution, dried over MgSO$_4$ and filtered. The solvent of the organic phase was evapored under reduced pressure. The purification of the crude product was carried out on the HPLC system.

Yield: 19.5 mg, 7.33 µmol, 23 % of a white solid as TFA salt (1:1/ product: TFA).

ESI: (calculated): [M-H]⁻ 998.11 g/mol

           (found): [M-H]⁻ 998.53 g/mol.

MALDI: (calculated): [M+H]⁺ 1000.13 g/mol

           (found): [M+H]⁺ 1000.19 g/mol.

HRMS: (calculated) [M+Na⁺] 1021.3864 g/mol

           (found) [M+Na⁺] 1021.3902 g/mol.

^{1}H NMR (500 MHz, DMSO) δ = 9.60 (s, 1H), 8.98 (s, 1H), 8.55 (t, ^{3}J = 6.1 Hz, 1H), 8.49 (t, ^{3}J = 5.6 Hz, 1H), 8.16 (d, ^{4}J = 2.1 Hz, 1H), 7.97 (s, 1H), 7.93 (d, ^{3}J = 8.5 Hz, 2H), 7.86 (d, ^{3}J = 9.3 Hz, 1H), 7.68 (d, ^{3}J = 8.5 Hz, 2H), 7.53 (dd, ^{3}J = 8.4 Hz, ^{4}J = 2.2 Hz, 1H), 7.43 - 7.37 (m, 4H), 7.28 (d, ^{3}J = 8.4 Hz, 1H), 6.82 (s, 1H), 4.55 (d, ^{3}J = 9.4 Hz, 1H), 4.47 – 4.40 (m, 2H), 4.35 (s, 1H), 4.24 - 4.20 (m, 1H), 3.78 – 3.73 (m, 4H), 3.69 - 3.65 (m, 2H), 3.30 - 3.26 (m, 2H), 2.92 – 2.88 (m, 4H), 2.44 (s, 3H), 2.34 - 2.28 (m, 1H), 2.21 - 2.15 (m, 1H), 2.08 – 2.00 (m, 1H), 1.93 - 1.88 (m, 1H), 1.56 - 1.52 (m, 4H), 0.94 (s, 9H) ppm.

^{13}C NMR (126 MHz, DMSO) δ = 172.0, 171.9, 169.7, 165.7, 162.9, 161.1, 151.5, 147.7, 144.6, 142.5, 139.5, 139.2, 138.6 (q, ^{2}J = 32 Hz), 134.6, 133.3, 132.4, 131.2, 129.6, 128.6, 127.9, 127.4, 126.0, 124.0, 123.1, 122.3, 122.1 (q, ^{1}J = 276 Hz), 120.6, 119.0, 111.7, 68.9, 66.2, 58.7, 56.4, 56.3, 53.6, 51.6, 41.8, 41.6, 37.9, 35.2, 34.7, 28.9, 26.4, 23.1, 18.1, 16.7, 15.9 ppm.

7.3.4 Synthesis of NanoBRET Tracer molecules

Synthesis of tert-butyl (1-(3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-1-oxo-5,8,11,14,17,20,23,26,29-nonaoxa-2-azahentriacontan-31-yl)carbamate (6h)

22 mg (40 µmol, 1.0eq) tert-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate were dissolved in 0.5 mL DCM and 0.5 mL TFA and stired at rt for 1 h. Excess solvent was evapored. The solid was dissolved in 0.5 mL DMF, then 137 µL (720 µmol, 20 eq) DIEA and 18 mg (47 µmol, 1.2 eq) HATU were added. After 15 min, a solution of 23.1 mg (42 µmol, 1.05 eq) tert-butyl (29-amino-3,6,9,12,15,18,21,24,27-nonaoxanonacosyl)carbamate in 0.5 mL DMF was added. The solution was stirred for 3 h at rt. The reaction mixture was quenched with 2 mL water and 2 mL saturated $NaHCO_3$, then the reaction was extracted 3x with EA. The organic phase was dried over $MgSO_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using by HPLC.

Yield: 41 mg, 35.6 µmol, 89% of a colourless oil.

MALDI: (calculated) [M-Boc+H$^+$] 939.47 g/mol

(found) [M-Boc+H$^+$] 939.43 g/mol.

^{1}H NMR (400 MHz, MeOD) δ = 8.28 (d, ^4J = 2.1 Hz, 1H), 8.04 (s, 1H), 7.94 (d, ^3J = 8.6 Hz, 2H), 7.78 – 7.71 (m, 2H), 7.58 (dd, ^3J = 8.4 Hz, ^4J = 2.2 Hz, 1H), 7.40 (d, ^3J = 8.4 Hz, 1H), 6.94 (s, 1H), 3.72 – 3.56 (m, 48H), 2.97 (s, 3H), 1.43 (s, 9H) ppm.

Synthesis of tert-butyl (1-(3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-1-oxo-6,9,12-trioxa-2-azapentadecan-15-yl)carbamate (6i)

84 mg   (151 µmol,   1.0 eq)   tert-butyl   3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate were dissolved in 1 mL DCM and 1 mL TFA and stirred at rt for 1 h. Excess solvent was evapored. The solid was dissolved in 2 mL DMF, then 526 µL (3.02 mmol, 20 eq) DIEA and 68.9 mg (181 µmol, 1.2 eq) HATU were added. After 15 min, a solution of 50.8 mg (158 µmol, 1.05 eq) tert-butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate in 1 mL DMF was added. The solution was stirred for 3 h at rt. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 3x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using by HPLC.

Yield: 94.5 mg, 118 µmol, 78% of a colourless oil.

ESI: (calculated) [M+Na$^+$] 825.37 g/mol
        (found) [M+Na$^+$] 825.05 g/mol.

HPLC: RT = 11.9 min (254nm, 100%).

^{1}H NMR (600 MHz, MeOD) δ= 8.29 (s, 1H), 8.00 (s, 1H), 7.89 (d, ^3J = 8.4 Hz, 2H, 7.71 (d, ^3J = 8.4 Hz, 2H), 7.51 (dd, ^3J = 8.3 Hz, ^4J = 2.0 Hz), 7.33 (d, ^3J = 8.3 Hz, 1H), 6.92 (s, 1H), 3.68 – 3.64 (m, 2H), 3.63 – 3.57

(m, 6H), 3.55 − 3.51 (m, 2H), 3.50 (t, ^3J = 6.7 Hz, 2H), 3.46 (t, ^3J = 6.2 Hz, 2H), 3.09 (t, ^3J = 6.8 Hz, 2H), 3.01 (t, ^3J = 4.2 Hz, 4H), 2.69 (s, 4H), 2.39 (s, 3H), 1.96 − 1.82 (m, 2H), 1.76 − 1.62 (m, 2H), 1.41 (s, 9H) ppm.

^{13}C NMR (151 MHz, MeOD) δ = 169.7, 165.0, 164.3, 164.3, 145.3, 144.7, 141.41 (d, J = 33.7 Hz), 140.5, 139.3, 137.5, 134.4, 133.9, 129.5, 128.4, 127.3, 125.0, 123.4 (q, J = 275 Hz), 123.2, 122.7, 121.6, 119.8 (m), 114.6 (d, J = 8.2 Hz), 79.8, 72.5, 71.6, 71.3, 71.2, 70.6, 70.4, 56.2, 52.4, 45.5, 38.6, 37.8, 30.4, 30.0, 29.2, 28.3 ppm.

Synthesis of N-(4'-((2-(2-(3-(5,5-difluoro-7-(1H-pyrrol-2-yl)-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)propanamido)ethoxy)ethyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (21a)

12 mg (14 µmol, 1.0 eq) tert-butyl (2-(2-(3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxamido)ethoxy)ethyl)carbamate were dissolved in 0.5 mL DCM and 0.5 mL TFA and stired at rt for 1 h. Excess solvent was evapored. The solid was dissolved in 0.5 mL DMF, then 19 µL (111 µmol, 8.0 eq) DIEA and 6.2 mg (15 µmol, 1.1 eq) 2,5-dioxopyrrolidin-1-yl-3-(5,5-difluoro-7-(1H-pyrrol-2-yl)-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)propanoate in 0.5 mL DMF was added. The solution was stirred for 3 h at rt. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 3x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using by HPLC.

Yield: 6.35 mg, 7.08 µmol, 77 % of a purple solid.

R_f (20% MeOH/ CH_2Cl_2): 0.70.

HPLC: RT = 12.1 min (254 nm, 95%).

HRMS: (calculated) [M+Na$^+$] 920.3449 g/mol

(found) [M+Na$^+$] 920.3459 g/mol.

^{1}H NMR (500 MHz, MeOD) δ = 8.21 (d, ^4J = 2.1 Hz, 1H), 8.01 (s, 1H), 7.85 (d, ^3J = 8.4 Hz, 2H), 7.64 (d, ^3J = 8.4 Hz, 2H), 7.46 (dd, ^3J = 8.4 Hz, ^4J = 2.1 Hz, 1H), 7.27 (d, ^3J = 8.4 Hz, 1H), 7.21 – 7.07 (m, 4H), 7.02 – 6.90 (m, 2H), 6.85 (d, ^3J = 3.9 Hz, 1H), 6.32 (dd, ^3J = 3.8 Hz, ^4J = 2.6 Hz, 1H), 6.26 (d, ^3J = 3.9 Hz, 1H), 3.61 (m, 8H), 3.40 (t, ^3J = 5.2 Hz, 2H), 3.35 – 3.20 (m, 6H), 3.13 (t, ^3J = 12.8 Hz, 2H), 2.96 (s, 3H), 2.61 (t, ^3J = 7.6 Hz, 2H) ppm.

^{13}C NMR (126 MHz, MeOD) δ = 174.97, 169.9, 165.3, 163.9, 156.2, 152.1, 144.3, 143.9, 141.4 (q, J = 32.9 Hz), 139.7, 138.9, 138.6, 134.9, 134.4, 133.8, 133.1, 129.0, 127.9, 127.4, 126.0, 124.9, 124.6, 123.8, 123.4 (q, J = 273 Hz), 122.2, 121.0, 120.6, 119.0, 117.2, 114.4, 112.3, 70.5, 70.4, 55.0, 50.3, 43.7, 40.9, 40.4, 36.1, 25.6 ppm.

Synthesis of N-(4'-((33-(5,5-difluoro-7-(1H-pyrrol-2-yl)-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)-31-oxo-3,6,9,12,15,18,21,24,27-nonaoxa-30-azatritriacontyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (21b)

12.5 mg (12 µmol, 1.0 eq) tert-butyl (1-(3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-1-oxo-5,8,11,14,17,20,23,26,29-nonaoxa-2-azahentriacontan-31-yl)carbamate were dissolved in 0.5 mL DCM and 0.5 mL TFA and stired at rt for 1 h. Excess solvent was evapored. The solid was dissolved in 0.5 mL DMF, then 17 µL (10 µmol, 2.0 eq) DIEA and 5.8 mg (14 µmol, 1.1 eq) 2,5-dioxopyrrolidin-1-yl-3-(5,5-difluoro-7-(1H-pyrrol-2-yl)-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)propanoate in 0.5 mL DMF was added. The solution was stirred for 3 h at rt. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO₃, then the reaction was extracted 3x with EA. The organic phase was dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The crude product was purified using by HPLC.

Yield: 4.88 mg, 3.9 µmol, 33% of a purple solid.

HPLC: RT = 12.4 min (254 nm, 100%).

HRMS: (calculated) [M+Na⁺] 1272.5546 g/mol
(found) [M+Na⁺] 1272.5583 g/mol.

^{1}H NMR (400 MHz, MeOD) δ = 8.27 (d, ^4J = 2.1 Hz, 1H), 8.02 (s, 1H), 7.92 (d, ^3J = 8.5 Hz, 2H), 7.72 (d, ^3J = 8.5 Hz, 2H), 7.56 (dd, ^3J = 8.4 Hz, ^4J = 2.2 Hz, 1H), 7.36 (d, ^3J = 8.4 Hz, 1H), 7.22 (s, 1H), 7.21 – 7.13 (m, 3H), 7.00 (d, ^4J = 4.6 Hz, 1H), 6.94 (s, 1H), 6.91 (d, ^4J = 3.9 Hz, 1H), 6.35 - 6.34 (m, 1H), 6.32 (d, ^4J = 4.0 Hz,

1H), 3.75 – 3.47 (m, 44H), 3.36 (t, ^3J = 5.4 Hz, 2H), 3.27 (t, ^3J = 7.7 Hz, 4H), 2.95 (s, 3H), 2.70 – 2.56 (m, 2H) ppm.

Synthesis   of   N-(4'-((17-(5,5-difluoro-7-(1H-pyrrol-2-yl)-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)-15-oxo-4,7,10-trioxa-14-azaheptadecyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (21c)

10 mg   (12 µmol,   1.0 eq)   tert-butyl   (1-(3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-1-oxo-6,9,12-trioxa-2-azapentadecan-15-yl)carbamate were dissolved in 0.5 mL DCM and 0.5 mL TFA and stired at rt for 1 h. Excess solvent was evapored. The solid was dissolved in 0.5 mL DMF, then 17 µL (10 µmol, 2.0 eq) DIEA and 5.8 mg (14 µmol, 1.1 eq) 2,5-dioxopyrrolidin-1-yl-3-(5,5-difluoro-7-(1H-pyrrol-2-yl)-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)propanoate in 0.5 mL DMF was added. The solution was stirred for 3 h at rt. The reaction mixture was quenched with 2 mL water and 2 mL saturated NaHCO$_3$, then the reaction was extracted 3x with EA. The organic phase was dried over MgSO$_4$, filtered and the solvent was removed under reduced pressure. The crude product was purified using by HPLC.

Yield: 8.07 mg, 7.96 µmol, 66% of a purple solid.

R$_f$ (20% MeOH/ CH$_2$Cl$_2$): 0.76.

HPLC: RT = 12.4 min (254 nm, 100%).

HRMS: (calculated) [M+Na$^+$] 1036.4286 g/mol

(found) [M+Na$^+$] 1036.4303 g/mol.

^{1}H NMR (600 MHz, MeOD) δ = 8.26 (d, ^4J = 1.9 Hz, 1H), 8.03 (s, 1H), 7.88 (d, ^3J = 8.3 Hz, 2H), 7.70 (d, ^3J = 8.4 Hz, 2H), 7.54 (dd, ^3J = 8.4 Hz, ^4J = 2.0 Hz, 1H), 7.35 (d, ^3J = 8.4 Hz, 1H), 7.23 – 7.13 (m, 4H), 6.99 (d, ^4J = 4.6 Hz, 1H), 6.94 (s, 1H), 6.89 (d, ^4J = 3.9 Hz, 1H), 6.38 – 6.32 (m, 1H), 6.28 (d, 4J = 3.9 Hz, 1H), 3.62

- 3.57 (m, 10H), 3.50 - 3.47 (m, 4H), 3.43 (t, ^3J = 6.1 Hz, 2H), 3.28 - 3.22 (m, 8H), 3.13 (t, ^3J = 11.6 Hz, 2H), 2.94 (s, 3H), 2.59 (t, ^3J = 7.7 Hz, 2H), 1.87 (p, ^3J = 6.3 Hz, 2H), 1.70 (p, ^3J = 6.4 Hz, 2H) ppm.

7.4 Differential Scanning Fluorimetrie

Table 16: Thermal shift experiments of **OICR-9429** derived molecules (**6a-g**), degraders (**7a-e**), (**8a-j**), (**9a-c**) and the negative controls (**nc_VHL**) and (**nc_WDR5**). ΔT_m: thermal shift change; SD: standard derivation; R1-R3: replicate 1-3. As negative controls, DMSO and Thalidomide, Idasanutlin and VH032 were used. As positive control **OICR-9429** was used. The used concentrations for the experiments were 2 µM WDR5 and 10 µM compound. Table adapted with permission from "Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) Degraders by Dölle, Adhikari *et al.*[174] Copyright 2021 American Chemical Society.

ID	ΔT_m [K]	SD [K]	R1 ΔT_m [K]	R2 ΔT_m [K]	R3 ΔT_m [K]
6a	1,2	0,1	1,2	1,3	1,1
6b	3,5	0,2	3,6	3,3	3,4
6c	12,7	0,3	13,0	12,7	12,3
6d	20,8	0,6	20,3	21,5	20,7
6e	5,7	0,4	6,1	5,2	5,7
6f	4,1	0,6	5,0	3,4	4,0
6g	4,2	0,7	3,4	4,2	5,1
7a	13,6	0,2	13,4	13,7	13,6
7b	12,7	0,3	13,0	12,6	12,3
7c	9,0	0,5	8,9	9,5	8,6
7d	11,9	0,3	11,8	12,3	11,7
7e	12,5	0,6	12,8	11,8	12,8
8a	15,3	0,2	15,2	15,3	15,6
8b	7,7	0,5	7,6	7,4	8,3
8c	12,5	0,2	12,4	12,3	12,7
8d	15,6	0,0	15,6	15,6	15,5
8e	11,0	0,3	10,9	11,5	10,7
8f	10,4	0,7	10,8	11,0	9,4
8g	13,2	0,1	13,2	13,1	13,1
8h	9,7	2,8	8,2	7,9	12,9
8i	3,5	0,4	3,8	3,0	3,7
8j	14,0	0,0	14,0	14,0	n.d.
9a	0,9	0,2	1,2	0,8	0,8
9b	0,3	0,4	0,7	-0,3	0,5
9c	0,7	0,2	0,6	0,6	1,0
OICR-9429	13,3	0,1	13,2	13,1	13,6
DMSO	0,0	0,3	-0,1	-0,4	0,3

22/ nc_VHL	12,2	0,1	12,2	12,4	12,1
23/ nc_WDR5	0,0	0,2	0,0	-0,1	0,2
VH032	-0,4	0,1	-0,3	-0,5	-0,5
Thalidomide	0,0	-0,1	0,3	0,0	-0,5
Idasanutlin	-0,2	0,1	-0,1	-0,1	-0,4

7.5 Isothermal Titration Calorimetry

Table 17: Thermodynamic properties of **OICR-9429** derived molecule (**6d**), degraders (**7a**), (**8a**), (**8e-j**) and pyrroloimidazole-based inhibitor (**17**) and degrader (**20b**). K_d: dissociation constant; SD: standard deviation; n: stoichiometry; ΔH: enthalpy change ΔS: entropy change; T: Temperature. Table adapted with permission from "Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) Degraders by Dölle, Adhikari *et al.*[174] Copyright 2021 American Chemical Society.

ID	K_d [nM]	SD [nM]	n	ΔH [kcal/mol]	$T\Delta S$ [kcal/mol]
6d	25	6	1.0	-9.4	0.8
7a	12	4	1.0	-8.1	2.6
8a	41	9	1.0	-10	-0.2
8e	9	2	1.1	-6.3	4.5
8f	6	2	1.0	-10	1.1
8g	18	5	1.1	-7.4	3.2
8h	12	4	1.0	-9.3	1.4
8i	11	3	1.1	-10	0.7
8j	33	5	1.0	-7.9	2.2
14	125	34	1.0	-4.9	4.4
17b	97	31	1.0	-6.6	2.8

Figure 22: ITC curves of **OICR-9429** derived molecule (**6d**) and degraders (**7a**), (**8a**), (**8e-j**). Figure reprinted

8. Abbreviations

Å	Ångström
ACN	acetonitrile
ADI1	2-dihydroxy-3-keto-5-methylthiopentene dioxygenase
ARID	AT-rich interactive domain-containing protein
ASH2L	Absent-Small-Homeotic-2-Like protein
ATAC	Ada2-containing
ATRX	ATP-dependent helicase
βTRCP	beta-transducin repeat containing
BAF	BRG1/BRM-associated factor
BET	Bromodomain extra-terminal
Boc	tertbutyloxycarbonyl
BODIPY	4,4-difluoro-4-bora-3a,4a-diaza-*s*-indacene
BRCA1	Breast cancer 1
BRD	Bromodomain
BRET	Bioluminescence resonance energy transfer
BR	Basic region
C7orf26	Chromosome 7 Open Reading Frame 26
C8orf	Human Ribosomal biogenesis factor
CBP	CREB-binding protein
CCDC117	Coiled-coil domain-containing protein 117
C/EBPa	CCAAT/enhancer-binding protein alpha
CGGBP1	CGG triplet repeat-binding protein 1
CHIP-Seq	Chromatin Immuno Precipitation DNA-Sequencing
c-Hex	cyclohexane
CHX	cycloheximide
c-MYC	Cellular MYC
CRBN	Cereblon
CUL4	Cullin 4
DCAF16	DDB1 And CUL4 Associated Factor 16

DCM	Dichloromethane
DDB1	DNA damage binding protein 1
DEAD	Diethyl azodicarboxylate
DIEA	N,N-Diisoproylethylamine
DLD	Dihydrolipoyl dehydrogenase
DNA	Desoxyribonucleid acid
DNMT	DNA (cytosine-5)-methyltransferase family
DMF	N,N-Dimethylformamide
DMSO	Dimethylsulfoxide
DSF	differential scanning fluorimetrie
dTAG	degradation tag
DYP30	Dumpy-30 protein
EA	ethyl acetate
EM	electron microscopy
ESI	electronspray ionozation
EtOH	ethanol
eq	equivalent
EZH2	Enhancer of zeste homolog 2
FC	fold change
G	free energy
GO enrichment	Gene Ontology term enrichment
h	hours
H	enthalpy
HAF	Histone acetylase
HATU	1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate
HDAC	Histone deacetylase
HLH	Helix-loop-helix
HMT	Histone Lysine Methyltransferase
HOX	homeobox
HPLC	high purity liquid chromatography
HRMS	High resolution mass spectrometry

HRNPU	Heterogeneous nuclear ribonucleoprotein U
IAP	Inducer of Apoptosis
IDH	isocitrate dehydrogenase
INO80E	INO80 complex subunit E
ITC	isothermal titration calorimetry
JARID1C	Lysine-specific demethylase 5C
K	Kelvin
KANSL1	KAT8 Regulatory NSL Complex Subunit 1
kJ	kilo Joule
KMD	Lysine demethylase
KMT	Lysine Methyltransferase
LgBit	Large Bit
lncRNA	Long non-coding RNA
LSD1	Lysine-specific histone demethylase 1A
LZ	leucine zipper
M	molar
MAX	myc-associated factor X
Mb	MYC boc
MBDs	methylcytosine-binding proteins
MDM2	Mouse double minute 2 homolog
MeOH	methanol
min	minutes
MLL	mixed lineage leukemia
mRNA	messenger RNA
MS	mass spectrometry
MW	microwave
μM	mircomolar
mM	millimolar
n	stochiometry
NanoLuc	Nanoluciferase
NCOA4	Nuclear receptor coactivator 4

nM	nanomolar
NMC	NUT midline carcinoma
NMP	N-Methylpyrrolidone
NMR	nulear magnetic resonance
NLS	non-specific lethal
NUT	Nuclear protein in testis
Oct4	octamer-binding transcription factor 4
p	significance
Pax7	Paired box protein 7
PBAF	polybromo-associated BAF factor
PEG	Polyethyleneglycole
PGD	6-phosphogluconate dehydrogenase
POI	Protein of interest
PPI	Protein-protein interaction
PROTAC	Proteolysis targeting chimera
PSG	Protein synthesis genes
qPCR	quantitative polymerase chain reation
RbBP5	Retinoblastoma Binding Protein 5
RING	Really interesting new gene
RNF4	RING finger protein 4
RPC10	DNA-directed RNA polymerase III subunit
RPG	Ribosomal protein genes
RPL22L1	60S Ribosomal protein L22-like 1
RNA	Ribonucleid acid
rt	room temperature
S	entropy
SAR	structure activity relationship
SD	standard deviation
SE	super enhancer
SET1	Suppressor of variegation 3–9, Enhancer of Zeste, Trithorax
SMARCA2/4	SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily A2/ 4

S_N	nucleophilic substitution
S_NAR	nucleophilic aromatic substitution
SNF	SWI/SNF chromatin-remodeling complex subunit
STOML2	Stomatin-like protein 2
T	Temperature
TET	ten-eleven translocation
TFA	Triflouroacetic acid
THF	Tetrahydrofuran
TLC	thin layer chromatography
TPD	Target protein degradation
TRIM	tripartite motif family
tRNA	Transfer RNA
Ts	Tosylate
TSA	thermal shift assay
UPS	Ubiqutin Proteasome System
UTX	Ubiquitously transcribed tetratricopeptide repeat, X chromosome
VHL	Von Hippel Lindau
WARS	Tryptophan-tRNA ligase
WBM	WDR5 binding motif
WDR5	WD40- repeat containing protein 5
Win	WDR5 interacting
XRCC3	DNA repair protein

9. References

1.   Luger, K.; Mäder, A. W.; Richmond, R. K.; Sargent, D. F.; Richmond, T. J., Crystal structure of the nucleosome core particle at 2.8 Å resolution. *Nature* **1997,** *389* (6648), 251-260.

2.   Bannister, A. J.; Kouzarides, T., Regulation of chromatin by histone modifications. *Cell Research* **2011,** *21* (3), 381-395.

3.   Jenuwein, T.; Allis, C. D., Translating the histone code. *Science* **2001,** *293* (5532), 1074-80.

4.   Park, S. H.; Ayoub, A.; Lee, Y.-T.; Xu, J.; Kim, H.; Zheng, W.; Zhang, B.; Sha, L.; An, S.; Zhang, Y.; Cianfrocco, M. A.; Su, M.; Dou, Y.; Cho, U.-S., Cryo-EM structure of the human MLL1 core complex bound to the nucleosome. *Nature Communications* **2019,** *10* (1), 5540.

5.   Rodríguez-Paredes, M.; Esteller, M., Cancer epigenetics reaches mainstream oncology. *Nature Medicine* **2011,** *17* (3), 330-339.

6.   Zhong, S.; Fei, Z.; Chen, Y. R.; Zheng, Y.; Huang, M.; Vrebalov, J.; McQuinn, R.; Gapper, N.; Liu, B.; Xiang, J.; Shao, Y.; Giovannoni, J. J., Single-base resolution methylomes of tomato fruit development reveal epigenome modifications associated with ripening. *Nat Biotechnol* **2013,** *31* (2), 154-9.

7.   Lang, Z.; Wang, Y.; Tang, K.; Tang, D.; Datsenka, T.; Cheng, J.; Zhang, Y.; Handa, A. K.; Zhu, J. K., Critical roles of DNA demethylation in the activation of ripening-induced genes and inhibition of ripening-repressed genes in tomato fruit. *Proc Natl Acad Sci U S A* **2017,** *114* (22), E4511-e4519.

8.   Dahlet, T.; Argüeso Lleida, A.; Al Adhami, H.; Dumas, M.; Bender, A.; Ngondo, R. P.; Tanguy, M.; Vallet, J.; Auclair, G.; Bardet, A. F.; Weber, M., Genome-wide analysis in the mouse embryo reveals the importance of DNA methylation for transcription integrity. *Nature Communications* **2020,** *11* (1), 3153.

9.   Etchegaray, J. P.; Mostoslavsky, R., Interplay between Metabolism and Epigenetics: A Nuclear Adaptation to Environmental Changes. *Molecular cell* **2016,** *62* (5), 695-711.

10.   Zhang, J.; Zhang, Y. Z.; Jiang, J.; Duan, C. G., The Crosstalk Between Epigenetic Mechanisms and Alternative RNA Processing Regulation. *Front Genet* **2020,** *11*, 998.

11.   Hanahan, D.; Weinberg, R. A., Hallmarks of cancer: the next generation. *Cell* **2011,** *144* (5), 646-74.

12.   Baylin, S. B.; Jones, P. A., Epigenetic Determinants of Cancer. *Cold Spring Harbor perspectives in biology* **2016,** *8* (9).

13.   Feinberg, A. P., Cancer epigenetics is no Mickey Mouse. *Cancer Cell* **2005,** *8* (4), 267-8.

14.   Jones, P. A.; Laird, P. W., Cancer epigenetics comes of age. *Nat Genet* **1999,** *21* (2), 163-7.

15.   Esteller, M., Epigenetics in cancer. *The New England journal of medicine* **2008,** *358* (11), 1148-59.

16.   Esteller, M., Cancer epigenomics: DNA methylomes and histone-modification maps. *Nature reviews. Genetics* **2007,** *8* (4), 286-98.

17.   Jones, P. A.; Taylor, S. M., Cellular differentiation, cytidine analogs and DNA methylation. *Cell* **1980,** *20* (1), 85-93.

18.   Plass, C.; Pfister, S. M.; Lindroth, A. M.; Bogatyrova, O.; Claus, R.; Lichter, P., Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. *Nature reviews. Genetics* **2013,** *14* (11), 765-80.

19.   Shen, H.; Laird, P. W., Interplay between the cancer genome and epigenome. *Cell* **2013,** *153* (1), 38-55.

20.   You, J. S.; Jones, P. A., Cancer genetics and epigenetics: two sides of the same coin? *Cancer Cell* **2012,** *22* (1), 9-20.

21.   Garraway, L. A.; Lander, E. S., Lessons from the cancer genome. *Cell* **2013,** *153* (1), 17-37.

22.   Tarakhovsky, A., Tools and landscapes of epigenetics. *Nature immunology* **2010,** *11* (7), 565-8.

23.   O'Connor, O. A.; Bhagat, G.; Ganapathi, K.; Pedersen, M. B.; D'Amore, F.; Radeski, D.; Bates, S. E., Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice. *Clinical cancer research : an official journal of the American Association for Cancer Research* **2014,** *20* (20), 5240-54.

24.   Biswas, S.; Rao, C. M., Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy. *European journal of pharmacology* **2018,** *837*, 8-24.

25.   Bushey, A. M.; Dorman, E. R.; Corces, V. G., Chromatin insulators: regulatory mechanisms and epigenetic inheritance. *Molecular cell* **2008,** *32* (1), 1-9.

26.   Filippakopoulos, P.; Knapp, S., Targeting bromodomains: epigenetic readers of lysine acetylation. *Nature Reviews Drug Discovery* **2014,** *13* (5), 337-356.

27.   Donati, B.; Lorenzini, E.; Ciarrocchi, A., BRD4 and Cancer: going beyond transcriptional regulation. *Molecular cancer* **2018,** *17* (1), 164.

28.   Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E., Selective inhibition of BET bromodomains. *Nature* **2010,** *468* (7327), 1067-73.

29.   Stathis, A.; Bertoni, F., BET Proteins as Targets for Anticancer Treatment. *Cancer Discov* **2018,** *8* (1), 24-36.

30.   Kadoch, C.; Crabtree, G. R., Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. *Sci Adv* **2015,** *1* (5), e1500447.

31.   Alfert, A.; Moreno, N.; Kerl, K., The BAF complex in development and disease. *Epigenetics & chromatin* **2019,** *12* (1), 19.

32.   Hodges, C.; Kirkland, J. G.; Crabtree, G. R., The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. *Cold Spring Harbor perspectives in medicine* **2016,** *6* (8).

33.   Bracken, A. P.; Brien, G. L.; Verrijzer, C. P., Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancer. *Genes & development* **2019,** *33* (15-16), 936-959.

34.   Varela, I.; Tarpey, P.; Raine, K.; Huang, D.; Ong, C. K.; Stephens, P.; Davies, H.; Jones, D.; Lin, M. L.; Teague, J.; Bignell, G.; Butler, A.; Cho, J.; Dalgliesh, G. L.; Galappaththige, D.; Greenman, C.; Hardy, C.; Jia, M.; Latimer, C.; Lau, K. W.; Marshall, J.; McLaren, S.; Menzies, A.; Mudie, L.; Stebbings, L.; Largaespada, D. A.; Wessels, L. F.; Richard, S.; Kahnoski, R. J.; Anema, J.; Tuveson, D. A.; Perez-Mancera, P. A.; Mustonen, V.; Fischer, A.; Adams, D. J.; Rust, A.; Chan-on, W.; Subimerb, C.; Dykema, K.; Furge, K.; Campbell, P. J.; Teh, B. T.; Stratton, M. R.; Futreal, P. A., Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. *Nature* **2011,** *469* (7331), 539-42.

35.   Shi, Y., Histone lysine demethylases: emerging roles in development, physiology and disease. *Nature reviews. Genetics* **2007,** *8* (11), 829-33.

36.   Chi, P.; Allis, C. D.; Wang, G. G., Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. *Nat Rev Cancer* **2010,** *10* (7), 457-69.

37.   Herz, H. M.; Garruss, A.; Shilatifard, A., SET for life: biochemical activities and biological functions of SET domain-containing proteins. *Trends in biochemical sciences* **2013,** *38* (12), 621-39.

38.   Glozak, M. A.; Seto, E., Histone deacetylases and cancer. *Oncogene* **2007,** *26* (37), 5420-32.

39.   Li, Y.; Seto, E., HDACs and HDAC Inhibitors in Cancer Development and Therapy. *Cold Spring Harbor perspectives in medicine* **2016,** *6* (10).

40.   Romero, D., HDAC inhibitors tested in phase III trial. *Nature reviews. Clinical oncology* **2019,** *16* (8), 465.

41.   Hontecillas-Prieto, L.; Flores-Campos, R.; Silver, A.; de Álava, E.; Hajji, N.; García-Domínguez, D. J., Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials. *Front Genet* **2020,** *11*, 578011.

42.   Manzo, F.; Tambaro, F. P.; Mai, A.; Altucci, L., Histone acetyltransferase inhibitors and preclinical studies. *Expert Opin Ther Pat* **2009,** *19* (6), 761-74.

43.   Bernstein, B. E.; Humphrey, E. L.; Erlich, R. L.; Schneider, R.; Bouman, P.; Liu, J. S.; Kouzarides, T.; Schreiber, S. L., Methylation of histone H3 Lys 4 in coding regions of active genes. *Proc Natl Acad Sci U S A* **2002,** *99* (13), 8695-700.

44.   Bannister, A. J.; Schneider, R.; Myers, F. A.; Thorne, A. W.; Crane-Robinson, C.; Kouzarides, T., Spatial distribution of di- and tri-methyl lysine 36 of histone H3 at active genes. *J Biol Chem* **2005,** *280* (18), 17732-6.

45.   Mohan, M.; Herz, H. M.; Takahashi, Y. H.; Lin, C.; Lai, K. C.; Zhang, Y.; Washburn, M. P.; Florens, L.; Shilatifard, A., Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). *Genes & development* **2010,** *24* (6), 574-89.

46.   Greer, E. L.; Shi, Y., Histone methylation: a dynamic mark in health, disease and inheritance. *Nature reviews. Genetics* **2012,** *13* (5), 343-57.

47.   Song, Y.; Wu, F.; Wu, J., Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. *Journal of Hematology & Oncology* **2016,** *9* (1), 49.

48.   Shi, Y.; Lan, F.; Matson, C.; Mulligan, P.; Whetstine, J. R.; Cole, P. A.; Casero, R. A.; Shi, Y., Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. *Cell* **2004,** *119* (7), 941-53.

49.   Højfeldt, J. W.; Agger, K.; Helin, K., Histone lysine demethylases as targets for anticancer therapy. *Nature reviews. Drug discovery* **2013,** *12* (12), 917-30.

50.   Cao, F.; Townsend, E. C.; Karatas, H.; Xu, J.; Li, L.; Lee, S.; Liu, L.; Chen, Y.; Ouillette, P.; Zhu, J.; Hess, J. L.; Atadja, P.; Lei, M.; Qin, Z. S.; Malek, S.; Wang, S.; Dou, Y., Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. *Molecular cell* **2014,** *53* (2), 247-61.

51.   Shilatifard, A., The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. *Annu Rev Biochem* **2012,** *81*, 65-95.

52.   Sims, R. J., 3rd; Nishioka, K.; Reinberg, D., Histone lysine methylation: a signature for chromatin function. *Trends in genetics : TIG* **2003,** *19* (11), 629-39.

53.   Husmann, D.; Gozani, O., Histone lysine methyltransferases in biology and disease. *Nat Struct Mol Biol* **2019,** *26* (10), 880-889.

54.   Miller, J. L.; Grant, P. A., The role of DNA methylation and histone modifications in transcriptional regulation in humans. *Sub-cellular biochemistry* **2013,** *61*, 289-317.

55.   Malik, S.; Bhaumik, S. R., Mixed lineage leukemia: histone H3 lysine 4 methyltransferases from yeast to human. *Febs j* **2010,** *277* (8), 1805-21.

56.   Taverna, S. D.; Li, H.; Ruthenburg, A. J.; Allis, C. D.; Patel, D. J., How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. *Nat Struct Mol Biol* **2007,** *14* (11), 1025-1040.

57.   Vedadi, M.; Blazer, L.; Eram, M. S.; Barsyte-Lovejoy, D.; Arrowsmith, C. H.; Hajian, T., Targeting human SET1/MLL family of proteins. *Protein Sci* **2017,** *26* (4), 662-676.

58.   Ruthenburg, A. J.; Allis, C. D.; Wysocka, J., Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. *Molecular cell* **2007,** *25* (1), 15-30.

59.   Balgobind, B. V.; Raimondi, S. C.; Harbott, J.; Zimmermann, M.; Alonzo, T. A.; Auvrignon, A.; Beverloo, H. B.; Chang, M.; Creutzig, U.; Dworzak, M. N.; Forestier, E.; Gibson, B.; Hasle, H.; Harrison, C. J.; Heerema, N. A.; Kaspers, G. J.; Leszl, A.; Litvinko, N.; Nigro, L. L.; Morimoto, A.; Perot, C.; Pieters,

R.; Reinhardt, D.; Rubnitz, J. E.; Smith, F. O.; Stary, J.; Stasevich, I.; Strehl, S.; Taga, T.; Tomizawa, D.; Webb, D.; Zemanova, Z.; Zwaan, C. M.; van den Heuvel-Eibrink, M. M., Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. *Blood* **2009,** *114* (12), 2489-96.

60.   Winters, A. C.; Bernt, K. M., MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. *Frontiers in pediatrics* **2017,** *5*, 4.

61.   Tkachuk, D. C.; Kohler, S.; Cleary, M. L., Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. *Cell* **1992,** *71* (4), 691-700.

62.   Krivtsov, A. V.; Hoshii, T.; Armstrong, S. A., Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia. *Cold Spring Harbor perspectives in medicine* **2017,** *7* (11).

63.   Guenther, M. G.; Jenner, R. G.; Chevalier, B.; Nakamura, T.; Croce, C. M.; Canaani, E.; Young, R. A., Global and Hox-specific roles for the MLL1 methyltransferase. *Proc Natl Acad Sci U S A* **2005,** *102* (24), 8603-8.

64.   Milne, T. A.; Briggs, S. D.; Brock, H. W.; Martin, M. E.; Gibbs, D.; Allis, C. D.; Hess, J. L., MLL targets SET domain methyltransferase activity to Hox gene promoters. *Molecular cell* **2002,** *10* (5), 1107-17.

65.   Qian, C.; Zhou, M. M., SET domain protein lysine methyltransferases: Structure, specificity and catalysis. *Cell Mol Life Sci* **2006,** *63* (23), 2755-63.

66.   Dou, Y.; Milne, T. A.; Ruthenburg, A. J.; Lee, S.; Lee, J. W.; Verdine, G. L.; Allis, C. D.; Roeder, R. G., Regulation of MLL1 H3K4 methyltransferase activity by its core components. *Nat Struct Mol Biol* **2006,** *13* (8), 713-9.

67.   Jiang, H.; Shukla, A.; Wang, X.; Chen, W. Y.; Bernstein, B. E.; Roeder, R. G., Role for Dpy-30 in ES cell-fate specification by regulation of H3K4 methylation within bivalent domains. *Cell* **2011,** *144* (4), 513-25.

68.   Shinsky, S. A.; Monteith, K. E.; Viggiano, S.; Cosgrove, M. S., Biochemical reconstitution and phylogenetic comparison of human SET1 family core complexes involved in histone methylation. *J Biol Chem* **2015,** *290* (10), 6361-75.

69.   Patel, A.; Dharmarajan, V.; Vought, V. E.; Cosgrove, M. S., On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex. *J Biol Chem* **2009,** *284* (36), 24242-56.

70.   Steward, M. M.; Lee, J. S.; O'Donovan, A.; Wyatt, M.; Bernstein, B. E.; Shilatifard, A., Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. *Nat Struct Mol Biol* **2006,** *13* (9), 852-4.

71.   Haddad, J. F.; Yang, Y.; Takahashi, Y. H.; Joshi, M.; Chaudhary, N.; Woodfin, A. R.; Benyoucef, A.; Yeung, S.; Brunzelle, J. S.; Skiniotis, G.; Brand, M.; Shilatifard, A.; Couture, J. F., Structural Analysis

of the Ash2L/Dpy-30 Complex Reveals a Heterogeneity in H3K4 Methylation. *Structure* **2018,** *26* (12), 1594-1603.e4.

72.   Hsu, P. L.; Li, H.; Lau, H. T.; Leonen, C.; Dhall, A.; Ong, S. E.; Chatterjee, C.; Zheng, N., Crystal Structure of the COMPASS H3K4 Methyltransferase Catalytic Module. *Cell* **2018,** *174* (5), 1106-1116.e9.

73.   Zhang, H.; Li, M.; Gao, Y.; Jia, C.; Pan, X.; Cao, P.; Zhao, X.; Zhang, J.; Chang, W., Structural implications of Dpy30 oligomerization for MLL/SET1 COMPASS H3K4 trimethylation. *Protein & cell* **2015,** *6* (2), 147-51.

74.   Dong, X.; Peng, Y.; Peng, Y.; Xu, F.; He, X.; Wang, F.; Peng, X.; Qiang, B.; Yuan, J.; Rao, Z., Characterization and crystallization of human DPY-30-like protein, an essential component of dosage compensation complex. *Biochim Biophys Acta* **2005,** *1753* (2), 257-62.

75.   van Nuland, R.; Smits, A. H.; Pallaki, P.; Jansen, P. W.; Vermeulen, M.; Timmers, H. T., Quantitative dissection and stoichiometry determination of the human SET1/MLL histone methyltransferase complexes. *Molecular and cellular biology* **2013,** *33* (10), 2067-77.

76.   Xu, Z.; Gong, Q.; Xia, B.; Groves, B.; Zimmermann, M.; Mugler, C.; Mu, D.; Matsumoto, B.; Seaman, M.; Ma, D., A role of histone H3 lysine 4 methyltransferase components in endosomal trafficking. *The Journal of cell biology* **2009,** *186* (3), 343-53.

77.   Li, Y.; Han, J.; Zhang, Y.; Cao, F.; Liu, Z.; Li, S.; Wu, J.; Hu, C.; Wang, Y.; Shuai, J.; Chen, J.; Cao, L.; Li, D.; Shi, P.; Tian, C.; Zhang, J.; Dou, Y.; Li, G.; Chen, Y.; Lei, M., Structural basis for activity regulation of MLL family methyltransferases. *Nature* **2016,** *530* (7591), 447-52.

78.   Zhang, P.; Lee, H.; Brunzelle, J. S.; Couture, J. F., The plasticity of WDR5 peptide-binding cleft enables the binding of the SET1 family of histone methyltransferases. *Nucleic Acids Res* **2012,** *40* (9), 4237-46.

79.   Wysocka, J.; Swigut, T.; Milne, T. A.; Dou, Y.; Zhang, X.; Burlingame, A. L.; Roeder, R. G.; Brivanlou, A. H.; Allis, C. D., WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. *Cell* **2005,** *121* (6), 859-72.

80.   Mishra, B. P.; Zaffuto, K. M.; Artinger, E. L.; Org, T.; Mikkola, H. K.; Cheng, C.; Djabali, M.; Ernst, P., The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis. *Cell Rep* **2014,** *7* (4), 1239-47.

81.   Aho, E. R.; Wang, J.; Gogliotti, R. D.; Howard, G. C.; Phan, J.; Acharya, P.; Macdonald, J. D.; Cheng, K.; Lorey, S. L.; Lu, B.; Wenzel, S.; Foshage, A. M.; Alvarado, J.; Wang, F.; Shaw, J. G.; Zhao, B.; Weissmiller, A. M.; Thomas, L. R.; Vakoc, C. R.; Hall, M. D.; Hiebert, S. W.; Liu, Q.; Stauffer, S. R.; Fesik, S. W.; Tansey, W. P., Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity. *Cell Rep* **2019,** *26* (11), 2916-2928.e13.

82.   Aho, E. R.; Weissmiller, A. M.; Fesik, S. W.; Tansey, W. P., Targeting WDR5: A WINning Anti-Cancer Strategy? *Epigenetics insights* **2019,** *12*, 2516865719865282.

83.   Grebien, F.; Vedadi, M.; Getlik, M.; Giambruno, R.; Grover, A.; Avellino, R.; Skucha, A.; Vittori, S.; Kuznetsova, E.; Smil, D.; Barsyte-Lovejoy, D.; Li, F.; Poda, G.; Schapira, M.; Wu, H.; Dong, A.; Senisterra, G.; Stukalov, A.; Huber, K. V. M.; Schönegger, A.; Marcellus, R.; Bilban, M.; Bock, C.; Brown, P. J.; Zuber, J.; Bennett, K. L.; Al-awar, R.; Delwel, R.; Nerlov, C.; Arrowsmith, C. H.; Superti-Furga, G., Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. *Nature Chemical Biology* **2015,** *11* (8), 571-578.

84.   Bryan, A. F.; Wang, J.; Howard, G. C.; Guarnaccia, A. D.; Woodley, C. M.; Aho, E. R.; Rellinger, E. J.; Matlock, B. K.; Flaherty, D. K.; Lorey, S. L.; Chung, D. H.; Fesik, S. W.; Liu, Q.; Weissmiller, A. M.; Tansey, W. P., WDR5 is a conserved regulator of protein synthesis gene expression. *Nucleic Acids Res* **2020,** *48* (6), 2924-2941.

85.   Punzi, S.; Balestrieri, C.; D'Alesio, C.; Bossi, D.; Dellino, G. I.; Gatti, E.; Pruneri, G.; Criscitiello, C.; Lovati, G.; Meliksetyan, M.; Carugo, A.; Curigliano, G.; Natoli, G.; Pelicci, P. G.; Lanfrancone, L., WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. *Breast cancer research : BCR* **2019,** *21* (1), 123.

86.   Zhu, J.; Sammons, M. A.; Donahue, G.; Dou, Z.; Vedadi, M.; Getlik, M.; Barsyte-Lovejoy, D.; Al-awar, R.; Katona, B. W.; Shilatifard, A.; Huang, J.; Hua, X.; Arrowsmith, C. H.; Berger, S. L., Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. *Nature* **2015,** *525* (7568), 206-11.

87.   Terranova, R.; Agherbi, H.; Boned, A.; Meresse, S.; Djabali, M., Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. *Proc Natl Acad Sci U S A* **2006,** *103* (17), 6629-34.

88.   Wang, P.; Lin, C.; Smith, E. R.; Guo, H.; Sanderson, B. W.; Wu, M.; Gogol, M.; Alexander, T.; Seidel, C.; Wiedemann, L. M.; Ge, K.; Krumlauf, R.; Shilatifard, A., Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. *Molecular and cellular biology* **2009,** *29* (22), 6074-85.

89.   Li, X.; Song, Y., Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins. *J Hematol Oncol* **2021,** *14* (1), 56.

90.   Borkin, D.; He, S.; Miao, H.; Kempinska, K.; Pollock, J.; Chase, J.; Purohit, T.; Malik, B.; Zhao, T.; Wang, J.; Wen, B.; Zong, H.; Jones, M.; Danet-Desnoyers, G.; Guzman, M. L.; Talpaz, M.; Bixby, D. L.; Sun, D.; Hess, J. L.; Muntean, A. G.; Maillard, I.; Cierpicki, T.; Grembecka, J., Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. *Cancer Cell* **2015,** *27* (4), 589-602.

91.   Grembecka, J.; He, S.; Shi, A.; Purohit, T.; Muntean, A. G.; Sorenson, R. J.; Showalter, H. D.; Murai, M. J.; Belcher, A. M.; Hartley, T.; Hess, J. L.; Cierpicki, T., Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. *Nat Chem Biol* **2012,** *8* (3), 277-84.

92.   Shi, A.; Murai, M. J.; He, S.; Lund, G.; Hartley, T.; Purohit, T.; Reddy, G.; Chruszcz, M.; Grembecka, J.; Cierpicki, T., Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. *Blood* **2012,** *120* (23), 4461-9.

93.   Getlik, M.; Smil, D.; Zepeda-Velázquez, C.; Bolshan, Y.; Poda, G.; Wu, H.; Dong, A.; Kuznetsova, E.; Marcellus, R.; Senisterra, G.; Dombrovski, L.; Hajian, T.; Kiyota, T.; Schapira, M.; Arrowsmith, C. H.; Brown, P. J.; Vedadi, M.; Al-Awar, R., Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1). *J Med Chem* **2016,** *59* (6), 2478-96.

94.   Li, D. D.; Chen, W. L.; Wang, Z. H.; Xie, Y. Y.; Xu, X. L.; Jiang, Z. Y.; Zhang, X. J.; You, Q. D.; Guo, X. K., High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity. *Eur J Med Chem* **2016,** *124*, 480-489.

95.   Li, D. D.; Wang, Z. H.; Chen, W. L.; Xie, Y. Y.; You, Q. D.; Guo, X. K., Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. *Bioorg Med Chem* **2016,** *24* (22), 6109-6118.

96.   Alicea-Velázquez, N. L.; Shinsky, S. A.; Loh, D. M.; Lee, J. H.; Skalnik, D. G.; Cosgrove, M. S., Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes. *J Biol Chem* **2016,** *291* (43), 22357-22372.

97.   Avdic, V.; Zhang, P.; Lanouette, S.; Groulx, A.; Tremblay, V.; Brunzelle, J.; Couture, J. F., Structural and biochemical insights into MLL1 core complex assembly. *Structure* **2011,** *19* (1), 101-8.

98.   Dias, J.; Van Nguyen, N.; Georgiev, P.; Gaub, A.; Brettschneider, J.; Cusack, S.; Kadlec, J.; Akhtar, A., Structural analysis of the KANSL1/WDR5/KANSL2 complex reveals that WDR5 is required for efficient assembly and chromatin targeting of the NSL complex. *Genes & development* **2014,** *28* (9), 929-42.

99.   Guelman, S.; Kozuka, K.; Mao, Y.; Pham, V.; Solloway, M. J.; Wang, J.; Wu, J.; Lill, J. R.; Zha, J., The double-histone-acetyltransferase complex ATAC is essential for mammalian development. *Molecular and cellular biology* **2009,** *29* (5), 1176-88.

100.   Wu, M. Z.; Tsai, Y. P.; Yang, M. H.; Huang, C. H.; Chang, S. Y.; Chang, C. C.; Teng, S. C.; Wu, K. J., Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. *Molecular cell* **2011,** *43* (5), 811-22.

101.   Yates, J. A.; Menon, T.; Thompson, B. A.; Bochar, D. A., Regulation of HOXA2 gene expression by the ATP-dependent chromatin remodeling enzyme CHD8. *FEBS Lett* **2010,** *584* (4), 689-93.

102.   Guarnaccia, A. D.; Tansey, W. P., Moonlighting with WDR5: A Cellular Multitasker. *Journal of clinical medicine* **2018,** *7* (2).

103.   Thomas, L. R.; Wang, Q.; Grieb, B. C.; Phan, J.; Foshage, A. M.; Sun, Q.; Olejniczak, E. T.; Clark, T.; Dey, S.; Lorey, S.; Alicie, B.; Howard, G. C.; Cawthon, B.; Ess, K. C.; Eischen, C. M.; Zhao, Z.; Fesik, S. W.; Tansey, W. P., Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. *Molecular cell* **2015,** *58* (3), 440-52.

104.   Ge, Z.; Song, E. J.; Kawasawa, Y. I.; Li, J.; Dovat, S.; Song, C., WDR5 high expression and its effect on tumorigenesis in leukemia. *Oncotarget* **2016,** *7* (25), 37740-37754.

105.   Chen, X.; Xie, W.; Gu, P.; Cai, Q.; Wang, B.; Xie, Y.; Dong, W.; He, W.; Zhong, G.; Lin, T.; Huang, J., Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation. *Sci Rep* **2015,** *5*, 8293.

106.   Cui, Z.; Li, H.; Liang, F.; Mu, C.; Mu, Y.; Zhang, X.; Liu, J., Effect of high WDR5 expression on the hepatocellular carcinoma prognosis. *Oncology letters* **2018,** *15* (5), 7864-7870.

107.   Dai, X.; Guo, W.; Zhan, C.; Liu, X.; Bai, Z.; Yang, Y., WDR5 Expression Is Prognostic of Breast Cancer Outcome. *PLoS One* **2015,** *10* (9), e0124964.

108.   Vilhais-Neto, G. C.; Fournier, M.; Plassat, J.-L.; Sardiu, M. E.; Saraf, A.; Garnier, J.-M.; Maruhashi, M.; Florens, L.; Washburn, M. P.; Pourquié, O., The WHHERE coactivator complex is required for retinoic acid-dependent regulation of embryonic symmetry. *Nature Communications* **2017,** *8* (1), 728.

109.   Dang, C. V., MYC on the path to cancer. *Cell* **2012,** *149* (1), 22-35.

110.   Stine, Z. E.; Walton, Z. E.; Altman, B. J.; Hsieh, A. L.; Dang, C. V., MYC, Metabolism, and Cancer. *Cancer Discovery* **2015,** *5* (10), 1024.

111.   Baluapuri, A.; Wolf, E.; Eilers, M., Target gene-independent functions of MYC oncoproteins. *Nature reviews. Molecular cell biology* **2020,** *21* (5), 255-267.

112.   Adhikari, B.; Bozilovic, J.; Diebold, M.; Schwarz, J. D.; Hofstetter, J.; Schröder, M.; Wanior, M.; Narain, A.; Vogt, M.; Dudvarski Stankovic, N.; Baluapuri, A.; Schönemann, L.; Eing, L.; Bhandare, P.; Kuster, B.; Schlosser, A.; Heinzlmeir, S.; Sotriffer, C.; Knapp, S.; Wolf, E., PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase. *Nature Chemical Biology* **2020,** *16* (11), 1179-1188.

113.   Soucek, L.; Jucker, R.; Panacchia, L.; Ricordy, R.; Tatò, F.; Nasi, S., Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. *Cancer Res* **2002,** *62* (12), 3507-10.

114.   Sun, Y.; Bell, J. L.; Carter, D.; Gherardi, S.; Poulos, R. C.; Milazzo, G.; Wong, J. W.; Al-Awar, R.; Tee, A. E.; Liu, P. Y.; Liu, B.; Atmadibrata, B.; Wong, M.; Trahair, T.; Zhao, Q.; Shohet, J. M.; Haupt, Y.; Schulte, J. H.; Brown, P. J.; Arrowsmith, C. H.; Vedadi, M.; MacKenzie, K. L.; Hüttelmeir, S.; Perini, G.;

Marshall, G. M.; Braithwaite, A.; Liu, T., WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. *Cancer Res* **2015,** *75* (23), 5143-54.

115.   Marschalek, R., Mechanisms of leukemogenesis by MLL fusion proteins. *British journal of haematology* **2011,** *152* (2), 141-54.

116.   Sakamoto, K. M.; Kim, K. B.; Kumagai, A.; Mercurio, F.; Crews, C. M.; Deshaies, R. J., Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. *Proc Natl Acad Sci U S A* **2001,** *98* (15), 8554-9.

117.   Sakamoto, K. M.; Kim, K. B.; Verma, R.; Ransick, A.; Stein, B.; Crews, C. M.; Deshaies, R. J., Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. *Molecular & cellular proteomics : MCP* **2003,** *2* (12), 1350-8.

118.   Gu, S.; Cui, D.; Chen, X.; Xiong, X.; Zhao, Y., PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery. *BioEssays : news and reviews in molecular, cellular and developmental biology* **2018,** *40* (4), e1700247.

119.   Neklesa, T. K.; Winkler, J. D.; Crews, C. M., Targeted protein degradation by PROTACs. *Pharmacol Ther* **2017,** *174*, 138-144.

120.   Liu, J.; Chen, H.; Kaniskan, H. Ü.; Xie, L.; Chen, X.; Jin, J.; Wei, W., TF-PROTACs Enable Targeted Degradation of Transcription Factors. *Journal of the American Chemical Society* **2021,** *143* (23), 8902-8910.

121.   Doelle, A.; Adhikari, B.; Kraemer, A.; Weckesser, J.; Berner, N.; Berger, L.-M.; Diebold, M.; Szewczyk, M.; Barsyte-Lovejoy, D.; Arrowsmith, C.; Gerbel, J.; Loehr, F.; Doetsch, V.; Eilers, M.; Heinzlmeir, S.; Kuester, B.; Sotriffer, C.; Wolf, E.; Knapp, S., Design, Synthesis and Evaluation of WD-repeat containing protein 5 (WDR5) degraders. *bioRxiv* **2021**, 2021.04.12.439490.

122.   Bondeson, D. P.; Mares, A.; Smith, I. E.; Ko, E.; Campos, S.; Miah, A. H.; Mulholland, K. E.; Routly, N.; Buckley, D. L.; Gustafson, J. L.; Zinn, N.; Grandi, P.; Shimamura, S.; Bergamini, G.; Faelth-Savitski, M.; Bantscheff, M.; Cox, C.; Gordon, D. A.; Willard, R. R.; Flanagan, J. J.; Casillas, L. N.; Votta, B. J.; den Besten, W.; Famm, K.; Kruidenier, L.; Carter, P. S.; Harling, J. D.; Churcher, I.; Crews, C. M., Catalytic in vivo protein knockdown by small-molecule PROTACs. *Nat Chem Biol* **2015,** *11* (8), 611-7.

123.   Burslem, G. M.; Smith, B. E.; Lai, A. C.; Jaime-Figueroa, S.; McQuaid, D. C.; Bondeson, D. P.; Toure, M.; Dong, H.; Qian, Y.; Wang, J.; Crew, A. P.; Hines, J.; Crews, C. M., The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. *Cell Chem Biol* **2018,** *25* (1), 67-77.e3.

124.   Smith, B. E.; Wang, S. L.; Jaime-Figueroa, S.; Harbin, A.; Wang, J.; Hamman, B. D.; Crews, C. M., Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. *Nature Communications* **2019,** *10* (1), 131.

125.   Metzger, M. B.; Pruneda, J. N.; Klevit, R. E.; Weissman, A. M., RING-type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. *Biochim Biophys Acta* **2014,** *1843* (1), 47-60.

126.   George, A. J.; Hoffiz, Y. C.; Charles, A. J.; Zhu, Y.; Mabb, A. M., A Comprehensive Atlas of E3 Ubiquitin Ligase Mutations in Neurological Disorders. *Frontiers in Genetics* **2018,** *9* (29).

127.   Lescouzères, L.; Bomont, P., E3 Ubiquitin Ligases in Neurological Diseases: Focus on Gigaxonin and Autophagy. *Frontiers in physiology* **2020,** *11*, 1022.

128.   Zhao, Q.; Lan, T.; Su, S.; Rao, Y., Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. *Chem Commun (Camb)* **2019,** *55* (3), 369-372.

129.   Tinworth, C. P.; Lithgow, H.; Dittus, L.; Bassi, Z. I.; Hughes, S. E.; Muelbaier, M.; Dai, H.; Smith, I. E. D.; Kerr, W. J.; Burley, G. A.; Bantscheff, M.; Harling, J. D., PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding. *ACS Chem Biol* **2019,** *14* (3), 342-347.

130.   Ward, C. C.; Kleinman, J. I.; Brittain, S. M.; Lee, P. S.; Chung, C. Y. S.; Kim, K.; Petri, Y.; Thomas, J. R.; Tallarico, J. A.; McKenna, J. M.; Schirle, M.; Nomura, D. K., Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications. *ACS Chem Biol* **2019,** *14* (11), 2430-2440.

131.   Ottis, P.; Toure, M.; Cromm, P. M.; Ko, E.; Gustafson, J. L.; Crews, C. M., Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation. *ACS Chem Biol* **2017,** *12* (10), 2570-2578.

132.   Panicker, N.; Dawson, V. L.; Dawson, T. M., Activation mechanisms of the E3 ubiquitin ligase parkin. *Biochem J* **2017,** *474* (18), 3075-3086.

133.   Zhang, X.; Crowley, V. M.; Wucherpfennig, T. G.; Dix, M. M.; Cravatt, B. F., Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16. *Nat Chem Biol* **2019,** *15* (7), 737-746.

134.   Ito, T.; Ando, H.; Suzuki, T.; Ogura, T.; Hotta, K.; Imamura, Y.; Yamaguchi, Y.; Handa, H., Identification of a primary target of thalidomide teratogenicity. *Science* **2010,** *327* (5971), 1345-50.

135.   Donovan, K. A.; An, J.; Nowak, R. P.; Yuan, J. C.; Fink, E. C.; Berry, B. C.; Ebert, B. L.; Fischer, E. S., Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. *Elife* **2018,** *7*.

136.   Asatsuma-Okumura, T.; Ando, H.; De Simone, M.; Yamamoto, J.; Sato, T.; Shimizu, N.; Asakawa, K.; Yamaguchi, Y.; Ito, T.; Guerrini, L.; Handa, H., p63 is a cereblon substrate involved in thalidomide teratogenicity. *Nat Chem Biol* **2019,** *15* (11), 1077-1084.

137.   Fischer, E. S.; Böhm, K.; Lydeard, J. R.; Yang, H.; Stadler, M. B.; Cavadini, S.; Nagel, J.; Serluca, F.; Acker, V.; Lingaraju, G. M.; Tichkule, R. B.; Schebesta, M.; Forrester, W. C.; Schirle, M.; Hassiepen, U.; Ottl, J.; Hild, M.; Beckwith, R. E.; Harper, J. W.; Jenkins, J. L.; Thomä, N. H., Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. *Nature* **2014,** *512* (7512), 49-53.

138.   Botting, J., The History of Thalidomide. *Drug news & perspectives* **2002,** *15* (9), 604-611.

139.   Liu, Y.; Huang, X.; He, X.; Zhou, Y.; Jiang, X.; Chen-Kiang, S.; Jaffrey, S. R.; Xu, G., A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. *Faseb j* **2015,** *29* (12), 4829-39.

140.   Galdeano, C.; Gadd, M. S.; Soares, P.; Scaffidi, S.; Van Molle, I.; Birced, I.; Hewitt, S.; Dias, D. M.; Ciulli, A., Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities. *Journal of Medicinal Chemistry* **2014,** *57* (20), 8657-8663.

141.   Cardote, T. A. F.; Gadd, M. S.; Ciulli, A., Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase Complex. *Structure* **2017,** *25* (6), 901-911.e3.

142.   Cyrus, K.; Wehenkel, M.; Choi, E. Y.; Lee, H.; Swanson, H.; Kim, K. B., Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs. *ChemMedChem* **2010,** *5* (7), 979-85.

143.   Rodriguez-Gonzalez, A.; Cyrus, K.; Salcius, M.; Kim, K.; Crews, C. M.; Deshaies, R. J.; Sakamoto, K. M., Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. *Oncogene* **2008,** *27* (57), 7201-11.

144.   Sharma, L. K.; Lee, N. R.; Jang, E. R.; Lei, B.; Zhan, C. G.; Lee, W.; Kim, K. B., Activity-based near-infrared fluorescent probe for LMP7: a chemical proteomics tool for the immunoproteasome in living cells. *Chembiochem* **2012,** *13* (13), 1899-903.

145.   Winter, G. E.; Buckley, D. L.; Paulk, J.; Roberts, J. M.; Souza, A.; Dhe-Paganon, S.; Bradner, J. E., DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. *Science* **2015,** *348* (6241), 1376-81.

146.   Lu, J.; Qian, Y.; Altieri, M.; Dong, H.; Wang, J.; Raina, K.; Hines, J.; Winkler, J. D.; Crew, A. P.; Coleman, K.; Crews, C. M., Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. *Chem Biol* **2015,** *22* (6), 755-63.

147.   Zengerle, M.; Chan, K. H.; Ciulli, A., Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. *ACS Chem Biol* **2015,** *10* (8), 1770-7.

148.   Lai, A. C.; Toure, M.; Hellerschmied, D.; Salami, J.; Jaime-Figueroa, S.; Ko, E.; Hines, J.; Crews, C. M., Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. *Angew Chem Int Ed Engl* **2016,** *55* (2), 807-10.

149.   Robb, C. M.; Contreras, J. I.; Kour, S.; Taylor, M. A.; Abid, M.; Sonawane, Y. A.; Zahid, M.; Murry, D. J.; Natarajan, A.; Rana, S., Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). *Chem Commun (Camb)* **2017,** *53* (54), 7577-7580.

150.   Bondeson, D. P.; Smith, B. E.; Burslem, G. M.; Buhimschi, A. D.; Hines, J.; Jaime-Figueroa, S.; Wang, J.; Hamman, B. D.; Ishchenko, A.; Crews, C. M., Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. *Cell Chem Biol* **2018,** *25* (1), 78-87.e5.

151.   Zhang, C.; Han, X. R.; Yang, X.; Jiang, B.; Liu, J.; Xiong, Y.; Jin, J., Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). *Eur J Med Chem* **2018,** *151*, 304-314.

152.   Crew, A. P.; Raina, K.; Dong, H.; Qian, Y.; Wang, J.; Vigil, D.; Serebrenik, Y. V.; Hamman, B. D.; Morgan, A.; Ferraro, C.; Siu, K.; Neklesa, T. K.; Winkler, J. D.; Coleman, K. G.; Crews, C. M., Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. *J Med Chem* **2018,** *61* (2), 583-598.

153.   Huang, H. T.; Dobrovolsky, D.; Paulk, J.; Yang, G.; Weisberg, E. L.; Doctor, Z. M.; Buckley, D. L.; Cho, J. H.; Ko, E.; Jang, J.; Shi, K.; Choi, H. G.; Griffin, J. D.; Li, Y.; Treon, S. P.; Fischer, E. S.; Bradner, J. E.; Tan, L.; Gray, N. S., A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. *Cell Chem Biol* **2018,** *25* (1), 88-99.e6.

154.   Olson, C. M.; Jiang, B.; Erb, M. A.; Liang, Y.; Doctor, Z. M.; Zhang, Z.; Zhang, T.; Kwiatkowski, N.; Boukhali, M.; Green, J. L.; Haas, W.; Nomanbhoy, T.; Fischer, E. S.; Young, R. A.; Bradner, J. E.; Winter, G. E.; Gray, N. S., Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. *Nat Chem Biol* **2018,** *14* (2), 163-170.

155.   Powell, C. E.; Gao, Y.; Tan, L.; Donovan, K. A.; Nowak, R. P.; Loehr, A.; Bahcall, M.; Fischer, E. S.; Jänne, P. A.; George, R. E.; Gray, N. S., Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). *J Med Chem* **2018,** *61* (9), 4249-4255.

156.   Cromm, P. M.; Samarasinghe, K. T. G.; Hines, J.; Crews, C. M., Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation. *J Am Chem Soc* **2018,** *140* (49), 17019-17026.

157.   Buhimschi, A. D.; Armstrong, H. A.; Toure, M.; Jaime-Figueroa, S.; Chen, T. L.; Lehman, A. M.; Woyach, J. A.; Johnson, A. J.; Byrd, J. C.; Crews, C. M., Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. *Biochemistry* **2018,** *57* (26), 3564-3575.

158.   Chen, H.; Chen, F.; Liu, N.; Wang, X.; Gou, S., Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway. *Bioorg Chem* **2018,** *81*, 536-544.

159.   Sun, Y.; Zhao, X.; Ding, N.; Gao, H.; Wu, Y.; Yang, Y.; Zhao, M.; Hwang, J.; Song, Y.; Liu, W.; Rao, Y., PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. *Cell Res* **2018,** *28* (7), 779-781.

160.   Zorba, A.; Nguyen, C.; Xu, Y.; Starr, J.; Borzilleri, K.; Smith, J.; Zhu, H.; Farley, K. A.; Ding, W.; Schiemer, J.; Feng, X.; Chang, J. S.; Uccello, D. P.; Young, J. A.; Garcia-Irrizary, C. N.; Czabaniuk, L.; Schuff, B.; Oliver, R.; Montgomery, J.; Hayward, M. M.; Coe, J.; Chen, J.; Niosi, M.; Luthra, S.; Shah, J. C.; El-

Kattan, A.; Qiu, X.; West, G. M.; Noe, M. C.; Shanmugasundaram, V.; Gilbert, A. M.; Brown, M. F.; Calabrese, M. F., Delineating the role of cooperativity in the design of potent PROTACs for BTK. *Proc Natl Acad Sci U S A* **2018,** *115* (31), E7285-e7292.

161.   Bian, J.; Ren, J.; Li, Y.; Wang, J.; Xu, X.; Feng, Y.; Tang, H.; Wang, Y.; Li, Z., Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity. *Bioorg Chem* **2018,** *81*, 373-381.

162.   Kang, C. H.; Lee, D. H.; Lee, C. O.; Du Ha, J.; Park, C. H.; Hwang, J. Y., Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC). *Biochem Biophys Res Commun* **2018,** *505* (2), 542-547.

163.   Burslem, G. M.; Song, J.; Chen, X.; Hines, J.; Crews, C. M., Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion. *J Am Chem Soc* **2018,** *140* (48), 16428-16432.

164.   Farnaby, W.; Koegl, M.; Roy, M. J.; Whitworth, C.; Diers, E.; Trainor, N.; Zollman, D.; Steurer, S.; Karolyi-Oezguer, J.; Riedmueller, C.; Gmaschitz, T.; Wachter, J.; Dank, C.; Galant, M.; Sharps, B.; Rumpel, K.; Traxler, E.; Gerstberger, T.; Schnitzer, R.; Petermann, O.; Greb, P.; Weinstabl, H.; Bader, G.; Zoephel, A.; Weiss-Puxbaum, A.; Ehrenhöfer-Wölfer, K.; Wöhrle, S.; Boehmelt, G.; Rinnenthal, J.; Arnhof, H.; Wiechens, N.; Wu, M. Y.; Owen-Hughes, T.; Ettmayer, P.; Pearson, M.; McConnell, D. B.; Ciulli, A., BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. *Nat Chem Biol* **2019,** *15* (7), 672-680.

165.   Gechijian, L. N.; Buckley, D. L.; Lawlor, M. A.; Reyes, J. M.; Paulk, J.; Ott, C. J.; Winter, G. E.; Erb, M. A.; Scott, T. G.; Xu, M.; Seo, H. S.; Dhe-Paganon, S.; Kwiatkowski, N. P.; Perry, J. A.; Qi, J.; Gray, N. S.; Bradner, J. E., Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. *Nat Chem Biol* **2018,** *14* (4), 405-412.

166.   Chu, T. T.; Gao, N.; Li, Q. Q.; Chen, P. G.; Yang, X. F.; Chen, Y. X.; Zhao, Y. F.; Li, Y. M., Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation. *Cell Chem Biol* **2016,** *23* (4), 453-61.

167.   Wang, F.; Jeon, K. O.; Salovich, J. M.; Macdonald, J. D.; Alvarado, J.; Gogliotti, R. D.; Phan, J.; Olejniczak, E. T.; Sun, Q.; Wang, S.; Camper, D.; Yuh, J. P.; Shaw, J. G.; Sai, J.; Rossanese, O. W.; Tansey, W. P.; Stauffer, S. R.; Fesik, S. W., Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design. *J Med Chem* **2018,** *61* (13), 5623-5642.

168.   Chacón Simon, S.; Wang, F.; Thomas, L. R.; Phan, J.; Zhao, B.; Olejniczak, E. T.; Macdonald, J. D.; Shaw, J. G.; Schlund, C.; Payne, W.; Creighton, J.; Stauffer, S. R.; Waterson, A. G.; Tansey, W. P.; Fesik, S. W., Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design. *J Med Chem* **2020,** *63* (8), 4315-4333.

169.   Carpino, L. A.; El-Faham, A.; Minor, C. A.; Albericio, F., Advantageous applications of azabenzotriazole (triazolopyridine)-based coupling reagents to solid-phase peptide synthesis. *Journal of the Chemical Society, Chemical Communications* **1994,** (2), 201-203.

170.   Valeur, E.; Bradley, M., Amide bond formation: beyond the myth of coupling reagents. *Chem Soc Rev* **2009,** *38* (2), 606-31.

171.   Carpino, L. A., 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive. *Journal of the American Chemical Society* **1993,** *115* (10), 4397-4398.

172.   Al-Warhi, T. I.; Al-Hazimi, H. M. A.; El-Faham, A., Recent development in peptide coupling reagents. *Journal of Saudi Chemical Society* **2012,** *16* (2), 97-116.

173.   Tang, X.; Tang, G.; Wang, H.; Luo, L.; Yang, D., A convenient and highly efficient synthesis of one kind of peptide nucleic acid monomer. *Bulletin of the Chemical Society of Ethiopia* **2012,** *26*.

174.   Dölle, A.; Adhikari, B.; Krämer, A.; Weckesser, J.; Berner, N.; Berger, L.-M.; Diebold, M.; Szewczyk, M. M.; Barsyte-Lovejoy, D.; Arrowsmith, C. H.; Gebel, J.; Löhr, F.; Dötsch, V.; Eilers, M.; Heinzlmeir, S.; Kuster, B.; Sotriffer, C.; Wolf, E.; Knapp, S., Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders. *Journal of Medicinal Chemistry* **2021**.

175.   Dale, N. C.; Johnstone, E. K. M.; White, C. W.; Pfleger, K. D. G., NanoBRET: The Bright Future of Proximity-Based Assays. *Frontiers in Bioengineering and Biotechnology* **2019,** *7* (56).

176.   Riching, K. M.; Mahan, S.; Corona, C. R.; McDougall, M.; Vasta, J. D.; Robers, M. B.; Urh, M.; Daniels, D. L., Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action. *ACS Chemical Biology* **2018,** *13* (9), 2758-2770.

177.   Guarnaccia, A. D.; Rose, K. L.; Wang, J.; Zhao, B.; Popay, T. M.; Wang, C. E.; Guerrazzi, K.; Hill, S.; Woodley, C. M.; Hansen, T. J.; Lorey, S. L.; Shaw, J. G.; Payne, W. G.; Weissmiller, A. M.; Olejniczak, E. T.; Fesik, S. W.; Liu, Q.; Tansey, W. P., Impact of WIN site inhibitor on the WDR5 interactome. *Cell Rep* **2021,** *34* (3), 108636.

178.   Fisher, S. L.; Phillips, A. J., Targeted protein degradation and the enzymology of degraders. *Curr Opin Chem Biol* **2018,** *44*, 47-55.

179.   Roy, M. J.; Winkler, S.; Hughes, S. J.; Whitworth, C.; Galant, M.; Farnaby, W.; Rumpel, K.; Ciulli, A., SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate. *ACS Chem Biol* **2019,** *14* (3), 361-368.

180.   Gadd, M. S.; Testa, A.; Lucas, X.; Chan, K. H.; Chen, W.; Lamont, D. J.; Zengerle, M.; Ciulli, A., Structural basis of PROTAC cooperative recognition for selective protein degradation. *Nat Chem Biol* **2017,** *13* (5), 514-521.

181.   Testa, A.; Hughes, S. J.; Lucas, X.; Wright, J. E.; Ciulli, A., Structure-Based Design of a Macrocyclic PROTAC. *Angew Chem Int Ed Engl* **2020,** *59* (4), 1727-1734.

182.   Meyer, C.; Burmeister, T.; Gröger, D.; Tsaur, G.; Fechina, L.; Renneville, A.; Sutton, R.; Venn, N. C.; Emerenciano, M.; Pombo-de-Oliveira, M. S.; Barbieri Blunck, C.; Almeida Lopes, B.; Zuna, J.; Trka, J.; Ballerini, P.; Lapillonne, H.; De Braekeleer, M.; Cazzaniga, G.; Corral Abascal, L.; van der Velden, V. H. J.; Delabesse, E.; Park, T. S.; Oh, S. H.; Silva, M. L. M.; Lund-Aho, T.; Juvonen, V.; Moore, A. S.; Heidenreich, O.; Vormoor, J.; Zerkalenkova, E.; Olshanskaya, Y.; Bueno, C.; Menendez, P.; Teigler-Schlegel, A.; zur Stadt, U.; Lentes, J.; Göhring, G.; Kustanovich, A.; Aleinikova, O.; Schäfer, B. W.; Kubetzko, S.; Madsen, H. O.; Gruhn, B.; Duarte, X.; Gameiro, P.; Lippert, E.; Bidet, A.; Cayuela, J. M.; Clappier, E.; Alonso, C. N.; Zwaan, C. M.; van den Heuvel-Eibrink, M. M.; Izraeli, S.; Trakhtenbrot, L.; Archer, P.; Hancock, J.; Möricke, A.; Alten, J.; Schrappe, M.; Stanulla, M.; Strehl, S.; Attarbaschi, A.; Dworzak, M.; Haas, O. A.; Panzer-Grümayer, R.; Sedék, L.; Szczepański, T.; Caye, A.; Suarez, L.; Cavé, H.; Marschalek, R., The MLL recombinome of acute leukemias in 2017. *Leukemia* **2018,** *32* (2), 273-284.

183.   Lorenzin, F.; Benary, U.; Baluapuri, A.; Walz, S.; Jung, L. A.; von Eyss, B.; Kisker, C.; Wolf, J.; Eilers, M.; Wolf, E., Different promoter affinities account for specificity in MYC-dependent gene regulation. *Elife* **2016,** *5*.

184.   Walz, S.; Lorenzin, F.; Morton, J.; Wiese, K. E.; von Eyss, B.; Herold, S.; Rycak, L.; Dumay-Odelot, H.; Karim, S.; Bartkuhn, M.; Roels, F.; Wüstefeld, T.; Fischer, M.; Teichmann, M.; Zender, L.; Wei, C. L.; Sansom, O.; Wolf, E.; Eilers, M., Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. *Nature* **2014,** *511* (7510), 483-7.

185.   Chen, W.; Chen, X.; Li, D.; Wang, X.; Long, G.; Jiang, Z.; You, Q.; Guo, X., Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity. *European Journal of Medicinal Chemistry* **2021,** *223*, 113677.

186.   Ye, X.; Chen, G.; Jin, J.; Zhang, B.; Wang, Y.; Cai, Z.; Ye, F., The Development of Inhibitors Targeting the Mixed Lineage Leukemia 1 (MLL1)-WD Repeat Domain 5 Protein (WDR5) Protein- Protein Interaction. *Curr Med Chem* **2020,** *27* (33), 5530-5542.

187.   Mullard, A., Targeted protein degraders crowd into the clinic. *Nature reviews. Drug discovery* **2021,** *20* (4), 247-250.

188.   Penzo, M.; Montanaro, L.; Treré, D.; Derenzini, M., The Ribosome Biogenesis-Cancer Connection. *Cells* **2019,** *8* (1), 55.

189.   Housman, G.; Byler, S.; Heerboth, S.; Lapinska, K.; Longacre, M.; Snyder, N.; Sarkar, S., Drug resistance in cancer: an overview. *Cancers (Basel)* **2014,** *6* (3), 1769-1792.

190.   Fedorov, O.; Niesen, F. H.; Knapp, S., Kinase inhibitor selectivity profiling using differential scanning fluorimetry. *Methods Mol Biol* **2012,** *795*, 109-18.

191.   Wanior, M.; Preuss, F.; Ni, X.; Krämer, A.; Mathea, S.; Göbel, T.; Heidenreich, D.; Simonyi, S.; Kahnt, A. S.; Joerger, A. C.; Knapp, S., Pan-SMARCA/PB1 Bromodomain Inhibitors and Their Role in Regulating Adipogenesis. *Journal of Medicinal Chemistry* **2020**.

10.   Appendix

ESI, ¹H-NMR, ¹³C-NMR and HPLC of N-(5-bromo-2-(4-methylpiperazin-1-yl)phenyl)-3-methylbenzamide

C:\Xcalibur\data\AD22_3_foam   8/1/2018 10:45:08 AM

AD22_3_foam #32-43   RT: 0.53-0.72   AV: 12   SB: 21 0.12-0.46   NL: 1.91E7
T: {0,0} + c ESI !corona sid=75.00 det=1506.00 Full ms [100.00-800.00]

Signal: MWD1 A, Sig=254,4 Ref=off

| RT [min]	Type	Width [min]	Area	Height	Area%
11.742	MM	0.2481	242.9475	16.3228	1.6890
12.395	MM	0.2417	271.0590	18.6918	1.8844
14.211	VV	0.2550	13870.0791	817.4152	96.4266
		Sum	14384.0856		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.737	MM	0.2260	211.1424	15.5726	2.0895
12.395	MM	0.2529	184.8797	12.1860	1.8296
14.211	VV	0.2523	9708.7354	580.0815	96.0808

Sum   10104.7575

RT [min]	Type	Width [min]	Area	Height	Area%
11.742	MM	0.1945	126.9072	10.8757	0.8444
12.396	MM	0.2314	247.7028	17.8418	1.6481
14.211	VV	0.2527	14654.5596	873.7964	97.5074

ESI and ^{1}H-NMR of *tert*-butyl 5-(3-(3-methylbenzamido)-4-(piperazin-1-yl)phenyl)-1*H*-indole-1-carboxylate (6a)

C:\Xcalibur\data\AD40_3h   8/16/2018 12:21:42 PM

AD40_3h #35-43 RT: 0.60-0.74 AV: 9 SB: 19 0.04-0.35 NL: 3.99E5
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [100.00-1000.00]

DPX250-2018-09-07-adkn.55862
AD40.1

ESI and ¹H-NMR of *N*-(5-(1*H*-indol-5-yl)-2-(piperazin-1-yl)phenyl)-3-methylbenzamide

C:\Xcalibur\data\AD37   8/13/2018 7:07:41 AM

AD37 #33-43 RT: 0.57-0.74 AV: 11 SB: 30 0.00-0.51 NL: 2.91E5
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [100.00-1000.00]

ESI, ¹H-NMR and HPLC of tert-butyl 5-(3-(2-chloro-4-fluoro-3-methyl-5-nitrobenzamido)-4-(4-methylpiperazin-1-yl)phenyl)-1H-indole-1-carboxylate

C:\Xcalibur\data\AD64   12/3/2018 9:17:16 AM

AD64 #39-44   RT: 0.68-0.77   AV: 6   SB: 26   0.07-0.52   NL: 3.49E6
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [200.00-1200.00]

Signal: MSD1 TIC, MS File

RT [min]	Type	Width [min]	Area	Height	Area%
13.614	BB	0.4825	440825536.0000	14593189.0000	100.0000
		Sum	440825536.0000		

Signal: MSD2 TIC, MS File

RT [min]	Type	Width [min]	Area	Height	Area%
12.838	BV	0.5139	19723108.0000	546568.7500	19.1017
13.623	VV	0.5145	21110724.0000	611107.0000	20.4456
15.941	VV	1.0243	21339308.0000	267287.7188	20.6670
17.900	VV	1.7478	41079972.0000	292904.9375	39.7857
		Sum	103253112.0000		

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.661	VV	0.1661	859.6909	81.4859	4.6480
13.414	VV	0.2077	17636.1641	1356.2094	95.3520
		Sum	18495.8550		

Signal: MWD1 E, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.661	VV	0.1626	868.4492	84.6968	7.4586
13.414	VV	0.2062	10775.1768	831.3713	92.5414
		Sum	11643.6260		

MSD1 TIC, MS File

13.614

Max : 7175168

ESI and ^{1}**H-NMR of tert-butyl 5-(3-(5-amino-2-chloro-4-fluoro-3-methylbenzamido)-4-(4-methylpiperazin-1-yl)phenyl)-1H-indole-1-carboxylate (6b)**

C:\Xcalibur\data\AD69   12/19/2018 2:43:50 PM

AD69 #32-42 RT: 0.54-0.71 AV: 11 SB: 16 0.07-0.33 NL: 2.44E7
T: {0,0} + c ESI !corona sid=75.00 det=1506.00 Full ms [105.00-1000.00]

HPLC, ESI and ^{1}H-NMR of *tert*-butyl 5-(3-amino-4-(4-methylpiperazin-1-yl)phenyl)-1*H*-indole-1-carboxylate (5a)

Peak RT   12.598

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.550	VV	0.2245	34534.6094	2480.0020	100.0000
		Sum	34534.6094		

Signal: MWD1 E, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.550	VV	0.2081	18136.9473	1409.5803	100.0000
		Sum	18136.9473		

C:\Xcalibur\data\AD74-1   2/12/2019 9:03:14 AM

AD74-1 #33-43   RT: 0.57-0.74   AV: 11   SB: 10   0.14-0.30   NL: 5.82E6
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [100.00-1000.00]


AV300-2019-01-23-adkn.26509
AD72
H1_1D CDCl3 /nmr kn 3

ESI, HPLC and ^{1}H-NMR of *tert*-butyl 5-(3-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4-(4-methylpiperazin-1-yl)phenyl)-1*H*-indole-1-carboxylate (6c)

C:\Xcalibur\data\AD74-2   2/12/2019 9:04:37 AM

AD74-2 #32-42 RT: 0.55-0.73 AV: 11 SB: 11 0.14-0.32 NL: 2.00E5
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [100.00-1000.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.346	VV	0.2079	27935.7637	2131.1035	98.3774
13.203	MM	0.1934	460.7658	34.4330	1.6226
		Sum	28396.5295		

Signal: MWD1 E, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.352	VV	0.2061	14929.4092	1175.6801	99.8037

13.204 MM   0.1128   29.3598   4.3397   0.1963

Sum   14958.7690

DRX600-2020-07-10-adkn.5061
Group AK_Knapp
AD74 F21

^{1}H-NMR of 4-(4-bromo-2-nitrophenyl)morpholine

^{1}H-NMR of 5-bromo-2-morpholinoaniline

¹H-NMR and ESI of tert-butyl 4'-morpholino-3'-(6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamido)-[1,1'-biphenyl]-4-carboxylate

C:\Xcalibur\data\AD165_weiß   2/15/2021 12:22:39 PM

AD165_weiß #30-42 RT: 0.51-0.73 AV: 13 SB: 13 0.16-0.37 NL: 1.83E6
T: {0,0} + c ESI !corona sid=75.00 det=1600.00 Full ms [105.00-1000.00]

ESI, ^{1}H-NMR of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (L0)

C:\Xcalibur\data\NK02   11/19/2019 9:56:33 AM

NK02 #31-43   RT: 0.52-0.72   AV: 13   SB: 14 0.07-0.29   NL: 8.68E3
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [105.00-500.00]

ESI, HPLC, ^{1}H-NMR and ^{13}C-NMR of tert-butyl (2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)carbamate (L1)

C:\Xcalibur\data\LL06-1   3/13/2019 12:21:42 PM

LL06-1 #34-41 RT: 0.58-0.71 AV: 8 SB: 5 0.16-0.23 NL: 1.00E6
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [100.00-900.00]


Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
3.313	BV	0.0953	471.4035	74.0216	0.8010
12.868	MM	0.2825	58377.2656	3443.8289	99.1990
		Sum	58848.6691		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.805	MM	0.2581	53369.2109	3445.7402	100.0000
		Sum	53369.2109		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
3.313	VV	0.0926	356.4311	58.9223	0.5828
12.774	MM	0.2846	60802.2852	3561.0684	99.4172

ESI, HPLC, ^{1}H-NMR and ^{13}C-NMR of tert-butyl (2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethyl)carbamate (L2)

C:\Xcalibur\data\LL07-1   3/13/2019 12:23:26 PM

LL07-1 #36-43 RT: 0.62-0.74 AV: 8 SB: 6 0.11-0.20 NL: 7.75E5
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [100.00-1000.00]


Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.128	MM	0.2843	58034.3398	3402.1462	100.0000
		Sum	58034.3398		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.126	VV	0.1779	50324.2734	3357.0464	100.0000

Sum   50324.2734

RT [min]	Type	Width [min]	Area	Height	Area%
11.164	MM	0.2940	61209.2969	3470.2668	100.0000

ESI, HPLC, ^{1}H-NMR of tert-butyl (17-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)carbamate (L3)

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
9.844	VV	0.2442	4875.1143	277.2130	6.8073
12.774	MM	0.3324	66741.1328	3346.6414	93.1927
		Sum	71616.2471		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
9.837	VV	0.2515	8863.7100	489.0014	13.2680
12.747	MM	0.2964	57941.5820	3258.0781	86.7320
		Sum	66805.2920		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
9.842	VV	0.2456	5633.9717	318.0999	7.2044
12.694	MM	0.3503	72567.7969	3452.9812	92.7956

C:\Xcalibur\data\NK05-1   11/28/2019 10:40:25 AM

NK05-1 #37-43 RT: 0.64-0.75 AV: 7 SB: 17 0.09-0.37 NL: 6.15E5
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [200.00-1200.00]

ESI, HPLC, ¹H-NMR and ¹³C-NMR of tert-butyl (23-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18,21-heptaoxatricosyl)carbamate (L4)

C:\Xcalibur\data\NK06-1   11/28/2019 10:41:49 AM

NK06-1 #36-42   RT: 0.62-0.73   AV: 7   SB: 11 0.02-0.20   NL: 1.12E5
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [200.00-1200.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.713	MM	0.3183	64034.5742	3352.9675	100.0000
		Sum	64034.5742		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%

12.705	MM	0.2795	54819.2344	3269.3167	100.0000
		Sum	54819.2344		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.692	MM	0.3332	69116.1953	3456.9661	100.0000

ESI, HPLC, ^{1}H-NMR of tert-butyl (4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)methyl)benzyl)carbamate (L5)

C:\Xcalibur\data\AD130-1   2/13/2020 9:55:03 AM

AD130-1 #36-43 RT: 0.62-0.74 AV: 8 SB: 11 0.09-0.26 NL: 8.73E4
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [105.00-900.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
13.136	VV	0.1695	14003.7656	1322.6830	24.3641
13.377	VV	0.1652	43473.3477	3166.8340	75.6359
		Sum	57477.1133		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%

13.136	VV	0.1658	8677.5889	844.7153	22.1242
13.377	VV	0.1573	30544.4863	2370.8906	77.8758
		Sum	39222.0752		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
13.136	MM	0.1585	12919.3477	1358.9250	21.3525
13.381	VV	0.1748	47585.8594	3308.0881	78.6475

ESI, HPLC, ¹H-NMR and ¹³C-NMR of tert-butyl (2-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropoxy)ethyl)carbamate (L6)

C:\Xcalibur\data\AD139   8/10/2020 12:24:15 PM

AD139 #35-42   RT: 0.61-0.73   AV: 8   SB: 10 0.09-0.25   NL: 1.98E6
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [200.00-1200.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.572	MM	0.2555	672.4956	43.8669	1.1729
12.080	VV	0.2221	56661.4414	3088.2632	98.8271
		Sum	57333.9370		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%

10.568	VV	0.2175	784.3678	51.8485	1.0468
12.146	MM	0.4020	74143.3516	3073.8215	98.9532
		Sum	74927.7194		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.573	MM	0.2640	536.8670	33.8943	0.8248
12.079	MM	0.3343	64556.0977	3218.7188	99.1752

AV500-2020-05-07-adkn.32688
Group AK_Knapp
AD139
1H DMSO /nmr/Tag-Messung Tag-Messung 43

ESI, HPLC, ^{1}H-NMR and ^{13}C-NMR of tert-butyl (2-(2-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropoxy)ethoxy)ethyl)carbamate (L7)

C:\Xcalibur\data\AD108-1   9/18/2019 7:35:17 AM

AD108-1 #32-42   RT: 0.56-0.74   AV: 11   SB: 8 0.11-0.23   NL: 3.01E6
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [105.00-1200.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.127	MM	0.4125	74880.8047	3025.3701	100.0000
		Sum	74880.8047		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%

12.117 MM	0.4749	82822.3672	2906.9238	100.0000
	Sum	82822.3672		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.077	MM	0.4308	80162.5781	3100.9529	100.0000

AV500-2019-09-20-adkn.30618
Group AK_Knapp
AD108
1H MeOD /nmr/Tag-Messung Tag-Messung 15

ESI, HPLC, ^{1}H-NMR and ^{13}C-NMR of tert-butyl ((S)-17-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-18,18-dimethyl-15-oxo-3,6,9,12-tetraoxa-16-azanonadecyl)carbamate (L8)

C:\Xcalibur\data\AD108-2   9/18/2019 7:36:29 AM

AD108-2 #30-41   RT: 0.52-0.72   AV: 12   SB: 8 0.00-0.13   NL: 1.01E6
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [105.00-1200.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
9.386	MM	0.2141	578.0328	44.9890	0.7538
12.094	MM	0.4188	76100.4609	3028.6030	99.2462
		Sum	76678.4938		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
9.401	MM	0.2216	570.3035	42.8859	0.6772
12.074	MM	0.4768	83642.8047	2923.6580	99.3228
		Sum	84213.1082		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
9.384	MM	0.2119	613.2241	48.2244	0.6948
12.124	MM	0.4631	87650.6875	3154.5259	99.3052
		Sum	88263.9116		

AV500-2019-09-20-adkn.30617
Group AK_Knapp
AD108
1H MeOD /nmr/Tag-Messung Tag-Messung 14

ESI, ¹H-NMR and ¹³C-NMR of tert-butyl (3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)carbamate (L9)

C:\Xcalibur\data\AD154   10/5/2020 3:02:50 PM

AD154 #33-42   RT: 0.57-0.73   AV: 10   SB: 9 0.02-0.16   NL: 7.31E6
T: {0,0} + c ESI !corona sid=75.00 det=1600.00 Full ms [100.00-1200.00]

ESI, ^{1}H-NMR and ^{13}C-NMR of tert-butyl (4-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutyl)carbamate (L10)

C:\Xcalibur\data\AD155   10/5/2020 3:04:33 PM

AD155 #32-42 RT: 0.56-0.73 AV: 11 SB: 10 0.05-0.21 NL: 5.31E6
T: {0,0} + c ESI !corona sid=75.00 det=1600.00 Full ms [100.00-1200.00]

AV300-2020-10-12-adkn.37731
Group AK_Knapp
AD155
1H MeOD /nmr Tag-Messung 14

ESI, HPLC, ¹H-NMR and ¹³C-NMR of tert-butyl (5-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamate (L11)

C:\Xcalibur\data\AD107   9/13/2019 6:56:17 AM

AD107 #32-43 RT: 0.55-0.75 AV: 12 SB: 7 0.07-0.18 NL: 1.11E6
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [200.00-1200.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.072	VV	0.2259	15183.3105	1018.8142	100.0000
		Sum	15183.3105		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.072	VV	0.2262	21853.1191	1455.2832	100.0000
		Sum	21853.1191		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.072	VV	0.2257	16775.8438	1126.5007	100.0000

AV500-2019-09-20-adkn.30616
Group AK_Knapp
AD107
1H MeOD /nmr/Tag-Messung Tag-Messung 13

ESI, HPLC, ¹H-NMR and ¹³C-NMR of tert-butyl (6-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)carbamate (L12)

AD113-1 #36-42 RT: 0.62-0.73 AV: 7 SB: 9 0.07-0.21 NL: 1.64E6
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [200.00-1200.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.297	VV	0.2391	40065.7813	2553.0674	100.0000
		Sum	40065.7813		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.298	MM	0.2941	51400.3750	2912.6912	100.0000
		Sum	51400.3750		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.296	VV	0.2173	44116.5742	2763.2627	100.0000

AV500-2019-10-21-adkn.30870
Group AK_Knapp
AD113
1H MeOD /nmr/Tag-Messung Tag-Messung 19

ESI, HPLC, ^{1}H-NMR and ^{13}C-NMR of tert-butyl (7-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)carbamate (L13)

C:\Xcalibur\data\AD106-2   9/16/2019 10:04:34 AM

AD106-2 #34-42 RT: 0.59-0.73 AV: 9 SB: 11 0.04-0.22 NL: 1.04E6
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [105.00-1200.00]

Signal: MWD1 A, Sig=254,4 Ref=off

| RT [min]	Type	Width [min]	Area	Height	Area%
12.062	VV	0.2181	3252.9497	223.1664	6.2811
12.541	VV	0.2368	48536.3945	2660.7231	93.7189
		Sum	51789.3442		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.061	MM	0.2245	4209.9492	312.5555	6.5658
12.558	MM	0.3742	59909.6172	2668.2478	93.4342
		Sum	64119.5664		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.062	VV	0.2166	3560.8386	246.4372	6.1048
12.564	MM	0.3241	54767.2188	2816.3435	93.8952

AV500-2019-09-20-adkn.30615
Group AK_Knapp
AD106
1H MeOD /nmr/Tag-Messung Tag-Messung 12

ESI, HPLC, ^{1}H-NMR and ^{13}C-NMR of tert-butyl (4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethyl)benzyl)carbamate (L14)

C:\Xcalibur\data\AD140   8/10/2020 12:22:34 PM

AD140 #35-42   RT: 0.61-0.73   AV: 8   SB: 7 0.09-0.20   NL: 3.27E6
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [200.00-1200.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.581	MM	0.4447	1334.5194	50.0107	1.9565
11.689	MM	0.1568	414.5808	44.0782	0.6078
12.451	MM	0.3501	66460.5781	3164.2292	97.4357
		Sum	68209.6783		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.582	MM	0.3997	1567.3302	65.3503	2.0085
11.687	MM	0.2019	685.3602	56.5747	0.8783
12.541	MM	0.4061	75781.6641	3110.1145	97.1132
		Sum	78034.3544		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.581	MM	0.4067	1300.0765	53.2741	1.7700
11.690	MM	0.1873	729.8845	64.9543	0.9937
12.459	MM	0.3645	71421.4219	3265.3564	97.2363

AV500-2020-05-07-adkn.32689
Group AK_Knapp
AD140
1H DMSO /nmr/Tag-Messung Tag-Messung 44

ESI, HPLC, ¹H-NMR and ¹³C-NMR of tert-butyl (5-(((S)-1-((2S,4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamate (L15)

C:\Xcalibur\data\AD152-2   9/17/2020 8:08:35 AM

AD152-2 #30-43   RT: 0.51-0.74   AV: 14   SB: 7 0.05-0.16   NL: 3.32E4
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [105.00-1000.00]

RT [min]	Type	Width [min]	Area	Height	Area%
12.025	VV	0.2315	1145.2445	72.0177	100.0000
		Sum	1145.2445		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.025	VV	0.2326	1672.4189	104.5707	100.0000
		Sum	1672.4189		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.025	VV	0.2292	1240.3011	78.9803	100.0000

ESI, HPLC, ^{1}H-NMR and ^{13}C-NMR of tert-butyl (2-(2-(3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxamido)ethoxy)ethyl)carbamate (6e)

C:\Xcalibur\data\AD133   5/4/2020 9:32:53 AM

AD133 #36-42 RT: 0.63-0.74 AV: 7 SB: 15 0.04-0.29 NL: 2.44E5
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [300.00-1500.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.636	VV	0.2088	960.0562	68.8025	96.2284
12.963	MM	0.1685	37.6289	3.7220	3.7716
		Sum	997.6851		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%

11.637	VV		0.2215		1175.1613		78.1245	98.9523
12.959	MM		0.2024		12.4427		1.0247	1.0477
		Sum			1187.6039			

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]		Area		Height	Area%
11.637	VV	0.2084		1095.8492		78.2365	95.5942
12.962	MM	0.2064		50.5057		4.0791	4.4058

ESI, HPLC, ^{1}H-NMR of tert-butyl (1-(3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-1-oxo-5,8,11,14,17,20,23-heptaoxa-2-azapentacosan-25-yl)carbamate (6f)

C:\Xcalibur\data\AD134   5/4/2020 9:35:13 AM

AD134 #38-42   RT: 0.67-0.74   AV: 5   SB: 9 0.04-0.18   NL: 5.92E5
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [300.00-1500.00]

Sum   42114393.0000

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.751	VV	0.2234	917.7254	61.0386	94.3249
12.958	MM	0.2044	55.2154	4.5021	5.6751
		Sum	972.9408		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.751	VV	0.2259	1091.4231	70.0104	98.2189
12.954	MM	0.2499	19.7914	1.3201	1.7811
		Sum	1111.2145		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.751	VV	0.2199	1049.4673	69.5902	94.7728
12.958	MM	0.2140	57.8829	4.5091	5.2272

ESI, HPLC and ¹H-NMR of tert-butyl (4-((3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxamido)methyl)benzyl)carbamate (6g)

AD135 #33-43 RT: 0.58-0.76 AV: 11 SB: 10 0.07-0.23 NL: 2.49E5
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [300.00-1500.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.212	VV	0.2107	791.6523	56.4203	91.4191
12.949	MM	0.2487	74.3068	4.9802	8.5809
		Sum	865.9591		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.211	VV	0.2149	943.0983	64.3726	96.0057
12.766	MM	0.2462	39.2378	2.6562	3.9943
		Sum	982.3361		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.212	VV	0.2120	907.8795	64.2070	92.2728
12.951	MM	0.2594	76.0286	4.8847	7.7272

MALDI and ¹H-NMR of tert-butyl (1-(3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-1-oxo-5,8,11,14,17,20,23,26,29-nonaoxa-2-azahentriacontan-31-yl)carbamate (6h)

Voyager Spec #1[BP = 939.4, 31058]

ESI, HPLC, ^{1}H-NMR and ^{13}C-NMR of tert-butyl (1-(3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-yl)-1-oxo-6,9,12-trioxa-2-azapentadecan-15-yl)carbamate (6i)

C:\Xcalibur\data\AD143-9   5/26/2020 9:16:14 AM

AD143-9 #38-42   RT: 0.67-0.74   AV: 5   SB: 13 0.07-0.29   NL: 4.26E5
T: {0,0} + c ESI !corona sid=75.00 det=1506.00 Full ms [300.00-1500.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.870	BV	0.2371	37841.2813	2359.7388	100.0000
		Sum	37841.2813		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%

11.871 VV		0.2203	42077.1367	2606.3718	100.0000
		Sum	42077.1367		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.869	VV	0.2388	42766.1367	2656.3064	100.0000

HPLC, HRMS, ¹H-NMR and ¹³C-NMR of N-(4'-((2-(2-(3-(5,5-difluoro-7-(1H-pyrrol-2-yl)-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)propanamido)ethoxy)ethyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (19a)

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.364	MM	0.3356	228.0416	11.3250	4.6822
12.138	MM	0.2965	4642.3574	260.9971	95.3178
		Sum	4870.3990		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.356	MM	0.3379	265.3242	13.0870	4.1852
12.139	MM	0.2911	6074.2964	347.7672	95.8148
		Sum	6339.6206		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.361	MM	0.3556	252.2446	11.8215	4.6842
12.139	MM	0.2909	5132.7949	294.1020	95.3158

AD148_F8 #1-20   RT: 0.00-1.53   AV: 20   NL: 2.45E5
T: FTMS + p MALDI Full ms [800.00-1350.00]

HPLC, HRMS, ¹H-NMR of N-(4'-((33-(5,5-difluoro-7-(1H-pyrrol-2-yl)-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)-31-oxo-3,6,9,12,15,18,21,24,27-nonaoxa-30-azatritriacontyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (19b)

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.357	VV	0.1987	2072.8545	168.3288	100.0000
		Sum	2072.8545		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.357	VV	0.2005	2813.1299	225.5552	100.0000
		Sum	2813.1299		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.357	VV	0.1988	2353.3545	190.8938	100.0000

C:\User\...\2020\10.08.2020\AD147_F7   8/11/2020 10:07:06 AM   AD147 mit HCCA gemessen.

AD147_F7 #1-12   RT: 0.01-0.90   AV: 12   NL: 5.68E5
T: FTMS + p MALDI Full ms [800.00-1350.00]

HPLC, HRMS and ^{1}H-NMR of N-(4'-((17-(5,5-difluoro-7-(1H-pyrrol-2-yl)-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-3-yl)-15-oxo-4,7,10-trioxa-14-azaheptadecyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (19c)

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.407	VV	0.2010	936.6609	77.5274	100.0000
		Sum	936.6609		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.406	VV	0.2034	1279.1853	104.0625	100.0000
		Sum	1279.1853		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.406	VV	0.2009	1061.8375	87.9442	100.0000

AD146_F6 #1-10 RT: 0.00-0.68 AV: 10 NL: 7.42E5
T: FTMS + p MALDI Full ms [800.00-1350.00]

Appendix of intermediates 3-6

ESI   and ^{1}H-NMR   of   1-(4-bromo-2-nitrophenyl)-4-methylpiperazine   (3)

C:\Xcalibur\data\AD14_2h   6/15/2018 12:18:41 PM

AD14_2h #32-44 RT: 0.54-0.75 AV: 13 SB: 11 0.19-0.36 NL: 8.65E6
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [105.00-600.00]

ESI, ¹H-NMR and HPLC of 5-bromo-2-(4-methylpiperazin-1-yl)aniline (4)

C:\Xcalibur\data\AD21_1   7/2/2018 9:10:28 AM

AD21_1 #36-43 RT: 0.61-0.73 AV: 8 SB: 10 0.07-0.23 NL: 5.44E6
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [100.00-600.00]

DPX250-2018-08-02-adkn.54465
AD21.3

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.879	BV	0.1668	11862.8955	1155.4844	99.6042
13.193	MM	0.0751	47.1392	10.4557	0.3958
		Sum	11910.0347		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.879	VV	0.1677	3558.1433	343.9120	98.2896
13.148	MM	0.1711	61.9159	6.0318	1.7104
		Sum	3620.0593		

ESI, HPLC, ^{1}H-NMR and ^{13}C-NMR of tert-butyl 3'-amino-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate (5b)

C:\Xcalibur\data\AD99-1   8/20/2019 8:21:08 AM

AD99-1 #36-43 RT: 0.61-0.73 AV: 8 SB: 9 0.02-0.16 NL: 1.27E7
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [100.00-700.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.363	MM	0.1143	179.2153	26.1271	2.7597
11.958	VV	0.1658	6113.2773	562.4454	94.1364
13.437	MM	0.1422	136.3742	15.9810	2.1000
14.731	MM	0.1515	65.1996	7.1723	1.0040
		Sum	6494.0666		

Signal: MWD1 E, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.363	MM	0.1024	45.8921	7.4716	0.8672
11.957	VV	0.1663	4796.4849	439.7085	90.6417
13.437	MM	0.1683	301.3157	29.8367	5.6941
14.728	MM	0.1462	148.0057	16.8705	2.7969

AV500-2019-08-22-adkn.30351
Group AK_Knapp
AD99
1H CD2Cl2 /nmr/Tag-Messung Tag-Messung 6

ESI, HPLC, ^{1}H-NMR and ^{13}C-NMR of tert-butyl 3'-(6-hydroxy-4-(trifluoromethyl)nicotinamido)-4'-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-4-carboxylate (6d)

C:\Xcalibur\data\AD100_1-F2   8/29/2019 9:34:41 AM

AD100_1-F2 #34-43 RT: 0.58-0.74 AV: 10 SB: 17 0.04-0.32 NL: 4.31E4
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [105.00-1000.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.354	MM	0.1955	264.3400	22.5354	2.2644
11.399	MM	0.1602	109.3309	11.3760	0.9366
11.979	MM	0.1438	97.5140	11.2982	0.8353
12.214	MM	0.1826	324.7970	29.6518	2.7823
12.838	VV	0.2499	10877.6895	661.4399	93.1814

Sum   11673.6714

RT [min]	Type	Width [min]	Area	Height	Area%
10.389	MM	0.1813	84.4925	7.7665	0.6195
11.983	MM	0.1406	191.5884	22.7102	1.4046
12.212	VV	0.2312	748.0756	50.1011	5.4845
12.838	VV	0.2487	12615.6523	771.6691	92.4914

MALDI, HRMS, HPLC, ¹H-NMR, ¹³C-NMR, ¹³C-NMR, ¹³C-DEPT90, ¹H-¹³C-HSQC, ¹H-¹³C-HMBC of *N*-(4'-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (7a)

Voyager Spec #1[BP = 843.4, 37589]

C:\User\...\2020\20.08.2020\AD 123_E6   8/20/2020 6:49:07 PM   AD 123 mit HCCA gemessen.

AD 123_E6 #1-9 RT: 0.00-0.60 AV: 9 NL: 1.87E7
T: FTMS + p MALDI Full ms [700.00-1700.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.614	MM	0.2199	202.6069	15.3539	100.0000
		Sum	202.6069		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.612	MM	0.2239	212.1426	15.7890	100.0000
		Sum	212.1426		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.612	MM	0.2276	238.7010	17.4816	100.0000

protac_700
compound #123 ~?mg in 500ul DMSO-d6 T=298K
13C DEPT90 (only CH groups detected) NS=1k Aq=1.5s D1=1.5s protac_700/63 17.3.2021
13C carrier at 140ppm, SW=80ppm, de=50us

HPLC, MALDI, HRMS, ^{1}H-NMR and ^{13}C-NMR, ^{13}C-NMR, ^{1}H-^{13}C-HSQC, ^{1}H-^{13}C-HMBC of *N*-(4'-((2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (7b)

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.847	MM	0.2960	6658.2402	374.9590	97.7984
12.950	MM	0.2326	149.8847	10.7386	2.2016
		Sum	6808.1249		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.847	MM	0.2924	6744.6553	384.4801	98.0727
12.829	MM	0.1510	132.5450	10.4535	1.9273
		Sum	6877.2003		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.847	VV	0.2405	7302.5942	412.6076	98.0674
12.952	MM	0.2115	143.9127	11.3433	1.9326

Voyager Spec #1[BP = 959.5, 37728]

C:\User\...\2020\20.08.2020\AD 120_E4   8/20/2020 6:46:39 PM   AD 120 mit HCCA gemessen.

AD 120_E4 #1-4   RT: 0.01-0.41   AV: 4   NL: 3.46E6
T: FTMS + p MALDI Full ms [700.00-1700.00]

MALDI, HRMS, HPLC, ¹H-NMR, ¹³C-NMR, ¹H-¹³C-HSQC, ¹H-¹³C-HMBC of *N*-(4'-((17-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (7c)

Voyager Spec #1[BP = 635.4, 5083]

C:\User\...\2020\20.08.2020\AD 124_E7   8/20/2020 6:50:51 PM   AD 124 mit HCCA gemessen.

AD 124_E7 #1-7   RT: 0.00-0.74   AV: 7   NL: 4.05E5
T: FTMS + p MALDI Full ms [700.00-1700.00]

**Signal:**   MWD1 A, Sig=254,4 Ref=off

| RT [min]	Type	Width [min]	Area	Height	Area%
11.593	VV	0.2390	18262.3613	1133.0564	100.0000
		Sum	18262.3613		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.593	VV	0.2389	22847.2031	1418.2609	100.0000
		Sum	22847.2031		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.593	VV	0.2401	19822.1172	1229.6807	100.0000

HRMS, MALDI, HPLC, ¹H-NMR, ¹³C-NMR, ¹H-¹³C-HSQC, ¹H-¹³C-HMBC of *N*-(4'-((23-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18,21-heptaoxatricosyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (7d)

C:\User\...\2020\20.08.2020\AD 125_E8   8/20/2020 6:52:37 PM   AD 125 mit HCCA gemessen.

AD 125_E8 #1-6   RT: 0.01-0.47   AV: 6   NL: 4.52E6
T: FTMS + p MALDI Full ms [700.00-1700.00]

Voyager Spec #1[BP = 1107.5, 56192]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.969	MM	0.3015	220.6292	12.1971	2.5413
11.697	MM	0.2683	8461.0498	525.6016	97.4587
		Sum	8681.6790		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.960	MM	0.2779	234.3564	14.0530	2.5827
11.692	MM	0.2764	8839.7959	533.0018	97.4173
		Sum	9074.1523		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.984	MM	0.3388	313.1158	15.4024	3.0819
11.695	MM	0.2776	9846.8340	591.2772	96.9181

MALDI, HRMS, ¹H-NMR, ¹³C-NMR, ¹H-¹³C-HSQC, ¹H-¹³C-HMBC and HPLC of N-(4'-((4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)methyl)benzyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (7e)

Voyager Spec #1[BP = 897.2, 20813]

C:\User\...\Knapp\2020\yyyyyyy\AD131_D8   9/18/2020 9:44:39 PM   AD131 mit HCCA gemessen.

AD131_D8 #1-7   RT: 0.01-0.27   AV: 7   NL: 3.49E6
T: FTMS + p MALDI Full ms [300.00-950.00]

RT [min]	Type	Width [min]	Area	Height	Area%
11.654	MM	0.1599	142.2890	14.8330	1.5723

		0.2775	8600.4414	516.4586	95.0367
12.065	MM	0.2775	8600.4414	516.4586	95.0367
12.892	MM	0.2353	306.8708	21.7380	3.3910
		Sum	9049.6012		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.659	MM	0.1161	118.6666	12.6600	1.3609
12.065	MM	0.2644	8392.1240	529.0167	96.2442
12.895	MM	0.1790	208.8267	19.4480	2.3949
		Sum	8719.6173		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.661	MM	0.1766	173.2003	16.3418	1.7365
12.065	MM	0.2720	9509.6045	582.6867	95.3410
12.889	MM	0.1962	291.4992	24.7618	2.9225

MALDI, HRMS, HPLC, ¹H-NMR, ¹³C-NMR, ¹H-¹³C-HSQC and ¹H-¹³C-HMBC of 6-hydroxy-N-(4'-((2-(3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropoxy)ethyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8a)

Voyager Spec #1[BP = 1076.2, 11779]

C:\User\...\2020\17.09.2020\AD141_F9   9/17/2020 9:48:54 AM   AD141 mit HCCA gemessen.

AD141_F9 #1-20 RT: 0.01-0.87 AV: 20 NL: 5.57E6
T: FTMS + p MALDI Full ms [1000.00-1250.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.278	VV	0.2050	7216.8145	486.5691	97.2523
11.786	MM	0.1465	203.8960	23.2009	2.7477
		Sum	7420.7104		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.278	VV	0.2150	9186.0752	582.5713	100.0000
		Sum	9186.0752		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.278	VV	0.2159	8699.8975	548.8284	100.0000

MALDI, HRMS, HPLC, ^{1}H-NMR and ^{13}C-NMR of 6-hydroxy-*N*-(4'-((2-(2-(3-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropoxy)ethoxy)ethyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8b)

Voyager Spec #1[BP = 1094.4, 1696]

C:\User\...\2020\19.11.2020\AD111_A1   11/19/2020 6:08:12 PM   AD111 mit HCCA gemessen.

AD111_A1 #1-4   RT: 0.00-0.27   AV: 4   NL: 3.82E6
T: FTMS + p MALDI Full ms [800.00-1400.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.319	VV	0.2071	54018.9102	3087.1851	100.0000
		Sum	54018.9102		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.316	VV	0.2211	60787.4297	3251.7109	100.0000
		Sum	60787.4297		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.318	VV	0.2136	59376.8555	3289.8892	100.0000

HRMS, MALDI, HPLC, ¹H-NMR and ¹³C-NMR of 6-hydroxy-*N*-(4'-(((*S*)-17-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-18,18-dimethyl-15-oxo-3,6,9,12-tetraoxa-16-azanonadecyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8c)

C:\User\...\2020\17.09.2020\AD112_F8   9/17/2020 9:47:40 AM   AD112 mit HCCA gemessen.

AD112_F8 #1-14   RT: 0.01-0.60   AV: 14   NL: 9.41E6
T: FTMS + p MALDI Full ms [1000.00-1250.00]

Voyager Spec #1[BP = 843.5, 45417]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.445	VV	0.2008	1150.3380	79.0589	98.6354
12.949	MM	0.1184	15.9151	2.2397	1.3646
		Sum	1166.2531		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.445	VV	0.2055	1419.3114	94.8723	100.0000
		Sum	1419.3114		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.445	VV	0.2004	1305.3274	89.3934	98.6329
12.952	MM	0.1277	18.0924	2.3606	1.3671

ESI, MALDI, HRMS, HPLC, ^{1}H-NMR, ^{13}C-NMR, ^{13}C-NMR and ^{1}H-^{13}C-HMBC of 6-hydroxy-N-(4'-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8d)

C:\Xcalibur\data\AD158-1   10/15/2020 6:50:44 AM

AD158-1 #34-42   RT: 0.60-0.74   AV: 9   SB: 11   0.02-0.20   NL: 1.85E3
T: {0,0} + c ESI !corona sid=75.00 det=1306.00 Full ms [200.00-1500.00]

Voyager Spec #1[BP = 318.1, 4476]

C:\User\...\2020\19.11.2020\AD158_A4   11/19/2020 6:13:30 PM   AD158 mit HCCA gemessen.

AD158_A4 #1-5   RT: 0.00-0.28   AV: 5   NL: 5.53E6
T: FTMS + p MALDI Full ms [800.00-1400.00]

RT [min]	Type	Width [min]	Area	Height	Area%
10.184	VV	0.2023	725.7850	53.8351	1.6325
11.567	VV	0.2195	42875.0313	2667.2349	96.4396
12.127	VV	0.1624	857.0851	76.6709	1.9279
		Sum	44457.9013		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.181	VV	0.2005	1076.0703	79.6896	2.0573
11.558	VV	0.1974	50273.9727	3016.5632	96.1188
12.123	VV	0.1574	953.9785	88.0350	1.8239
		Sum	52304.0214		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
10.184	VV	0.2011	783.1274	58.1524	1.5765
11.563	VV	0.2178	47934.4141	2930.3010	96.4971
12.127	VV	0.1643	956.9185	85.6613	1.9264

MALDI, HRMS, HPLC, ^{1}H-NMR and ^{13}C-NMR of 6-hydroxy-N-(4'-((3-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-3-oxopropyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8e)

Voyager Spec #1[BP = 1082.5, 24882]

C:\User\...\2020\19.11.2020\AD156_A2   11/19/2020 6:10:20 PM   AD156 mit HCCA gemessen.

AD156_A2 #1-11   RT: 0.00-1.06   AV: 11   NL: 6.24E4
T: FTMS + p MALDI Full ms [800.00-1400.00]


Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.239	VV	0.2244	10229.9883	672.8884	100.0000
		Sum	10229.9883		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.239	VV	0.2255	12384.9932	809.5344	100.0000
		Sum	12384.9932		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.239	VV	0.2257	11558.8154	758.7136	100.0000

^{1}H NMR spectrum peaks (ppm): 10.24, 9.92, 8.97, 8.57, 8.56, 8.55, 8.49, 8.48, 8.34, 8.16, 8.02, 8.00, 7.94, 7.93, 7.68, 7.67, 7.59, 7.58, 7.42, 7.41, 7.38, 7.37, 7.34, 7.33, 7.31, 4.57, 4.56, 4.45, 4.44, 4.43, 4.42, 4.41, 4.36, 4.24, 4.23, 4.21, 4.20, 3.70, 3.69, 3.67, 3.67, 3.65, 3.57, 3.55, 3.53, 3.51, 3.50, 3.48, 3.47, 3.32, 3.30, 3.17, 3.06, 2.86, 2.61, 2.60, 2.59, 2.57, 2.56, 2.55, 2.44, 2.06, 2.04, 2.03, 1.93, 1.92, 1.91, 1.90, 1.89, 0.93

Integrations: 0.88, 0.98, 0.97, 1.00, 0.96, 1.00, 1.00, 2.03, 2.00, 2.02, 2.04, 1.01, 1.01, 1.05, 1.02, 1.09, 1.25, 2.28, 2.07, 2.04, 2.02, 4.11, 3.00, 2.35, 3.03, 1.00, 1.00, 9.02

f1 (ppm): 11.5, 11.0, 10.5, 10.0, 9.5, 9.0, 8.5, 8.0, 7.5, 7.0, 6.5, 6.0, 5.5, 5.0, 4.5, 4.0, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0, 0.5, 0.0

^{13}C NMR spectrum peaks (ppm): 171.9, 170.4, 169.6, 165.8, 163.1, 161.1, 151.5, 147.6, 142.9, 142.0, 139.5, 139.0, 139.0, 138.8, 138.5, 138.3, 135.3, 133.3, 132.6, 131.2, 129.6, 128.6, 127.9, 127.4, 126.1, 125.3, 123.9, 123.2, 122.4, 121.0, 118.9, 111.7, 68.9, 58.7, 56.5, 56.4, 52.9, 48.1, 42.4, 41.7, 38.0, 36.3, 35.3, 34.9, 26.4, 15.9

f1 (ppm): 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10

AD157_A3 #1-4   RT: 0.00-0.34   AV: 4   NL: 1.61E6
T: FTMS + p MALDI Full ms [800.00-1400.00]

Signal: MWD1 A, Sig=254,4 Ref=off

| RT [min]	Type	Width [min]	Area	Height	Area%
11.279	VV	0.2370	9289.1738	585.9404	100.0000
		Sum	9289.1738		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.279	VV	0.2382	10607.9912	664.5951	100.0000
		Sum	10607.9912		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.279	VV	0.2376	10198.9717	641.1873	100.0000

{6.83,118.97}

{6.83,111.62}

{6.82,119.99}
{6.82,122.73}
{6.81,121.36}
{6.82,124.11}

{7.39,131.20}
{7.28,134.39}
{7.41,129.67}
{7.26,132.24}
{2.44,131.19}
{1.96,129.68}
{2.41,129.59}

{7.38,139.54}
{7.93,142.10}
{6.82,138.74}
{4.42,139.53}
{4.20,139.54}

{7.52,144.81}
{7.53,142.10}
{2.43,147.76}

{8.98,147.76}

ESI, HRMS, HPLC, ^{1}H-NMR, ^{13}C-NMR, ^{13}C-NMR, ^{1}H-^{13}C-HSQC and ^{1}H-^{13}C-HMBC (2x) of 6-hydroxy-*N*-(4'-((5-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8g/ Homer)

AD122-6 #9-11 RT: 0.54-0.68 AV: 3 SB: 5 0.07-0.34 NL: 2.78E6
T: {0,0} + c ESI !corona sid=75.00 det=1600.00 Full ms [200.00-1500.00]

C:\User\...\2020\20.08.2020\AD 122_E5   8/20/2020 6:47:54 PM   AD 122 mit HCCA gemessen.

AD 122_E5 #1-5 RT: 0.00-0.41 AV: 5 NL: 4.58E6
T: FTMS + p MALDI Full ms [700.00-1700.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.353	VV	0.2008	4513.2095	311.9199	100.0000
		Sum	4513.2095		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.353	VV	0.2029	5449.8301	372.0602	100.0000
		Sum	5449.8301		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.353	VV	0.2021	5101.9272	352.0205	100.0000

MALDI, HRMS, HPLC,¹H-NMR and ¹³C-NMR of 6-hydroxy-*N*-(4'-((6-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8h)


Voyager Spec #1[BP = 137.0, 55410]

C:\User\...\2020\17.09.2020\AD121_F10   9/17/2020 9:50:31 AM   AD121 mit HCCA gemessen.

AD121_F10 #1-16   RT: 0.00-0.68   AV: 16   NL: 1.30E6
T: FTMS + p MALDI Full ms [1000.00-1250.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.385	VV	0.2094	4595.4873	303.9242	100.0000
		Sum	4595.4873		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.385	VV	0.2101	5472.0347	360.5278	100.0000
		Sum	5472.0347		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.385	VV	0.2096	5170.4536	341.5610	100.0000

HPLC, MALDI, HRMS, ^{1}H-NMR,^{13}C-NMR, ^{1}H-^{13}C-HSQC and ^{1}H-^{13}C-HMBC of 6-hydroxy-*N*-(4'-((7-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8i)


Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.590	VV	0.2077	772.4310	50.7114	97.5053
12.955	MM	0.1361	19.7630	2.4203	2.4947
		Sum	792.1941		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.589	VV	0.2115	947.8234	60.6039	100.0000
		Sum	947.8234		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.590	VV	0.2078	879.9773	57.4239	97.6449
12.953	MM	0.1394	21.2239	2.5383	2.3551

Voyager Spec #1[BP = 1041.3, 13031]

C:\User\...\2020\20.08.2020\AD 110_E3   8/20/2020 6:45:29 PM   AD 110 mit HCCA gemessen.

AD 110_E3 #1-4 RT: 0.01-0.32 AV: 4 NL: 2.67E6
T: FTMS + p MALDI Full ms [700.00-1700.00]

MALDI, HRMS, HPLC, ¹H-NMR, ¹³C-NMR, ¹H-¹³C-HSQC and ¹H-¹³C-HMBC of 6-hydroxy-N-(4'-((4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethyl)benzyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (8j)

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.560	VV	0.2134	4870.5161	308.0758	100.0000
		Sum	4870.5161		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.560	VV	0.2151	5846.5635	366.4924	100.0000
		Sum	5846.5635		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.560	VV	0.2134	5481.1699	346.8157	100.0000

MALDI, HRMS, HPLC and ¹H-NMR of N-(4'-((2-(2-(4-((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxamido)-3-methoxybenzamido)ethoxy)ethyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (9a)

Voyager Spec #1[BP = 1184.1, 19013]

C:\User\...\2020\19.11.2020\AD138_A6   11/19/2020 6:18:40 PM   AD138 mit HCCA gemessen.

AD138_A6 #1-20   RT: 0.00-1.29   AV: 20   NL: 4.85E4
T: FTMS + p MALDI Full ms [800.00-1500.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.966	MM	0.1809	45.8666	4.2269	1.5833
14.363	VV	0.2753	2851.0457	147.6335	98.4167
		Sum	2896.9123		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.960	MM	0.2518	15.9346	1.0546	0.5114
14.363	VV	0.2623	3099.7249	162.6616	99.4886
		Sum	3115.6594		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.962	MM	0.2060	54.8831	4.4413	1.5802
14.363	VV	0.2919	3418.3169	178.0980	98.4198

MALDI, HRMS, HPLC and ¹H-NMR of N-(4'-((1-(4-((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxamido)-3-methoxyphenyl)-1-oxo-5,8,11,14,17,20,23-heptaoxa-2-azapentacosan-25-yl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (9b)

AD 136_E9 #1-16 RT: 0.00-1.43 AV: 16 NL: 3.57E4
T: FTMS + p MALDI Full ms [700.00-1700.00]

RT [min]	Type	Width [min]	Area	Height	Area%
13.388	MM	0.2391	223.4376	15.5738	3.8297
14.631	VV	0.4209	5610.9448	180.3722	96.1703
		Sum	5834.3824		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
13.385	MM	0.1997	178.9707	14.9336	3.1186
14.630	VV	0.3882	5559.8906	195.2569	96.8814
		Sum	5738.8614		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
13.386	MM	0.2384	306.7542	21.4423	4.6729
14.631	VV	0.4019	6257.7744	214.1512	95.3271

MWD1 A, Sig=254,4 Ref=off

MWD1 B, Sig=280,4 Ref=off

MWD1 F, Sig=260,4 Ref=off

MALDI, HRMS, HPLC, ^{1}H-NMR of N-(4'-((4-((4-((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxamido)-3-methoxybenzamido)methyl)benzyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-6-hydroxy-4-(trifluoromethyl)nicotinamide (9c)

Voyager Spec #1[BP = 242.3, 58541]

C:\User\...\2020\19.11.2020\AD144_A7   11/19/2020 6:20:51 PM   AD144 mit HCCA gemessen.

AD144_A7 #1-19   RT: 0.01-0.96   AV: 19   NL: 5.84E4
T: FTMS + p MALDI Full ms [800.00-1500.00]

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.962	MM	0.1568	35.1322	3.7335	1.8300
14.724	VV	0.3252	1884.6840	75.5157	98.1700
		Sum	1919.8162		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
14.722	VV	0.3226	2160.1218	87.6254	100.0000
		Sum	2160.1218		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
12.967	MM	0.1599	33.1664	3.4567	1.4688
14.724	VV	0.3246	2224.9216	89.0201	98.5312

MALDI, HRMS, HPLC and ¹H-NMR of 6-hydroxy-N-(4'-((5-(((S)-1-((2S,4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamoyl)-4-(4-methylpiperazin-1-yl)-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (22/ nc_VHL)

Voyager Spec #1[BP = 941.4, 31125]

C:\User\...\2020\16.12.2020\AD153_A4   12/16/2020 3:45:14 PM   AD153 mit HCCA gemessen.

AD153_A4 #1-13   RT: 0.00-0.55   AV: 13   NL: 2.10E7
T: FTMS + p MALDI Full ms [250.00-1100.00]

Signal: MSD1 TIC, MS File

RT [min]	Type	Width [min]	Area	Height	Area%
11.580	BB	0.3359	26619110.0000	1236768.2500	58.3972
18.536	BBA	0.3762	18963760.0000	840934.5625	41.6028
		Sum	45582870.0000		

Signal: MWD1 A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.353	VV	0.2008	4513.2095	311.9199	100.0000
		Sum	4513.2095		

Signal: MWD1 B, Sig=280,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.353	VV	0.2029	5449.8301	372.0602	100.0000
		Sum	5449.8301		

Signal: MWD1 F, Sig=260,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%
11.353	VV	0.2021	5101.9272	352.0205	100.0000

ESI, MALDI, HRMS, ^{1}H-NMR, ^{13}C-NMR and ^{1}H-^{13}C-HMBC 6-hydroxy-N-(4'-((5-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-5-oxopentyl)carbamoyl)-4-morpholino-[1,1'-biphenyl]-3-yl)-4-(trifluoromethyl)nicotinamide (23/ nc_WDR5)

C:\Xcalibur\data\ad167   2/17/2021 10:34:14 AM

ad167 #13-15   RT: 0.82-0.96   AV: 3   SB: 4 1.30-1.50   NL: 4.99E5
T: {0,1} - c ESI !corona sid=75.00 det=1600.00 Full ms [200.00-1500.00]

C:\User\...\2021\25.06.2021\AD167_E9   6/25/2021 1:54:44 PM   AD167 mit ClCCA gemessen.

AD167_E9 #1-6   RT: 0.00-0.22   AV: 6   NL: 3.92E7
T: FTMS + p MALDI Full ms [350.00-1100.00]

11.   List of figures

12.   List of schemes

13.   List of tables

14.   Acknowledgements

I would like to thank Andreas Krämer and Marek Wanior in particular for their competent lecturing skills, the quick review of my doctoral thesis and constant helpfulness. Furthermore, many thanks to Nadine Russ, Marcel Rak, Marek Wanior and Janik Weckesser for the excellent working atmosphere in the laboratory and on the other hand for their willingness to discuss, help and support in solving problems as well as all other colleagues of the working group.

Finally, I would like to thank my friends and my family who always supported me.

15.   Publications

Dölle, Adhikari, *et al*., "Design, Synthesis and Evaluation of WD40-repeat containing protein 5 (WDR5) degrader", *J. Med. Chem.* **2021**, *64* (15), 10682–10710.

16.   Eidesstattliche Erklärung

Erklärung

Ich erkläre hiermit, dass ich mich bisher keiner Doktorprüfung im Mathematisch-Naturwissenschaftlichen Bereich unterzogen habe.

Frankfurt am Main, den ....

(Unterschrift)

Versicherung

Ich erkläre hiermit, dass ich die vorgelegte Dissertation über

....

....

....

selbständig angefertigt und mich anderer Hilfsmittel als der in ihr angegebenen nicht bedient habe, insbesondere, dass alle Entlehnungen aus anderen Schriften mit Angabe der betreffenden Schrift gekennzeichnet sind. Ich versichere, die Grundsätze der guten wissenschaftlichen Praxis beachtet, und nicht die Hilfe einer kommerziellen Promotionsvermittlung in Anspruch genommen zu haben.

Frankfurt am Main, den ....

(Unterschrift)